<Bundle xmlns="http://hl7.org/fhir"><id value="ee31ee06-0a25-4a78-b90e-9022766fb989" /><identifier><system value="http://ema.europa.eu/fhir/epiGuid" /><value value="ee31ee06-0a25-4a78-b90e-9022766fb989" /></identifier><type value="collection" /><timestamp value="2025-06-04T14:15:22.4390336+02:00" /><entry><fullUrl value="8ad45d02-bb21-4495-8cbf-1f5484134252" /><resource><List><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) master document list</div></text><identifier><system value="http://ema.europa.eu/fhir/epiId" /><value value="EPI/24/129" /></identifier><status value="current" /><mode value="working" /><title value="all sections Spanish document" /><code><coding><system value="http://ema.europa.eu/fhir/documentType" /><code value="00001" /><display value="epiMasterList" /></coding></code><subject><reference value="subjectReference" /></subject><entry><item><reference value="referenceToDocument" /><display value="Ficha técnica o resumen de las características del producto" /></item></entry><entry><item><reference value="referenceToDocument" /><display value="Prospecto" /></item></entry></List></resource></entry><entry><fullUrl value="9450c786-f0a4-4d97-b89f-ff9b1c15061c" /><resource><Bundle><id value="9450c786-f0a4-4d97-b89f-ff9b1c15061c" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="9450c786-f0a4-4d97-b89f-ff9b1c15061c" /></identifier><type value="document" /><timestamp value="2025-06-04T14:15:22.4360691+02:00" /><entry><fullUrl value="9450c786-f0a4-4d97-b89f-ff9b1c15061c" /><resource><Composition><meta><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiCompositionSmPC" /><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiComposition" /><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUQRD-NAP-template-new-ORG-100003943-SmPC-es" /></meta><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://ema.europa.eu/fhir/CodeSystem/100000155531" /><code value="100000155532" /><display value="Ficha técnica o resumen de las características del producto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2025-06-04" /><author><reference value="Company Name" /></author><title value="Ficha técnica o resumen de las características del producto" /><section><title value="Ficha técnica o resumen de las características del producto" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029791" /><display value="Ficha técnica o resumen de las características del producto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="607c8627-89c7-4372-8f02-b6eca2cd2ff1"><title value="1. Nombre del medicamento" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029792" /><display value="1. NOMBRE DEL MEDICAMENTO" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Idacio 40 mg solución inyectable en jeringa precargada</span></p><p ><span>Idacio 40 mg solución inyectable en pluma precargada</span></p></div></text></section><section id="f2a2df55-191a-48f6-bd36-bb66fd9d3bcc"><title value="2. Composición cualitativa y cuantitativa" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029793" /><display value="2. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en jeringa precargada</span></span></p><p ><span> </span></p><p ><span>Cada jeringa precargada con una dosis única de 0,8 ml contiene 40 mg de adalimumab.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en pluma precargada</span></span></p><p ><span> </span></p><p ><span>Cada pluma precargada con una dosis única de 0,8 ml contiene 40 mg de adalimumab.</span></p><p ><span> </span></p><p ><span>Adalimumab es un anticuerpo monoclonal humano recombinante producido en células de Ovario de Hámster Chino.</span></p><p ><span> </span></p><p ><span>Para consultar la lista completa de excipientes, ver sección 6.1.</span></p></div></text></section><section id="0bc5cc03-b1d4-4172-97dd-8cd5c7e26fe3"><title value="3. Forma farmacéutica" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029797" /><display value="3. FORMA FARMACÉUTICA" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Solución inyectable (inyectable).</span></p><p ><span> </span></p><p ><span>Solución transparente, incolora.</span></p></div></text></section><section id="01339b3f-df9b-4e22-89cb-d1e8753d086a"><title value="4. Datos clínicos" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029798" /><display value="4. DATOS CLÍNICOS" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="88f9951c-b6f9-4a7f-a7d5-d2ea82cfced6"><title value="4.1. Indicaciones terapéuticas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029799" /><display value="4.1 Indicaciones terapéuticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Artritis reumatoide</span></span></p><p ><span> </span></p><p ><span>Idacio en combinación con metotrexato, está indicado para:</span></p><p ><span> </span></p><ul ><li><span>el tratamiento de la artritis reumatoide activa moderada a grave en pacientes adultos, cuando la respuesta a fármacos antirreumáticos modificadores de la enfermedad, incluyendo metotrexato, haya sido insuficiente.</span></li><li><span>el tratamiento de la artritis reumatoide activa, grave y progresiva en adultos no tratados previamente con metotrexato.</span></li></ul><p ><span> </span></p><p ><span>Idacio puede ser administrado en monoterapia en caso de intolerancia a metotrexato o cuando el tratamiento continuado con metotrexato no sea posible.</span></p><p ><span> </span></p><p ><span>Adalimumab ha demostrado reducir la tasa de progresión del daño de las articulaciones medido por rayos X y mejorar el rendimiento físico, cuando se administra en combinación con metotrexato.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Artritis idiopática juvenil</span></span></p><p ><span> </span></p><p ><em><span>Artritis idiopática juvenil poliarticular</span></em></p><p ><span> </span></p><p ><span>Idacio en combinación con metotrexato está indicado para el tratamiento de la artritis idiopática juvenil poliarticular activa en pacientes a partir de 2 años que han presentado una respuesta insuficiente a uno o más fármacos antirreumáticos modificadores de la enfermedad (FAMEs). Idacio puede ser administrado en monoterapia en caso de intolerancia a metotrexato o cuando el tratamiento continuado con metotrexato no sea posible (para consultar los datos de eficacia en monoterapia ver sección 5.1). No se ha estudiado el uso de adalimumab en pacientes menores de 2 años.</span></p><p ><span> </span></p><p ><em><span>Artritis asociada a entesitis</span></em></p><p ><em><span> </span></em></p><p ><span>Idacio está indicado para el tratamiento de la artritis asociada a entesitis activa en pacientes a partir de 6 años que han presentado una respuesta insuficiente, o son intolerantes, al tratamiento convencional (ver sección 5.1).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Espondiloartritis axial</span></span></p><p ><span> </span></p><p ><em><span>Espondilitis anquilosante (EA)</span></em></p><p ><em><span> </span></em></p><p ><span>Idacio está indicado para el tratamiento de adultos con espondilitis anquilosante activa grave que hayan presentado una respuesta insuficiente al tratamiento convencional.</span></p><p ><span> </span></p><p ><em><span>Espondiloartritis axial sin evidencia radiográfica de EA</span></em></p><p ><em><span> </span></em></p><p ><span>Idacio está indicado para el tratamiento de adultos con espondiloartritis axial grave sin evidencia radiográfica de EA pero con signos objetivos de inflamación por elevada Proteína C Reactiva y/o Imagen por Resonancia Magnética (IRM), que presentan una respuesta insuficiente o son intolerantes a fármacos antiinflamatorios no esteroideos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Artritis psoriásica</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la artritis psoriásica activa y progresiva en adultos cuando la respuesta al tratamiento previo con antirreumáticos modificadores de la enfermedad haya sido insuficiente. Se ha demostrado que adalimumab reduce la progresión del daño en las articulaciones periféricas medido por rayos X en pacientes que presentaban el patrón poliarticular simétrico de la enfermedad (ver sección 5.1) y que mejora la función física de los pacientes.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Psoriasis</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la psoriasis en placas crónica de moderada a grave en pacientes adultos que sean candidatos para un tratamiento sistémico.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Psoriasis pediátrica en placas</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la psoriasis crónica en placas grave en niños y adolescentes desde los 4 años de edad que hayan presentado una respuesta inadecuada o no sean candidatos apropiados para tratamiento tópico y fototerapias.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Hidradenitis supurativa (HS)</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la hidradenitis supurativa activa (acné inverso) de moderada a grave en pacientes adultos y adolescentes a partir de 12 años de edad con una respuesta insuficiente al tratamiento sistémico convencional de hidradenitis supurativa (ver las secciones 5.1 y 5.2).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Enfermedad de Crohn</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la enfermedad de Crohn activa de moderada a grave, en pacientes adultos que no hayan respondido a un tratamiento, completo y adecuado, con corticoesteroides y/o inmunosupresores, o que son intolerantes o tienen contraindicaciones médicas para dichos tratamientos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Enfermedad de Crohn pediátrica</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la enfermedad de Crohn activa de moderada a grave en pacientes pediátricos (a partir de los 6 años de edad) que han presentado una respuesta insuficiente al tratamiento convencional incluyendo tratamiento nutricional primario y un corticoesteroide y/o un inmunomodulador, o que son intolerantes o tienen contraindicados dichos tratamientos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Colitis ulcerosa</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado en el tratamiento de la colitis ulcerosa activa, de moderada a grave, en pacientes adultos que han presentado una respuesta inadecuada al tratamiento convencional, incluidos corticosteroides y 6-mercaptopurina (6-MP) o azatioprina (AZA), o que presentan intolerancia o contraindicaciones médicas a dichos tratamientos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Colitis ulcerosa pediátrica</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la colitis ulcerosa activa de moderada a grave en pacientes</span></p><p ><span>pediátricos (a partir de 6 años) que han presentado una respuesta insuficiente al tratamiento convencional con corticoesteroides y/o 6-mercaptopurina (6-MP) o azatioprina (AZA), o que son intolerantes o están contraindicados para dichos tratamientos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Uveítis</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado en el tratamiento de la uveítis no infecciosa intermedia y posterior y panuveítis en pacientes adultos que han presentado una respuesta inadecuada a corticoesteroides, que necesiten disminuir su tratamiento con corticoesteroides, o en aquellos en los que el tratamiento con corticoesteroides sea inapropiado.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Uveítis pediátrica</span></span></p><p ><span> </span></p><p ><span>Idacio está indicado para el tratamiento de la uveítis pediátrica anterior crónica no infecciosa en pacientes desde los 2 años de edad que han tenido una respuesta inadecuada o son intolerantes al tratamiento convencional, o en los que el tratamiento convencional no es adecuado.</span></p><p ><span> </span></p></div></text></section><section id="cc0e73c9-fe6a-47e8-ad9f-0b1fbb24ea73"><title value="4.2. Posología y forma de administración" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029800" /><display value="4.2 Posología y forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span>El tratamiento con Idacio debe ser iniciado y supervisado por médicos especialistas con experiencia en el diagnóstico y el tratamiento de aquellas indicaciones autorizadas para Idacio. Se aconseja a los oftalmólogos consultar con un especialista apropiado antes de iniciar el tratamiento con Idacio (ver sección 4.4). A los pacientes tratados con Idacio se les debe entregar la tarjeta de información para el paciente.</span></p><p><span> </span></p><p><span>Tras un adecuado aprendizaje de la técnica de inyección, los pacientes se pueden autoinyectar Idacio si el médico lo considera apropiado y les hace el seguimiento médico necesario.</span></p><p><span> </span></p><p><span>Durante el tratamiento con Idacio, se deben optimizar otros tratamientos concomitantes (p. ej. corticoesteroides y/o agentes inmunomoduladores).</span></p><p><span> </span></p></div></text><section id="7e437488-c52e-46a3-8203-d7b9e77fbb64"><title value="4.2.1. Posología" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029801" /><display value="Posología" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><em><span>Artritis reumatoide</span></em></p><p><em><span> </span></em></p><p><span>La dosis recomendada de Idacio para pacientes adultos con artritis reumatoide es 40 mg de adalimumab administrados en semanas alternas como dosis única en inyección por vía subcutánea. Durante el tratamiento con Idacio se debe mantener metotrexato .</span></p><p><span> </span></p><p><span>Durante el tratamiento con Idacio se pueden mantener glucocorticoides, salicilatos, fármacos antiinflamatorios no esteroideos, o analgésicos. Para la combinación con fármacos antirreumáticos modificadores de la enfermedad distintos de metotrexato ver las secciones 4.4 y 5.1.</span></p><p><span> </span></p><p><span>En monoterapia, los pacientes que experimenten una disminución en su respuesta con Idacio 40 mg en semanas alternas se pueden beneficiar de un aumento de la dosis a 40 mg de adalimumab cada semana u 80 mg cada dos semanas.</span></p><p><span> </span></p><p><span>Los datos disponibles sugieren que la respuesta clínica normalmente se alcanza dentro de las 12 semanas de tratamiento. La continuación del tratamiento se debe reconsiderar en pacientes que no hayan respondido en este periodo de tiempo.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Interrupción del tratamiento</span></span></em></p><p><em><span> </span></em></p><p><span>Puede ser necesario la interrupción del tratamiento, por ejemplo, antes de una cirugía o si se produce una infección grave.</span></p><p><span> </span></p><p><span>Los datos disponibles sugieren que cuando se vuelve a iniciar el tratamiento con adalimumab tras una interrupción de 70 días de duración o superior, se obtiene una respuesta clínica y un perfil de seguridad similar al observado antes de la interrupción del tratamiento.</span></p><p><span> </span></p><p><em><span>Espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA y artritis psoriásica</span></em></p><p><span> </span></p><p><span>La dosis recomendada de Idacio para pacientes con espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA y para pacientes con artritis psoriásica es de 40 mg de adalimumab administrados en semanas alternas como dosis única en inyección por vía subcutánea.</span></p><p><span> </span></p><p><span>Los datos disponibles sugieren que la respuesta clínica se consigue, por lo general, dentro de las primeras 12 semanas de tratamiento. La continuación con el tratamiento se debe reconsiderar en los pacientes que no hayan respondido en este periodo de tiempo.</span></p><p><span> </span></p><p><em><span>Psoriasis</span></em></p><p><em><span> </span></em></p><p><span>La posología recomendada de Idacio para pacientes adultos es de una dosis inicial de 80 mg administrada por vía subcutánea, seguida de 40 mg administrados por vía subcutánea en semanas alternas comenzando una semana después de la dosis inicial.</span></p><p><span> </span></p><p><span>La continuación del tratamiento más allá de 16 semanas se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido en este periodo de tiempo.</span></p><p><span> </span></p><p><span>Más allá de las 16 semanas, los pacientes con una respuesta inadecuada con Idacio 40 mg en semanas alternas se pueden beneficiar de un incremento de la dosis a 40 mg semanales u 80 mg cada dos semanas. Los beneficios y riesgos de la continuación del tratamiento semanal con 40 mg u 80 mg cada dos semanas se debe reconsiderar cuidadosamente en pacientes con una respuesta inadecuada tras el incremento de la dosis (ver sección 5.1). Si se alcanza una respuesta adecuada con 40 mg semanal u 80 mg cada dos semanas, la dosis se puede reducir posteriormente a 40 mg en semanas alternas.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span>Hidradenitis supurativa</span></em></p><p><span> </span></p><p><span>La pauta posológica recomendada de Idacio para pacientes adultos con hidradenitis supurativa (HS) es de una dosis inicial de 160 mg en el día 1 (administrada como 4 inyecciones de 40 mg en un día o 2 inyecciones diarias de 40 mg en dos días consecutivos), seguida de 80 mg dos semanas después, en el día 15 (administrada como 2 inyecciones de 40 mg en un día). Dos semanas después (día 29) continuar con una dosis de 40 mg semanal u 80 mg cada dos semanas (administrada como dos inyecciones de 40 mg en un día). Si es necesario se puede continuar el tratamiento con antibióticos durante el tratamiento con Idacio. Durante el tratamiento con Idacio se recomienda que el paciente utilice a diario un líquido antiséptico tópico en las lesiones de hidradenitis supurativa.</span></p><p><span> </span></p><p><span>La continuación del tratamiento más allá de 12 semanas se debe reconsiderar, de forma cuidadosa en pacientes que no hayan mejorado en este periodo de tiempo.</span></p><p><span> </span></p><p><span>Si se necesita interrumpir el tratamiento, se puede reintroducir Idacio 40 mg semanalmente u 80 mg cada dos semanas (ver sección 5.1).</span></p><p><span> </span></p><p><span>Se debe evaluar de forma periódica beneficio y el riesgo del tratamiento continuado a largo plazo (ver sección 5.1).</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span>Enfermedad de Crohn</span></em></p><p><em><span> </span></em></p><p><span>La pauta posológica inicial recomendada de Idacio para pacientes adultos con enfermedad de Crohn activa de moderada a grave es de 80 mg en la semana 0 seguido de 40 mg en la semana 2. En caso de que sea necesaria una respuesta más rápida al tratamiento, se puede cambiar la posología a 160 mg en la semana 0 (administrada mediante 4 inyecciones de 40 mg en un día o con 2 inyecciones de 40 mg por día durante dos días consecutivos), seguido de 80 mg en la semana 2 (administrada mediante dos inyecciones de 40 mg en un día), siendo consciente del mayor riesgo de reacciones adversas durante el inicio del tratamiento.</span></p><p><span> </span></p><p><span>Después de iniciar el tratamiento, la dosis recomendada es de 40 mg administrados en semanas alternas vía inyección subcutánea. De forma alternativa, si un paciente interrumpe el tratamiento con Idacio y los signos y síntomas de la enfermedad recurren, se puede readministrar Idacio. Hay poca experiencia en la readministración transcurridas más de 8 semanas desde la dosis previa.</span></p><p><span> </span></p><p><span>Los corticoesteroides se pueden reducir durante el tratamiento de mantenimiento, de acuerdo con las guías de práctica clínica.</span></p><p><span> </span></p><p><span>Algunos pacientes que han experimentado una disminución en su respuesta a Idacio 40 mg administrado cada dos semanas, se pueden beneficiar de un aumento en la dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p><span> </span></p><p><span>Algunos pacientes que no han respondido al tratamiento en la semana 4, se pueden beneficiar del tratamiento de mantenimiento continuado hasta la semana 12. El tratamiento continuado se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido dentro de este periodo de tiempo.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span>Colitis ulcerosa</span></em></p><p><span> </span></p><p><span>La dosis de inducción recomendada de Idacio para pacientes adultos con colitis ulcerosa de moderada a grave es de 160 mg en la semana 0 (administrada mediante 4 inyecciones de 40 mg en un día o con 2 inyecciones de 40 mg por día durante dos días consecutivos) y 80 mg en la semana 2 (administrada mediante dos inyecciones de 40 mg en un día). Después del tratamiento de inducción, la dosis recomendada es de 40 mg cada dos semanas mediante inyección por vía subcutánea.</span></p><p><span> </span></p><p><span>Los corticoesteroides se pueden reducir durante el tratamiento de mantenimiento, de acuerdo con las guías de práctica clínica.</span></p><p><span> </span></p><p><span>Algunos pacientes que han experimentado una disminución de su respuesta con Idacio 40 mg administrado cada dos semanas, se pueden beneficiar de un aumento de la dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p><span> </span></p><p><span>Los datos disponibles sugieren que la respuesta clínica se alcanza generalmente dentro de 2-8 semanas de tratamiento. El tratamiento con Idacio no se debe continuar en pacientes que no respondan dentro de este período de tiempo.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span>Uveítis</span></em></p><p><em><span> </span></em></p><p><span>La dosis recomendada de Idacio para pacientes adultos con uveítis es de una dosis inicial de 80 mg, seguida de 40 mg administrado en semanas alternas comenzando una semana después de la dosis inicial. Hay experiencia limitada en el inicio del tratamiento con adalimumab en monoterapia. El tratamiento con Idacio se puede iniciar en combinación con corticoesteroides y/o con otro agente inmunomodulador no biológico. El tratamiento concomitante con corticoesteroides puede ser ajustado de acuerdo con la práctica clínica comenzando dos semanas tras el inicio del tratamiento con Idacio.</span></p><p><span> </span></p><p><span>Se recomienda una evaluación anual del beneficio y riesgo del tratamiento continuado a largo plazo (ver sección 5.1).</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Poblaciones especiales</span></span></p><p><span> </span></p><p><em><span>Pacientes de edad avanzada</span></em></p><p><em><span> </span></em></p><p><span>No se requiere ajuste de dosis.</span></p><p><span> </span></p><p><em><span>Insuficiencia renal y/o hepática</span></em></p><p><em><span> </span></em></p><p><span>Adalimumab no se ha estudiado en estas poblaciones de pacientes, por lo que no hay recomendaciones de dosis.</span></p><p><span> </span></p><p><em><span>Población pediátrica</span></em></p><p><em><span> </span></em></p><p><em><span style="text-decoration: underline"><span>Artritis idiopática juvenil</span></span></em></p><p><em><span> </span></em></p><p><span>Artritis idiopática juvenil poliarticular desde los 2 años de edad</span></p><p><span> </span></p><p><span>La dosis recomendada de Idacio para pacientes con artritis idiopática juvenil poliarticular a partir de los 2 de edad se basa en el peso corporal (Tabla 1). Idacio se administra en semanas alterna</span><span>s en inyección por vía subcutánea.</span></p><p><span> </span></p><p><strong><span>      </span></strong><strong><span>Tabla 1. Dosis de Idacio para pacientes con artritis idiopática juvenil poliarticular</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Pauta posológica</span></strong></p></td></tr><tr><td><p style="text-align:center"><span>10 kg hasta &lt; 30 kg</span></p></td><td><p style="text-align:center"><span>20 mg en semanas alternas</span></p></td></tr><tr><td><p style="text-align:center"><span>≥ 30 kg</span></p></td><td><p style="text-align:center"><span>40 mg en semanas alternas</span></p></td></tr></table><p><span> </span></p><p><span>Los dat</span><span>os disponibles sugieren que la respuesta clínica se consigue, por lo general, dentro de las primeras 12 semanas de tratamiento. La continuación con el tratamiento se debe ser reconsiderar cuidadosamente en los pacientes que no hayan respondido en este periodo de tiempo</span></p><p><span> </span></p><p><span>El uso de adalimumab en pacientes menores de 2 años para esta indicación no es relevante.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><span>Artritis asociada a entesitis</span></p><p><span> </span></p><p><span>La dosis recomendada de Idacio para pacientes con artritis asociada a entesitis en pacientes a partir de 6 años se basa en el peso corporal (Tabla 2). Idacio se administra en semanas alternas en inyección por vía subcutánea.</span></p><p><span> </span></p><p><strong><span>              </span></strong><strong><span>Tabla 2. Dosis de Idacio para pacientes con artritis asociada a entesitis</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Pauta posológica</span></strong></p></td></tr><tr><td><p style="text-align:center"><span>15 kg hasta &lt; 30 kg</span></p></td><td><p style="text-align:center"><span>20 mg en semanas alternas</span></p></td></tr><tr><td><p style="text-align:center"><span>≥ 30 kg</span></p></td><td><p style="text-align:center"><span>40 mg en semanas alternas</span></p></td></tr></table><p><span> </span></p><p><span>No se ha estudiado el uso de adalimumab en pacientes con artritis asociada a entesitis menores de 6 años.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Artritis psoriásica y espondiloartritis axial incluyendo espondilitis anquilosante</span></span></em></p><p><span> </span></p><p><span>El uso de adalimumab en la población pediátrica para las indicaciones de espondilitis anquilosante y artritis psoriásica no es relevante.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Psoriasis pediátrica en placas</span></span></em></p><p><em><span> </span></em></p><p><span>La dosis recomendada de Idacio para pacientes con psoriasis pediátrica en placas desde los 4 a los 17 años de edad se basa en el peso corporal (Tabla 3). Idacio se administra mediante inyección por vía subcutánea.</span></p><p><span> </span></p><p><strong><span>                  </span></strong><strong><span>Tabla 3. Dosis de Ida</span></strong><strong><span>cio para pacientes pediátricos con psoriasis en placas</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Pauta posológica</span></strong></p></td></tr><tr><td><p style="text-align:center"><span>15 kg hasta &lt; 30 kg</span></p><p style="text-align:center"><span> </span></p></td><td><p style="text-align:center"><span>Dosis inicial de 20 mg, seguida de 20 mg administrados en semanas alternas empezando una semana después de la dosis inicial</span></p></td></tr><tr><td><p style="text-align:center"><span>≥ 30 kg</span></p><p style="text-align:center"><span> </span></p></td><td><p style="text-align:center"><span>Dosis ini</span><span>cial de 40 mg, seguida de 40 mg administrados en semanas alternas empezando una semana después de la dosis inicial</span></p></td></tr></table><p><span> </span></p><p><span>La continuación del tratamiento más allá de 16 semanas se debe reconsiderar de forma cuidadosa en pacientes que no hayan respondido en este periodo de tiempo.</span></p><p><span> </span></p><p><span>En el caso de que esté indicado el retratamiento con Idacio, se deben seguir las indicaciones anteriores en cuanto a la dosis y la duración del tratamiento.</span></p><p><span> </span></p><p><span>La seguridad de adalimumab en pacientes pediátricos psoriasis en placas ha sido evaluada durante una media de 13 meses.</span></p><p><span> </span></p><p><span>El uso de para adalimumab en niños menores de 4 años para esta indicación no es relevante.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Hidradenitis supurativa en adolescentes (a partir de 12 años de edad, con un peso de al menos 30 kg)</span></span></em></p><p><span> </span></p><p><span>No hay ensayos clínicos con adalimumab en pacientes adolescentes con HS. La posología de adalimumab en estos pacientes se ha determinado a partir de modelos farmacocinéticos y simulación (ver sección 5.2).</span></p><p><span> </span></p><p><span>La dosis recomendada de Idacio es de 80 mg en la semana 0 seguida de 40 mg en semanas alternas comenzando en la semana 1 mediante inyección vía subcutánea.</span></p><p><span> </span></p><p><span>En pacientes adolescentes con una respuesta inadecuada con Idacio 40 mg en semanas alternas, se puede considerar un incremento de dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p><span> </span></p><p><span>Si es necesario se puede continuar el tratamiento con antibióticos durante el tratamiento con Idacio. Durante el tratamiento con Idacio se recomienda que el paciente utilice a diario un líquido antiséptico tópico en las lesiones de hidradenitis supurativa.</span></p><p><span> </span></p><p><span>La continuación del tratamiento más allá de 12 semanas se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan mejorado en este periodo de tiempo.</span></p><p><span> </span></p><p><span>Si se necesita interrumpir el tratamiento, se puede reintroducir Idacio según proceda.</span></p><p><span> </span></p><p><span>Se debe evaluar de forma periódica el beneficio y el riesgo del tratamiento continuado a largo plazo (ver datos en adultos en sección 5.1).</span></p><p><span> </span></p><p><span>El uso de adalimumab en niños menores de 12 años para la indicación de enfermedad de hidradenitis supurativa no es relevante.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Enfermedad de Crohn pediátrica</span></span></em></p><p><em><span> </span></em></p><p><span>La dosis recomendada de Idacio para pacientes con enfermedad de Crohn desde los 6 hasta los 17 años de edad se basa en el peso corporal (Tabla 4). Idacio se administra en inyección por vía subcutánea.</span></p><p><span> </span></p><p><strong><span>                  </span></strong><strong><span>Tabla 4. Dosis de Idacio para pacientes pediátricos con enfermedad de Crohn</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis de inducción</span></strong></p><p style="text-align:center"><strong><span> </span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis de mantenimiento empezando en la semana 4</span></strong></p><p style="text-align:center"><strong><span> </span></strong></p></td></tr><tr><td><p style="text-align:center"><span>&lt; 40 kg</span></p><p style="text-align:center"><span> </span></p></td><td><ul><li><span>40 mg en la semana 0 y 20 mg en la semana 2</span></li></ul><p><span> </span></p><p><span>En caso de que sea necesario una respuesta más rápida al tratamiento siendo conscientes de que el riesgo de efectos adversos puede ser mayor con el uso de una dosis de inducción más alta, puede usarse la siguiente dosis:</span></p><ul><li><span>80 mg en la semana 0 y 40 mg en la semana 2</span></li></ul></td><td><p style="text-align:center"><span>20 mg en semanas alternas</span></p><p style="text-align:center"><span> </span></p></td></tr><tr><td><p style="text-align:center"><span>≥ 40 kg</span></p><p style="text-align:center"><span> </span></p></td><td><ul><li><span>80 mg en la semana 0 y 40 mg en la semana 2</span></li></ul><p><span> </span></p><p><span>En caso de que sea necesario una respuesta más rápida al tratamiento siendo conscientes de que el riesgo de efectos adversos puede ser mayor con el uso de una dosis de inducción más alta, puede usarse l</span><span>a siguiente dosis:</span></p><ul><li><span>160 mg en la semana 0 y 80 mg en la semana 2</span></li></ul></td><td><p style="text-align:center"><span>40 mg en semanas alternas</span></p><p style="text-align:center"><span> </span></p></td></tr></table><p><span> </span></p><p><span>Los pacientes que tengan una respuesta insuficiente se pueden beneficiar de un aumento en la dosis:</span></p><ul><li><span>&lt; 40 kg: 20 mg cada semana</span></li><li><span>≥ 40 kg: 40 mg cada semana u 80 mg cada dos semanas</span></li></ul><p><span> </span></p><p><span>El tratamiento continuado se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido en la semana 12.</span></p><p><span> </span></p><p><span>El uso de adalimumab en niños menores de 6 años para la indicación de enfermedad de Crohn no es relevante.</span></p><p><span> </span></p><p><span>Idacio p</span><span>uede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Colitis ulcerosa pediátrica</span></span></em></p><p><span> </span></p><p><span>La dosis recomendada de Idacio para pacientes de 6 a 17 años con colitis ulcerosa se basa en el peso corporal (Tabla 5). Idacio se administra mediante inyección subcutánea.</span></p><p><span> </span></p><p><strong><span>                    </span></strong><strong><span>Tabla 5. Dosis de Idacio para pacientes pediátricos con colitis ulcerosa</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis de inducción</span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis de</span></strong></p><p style="text-align:center"><strong><span>mantenimiento</span></strong></p><p style="text-align:center"><strong><span>Comienza en la</span></strong></p><p style="text-align:center"><strong><span>semana 4*</span></strong></p></td></tr><tr><td><p><span>&lt; 40 kg</span></p></td><td><ul><li><span>80 mg en</span><span>la semana 0 (administrados como dos inyecciones de</span></li></ul><p><span>40 mg en un día) y</span></p><ul><li><span>40 mg en la semana 2 (administrados como una inyección de</span></li></ul><p><span>40 mg)</span></p></td><td><p style="text-align:center"><span>40 mg en</span></p><p style="text-align:center"><span>semanas</span></p><p style="text-align:center"><span>alternas</span></p></td></tr><tr><td><p><span>≥ 40 kg</span></p></td><td><div><ul><li><span>160 mg en la semana 0 (administrados como cuatro inyecciones</span></li></ul></div><p><span>de 40 mg en un día o d</span><span>os inyecciones de 40 mg al día en dos días</span></p><p><span>consecutivos) y</span></p><div><ul><li><span>80 mg en la semana 2 (administrados como dos inyecciones de</span></li></ul></div><p><span>40 mg en un día)</span></p><p><span> </span></p></td><td><p style="text-align:center"><span>80 mg en</span></p><p style="text-align:center"><span>semanas</span></p><p style="text-align:center"><span>alternas</span></p></td></tr></table><p><span>*</span><span>Los pacientes pediátricos que cumplan 18 años durante el tratamiento con Idacio deben continuar con la dosis de mantenimiento prescrita.</span></p><p><span> </span></p><p><span>El tratamiento continuado tras 8 semanas se debe reconsiderar, de fo</span><span>rma cuidadosa, en pacientes que</span><span>no muestran signos de respuesta transcurrido este tiempo.</span></p><p><span> </span></p><p><span>El uso de adalimumab en niños menores de 6 años para la indicación no es relevante.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en distintas presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p><p><em><span style="text-decoration: underline"><span>Uveítis pediátrica</span></span></em></p><p><span> </span></p><p><span>La dosis recomendada de</span><span>Idacio</span><span>en pacientes pediátricos con uveítis desde los 2 años de edad se basa en el peso corporal (Tabla 6).</span><span>Idacio</span><span>se administra en inyección por vía subcutánea.</span></p><p><span> </span></p><p><span>En uveítis pediátrica, no hay experiencia en el tratamiento con adalimumab sin un tratamiento concom</span><span>itante con metotrexato.</span></p><p><span> </span></p><p><strong><span>                       </span></strong><strong><span>Tabla 6. Dosis de</span></strong><strong><span>Idacio</span></strong><strong><span>para pacientes pediátricos con uveítis</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><thead><tr><td><p style="text-align:center"><strong><span>Peso del paciente</span></strong></p></td><td><p style="text-align:center"><strong><span>Pauta posológica</span></strong></p></td></tr><tr><td><p style="text-align:center"><span>&lt; 30 kg</span></p></td><td><p style="text-align:center"><span>20 mg en semanas alternas en combinación con metotrexato</span></p></td></tr><tr><td><p style="text-align:center"><span>≥ 30 kg</span></p></td><td><p style="text-align:center"><span>40 mg en semanas alternas en com</span><span>binación con metrotexato</span></p></td></tr></thead></table><p><span> </span></p><p><span>Cuando se inicie el tratamiento con</span><span>Idacio</span><span>, se puede administrar una dosis de carga de 40 mg para pacientes de &lt; 30 kg o de 80 mg para pacientes ≥ 30 kg una semana antes de empezar el tratamiento de mantenimiento. No se dispone de datos clínicos sobre el uso de una dosis de carga de adalimumab en niños menores de 6 años (ver sección 5.2).</span></p><p><span> </span></p><p><span>El uso de</span><span>Idacio</span><span>en niños menores de 2 años en esta indicación no es relevante.</span></p><p><span> </span></p><p><span>Se recomienda evaluar de manera anual el beneficio y el riesgo</span><span>en tratamientos continuados a largo plazo (ver sección 5.1).</span></p><p><span> </span></p><p><span>Idacio</span><span>puede estar disponible en otras presentaciones en función de las necesidades individuales del tratamiento.</span></p><p><span> </span></p></div></text></section><section id="f7598547-366f-4e5f-8022-77289af49fc1"><title value="4.2.2. Forma de administración" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029803" /><display value="Forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span>Idacio se administra mediante inyección subcutánea. Las instrucciones completas para su uso se describen en el prospecto</span></p><p><span> </span></p><p><span>Idacio está disponible en otras presentaciones.</span></p><p><span> </span></p></div></text></section></section><section id="59f4a208-5462-427b-a1a2-b418ab8cebcf"><title value="4.3. Contraindicaciones" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029805" /><display value="4.3 Contraindicaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>Hipersensibilidad al principio activo o a alguno de los excipientes, incluidos en la sección 6.1.</span></p><p ><span> </span></p><p ><span>Tuberculosis activa u otras infecciones graves tales como sepsis, e infecciones oportunistas (ver sección 4.4).</span></p><p ><span> </span></p><p ><span>Insuficiencia cardiaca moderada a grave (NYHA clases III/IV) (ver sección 4.4).</span></p><p ><span> </span></p></div></text></section><section id="b3a22272-d387-4562-b154-1cc30799783b"><title value="4.4. Advertencias y precauciones especiales de empleo" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029806" /><display value="4.4 Advertencias y precauciones especiales de empleo" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Trazabilidad</span></span></p><p ><span> </span></p><p ><span>Con objeto de mejorar la trazabilidad de los medicamentos biológicos, el nombre y el número de lote del medicamento administrado deben estar claramente registrados.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Infecciones</span></span></p><p ><span> </span></p><p ><span>Los pacientes que están en tratamiento con antagonistas del TNF son más susceptibles de padecer infecciones graves. La función pulmonar alterada puede incrementar el riesgo de desarrollar infecciones. Por lo tanto, se debe controlar estrechamente a los pacientes para la detección de infecciones (incluyendo tuberculosis), antes, durante y después del tratamiento con Idacio. Dado que la eliminación de adalimumab puede tardar hasta cuatro meses, se debe continuar controlando a los pacientes durante este periodo.</span></p><p ><span> </span></p><p ><span>El tratamiento con Idacio no se debe iniciar en pacientes con infecciones activas, incluyendo infecciones crónicas o localizadas, hasta que las infecciones estén controladas. Se debe considerar el riesgo y el beneficio antes de iniciar el tratamiento con Idacio en pacientes que han estado expuestos a tuberculosis y en pacientes que han viajado a áreas de alto riesgo de tuberculosis o áreas endémicas de micosis, como histoplasmosis, coccidiomicosis o blastomicosis (ver</span><em><span>Otras infecciones oportunistas</span></em><span>).</span></p><p ><span> </span></p><p ><span>Los pacientes que desarrollen una nueva infección mientras estén bajo tratamiento con Idacio se deben controlar estrechamente y someterse a una evaluación diagnóstica completa. La administración de Idacio debe interrumpirse si un paciente desarrolla una infección grave nueva o sepsis, y se debe iniciar el tratamiento antimicrobiano o antifúngico apropiado hasta que la infección esté controlada. Los médicos deben tener precaución cuando consideren el uso de Idacio en pacientes con antecedentes de infección recurrente o con condiciones subyacentes que puedan predisponer a los pacientes a infecciones, incluido el uso concomitante de medicamentos inmunosupresores.</span></p><p ><span> </span></p><p ><em><span>Infecciones graves</span></em></p><p ><span> </span></p><p ><span>Se han notificado infecciones graves, incluyendo sepsis, de origen bacteriano, micobacteriano, fúngicas invasivas, parasitarias, virales u otras infecciones oportunistas como listeriosis, legionelosis y pneumocistis en pacientes en tratamiento con adalimumab.</span></p><p ><span> </span></p><p ><span>Otras infecciones graves observadas en los ensayos clínicos incluyen neumonía, pielonefritis, artritis séptica y septicemia. Se han notificado casos de hospitalizaciones o desenlaces mortales asociados a estas infecciones.</span></p><p ><span> </span></p><p ><em><span>Tuberculosis</span></em></p><p ><em><span> </span></em></p><p ><span>Se han notificado casos de tuberculosis, incluido reactivación y tuberculosis de nueva aparición, en pacientes en tratamiento con adalimumab. Las notificaciones incluyeron casos de tuberculosis pulmonar y extrapulmonar, es decir, diseminada.</span></p><p ><span> </span></p><p ><span>Antes de iniciar el tratamiento con Idacio, se debe evaluar en todos los pacientes la existencia de tuberculosis activa o inactiva (latente). Esta evaluación debe incluir una valoración médica detallada del paciente con antecedentes de tuberculosis o posible exposición previa a personas con tuberculosis activa y tratamiento inmunosupresor previo y/o actual. Se deben realizar pruebas de detección adecuadas (es decir, prueba cutánea de la tuberculina y radiografía de tórax) en todos los pacientes (aplicando recomendaciones locales). Se recomienda anotar en la tarjeta de información para el paciente la realización y resultados de estas pruebas. Se recuerda a los médicos el riesgo de falsos negativos en la prueba cutánea de la tuberculina, en especial en pacientes que están gravemente enfermos o inmunodeprimidos.</span></p><p ><span> </span></p><p ><span>Si se diagnostica tuberculosis activa, no se debe iniciar el tratamiento con Idacio (ver sección 4.3).</span></p><p ><span> </span></p><p ><span>En todas las situaciones descritas a continuación, el balance beneficio/riesgo del tratamiento con Idacio debe ser cuidadosamente considerado.</span></p><p ><span> </span></p><p ><span>Si se tienen sospechas de tuberculosis latente, se debe consultar con un médico con experiencia en el tratamiento de la tuberculosis.</span></p><p ><span> </span></p><p ><span>Si se diagnostica tuberculosis latente, se debe iniciar el tratamiento con una profilaxis antituberculosa antes de comenzar el tratamiento con Idacio y de acuerdo con las recomendaciones locales.</span></p><p ><span> </span></p><p ><span>Se debe considerar también el uso de profilaxis antituberculosa antes del inicio del tratamiento con Idacio en pacientes con factores de riesgo múltiples o significativos a pesar de un resultado negativo en la prueba para la tuberculosis y en pacientes con antecedentes de tuberculosis latente o activa en los que no se haya podido confirmar el curso adecuado del tratamiento.</span></p><p ><span> </span></p><p ><span>A pesar de la profilaxis para la tuberculosis, se han producido casos de reactivación de la misma en pacientes tratados con adalimumab. Algunos pacientes que habían recibido un tratamiento satisfactorio para la tuberculosis activa han vuelto a desarrollar tuberculosis mientras estaban en tratamiento con adalimumab.</span></p><p ><span> </span></p><p ><span>Se deben dar instrucciones a los pacientes para que consulten con su médico si apareciesen signos/síntomas que sugieran tuberculosis (p. ej. tos persistente, debilidad/pérdida de peso, febrícula, apatía) durante o después del tratamiento con Idacio.</span></p><p ><span> </span></p><p ><em><span>Otras infecciones oportunistas</span></em></p><p ><em><span> </span></em></p><p ><span>Se han observado infecciones oportunistas, incluyendo infecciones fúngicas invasivas, en pacientes en tratamiento con adalimumab. Estas infecciones no se han identificado de forma sistemática en pacientes en tratamiento con antagonistas del TNF lo que ha originado retrasos en el tratamiento apropiado, en ocasiones con consecuencias mortales.</span></p><p ><span> </span></p><p ><span>Se tendrá en cuenta la posibilidad de una infección fúngica invasiva en aquellos pacientes que desarrollen signos y síntomas como fiebre, malestar, pérdida de peso, sudoración, tos, disnea y/o infiltraciones pulmonares u otros síntomas de enfermedad sistémica grave con o sin shock concomitante. En estos pacientes se debe suspender inmediatamente la administración de Idacio. El diagnóstico y la administración de tratamiento antifúngico empírico en estos pacientes se debe realizar de acuerdo con un médico con experiencia previa en el cuidado de pacientes con infecciones fúngicas invasivas.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Reactivación de Hepatitis B</span></span></p><p ><span> </span></p><p ><span>Se han producido casos de reactivación de la hepatitis B en pacientes que estaban recibiendo antagonistas del TNF (Factor de necrosis tumoral), incluyendo adalimumab, los cuales son portadores crónicos del virus (por ejemplo, antígeno de superficie positivo), en algunos casos con desenlace mortal. Se debe analizar una posible infección previa con VHB en los pacientes antes de iniciar el tratamiento con Idacio. Para aquellos pacientes con análisis positivo para infección de hepatitis B, se recomienda consultar con un médico especialista en el tratamiento de la hepatitis B.</span></p><p ><span> </span></p><p ><span>Se controlarán estrechamente los signos y síntomas de infección activa por VHB durante todo el tratamiento con Idacio y hasta varios meses después de la finalización del tratamiento en aquellos portadores de VHB que requieran tratamiento con Idacio. No existen datos adecuados acerca de la prevención de la reactivación del VHB en pacientes portadores del VHB que reciban de forma conjunta tratamiento antiviral y un antagonista del TNF. En pacientes que sufran una reactivación del VHB, se debe interrumpir el tratamiento con Idacio e iniciar un tratamiento antiviral efectivo con el tratamiento de soporte apropiado.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Efectos neurológicos</span></span></p><p ><span> </span></p><p ><span>Los antagonistas del TNF incluyendo adalimumab se han asociado en casos raros con la nueva aparición o exacerbación de los síntomas clínicos y/o evidencia radiográfica de enfermedad desmielinizante del sistema nervioso central, incluyendo esclerosis múltiple y neuritis óptica, y enfermedad desmielinizante del sistema nervioso periférico, incluyendo Síndrome de Guillain-Barré. Los médicos deberán considerar con precaución el uso de Idacio en pacientes con trastornos desmielinizantes del sistema nervioso central o periférico preexistentes o de reciente aparición; si se desarrolla cualquiera de estos trastornos se debe considerar la interrupción del tratamiento con Idacio. Existe una asociación conocida entre la uveítis intermedia y los trastornos desmielinizantes centrales. Antes del inicio del tratamiento con Idacio y de forma regular durante el tratamiento se debe realizar una evaluación neurológica en pacientes con uveítis intermedia no infecciosa para valorar trastornos desmielinizantes centrales preexistentes o en desarrollo.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Reacciones alérgicas</span></span></p><p ><span> </span></p><p ><span>Las reacciones alérgicas graves asociadas a adalimumab fueron raras durante los ensayos clínicos. Las reacciones alérgicas no-graves asociadas con adalimumab fueron poco frecuentes durante los ensayos clínicos. Se han recibido notificaciones de reacciones alérgicas graves que incluyeron anafilaxia tras la administración de adalimumab. Si aparece una reacción anafiláctica u otra reacción alérgica grave, se debe interrumpir inmediatamente la administración de Idacio e iniciar el tratamiento apropiado.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Inmunosupresión</span></span></p><p ><span> </span></p><p ><span>En un estudio de 64 pacientes con artritis reumatoide que fueron tratados con adalimumab, no se observó evidencia de descenso de hipersensibilidad retardada, descenso de los niveles de inmunoglobulinas, o cambio en el recuento de células efectoras T, B y células NK, monocitos/macrófagos, y neutrófilos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Neoplasias malignas y trastornos linfoproliferativos</span></span></p><p ><span> </span></p><p ><span>En las partes controladas de los ensayos clínicos de los antagonistas del TNF, se han observado más casos de neoplasias malignas, incluido el linfoma, entre los pacientes que recibieron un antagonista del TNF en comparación con el grupo control. Sin embargo, la incidencia fue rara. En el entorno poscomercialización se han notificado casos de leucemia en pacientes tratados con antagonistas del TNF. Existe un mayor riesgo basal de linfomas y leucemia en pacientes con artritis reumatoide con enfermedad inflamatoria de alta actividad, que complica la est</span><span>imación del riesgo. Con el conocimiento actual, no se puede excluir un posible riesgo de desarrollo de linfomas, leucemia, y otras neoplasias malignas en pacientes tratados con antagonistas del TNF.</span></p><p ><span> </span></p><p ><span>Se ha notificado la aparición de neoplasias malignas, algunas mortales, entre niños, adolescentes y jóvenes adultos (hasta 22 años de edad) tratados con agentes antagonistas del TNF (inicio del tratamiento ≤ 18 años), incluyendo adalimumab en el entorno poscomercialización Aproximadamente, la mitad de los casos</span><span>fueron linfomas. Los demás casos representan una variedad de neoplasias malignas e incluyen cánceres raros normalmente asociados con inmunosupresión. No se puede excluir el riesgo de desarrollar neoplasias malignas en niños y adolescentes tratados con antagonistas del TNF.</span></p><p ><span> </span></p><p ><span>Durante la poscomercialización, se han identificado casos raros de linfoma hepatoesplénico de células T en pacientes tratados con adalimumab. Estos casos raros de linfoma de células T cursan con una progresión muy agresiva y por lo general mortal de la enfermedad. Algunos de estos linfomas hepatoesplénicos de células T con adalimumab se han presentado en pacientes adultos jóvenes en tratamiento concomitante con azatioprina o 6 - mercaptopurina utilizada para la enfermedad inflamatoria intestinal. El riesgo potencial de la combinación de azatiopina o 6-mercaptopurina y adalimumab debe ser cuidadosamente considerado. No se puede descartar el riesgo de desarrollar linfoma hepatoesplénico de células T en pacientes tratados con Idacio (ver sección 4.8).</span></p><p ><span> </span></p><p ><span>No se han realizado estudios que incluyan pacientes con antecedentes de neoplasias malignas o en los que el tratamiento con adalimumab continúe tras desarrollar una enfermedad neoplásica maligna. Por tanto, se deben tomar precauciones adicionales al considerar el tratamiento de estos pacientes con Idacio (ver sección 4.8).</span></p><p ><span> </span></p><p ><span>En todos los pacientes, y en particular en aquellos que hayan recibido un tratamiento inmunosupresor extenso o pacientes con psoriasis y tratamiento previo con Psoraleno más ultravioleta (PUVA), se debe examinar la presencia de cáncer de piel de tipo no-melanoma antes y durante el tratamiento con Idacio. Se han notificado también casos de melanoma y carcinoma de células de Merkel en pacientes en tratamiento con antagonistas del TNF incluyendo adalimumab (ver sección 4.8).</span></p><p ><span> </span></p><p ><span>En un ensayo clínico exploratorio que evaluaba el uso de otro antagonista del TNF, infliximab, en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave, se registraron más casos de neoplasias malignas, la mayoría del pulmón, o cabeza y cuello, en pacientes en tratamiento con infliximab comparado con el grupo control. Todos los pacientes presentaban antecedentes de tabaquismo importante. Por tanto, se debe tener especial cuidado cuando se utilice cualquier antagonista de TNF en pacientes con EPOC, así como en pacientes con un elevado riesgo de sufrir neoplasias malignas por fumar en exceso.</span></p><p ><span> </span></p><p ><span>Con los datos disponibles actualmente se desconoce si el tratamiento con adalimumab influye en el riesgo de desarrollar displasia o cáncer de colon. Se debe cribar para displasia a intervalos regulares antes del tratamiento y durante el curso de la enfermedad a todos los pacientes con colitis ulcerosa que presenten un riesgo incrementado de displasia o carcinoma de colon (por ejemplo, pacientes con colitis ulcerosa de larga duración o con colangitis esclerosante primaria), o que tengan antecedentes de displasia o carcinoma de colon. Esta evaluación debe incluir colonoscopia y biopsias según recomendaciones locales.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Reacciones hematológicas</span></span></p><p ><span> </span></p><p ><span>En raras ocasiones se han descrito casos de pancitopenia, incluyendo anemia aplásica, con antagonistas del TNF. Se han descrito con adalimumab reacciones adversas del sistema hematológico, incluyendo citopenias significativas desde el punto de vista médico (ej. trombocitopenia, leucopenia). Se debe aconsejar a todos los pacientes que consulten inmediatamente con su médico en caso de presentar signos y síntomas de discrasias sanguíneas (ej. fiebre persistente, cardenales, hemorragia, palidez) cuando estén siendo tratados con Idacio. En pacientes con anomalías hematológicas significativas confirmadas debe considerarse la interrupción del tratamiento con Idacio.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Vacunas</span></span></p><p ><span> </span></p><p ><span>En un ensayo con 226 sujetos adultos con artritis reumatoide que fueron tratados con adalimumab o placebo se observó una respuesta de anticuerpos similar frente a la vacuna estándar neumocócica 23-valente y la vacuna trivalente para el virus de la gripe. No se dispone de datos sobre la transmisión secundaria de infecciones por vacunas vivas en pacientes tratados con adalimumab.</span></p><p ><span> </span></p><p ><span>En pacientes pediátricos se recomienda, si es posible, que se actualice el calendario de vacunaciones de acuerdo con las directrices de inmunización en vigor antes de iniciar el tratamiento con adalimumab.</span></p><p ><span> </span></p><p ><span>Los pacientes en tratamiento con adalimumab pueden ser vacunados, excepto con vacunas de microorganismos vivos. No se recomienda la administración de vacunas de microorganismos vivos (p.ej., vacuna BCG) a lactantes expuestos a adalimumab en el útero durante los 5 meses siguientes a la última inyección de adalimumab de la madre durante el embarazo.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Insuficiencia cardiaca congestiva</span></span></p><p ><span> </span></p><p ><span>En un ensayo clínico con otro antagonista del TNF se ha observado empeoramiento de la insuficiencia cardiaca congestiva y aumento de la mortalidad debida a esta patología. También se han notificado casos de empeoramiento de la insuficiencia cardiaca congestiva en pacientes tratados con adalimumab. Idacio debe utilizarse con precaución en pacientes con insuficiencia cardiaca leve (NYHA clases I/II). Idacio está contraindicado en insuficiencia cardiaca moderada o grave (ver sección 4.3). El tratamiento con Idacio debe interrumpirse en pacientes que desarrollen insuficiencia cardiaca congestiva nueva o presenten un empeoramiento de los síntomas.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Procesos autoinmunes</span></span></p><p ><span> </span></p><p ><span>El tratamiento con Idacio puede dar lugar a la formación de autoanticuerpos. Se desconoce el impacto del tratamiento a largo plazo con adalimumab sobre el desarrollo de enfermedades autoinmunes. Si un paciente desarrolla síntomas parecidos a los de un síndrome tipo lupus después del tratamiento con Idacio y da positivo a los anticuerpos frente al ADN bicatenario, se debe interrumpir el tratamiento con Idacio (ver sección 4.8).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Administración concomitante de FAMEs biológicos o antagonistas del TNF</span></span></p><p ><span> </span></p><p ><span>En ensayos clínicos se han observado infecciones graves con el uso concurrente de anakinra y otro antagonista del TNF, etanercept, sin beneficio clínico añadido en comparación con el uso de etanercept solo. Por la naturaleza de los efectos adversos observados en el tratamiento combinado de etanercept y anakinra, la combinación de anakinra y otros antagonistas del TNF puede producir una toxicidad similar. Por lo tanto, no se recomienda la combinación adalimumab y anakinra. (Ver sección 4.5).</span></p><p ><span> </span></p><p ><span>Basándose en el posible incremento del riesgo de infecciones, incluyendo infecciones graves, y otras interacciones farmacológicas potenciales, no se recomienda la administración concomitante de adalimumab con otros FAMEs biológicos (por ejemplo, anakinra y abatacept) u otros antagonistas del TNF. (Ver sección 4.5).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Cirugía</span></span></p><p ><span> </span></p><p ><span>La experiencia de seguridad de intervenciones quirúrgicas en pacientes tratados con adalimumab es limitada. Si se planifica una intervención quirúrgica debe considerarse la larga semivida de eliminación de adalimumab. Los pacientes tratados con Idacio que requieran cirugía, deben controlarse muy de cerca por la aparición de infecciones y tomar las medidas apropiadas. La experiencia de seguridad en los pacientes a los que se les ha practicado una artroplastia, mientras estaban en tratamiento con adalimumab, es limitada.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Obstrucción del intestino delgado</span></span></p><p ><span> </span></p><p ><span>Un fallo en la respuesta al tratamiento para la enfermedad de Crohn puede indicar la presencia de estenosis fibróticas establecidas que pueden requerir tratamiento quirúrgico. Los datos disponibles sugieren que adalimumab no empeora ni causa las estenosis.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Pacientes de edad avanzada</span></span></p><p ><span> </span></p><p ><span>La frecuencia de infecciones graves en sujetos mayores de 65 años (3,7%) tratados con adalimumab fue mayor que para aquellos menores de 65 años (1,5%). Algunas de dichas infecciones tuvieron un resultado mortal. Se debe prestar una atención particular en relación al riesgo de infecciones cuando se trate a pacientes de edad avanzada.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Población pediátrica</span></span></p><p ><span> </span></p><p ><span>Ver Vacunas arriba.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Excipientes con efecto conocido</span></span></p><p ><span> </span></p><p ><span>Este medicamento contiene menos de 23 mg de sodio (1mmol) por dosis de 0,8 ml; esto es, esencialmente “exento de sodio”.</span></p><p ><span> </span></p></div></text></section><section id="883252e3-e8f2-435b-b8c4-3ccc8dc4453f"><title value="4.5. Interacción con otros medicamentos y otras formas de interacción" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029809" /><display value="4.5 Interacción con otros medicamentos y otras formas de interacción" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>Adalimumab ha sido estudiado en pacientes con artritis reumatoide, artritis idiopática juvenil poliarticular y artritis psoriásica tratados con adalimumab tanto en monoterapia como con metotrexato de forma concomitante. Cuando se administró adalimumab junto con metotrexato, la formación de anticuerpos fue inferior en comparación con el uso como monoterapia. La administración de adalimumab sin metotrexato resultó en un incremento de la formación de anticuerpos, del aclaramiento y redujo la eficacia de adalimumab (ver sección 5.1).</span></p><p ><span> </span></p><p ><span>La administración conjunta de Idacio y anakinra no está recomendada (ver sección 4.4 “Administración concomitante de FAMEs biológicos o antagonistas del TNF”).</span></p><p ><span> </span></p><p ><span>La administración conjunta de Idacio y abatacept no está recomendada (ver sección 4.4 “Administración concomitante de FAMEs biológicos o antagonistas del TNF”).</span></p><p ><span> </span></p></div></text></section><section id="00016066-84ef-413b-ac46-352f93054147"><title value="4.6. Fertilidad, embarazo y lactancia" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029811" /><display value="4.6 Fertilidad, embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Mujeres en edad fértil</span></span></p><p ><span> </span></p><p ><span>Las mujeres en edad fértil deben considerar utilizar un método anticonceptivo adecuado para prevenir el embarazo y continuar su uso durante al menos cinco meses tras el último tratamiento con Idacio.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Embarazo</span></span></p><p ><span> </span></p><p ><span>Un gran número de embarazos (aproximadamente 2.100) seguidos de forma prospectiva y expuestos a adalimumab, resultando en nacimientos con vida conocidos, incluyendo más de 1.500 expuestos durante el primer trimestre, no indican un aumento en la tasa de malformación en el recién nacido.</span></p><p ><span> </span></p><p ><span>En un registro de cohortes prospectivo, fueron reclutadas 257 mujeres con artritis reumatoide (AR) o enfermedad de Crohn (EC) tratadas con adalimumab al menos durante el primer trimestre, y 120 mujeres con AR o EC no tratadas con adalimumab. La variable principal fue la prevalencia de las principales anomalías congénitas que se dan al nacer. La tasa de embarazos que termina con, al menos, un recién nacido vivo con un defecto congénito grave fue de 6/69 (8,7%) en mujeres con AR tratadas con adalimumab y 5/74 (6,8%) en mujeres con AR sin tratamiento (OR no ajustado 1,31, 95% IC 0,38-4,52) y 16/152 (10,5%) en mujeres con EC tratadas con adalimumab y 3/32 (9,4%) en mujeres con EC no tratadas (OR no ajustado 1,14, IC 95% 0,31-4,16 ). El OR ajustado (teniendo en cuenta las diferencias basales) fue de 1,10 (IC del 95% 0,45 a 2,73) para AR y EC combinadas. No hubo diferencias claras entre las mujeres tratadas con adalimumab y las no tratadas para las variables secundarias de abortos espontáneos, defectos de nacimiento menores, parto prematuro, tamaño al nacer e infecciones graves u oportunistas, y no se notificaron nacimientos de niños muertos o neoplasias malignas. La interpretación de los datos puede verse afectada debido a las limitaciones metodológicas del estudio, incluyendo el pequeño tamaño de la muestra y el diseño no aleatorizado.</span></p><p ><span> </span></p><p ><span>En un estudio de toxicidad para el desarrollo realizado en monos, no hubo indicios de toxicidad maternal, embriotoxicidad o teratogenicidad. No se dispone de datos preclínicos sobre toxicidad postnatal de adalimumab (ver sección 5.3).</span></p><p ><span> </span></p><p ><span>Debido a la inhibición del TNF</span><span>?</span><span>,</span><span>la administración de adalimumab durante el embarazo podría afectar a la respuesta inmune normal en el recién nacido. Adalimumab solo debe usarse durante el embarazo en caso de ser claramente necesario.</span></p><p ><span> </span></p><p ><span>Adalimumab puede atravesar la placenta al suero de niños nacidos de madres tratadas con adalimumab durante el embarazo. Como consecuencia, estos niños pueden tener un riesgo incrementado de infecciones. No se recomienda la administración de vacunas vivas (p.ej., vacuna BCG) a niños expuestos a adalimumab en el útero hasta 5 meses después de la última inyección de adalimumab de la madre durante el embarazo.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Lactancia</span></span></p><p ><span> </span></p><p ><span>La información limitada extraída de la literatura publicada indica que adalimumab se excreta a través de la leche materna en concentraciones muy bajas con una presencia de adalimumab en leche humana en concentraciones del 0,1% al 1% del nivel sérico materno. Administrada por vía oral, la inmunoglobulina G se somete a proteolisis intestinal y tiene una biodisponibilidad escasa. No se prevén efectos en neonatos/lactantes alimentados con leche materna. En consecuencia, Idacio puede usarse durante la lactancia.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Fertilidad</span></span></p><p ><span> </span></p><p ><span>No hay datos preclínicos disponibles sobre el efecto de adalimumab en la fertilidad.</span></p><p ><span> </span></p></div></text></section><section id="66cd10f6-24db-4cad-a82d-1202c1d5065f"><title value="4.7. Efectos sobre la capacidad para conducir y utilizar máquinas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029815" /><display value="4.7 Efectos sobre la capacidad para conducir y utilizar máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>La influencia de Idacio sobre la capacidad para conducir y utilizar máquinas es pequeña. Se pueden producir vértigos y alteraciones de la visión tras la administración de Idacio (ver Sección 4.8).</span></p><p ><span> </span></p></div></text></section><section id="7ed7fcc5-95bd-42b8-b4cf-de407a099197"><title value="4.8. Reacciones adversas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029816" /><display value="4.8 Reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span style="text-decoration: underline"><span>Resumen del perfil de seguridad</span></span></p><p><span> </span></p><p><span>Adalimumab se ha estudiado en 9.506 pacientes en ensayos pivotales controlados y abiertos durante un máximo de 60 meses o más. Estos ensayos clínicos incluyeron pacientes con artritis reumatoide reciente o de larga duración, artritis idiopática juvenil (artritis idiopática juvenil poliarticular y artritis asociada a entesitis) así como con espondiloartritis axial (espondilitis anquilosante, y espondiloartritis axial sin evidencia radiográfica de EA), artritis psoriásica, enfermedad de Crohn, colitis ulcerosa, psoriasis, hidradenitis supurativa y uveítis. Los datos están basados en ensayos pivotales controlados que abarcaron 6.089 pacientes tratados con adalimumab y 3.801 pacientes con placebo o comparador activo durante el periodo controlado.</span></p><p><span> </span></p><p><span>La proporción de pacientes que interrumpió el tratamiento debido a reacciones adversas durante la fase doble ciego y controlada de los ensayos pivotales fue 5,9 % para los pacientes tratados con adalimumab y 5,4 % para el grupo control.</span></p><p><span> </span></p><p><span>Las reacciones adversas notificadas más frecuentemente fueron infecciones (como nasofaringitis, infección del tracto respiratorio superior y sin</span><span>usitis), reacciones en el lugar d</span><span>e inyección (eritema, picores, hemorragia, dolor o hinchazón), cefalea y dolor músculo esquelético.</span></p><p><span> </span></p><p><span>Se han notificado reacciones adversas graves con adalimumab. Los antagonistas del TNF, como adalimumab, afectan al sistema inmune, y su uso puede afectar a la defensa del cuerpo contra infecciones y cáncer.</span></p><p><span> </span></p><p><span>Se han notificado también con el uso de adalimumab infecciones mortales o potencialmente mortales (incluyendo sepsis, infecciones oportunistas y tuberculosis), reactivación del VHB y varios tipos de tumores (incluyendo leucemia, linfoma y linfoma hepatoesplénico de células T).</span></p><p><span> </span></p><p><span>También se han notificado reacciones hematológicas, neurológicas y autoinmunes graves. Estas incluyen notificaciones raras de pancitopenia, anemia aplásica, acontecimientos desmielinizantes centrales y periféricos y notificaciones de lupus, enfermedades relacionadas con lupus y síndrome de Stevens-Johnson.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Población pediátrica</span></span></p><p><span> </span></p><p><span>En general, las reacciones adversas en pacientes pediátricos fueron similares en frecuencia y tipo a las observadas en pacientes adultos.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Tabla de reacciones adversas</span></span></p><p><span> </span></p><p><span>La siguiente lista de reacciones adversas se basa en la experiencia de ensayos clínicos y en la experiencia poscomercialización y se enumeran según el sistema MedDRA de clasificación de órganos y f</span><span>recuencias en la Tabla 7: muy frecuentes ( ≥1/10); frecuentes (≥1/100 a &lt;1/10); poco frecuentes (≥1/1.000 a &lt;1/100); raras (≥1/10.000 a &lt;1/1.000) y frecuencia no conocida (no puede estimarse a partir de los datos disponibles). Las reacciones adversas se en</span><span>umeran en orden decreciente de gravedad dentro de cada intervalo de frecuencia. Las frecuencias incluidas son las más altas observadas en las diferentes indicaciones. En los casos en los que se incluye información adicional en las secciones 4.3, 4.4 y 4.8, aparece un asterisco (*) en la columna Sistema de Clasificación de Órganos (SOC).</span></p><p><span> </span></p><p><strong><span>                                                           </span></strong><strong><span>Tabla 7</span></strong></p><p><strong><span>                                                </span></strong><strong><span>Reacciones adversas</span></strong></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td><p><strong><span>Sistema de clasificación de órganos</span></strong></p></td><td><p><strong><span>Frecuencia</span></strong></p></td><td><p><strong><span>Reacciones adversas</span></strong></p></td></tr><tr><td rowspan="3"><p><span>Infecciones e infestaciones*</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Infecciones del tracto respiratorio (incluyendo infecciones respiratorias del tracto inferior y superior, neumonía, sinusitis, faringitis, nasofaringitis y neumonía herpética)</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Infecciones sistémicas (incluyendo sepsis, candidiasis y gripe),</span></p><p><span>infecciones intestinales (incluyendo gastroenteritis viral),</span></p><p><span>infecciones de la piel y tejidos blandos (incluyendo paroniquia, celulitis, impétigo, fascitis necrotizante y herpes zoster),</span></p><p><span>infección de oídos,</span></p><p><span>infecciones orales (incluyendo herpes simple, herpes oral e infecciones dentales),</span></p><p><span>infecciones del tracto reproductor (incluyendo infección micótica vulvovaginal),</span></p><p><span>infecciones del tracto urinario (incluyendo pielonefritis),</span></p><p><span>infecciones fúngicas,</span></p><p><span>infecciones de las articulaciones</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Infecciones neurológicas (incluyendo meningitis viral), infecciones oportunistas y tuberculosis (incluyendo coccidiomicosis, histoplasmosis, infecciones por el complejo mycobacterium avium), infecciones bacterianas,</span></p><p><span>infecciones oculares, diverticulitis</span><span>1)</span></p></td></tr><tr><td rowspan="4"><p><span>Neoplasias benignas, malignas y no especificadas (incluyendo quistes y pólipos)*</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Cáncer de piel excluido el melanoma (incluyendo carcinoma de células basales y carcinoma de células escamosas),</span></p><p><span>neoplasia benigna</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Linfoma**,</span></p><p><span>neoplasia de órganos sólidos (incluyendo cáncer de mama, neoplasia pulmonar y neoplasia tiroidea),</span></p><p><span>melanoma**</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Leucemia</span><span>1)</span></p></td></tr><tr><td><p><span>No conocida</span></p></td><td><p><span>Linfoma hepatoesplénico de células T</span><span>1)</span></p><p><span>carcinoma de células de Merkel (carcinoma neuroendocrino de la piel)</span><span>1)</span></p><p><span>Sarcoma de Kaposi</span></p></td></tr><tr><td rowspan="4"><p><span>Trastornos de la sangre y del sistema linfático*</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Leucopenia (incluyendo neutropenia y agranulocitosis),</span></p><p><span>Anemia</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Leucocitosis,</span></p><p><span>Trombocitopenia</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Púrpura trombocitopénica idiopática</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Pancitopenia</span></p></td></tr><tr><td rowspan="3"><p><span>Trastornos del sistema inmunológico*</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Hipersensibilidad,</span></p><p><span>alergias (incluyendo alergia estacional)</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Sarcoidosis</span><span>1)</span><span>,</span></p><p><span>Vasculitis</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Anafilaxia</span><span>1)</span></p></td></tr><tr><td rowspan="2"><p><span>Trastornos del metabolismo y de la nutrición</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Lípidos elevados</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Hipopotasemia,</span></p><p><span>incremento de ácido úrico,</span></p><p><span>sodio plasmático anormal,</span></p><p><span>hipocalcemia,</span></p><p><span>hiperglucemia,</span></p><p><span>hipofosfatemia,</span></p><p><span>deshidratación</span></p></td></tr><tr><td><p><span>Trastornos psiquiátricos</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Alteraciones del estado de ánimo (incluyendo depresión)</span></p><p><span>ansiedad,</span></p><p><span>insomnio</span></p></td></tr><tr><td rowspan="4"><p><span>Trastornos del sistema nervioso*</span></p><p><span> </span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Cefalea</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Parestesias, (incluyendo hipoestesia),</span></p><p><span>migraña,</span></p><p><span>compresión radicular</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Accidente cerebrovascular</span><span>1)</span><span>,</span></p><p><span>temblor,</span></p><p><span>neuropatía</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Esclerosis múltiple,</span></p><p><span>trastornos desmielinizantes (por ejemplo, neuritis óptica, síndrome de Guillain-Barré)</span><span>1)</span></p></td></tr><tr><td rowspan="2"><p><span>Trastornos oculares</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Alteración visual,</span></p><p><span>conjuntivitis,</span></p><p><span>blefaritis,</span></p><p><span>hinchazón de ojos</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Diplopía</span></p></td></tr><tr><td rowspan="2"><p><span>Trastornos del oído y del laberinto</span></p><p><span> </span></p></td><td><p><span>Frecuentes</span></p><p><span> </span></p></td><td><p><span>Vértigo</span></p><p><span> </span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Sordera,</span></p><p><span>Tinitus</span></p></td></tr><tr><td rowspan="3"><p><span>Trastornos cardiacos*</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Taquicardia</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Infarto de miocardio</span><span>1)</span><span>,</span></p><p><span>arritmia,</span></p><p><span>insuficiencia cardiaca congestiva</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Paro cardiaco</span></p></td></tr><tr><td rowspan="2"><p><span>Trastornos vasculares</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Hipertensión,</span></p><p><span>rubefacción,</span></p><p><span>hematomas</span></p></td></tr><tr><td><p><span>Poco Frecuentes</span></p></td><td><p><span>Aneurisma aórtico,</span></p><p><span>oclusión vascular arterial,</span></p><p><span>tromboflebitis</span></p></td></tr><tr><td rowspan="3"><p><span>Trastornos respiratorios, torácicos y mediastínicos*</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Asma,</span></p><p><span>disnea,</span></p><p><span>tos</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Embolia pulmonar</span><span>1)</span><span>,</span></p><p><span>Enfermedad pulmonar intersticial,</span></p><p><span>enfermedad pulmonar obstructiva crónica,</span></p><p><span>neumonitis,</span></p><p><span>derrame pleural</span><span>1)</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Fibrosis pulmonar</span><span>1)</span></p></td></tr><tr><td rowspan="4"><p><span>Trastornos gastrointestinales</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Dolor abdominal,</span></p><p><span>náuseas y vómitos</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Hemorragia gastrointestinal,</span></p><p><span>dispepsia,</span></p><p><span>enfermedad de reflujo gastroesofágico,</span></p><p><span>síndrome Sicca</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Pancreatitis,</span></p><p><span>disfagia,</span></p><p><span>edema facial</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Perforación intestinal</span><span>1)</span></p><p><strong><span> </span></strong></p></td></tr><tr><td rowspan="4"><p><span>Trastornos hepatobiliares*</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Enzimas hepáticas elevadas</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Colecistitis y colelitiasis,</span></p><p><span>esteatosis hepática,</span></p><p><span>Bilirrubina elevada</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Hepatitis,</span></p><p><span>reactivación de la hepatitis B</span><span>1)</span></p><p><span>hepatitis autoinmune</span><span>1)</span></p></td></tr><tr><td><p><span>No conocida</span></p></td><td><p><span>Fallo hepático</span><span>1)</span></p></td></tr><tr><td rowspan="4"><p><span>Trastornos de la piel y del tejido subcutáneo</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Erupción (incluyendo erupción exfoliativa)</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Empeoramiento de la psoriasis existente o psoriasis de nueva aparición (incluyendo psoriasis pustulosa palmoplantar)</span><span>1)</span><span>,</span></p><p><span>urticaria,</span></p><p><span>cardenales (incluyendo púrpura),</span></p><p><span>dermatitis (incluyendo eccema),</span></p><p><span>onicoclasia,</span></p><p><span>hiperhidrosis,</span></p><p><span>alopecia</span><span>1)</span><span>,</span></p><p><span>prurito</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Sudores nocturnos,</span></p><p><span>cicatrices</span></p></td></tr><tr><td><p><span>Raras</span></p></td><td><p><span>Eritema multiforme</span><span>1)</span><span>,</span></p><p><span>síndrome de Stevens-Johnson</span><span>1)</span><span>,</span></p><p><span>angioedema</span><span>1)</span><span>,</span></p><p><span>vasculitis cutánea</span><span>1)</span></p><p><span>reacción liquenoide en la piel</span><span>1)</span></p></td></tr><tr><td><p><span> </span></p></td><td><p><span>No conocida</span></p></td><td><p><span>Empeoramiento de los síntomas de la dermatomiositis</span><span>1)</span></p></td></tr><tr><td rowspan="4"><p><span>Trastornos musculoesqueléticos y del tejido conjuntivo</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Dolor musculoesquelético</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Espasmos musculares (incluyendo creatina fosfoquinasa en sangre elevada)</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Rabdomiolisis,</span></p><p><span>lupus eritematoso sistémico</span></p></td></tr><tr><td><p><span>Raros</span></p></td><td><p><span>Síndrome tipo lupus</span><span>1)</span></p></td></tr><tr><td rowspan="2"><p><span>Trastornos renales y urinarios</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Insuficiencia renal,</span></p><p><span>hematuria</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Nicturia</span></p></td></tr><tr><td><p><span>Trastornos del aparato reproductor y de la mama</span></p></td><td><p><span>Poco frecuentes</span></p></td><td><p><span>Disfunción eréctil</span></p></td></tr><tr><td rowspan="3"><p><span>Trastornos generales y alteraciones en el lugar de administración*</span></p></td><td><p><span>Muy frecuentes</span></p></td><td><p><span>Reacción en la zona de inyección (incluyendo eritema en la zona de inyección)</span></p></td></tr><tr><td><p><span>Frecuentes</span></p></td><td><p><span>Dolor de pecho,</span></p><p><span>edema,</span></p><p><span>pirexia</span><span>1)</span></p></td></tr><tr><td><p><span>Poco frecuentes</span></p></td><td><p><span>Inflamación</span></p></td></tr><tr><td rowspan="2"><p><span>Exploraciones complementarias</span><span>*</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Trastornos de la coagulación y hemorrágicos (incluyendo</span><span>prolongación del tiempo de tromboplastina parcial activada),</span></p><p><span>Determinación de autoanticuerpos positiva (incluyendo anticuerpos de ADN bicatenario),</span></p><p><span>lactato deshidrogenasa en sangre elevada</span></p></td></tr><tr><td><p><span>No conocida</span></p></td><td><p><span>Aumento de peso</span><span>2)</span></p></td></tr><tr><td><p><span>Lesiones traumáticas, intoxicaciones y complicaciones procedimentales</span></p></td><td><p><span>Frecuentes</span></p></td><td><p><span>Alteración de la cicatrización</span></p></td></tr></table><p><span>*Se incluye información adicional en las secciones 4.3, 4.4 y 4.8</span></p><p><span>**incluyendo los estudios de extensión abierta.</span></p><p><span>1)</span><span>incluyendo los datos de notificaciones espontáneas.</span></p><p><span>??</span><span>?</span><span>El cambio medio de peso desde el inicio para adalimumab fue de entre 0,3 kg y 1,0 kg en las indicaciones en adultos en comparación con entre (menos) -0,4 kg y 0,4 kg para el placebo durante un período de tratamiento de 4-6 meses. También se ha observado</span><span>un aumento de peso de 5-6 kg en estudios de extensión a largo plazo con exposiciones medias de aproximadamente 1-2 años sin grupo de control, particularmente en pacientes con enfermedad de Crohn y colitis ulcerosa. El mecanismo que subyace a este efecto no está claro pero podría estar relacionado con el efecto antiinflamatorio de adalimumab.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Hidradenitis supurativa</span></span></p><p><span> </span></p><p><span>El perfil de seguridad de los pacientes con hidradenitis supurativa en tratamiento semanal con adalimumab fue consistente con el perfil de seguridad conocido de adalimumab.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Uveítis</span></span></p><p><span> </span></p><p><span>El perfil de seguridad de los pacientes con uveítis en tratamiento con adalimumab en semanas alternas fue consistente con el perfil de seguridad conocido de adalimumab.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Descripción de reacciones adversas seleccionadas</span></span></p><p><span> </span></p><p><em><span>Reacciones en la zona de inyección</span></em></p><p><em><span> </span></em></p><p><span>En los ensayos controlados pivotales en adultos y niños, el 12,9 % de los pacientes tratados con adalimumab desarrollaron reacciones en la zona de inyección (eritema y/o picores, hemorragia, dolor o hinchazón), comparado con el 7,2 % de los pacientes tratados con placebo o control activo. No se consideró necesario interrumpir el medicamento debido a las reacciones en la zonade administración.</span></p><p><span> </span></p><p><em><span>Infecciones</span></em></p><p><em><span> </span></em></p><p><span>En los ensayos controlados pivotales en adultos y niños, la incidencia de infecciones fue de 1,51 por paciente/año en los pacientes tratados con adalimumab y 1,46 por paciente/año en los pacientes tratados con placebo y control activo. Las infecciones consistieron fundamentalmente en nasofaringitis, infecciones del tracto respiratorio superior y sinusitis. La mayoría de los pacientes continuaron con adalimumab tras resolverse la infección.</span></p><p><span> </span></p><p><span>La incidencia de infecciones graves fue de 0,04 por paciente/año en los pacientes tratados con adalimumab y 0,03 por paciente/año en los pacientes tratados con placebo y control activo.</span></p><p><span> </span></p><p><span>En ensayos controlados abiertos en adultos y pediátricos con adalimumab, se han notificado infecciones graves (incluyendo las mortales, que han ocurrido en casos raros), entre las que se incluyen notificaciones de tuberculosis (incluida la miliar y la localización extrapulmonar) e infecciones oportunistas invasivas (por ejemplo: histoplasmosis diseminada o extrapulmonar, blastomicosis, coccidiomicosis, pneumocistis, candidiasis, aspergilosis y listeriosis). La mayoría de los casos de tuberculosis tuvieron lugar durante los primeros ocho meses del tratamiento y reflejan la exacerbación de una enfermedad latente.</span></p><p><span> </span></p><p><em><span>Neoplasias malignas y trastornos linfoproliferativos</span></em></p><p><span> </span></p><p><span>No se han observado neoplasias malignas durante los ensayos con adalimumab en 249 pacientes pediátricos de artritis idiopática juvenil (artritis idiopática juvenil poliarticular y artritis asociada a entesitis) con una exposición de 655,6 pacientes/año. Adicionalmente, no se observaron neoplasias malignas en 192 pacientes pediátricos con una exposición de 498,1 pacientes/año durante ensayos de adalimumab en pacientes pediátricos con enfermedad de Crohn. No se han observado neoplasias malignas en 77 pacientes pediátricos con una exposición de 80,0 pacientes/año durante un ensayo de adalimumab en pacientes pediátricos con psoriasis en placas crónica.</span><span>No se han observado enfermedades neoplásicas malignas en 93 pacientes pediátricos expuestos a 65,3 pacientes/año durante un ensayo de adalimumab en pacientes pediátricos con colitis ulcerosa.</span><span>No se observaron neoplasias malignas en 60 pacientes pediátricos con una exposición de 58,4 pacientes al año durante un ensayo de adalimumab en pacientes pediátricos con uveítis.</span></p><p><span> </span></p><p><span>Durante las fases controladas de los ensayos clínicos pivotales con adalimumab en adultos que duraron un mínimo de 12 semanas en pacientes con artritis reumatoide activa de moderada a grave, espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA, artritis psoriásica, psoriasis, hidradenitis supurativa, enfermedad de Crohn, colitis ulcerosa y uveítis, se observaron neoplasias malignas, diferentes a linfoma y cáncer de piel (tipo no melanoma), con una incidencia de 6,8 (4,4 – 10,5) por 1.000 pacientes/año (IC 95 %) en los 5.291 pacientes tratados con adalimumab, frente a una incidencia de 6,3 (3,4 – 11,8) por 1.000 pacientes/año en los 3.444 pacientes del grupo control (la duración media del tratamiento fue de 4,0 meses para los pacientes tratados con adalimumab y de 3,8 meses para los pacientes tratados del grupo control). La incidencia de cáncer de piel (tipo no melanoma) fue de 8,8 (6,0 – 13,0) por 1.000 pacientes/año (IC 95 %) en los pacientes tratados con adalimumab y 3,2 (1,3 – 7,6) por 1.000 pacientes/año en los pacientes control. De estos casos de cáncer de piel, el carcinoma de células escamosas se produjo con una incidencia de 2,7 (1,4 – 5,4) por 1.000 pacientes/año (IC 95 %) en los pacientes tratados con adalimumab y de un 0,6 (0,1 – 4,5) por 1.000 pacientes/año en los pacientes del grupo control. La incidencia de linfomas fue de 0,7 (0,2 – 2,7) por 1.000 pacientes/año (IC 95 %) entre los pacientes tratados con adalimumab y de 0,6 (0,1 – 4,5) por 1.000 pacientes/año en los pacientes del grupo control.</span></p><p><span> </span></p><p><span>Cuando se combinan los datos obtenidos en las fases controladas de estos ensayos clínicos y los ensayos de extensión abiertos en curso y completados, con una duración media aproximada de 3,3 años que incluyen 6.427 pacientes y más de 26.439 pacientes/año de tratamiento, la incidencia observada de neoplasias malignas, excluyendo linfomas y cáncer de piel (tipo no melanoma), es de aproximadamente 8,5 por 1.000 pacientes/año. La incidencia observada de cáncer de piel (tipo no melanoma) es de un 9,6 por 1.000 pacientes/año, aproximadamente. La incidencia observada de linfomas es de 1,3 por 1.000 pacientes/año, aproximadamente.</span></p><p><span> </span></p><p><span>En la experiencia pos-comercialización desde enero de 2003 a diciembre de 2010, principalmente en pacientes con artritis reumatoide, la incidencia espontánea registrada de neoplasias malignas es de 2,7 por 1000 pacientes tratados/año, aproximadamente. La frecuencia espontánea registrada para cáncer de piel (tipo no melanoma) y linfomas es de aproximadamente 0,2 y 0,3 por 1000 pacientes tratados/año, respectivamente (ver sección 4.4).</span></p><p><span> </span></p><p><span>Durante la comercialización se han notificado casos raros de linfoma hepatoesplénico de células T en pacientes tratados con adalimumab (ver sección 4.4).</span></p><p><span> </span></p><p><em><span>Autoanticuerpos</span></em></p><p><em><span> </span></em></p><p><span>Se analizaron muestras séricas a distintos tiempos de los pacientes para la detección de autoanticuerpos en los ensayos I-V de artritis reumatoide. En dichos ensayos, el 11,9 % de los pacientes tratados con adalimumab y el 8,1 % de los pacientes tratados con placebo y control activo que tuvieron títulos de anticuerpos antinucleares basales negativos dieron títulos positivos en la semana 24. Dos pacientes de los 3.441 tratados con adalimumab en todos los ensayos de artritis reumatoide y artritis psoriásica desarrollaron signos clínicos que sugerían un síndrome tipo lupus de reciente aparición. Los pacientes mejoraron tras interrumpir el tratamiento. Ningún paciente desarrolló lupus, nefritis o síntomas a nivel del sistema nervioso central.</span></p><p><span> </span></p><p><em><span>Efectos hepatobiliares</span></em></p><p><em><span> </span></em></p><p><span>En los ensayos clínicos contr</span><span>olados fase 3 de adalimumab en pacientes con artritis reumatoide y artritis psoriásica con un rango de duración del periodo de control de 4 a 104 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 3,7% de los pacientes tratados con adalimumab y en un 1,6% de los pacientes del grupo control.</span></p><p><span> </span></p><p><span>En los ensayos clínicos controlados fase 3 de adalimumab en pacientes de 4 a 17 años con artritis idiopática juvenil poliarticular y en pacientes de 6 a 17 años con artritis asociada a entesitis, se produjo un aumento de ALT≥ 3 SLN en un 6,1% de los pacientes tratados con adalimumab y en un 1,3% de los pacientes del grupo control. La mayoría de los aumentos de ALT se produjeron con el uso en combinación con metotrexato. No se produjeron aumentos de la ALT≥ 3 SLN en los ensayos de fase 3 de adalimumab en pacientes con artritis idiopática juvenil poliarticular de 2 a 4 años de edad.</span></p><p><span> </span></p><p><span>En los ensayos clínicos controlados fase 3 de adalimumab en pacientes con enfermedad de Crohn y colitis ulcerosa con un rango de duración del periodo de control de 4 a 52 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 0,9% de los pacientes tratados con adalimumab y en un 0,9% de los pacientes del grupo control.</span></p><p><span> </span></p><p><span>En los ensayos Fase 3 de adalimumab en pacientes con enfermedad de Crohn pediá</span><span>trica en los que se evaluó la eficacia y la seguridad de dos pautas de administración ajustadas por peso corporal en mantenimiento tras un tratamiento de inducción ajustado por peso corporal hasta 52 semanas de tratamiento, se observaron aumentos de la ALT ≥ 3 sobre el límite normal en el 2,6% (5/192) de los pacientes, 4 de los cuales recibieron inmunosupresores concomitantes inicialmente.</span></p><p><span> </span></p><p><span>En los ensayos clínicos controlados fase 3 de adalimumab en pacientes con psoriasis en placas con un rango de duración del periodo de control de 12 a 24 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 1,8% de los pacientes tratados con adalimumab y en un 1,8% de los pacientes del grupo control.</span></p><p><span>No se produjeron aumentos de ALT≥3 SLN en los ensayos clínicos fase 3 de adalimumab en pacientes pediátricos con psoriasis en placas.</span></p><p><span> </span></p><p><span>En ensayos controlados con adalimumab (dosis ini</span><span>cial de 160 mg en la semana 0 y 80 mg en la semana 2, seguido de 40 mg semanales a partir de la semana 4), se produjeron aumentos de ALT ≥ 3 SLN en un 0,3% de los pacientes tratados con adalimumab y un 0,6% de los pacientes del grupo control, en pacientes con hidradenitis supurativa con una duración del periodo control de 12 a 16 semanas.</span></p><p><span> </span></p><p><span>En los ensayos clínicos controlados con adalimumab (dosis inicial de 80 mg en la semana 0 seguido de 40 mg en semanas alternas comenzando en la semana 1) en pacientes adultos con uveítis hasta 80 semanas con una exposición media de 166,5 días y 105,0 días para pacientes en tratamiento con adalimumab y pacientes control respectivamente, se produjeron aumentos de ALT ≥ 3 SLN en un 2,4% de los pacientes en tratamiento con adalimumab y en un 2,4% en los pacientes control.</span></p><p><span> </span></p><p><span>En el ensayo controlado de fase 3 de adalimumab en pacientes pediátricos con colitis ulcerosa (N = 93), que evaluó la eficacia y la seguridad de una dosis de mantenimiento de 0,6 mg/kg (máximo de 40 mg) en semanas alternas (N = 31) y de una dosis de mantenimiento de 0,6 mg/kg (máximo de 40 mg) cada semana (N = 32), tras una dosis de inducción ajustada al peso corporal de 2,4 mg/kg (máximo de 160 mg) en la semana 0 y la semana 1, y de 1,2 mg/kg (máximo de 80 mg) en la semana 2 (N = 63), o una dosis de inducción de 2,4 mg/kg (máximo de 160 mg) en la semana 0, placebo en la semana 1, y 1,2 mg/kg (máximo de 80 mg) en la semana 2 (N = 30), se produjeron aumentos de ALT ≥ 3 SLN en un 1,1% (1/93) de los pacientes.</span></p><p><span> </span></p><p><span>En los ensayos clínicos de todas las indicaciones, los pacientes con ALT elevada fueron asintomáticos y en la mayoría de los casos estos aumentos fueron transitorios y se resolvieron en el curso del tratamiento. Sin embargo, en pacientes que han recibido adalimumab, se han notificado además casos de fallo hepático, así como afecciones hepáticas menos graves que pueden preceder a la insuficiencia hepática, tales como hepatitis, incluida la hepatitis autoinmune, en el periodo de poscomercialización.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Tratamiento concomitante con azatioprina/6-mercaptopurina</span></span></p><p><span> </span></p><p><span>En estudios de enfermedad de Crohn con pacientes adultos, se vieron mayores incidencias de neoplasias malignas y efectos adversos relacionados con infecciones graves con la combinación de adalimumab y azatioprina/6-mercaptopurina comparado con adalimumab solo.</span></p><p><span> </span></p></div></text><section id="d8bd38ab-d042-4208-8485-e33e720f2083"><title value="4.8.2. Notificación de sospechas de reacciones adversas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029818" /><display value="Notificación de sospechas de reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span>Es importante notificar sospechas de reacciones adversas al medicamento tras su autorización. Ello permite una supervisión continuada de la relación beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del</span><span>sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="text-decoration: underline"><span>Apéndice V</span></span></a><span>.</span></p><p><span> </span></p></div></text></section></section><section id="7726ee53-ebee-4ec8-95ac-1a6ee3a6b464"><title value="4.9. Sobredosis" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029819" /><display value="4.9 Sobredosis" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>No se observó toxicidad limitante de la dosis durante los ensayos clínicos en pacientes. El nivel de dosis más alto evaluado ha sido la administración intravenosa repetida de dosis de 10 mg/kg, que supone aproximadamente 15 veces la dosis recomendada.</span></p><p ><span> </span></p></div></text></section></section><section id="a9c9d5ee-7b5d-4121-b422-946ab721ed0a"><title value="5. Propiedades farmacológicas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029821" /><display value="5. PROPIEDADES FARMACOLÓGICAS" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="b0472768-02fe-4313-abe6-19b669520bd3"><title value="5.1. Propiedades farmacodinámicas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029822" /><display value="5.1 Propiedades farmacodinámicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>Grupo farmacoterapéutico: Inmunosupresores, inhibidores del Factor de Necrosis Tumoral alfa (TNF-α). Código ATC: L04AB04</span></p><p ><span> </span></p><p ><span>Idacio es un medicamento biosimilar. La información detallada sobre este medicamento está disponible en la página web de la Agencia E</span><span>uropea de Medicamentos</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline"><span>http://www.ema.europa.eu</span></span></a></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Mecanismo de acción</span></span></p><p ><span> </span></p><p ><span>Adalimumab se une específicamente al TNF (Factor de necrosis tumoral) y neutraliza su función biológica al bloquear su interacción con los receptores p55 y p75 del TNF en la superficie celular.</span></p><p ><span> </span></p><p ><span>Adalimumab también modula la respuesta biológica inducida o regulada por el TNF, incluyendo cambios en los niveles de las moléculas de adhesión responsables de la migración leucocitaria (ELAM-1, VCAM-1, e ICAM-1 con una CI50 de 0,1-0,2 nM).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Efectos farmacodinámicos</span></span></p><p ><span> </span></p><p ><span>Tras el tratamiento con adalimumab, se observó una rápida disminución de los niveles de los componentes de fase aguda de inflamación (proteína C reactiva, PCR) y velocidad de sedimentación globular (VSG)) y de las citoquinas plasmáticas (IL-6) comparado con el inicial en pacientes con artritis reumatoide. Los niveles plasmáticos de metaloproteinasas de la matriz (MMP-1 y MMP-3) que participan en la remodelación tisular responsable de la destrucción del cartílago también disminuyeron tras la administración de adalimumab. Los pacientes tratados con adalimumab generalmente experimentaron mejorías en los signos hematológicos de inflamación crónica.</span></p><p ><span> </span></p><p ><span>En pacientes con artritis idiopática juvenil poliarticular, enfermedad de Crohn, colitis ulcerosa e hidradenitis supurativa se ha observado un rápido descenso en los niveles de Proteína C reactiva (PCR), después del tratamiento con adalimumab. En pacientes con enfermedad de Crohn se observó una reducción en el número de células que expresan marcadores inflamatorios en el colon, incluyendo una reducción significativa en la expresión del TNF</span><span>?</span><span>. Los estudios endoscópicos de la mucosa intestinal han mostrado evidencias de cicatrización de mucosa en pacientes tratados con adalimumab.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Eficacia clínica y seguridad</span></span></p><p ><span> </span></p><p ><em><span>Artritis reumatoide</span></em></p><p ><em><span> </span></em></p><p ><span>Adalimumab se evaluó en más de 3.000 pacientes en el conjunto de los ensayos clínicos de artritis reumatoide. La eficacia y seguridad de adalimumab en el tratamiento de la artritis reum</span><span>atoide fue evaluada mediante cinco ensayos aleatorios, doble ciego y controlados. Algunos de estos pacientes fueron sometidos a tratamiento durante un máximo de 120 meses.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide I se evaluaron 271 pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años, que no habían respondido al tratamiento con al menos un fármaco antirreumático modificador de la enfermedad y mostraban una respuesta no suficientemente eficaz al metotrexato a dosis entre 12,5 y 25 mg (10 mg si</span><span>no toleraban el metotrexato) semanales y cuyas dosis de metotrexato se mantuvieron fijas de 10 a 25 mg semanales. Se administraron dosis de 20, 40 y 80 mg de adalimumab o de placebo en semanas alternas durante un periodo de 24 semanas.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide II se evaluaron 544 pacientes con artritis reumatoide activa moderada a grave con edades</span><span>?</span><span> </span><span>18 años, que no habían respondido al tratamiento con al menos un fármaco antirreumático modificador de la enfermedad.</span></p><p ><span>Se administraron dosis de 20 o de 40 mg de adalimumab mediante inyección subcutánea en semanas alternas con placebo en las semanas intermedias, o cada semana durante un periodo de 26 semanas; el placebo se administró cada semana durante el mismo periodo. No se permitió el tratamiento con ningún otro fármaco antirreumático modificador de la enfermedad.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide III se evaluaron</span><span>619 pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años, y que mostraban una respuesta ineficaz al metotrexato a dosis entre 12,5 y 25 mg o mostraron intolerancia a 10 mg de metotrexato semanales. Había tres grupos en este ensayo. Al p</span><span>rimero se le administraron inyecciones de placebo durante 52 semanas. Al segundo se le administraron 20 mg de adalimumab semanales durante 52 semanas. Al tercero se le administraron 40 mg de adalimumab en semanas alternas, con inyecciones de placebo en las semanas intermedias. Una vez completadas las primeras 52 semanas, 457 pacientes fueron incluidos en una fase de extensión abierta en la cual se administraron 40 mg de adalimumab/MTX en semanas alternas durante un máximo de 10 años.</span></p><p ><span> </span></p><p ><span>En el ensayo de artrit</span><span>is reumatoide IV se evaluó fundamentalmente la seguridad en 636 pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años. Los pacientes podían bien no haber sido tratados previamente con fármacos antirreumáticos modificadores de la enfermeda</span><span>d o bien seguir con su tratamiento reumatológico anterior, siempre y cuando hubiese sido un tratamiento continuado durante al menos 28 días. Estos tratamientos incluyen metotrexato, leflunomida, hidroxicloroquina, sulfasalazina y/o sales de oro. Los pacientes se aleatorizaron a los grupos de tratamiento con 40 mg de adalimumab o placebo en semanas alternas durante un periodo de 24 semanas.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide V se evaluaron 799 pacientes adultos sin tratamiento previo con metotrexato con artritis reumatoide temprana moderada a grave (duración media de la enfermedad menor de 9 meses). Este ensayo evaluó la eficacia de adalimumab 40 mg administrado en semanas alternas en tratamiento combinado con metotrexato, adalimumab 40 mg administrado en semanas alternas en monoterapia y la monoterapia con metotrexato en la reducción de los signos, síntomas y velocidad de progresión del daño articular en la artritis reumatoide durante 104 semanas. Tras completar las primeras 104 semanas, se incluyeron 497 pacientes en una fase de extensión abierta en la que se administraron 40 mg de adalimumab en semanas alternas hasta un periodo de 10 años.</span></p><p ><span> </span></p><p ><span>La variable principal de los ensayos de artritis reumatoide I, II y III, y la secundaria del ensayo de artritis reumatoide IV era el porcentaje de pacientes que alcanzaron una respuesta ACR 20 en la semana 24 o en la 26. La variable principal del ensayo de artritis reumatoide V era el porcentaje de pacientes que alcanzaron una respuesta ACR 50 en la semana 52. Los ensayos de artritis reumatoide III y V tenían otra variable principal adicional a las 52 semanas, el retraso en la progresión de la enfermedad (detectado por medio de rayos-X). El ensayo de artritis reumatoide III tenía también la variable principal de cambios en la calidad de vida.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Respuesta ACR</span></span></em></p><p ><em><span> </span></em></p><p ><span>El porcentaje de pacientes tratados con adalimumab que alcanzaron respuestas ACR 20, 50 y 70 fue constante durante los ensayos de artritis reumatoide I, II y III. Los resultados de los pacientes que recibieron dosis de 40 mg en semanas alternas se resumen en la Tabla 8.</span></p><p ><span> </span></p><p ><strong><span>                                                             </span></strong><strong><span>Tabla 8</span></strong></p><p ><strong><span>                          </span></strong><strong><span>Respuestas ACR en ensayos controlados con placebo</span></strong></p><p ><strong><span>                                                 </span></strong><strong><span>(porcentaje de pacientes)</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="567" height="242" alt="" /></p><p ><span>a</span><span>Ensayo de artritis reumatoide I a las 24 semanas, ensayo de artritis reumatoide II a las 26 semanas, y ensayo de artritis reumatoide III a las 24 y 52 semanas</span></p><p ><span>b</span><span>40 mg adalimumab administrados en semanas alternas</span></p><p ><span>c</span><span>MTX = metotrexato</span></p><p ><span>**p&lt;0,01, adalimumab versus placebo</span></p><p ><span> </span></p><p ><span>En los ensayos de artritis reumatoide I-IV, todos los componentes individuales de los criterios de respuesta ACR (número de articulaciones doloridas e inflamadas, valoración por parte del médico y del paciente de la actividad de la enfermedad y dolor, resultados del índice de discapacidad (HAQ) y valores PCR (mg/dl)) mejoraron a las 24 o 26 semanas comparado con placebo. En el ensayo de artritis reumatoide III, estas mejorías se mantuvieron durante 52 semanas.</span></p><p ><span> </span></p><p ><span>En la fase de extensión abierta del ensayo III de AR, la mayoría de los pacientes con respuesta ACR mantuvieron esta respuesta a los 10 años. De 207 pacientes que fueron aleatorizados a adalimumab 40 mg en semanas alternas, 114 pacientes continuaron con adalimumab 40 mg en semanas alternas durante 5 años. De estos, 86 pacientes (75,4%) tenían respuesta ACR 20; 72 pacientes (63,2%) tenían respuesta ACR 50; y 41 pacientes (36%) tenían respuesta ACR 70. De 207 pacientes, 81 continuaron con adalimumab 40 mg en semanas alternas durante 10 años. De estos, 64 pacientes (79,0%) tenían respuesta ACR 20; 56 pacientes (69,1%) tenían respuesta ACR 50; y 43 pacientes (53,1%) tenían respuesta ACR 70.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide IV, la respuesta ACR 20 en pacientes tratados con adalimumab y cuidados estándar fue mejor de forma estadísticamente significativa que en pacientes tratados con placebo y cuidados estándar (p&lt;0,001).</span></p><p ><span> </span></p><p ><span>En los ensayos de artritis reumatoide I-IV, los pacientes tratados con adalimumab alcanzaron respuestas ACR 20 y 50 estadísticamente significativas comparado con placebo tan solo una a dos semanas después de iniciar el tratamiento.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide V con pacientes con artritis reumatoide temprana sin tratamiento previo con metotrexato, el tratamiento combinado con adalimumab y metotrexato resultó en a una respuesta ACR significativamente mayor y más rápida que en la monoterapia con metotrexato y en la monoterapia con adalimumab en la semana 52 y dichas respuestas se mantuvieron en la semana 104 (ver Tabla 9).</span></p><p ><span> </span></p><p ><strong><span>                                                            </span></strong><strong><span>Tabla 9</span></strong></p><p ><strong><span>                      </span></strong><strong><span>Respuestas ACR en el Ensayo de artritis reumatoide V</span></strong></p><p ><strong><span>                                               </span></strong><strong><span>(Porcentaje de pacientes)</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="567" height="327" alt="" /></p><p ><span> </span></p><p ><span>En la extensión abierta del ensayo de artritis reumatoide V, se mantuvieron las respuestas ACR tras un seguimiento de hasta un periodo de 10 años. De los 542 pacientes que fueron aleatorizados a recibir adalimumab 40 mg en semanas alternas, 170 pacientes continuaron con adalimumab 40 mg en semanas alternas hasta completar 10 años de tratamiento. Entre esos, 154 pacientes (90,6%) obtuvieron respuestas ACR 20; 127 pacientes (74,7%) obtuvieron respuestas ACR 50; y 102 pacientes (60,0%) obtuvieron respuestas ACR 70.</span></p><p ><span> </span></p><p ><span>En la semana 52, el 42,9 % de los pacientes que recibieron tratamiento combinado adalimumab/metotrexato alcanzó la remisión clínica (DAS28 (PCR) &lt; 2,6) comparado con el 20,6 % de los pacientes en monoterapia con metotrexato y el 23,4 % de los pacientes en monoterapia con adalimumab. La combinación adalimumab/metotrexato era clínica y estadísticamente superior a la monoterapia con metotrexato (p&lt;0,001) y a la monoterapia con adalimumab (p &lt;0,001) a la hora de reducir la gravedad de la enfermedad en pacientes diagnosticados con artritis reumatoide reciente moderada a grave. La respuesta a las dos monoterapias fue similar (p=0,447). De los 342 sujetos inicialmente aleatorizados a recibir adalimumab en monoterapia o la combinación adalimumab/metotrexato que se incluyeron en la extensión abierta del estudio, 171 sujetos completaron 10 años de tratamiento con adalimumab. Entre esos, se reportó que 109 sujetos (63,7%) estaban en remisión a los 10 años.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Respuesta radiográfica</span></span></em></p><p ><em><span> </span></em></p><p ><span>En el ensayo de artritis reumatoide III, en el que los pacientes tratados con adalimumab habían tenido artritis reumatoide durante una media de 11 años, se valoró radiográficamente el daño estructural en las articulaciones y se expresó como el cambio en el Índice Total de Sharp modificado y sus componentes, el índice de erosión y el índice de estrechamiento del espacio articular. Los pacientes tratados con adalimumab/metotrexato demostraron una progresión radiográfica significativamente menor que los pacientes tratados sólo con metotrexato a los 6 y 12 meses (ver Tabla 10).</span></p><p ><span> </span></p><p ><span>En la extensión abierta del estudio de artritis reumatoide III, la reducción en la frecuencia de la progresión del daño estructural se mantuvo durante 8 y 10 años en un subgrupo de pacientes. A los 8 años se evaluaron radiográficamente 81 de los 207 pacientes tratados con adalimumab 40 mg en semanas alternas. De los pacientes analizados, 48 no mostraron progresión del daño estructural, definido como un cambio desde el basal en el índice total de Sharp modificado de 0,5 o menos. A los 10 años, 79 de 207 pacientes originalmente tratados con 40 mg de adalimumab en semanas alternas se evaluaron radiográficamente. De estos, 40 pacientes no mostraron progresión del daño estructural definido por un cambio desde el basal en el índice total de Sharp modificado de 0,5 o menos.</span></p><p ><span> </span></p><p ><strong><span>                                                                </span></strong><strong><span>Tabla 10</span></strong></p><p ><strong><span> </span></strong><strong><span>Cambios radiográficos medios durante 12 meses en el Ensayo de artritis reumatoide III</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="567" height="105" alt="" /></p><p ><span>a</span><span>metotrexato</span></p><p ><span>b</span><span>IC 95 % para las diferencias en el cambio de los índices entre metotrexato y adalimumab.</span></p><p ><span>c</span><span>Basado en análisis de rango</span></p><p ><span>d</span><span>Estrechamiento del espacio articular (JSN, por sus siglas en inglés)</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide V, el daño estructural en las articulaciones se valoró radiográficamente y se expresó como cambio en el Índice Total de Sharp modificado (ver Tabla 11).</span></p><p ><span> </span></p><p ><strong><span>                                                                        </span></strong><strong><span>Tabla 11</span></strong></p><p ><strong><span>  </span></strong><strong><span>Principales cambios radiográficos en la semana 52 en el ensayo de artritis reumatoide V</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="567" height="171" alt="" /></p><p ><span>a</span><span>valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con metotrexato y la terapia combinada con adalimumab/metotrexato usando el test de Mann-Whitney U.</span></p><p ><span>b</span><span>valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la terapia combinada con adalimumab/metotrexato usando el test de Mann-Whitney U.</span></p><p ><span>c</span><span>valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la monoterapia con metotrexato usando el test de Mann-Whitney U.</span></p><p ><span> </span></p><p ><span>En las siguientes 52 semanas y en las 104 semanas de tratamiento, el porcentaje de pacientes sin progresión (cambio de la línea base del Índice Total de Sharp≤ 0,5) fue significativamente mayor con el tratamiento combinado adalimumab/metotrexato (63,8 % y</span><span>61,2 % respectivamente) comparado con la monoterapia con metotrexato (37,4 % y 33,5 % respectivamente, p&lt;0,001) y con la monoterapia con adalimumab (50,7 %, p&lt;0,002 y 44,5 %, p&lt;0,001 respectivamente).</span></p><p ><span> </span></p><p ><span>En la extensión abierta del ensayo de artritis reumatoide V, el cambio medio desde la basal en el Índice Total de Sharp modificado a los 10 años fue de 10,8, 9,2 y 3,9 en los pacientes inicialmente aleatorizados a recibir metotrexato en monoterapia, adalimumab en monoterapia y la combinación adalimumab/metotrexato respectivamente. La proporción correspondiente de pacientes sin progresión radiográfica fue de 31,3%, 23,7% y 36,7% respectivamente.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Calidad de vida y rendimiento físico</span></span></em></p><p ><em><span> </span></em></p><p ><span>La calidad de vida relacionada con la salud y el rendimiento físico se evaluaron usando el índice de discapacidad del Cuestionario de Evaluación del Estado de Salud (HAQ, por sus siglas en inglés) en los cuatro ensayos originales controlados, siendo este uno de los objetivos fundamentales a la semana 52 en el ensayo de artritis reumatoide III. En los cuatro ensayos, todas las dosis/pautas de adalimumab mostraron de forma estadísticamente significativa superioridad en la mejoría en el índice de discapacidad del HAQ desde el nivel basal hasta el mes 6 comparado con placebo, y en el ensayo de artritis reumatoide III se observó lo mismo a la semana 52. Los resultados del Cuestionario de Salud Abreviado (SF 36, por sus siglas en inglés) para todas las dosis/pautas de adalimumab en los cuatro ensayos respaldan estos hallazgos, con unos resultados del resumen del componente físico (PCS, por sus siglas en inglés) estadísticamente significativos, así como unos resultados estadísticamente significativos en la escala de dolor y de la vitalidad para la dosis de 40 mg en semanas alternas. Se ha observado una disminución estadísticamente significativa de la fatiga, medida mediante la escala de valoración funcional del tratamiento de enfermedades crónicas (FACIT, por sus siglas en inglés) en los tres ensayos en los que se evaluó (ensayos de artritis reumatoide I, III, IV).</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide III, la mayoría de los pacientes que consiguieron mejora en la función física y continuaron el tratamiento, mantuvieron la mejora durante las 520 semanas (120 meses) de tratamiento abierto. La mejora en la calidad de vida se midió hasta la semana 156 (36 meses) manteniéndose a lo largo de este periodo de tiempo.</span></p><p ><span> </span></p><p ><span>En el ensayo de artritis reumatoide V, la mejoría en el índice de discapacidad del Cuestionario HAQ y del componente físico del SF 36 mostró una mejora superior (p&lt;0,001) para la combinación adalimumab/metotrexato frente a la monoterapia con metotrexato y la monoterapia con adalimumab en la semana 52, que se mantuvo en la semana 104. Entre los 250 sujetos que completaron la extensión abierta del estudio, las mejorías en la función física se mantuvieron durante los 10 años de tratamiento.</span></p><p ><span> </span></p><p ><em><span>Espondiloartritis axial</span></em></p><p ><em><span> </span></em></p><p ><em><span style="text-decoration: underline"><span>Espondilitis anquilosante (EA)</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó el tratamiento con adalimumab 40 mg cada 2 semanas mediante dos ensayos aleatorizados, doble-ciego controlados con placebo de 24 semanas de duración en 393 pacientes con espondilitis anquilosante activa (la media de partida de la actividad basal de la enfermedad según el índice funcional de Bath (BASDAI, por sus siglas en inglés) fue de 6,3 en todos los grupos) que habían presentado una respuesta inadecuada a la terapia convencional. 79 pacientes (20,1%) fueron tratados concomitantemente con un fármaco antirreumático modificador de la enfermedad, y 37 pacientes (9,4 %) con glucocorticoides. Tras el periodo doble-ciego se continuó con un periodo abierto durante el cual los pacientes recibieron adalimumab 40 mg cada dos semanas por vía subcutánea, durante 28 semanas adicionales. Los pacientes (n = 215; 54,7 %) que no consiguieron una puntuación de 20 en el índice ASAS (Assessment in Ankylosing Spondylitis, o Evaluaciones en Espondilitis Anquilosante) a la semana 12, 16 o 20 recibieron prematuramente tratamiento de rescate con Adalimumab 40 mg subcutáneo administrado en semanas alternas y, posteriormente fueron considerados como no-respondedores en los análisis estadísticos doble ciego.</span></p><p ><span> </span></p><p ><span>En el ensayo de espondilitis anquilosante más amplio (I), con 315 pacientes, los resultados mostraron una mejora estadísticamente significativa de los signos y síntomas de la espondilitis anquilosante en pacientes tratados con adalimumab comparado con placebo. La primera respuesta significativa fue observada en la segunda semana y se mantuvo durante 24 semanas (Tabla 12).</span></p><p ><span> </span></p><p ><strong><span>                                                                           </span></strong><strong><span>Tabla 12</span></strong></p><p ><strong><span>                             </span></strong><strong><span>Respuesta de eficacia en el Ensayo I de espondilitis anquilosante</span></strong></p><p ><strong><span>                                                            </span></strong><strong><span>controlado con placebo.</span></strong></p><p ><strong><span>                                               </span></strong><strong><span>Reducción de signos y síntomas</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="506" height="337" alt="" /></p><p ><span>***, ** Estadísticamente significativa a p&lt;0,001, &lt;0,01 para todas las comparaciones entre adalimumab y placebo en las semanas 2, 12 y 24.</span></p><p ><span>a</span><span>Evaluaciones en Espondilitis Anquilosante</span></p><p ><span>b</span><span>Índice de Bath para la actividad de la enfermedad Espondilitis Anquilosante.</span></p><p ><span> </span></p><p ><span>Los pacientes tratados con adalimumab tienen una mejoría significativamente mayor en la semana 12, la cual se mantiene hasta la semana 24 tanto en el SF36 como en el Cuestionario de Calidad de Vida de Espondilitis anquilosante (ASQoL, por sus siglas en inglés).</span></p><p ><span> </span></p><p ><span>Se observaron tendencias similares (no todas estadísticamente significativas) en un ensayo de espondilitis anquilosante más pequeño aleatorizado, doble ciego, controlado con placebo (II) de 82 pacientes adultos con espondilitis anquilosante activa.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Espondiloartritis axial sin evidencia radiográfica de EA</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la seguridad y eficacia de adalimumab en dos ensayos aleatorizados, doble ciego, controlados con placebo en pacientes con espondiloartritis axial no radiográfica (EspA ax-nr). El ensayo EspA ax-nr I evaluó pacientes con EspA ax-nr activa. El ensayo EspA ax-nr II era un estudio de retirada de tratamiento en pacientes con EspA ax-nr activa que alcanzaron la remisión durante la fase abierta del tratamiento con adalimumab.</span></p><p ><span> </span></p><p ><span>Ensayo EspA ax-nr I</span></p><p ><span> </span></p><p ><span>En el ensayo EspA ax-nr I, se evaluó el tratamiento con adalimumab 40 mg en semanas alternas en un ensayo aleatorizado, doble ciego, controlado con placebo de 12 semanas de duración en 185 pacientes con EspA ax-nr activa (la media de partida de la actividad basal de la enfermedad según el índice funcional de Bath [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] fue de 6,4 en pacientes tratados con adalimumab y 6,5 en aquellos en placebo)</span><span>que presentaron respuesta insuficiente o intolerancia a ≥ 1 AINEs, o contraindicación para AINEs.</span></p><p ><span> </span></p><p ><span>Al inicio del ensayo treinta y tres (18%) pacientes fueron tratados concomitantemente con un fármaco antirreumático modificador de la enfermedad, y 146 (79%</span><span>) de los pacientes con AINEs. Tras el periodo doble ciego se continuó con un periodo de extensión abierto durante el cual los pacientes recibieron adalimumab 40 mg en semanas alternas por vía subcutánea durante un periodo adicional de 144 semanas. Los resultados de la Semana 12 mostraron una mejoría estadísticamente significativa de los signos y síntomas de la EspA ax-nr activa en pacientes tratados con adalimumab comparado con placebo (Tabla 13).</span></p><p ><span> </span></p><p ><strong><span>                                                                    </span></strong><strong><span>Tabla 13</span></strong></p><p ><strong><span>                          </span></strong><strong><span>Respuesta de eficacia en el ensayo de EspA ax-nr controlado con placebo</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="494" height="245" alt="" /></p><p ><span>a</span><span>Sociedad internacional de Evaluación de las Espondiloartritis</span></p><p ><span>b</span><span>Índice de Bath para la actividad de la enfermedad Espondilitis Anquilosante.</span></p><p ><span>c</span><span>Puntuación de la actividad de la enfermedad de Espondilitis Anquilosante</span></p><p ><span>d</span><span>Cambio medio a partir del valor basal</span></p><p ><span>e</span><span>n=91 placebo y n=87 adalimumab</span></p><p ><span>f</span><span>Proteína C Reactiva de alta sensibilidad (mg/L)</span></p><p ><span>g</span><span>n=73 placebo y n=70 adalimumab</span></p><p ><span>h</span><span>Consorcio de Canadá de Investigación de Espondiloartritis</span></p><p ><span>i</span><span>n=84 placebo y adalimumab</span></p><p ><span>j</span><span>n=82 placebo y n=85 adalimumab</span></p><p ><span>***, **, * Estadísticamente significativa a p&lt;0,001, &lt;0,01, y &lt; 0,05, respectivamente, para todas las comparaciones entre adalimumab y placebo.</span></p><p ><span> </span></p><p ><span>Durante la fase de extensión abierta, las mejoras de los signos y síntomas del tratamiento con Idacio se mantuvieron hasta la semana 156.</span></p><p ><span> </span></p><p ><span>Inhibición de la inflamación</span></p><p ><span> </span></p><p ><span>En los pacientes tratados con adalimumab se mantuvo una mejoría significativa de los signos de inflamación en las Articulaciones Sacroilíacas y Espinal, medido por PCR hs y RMN, hasta las semanas 156 y 104, respectivamente.</span></p><p ><span> </span></p><p ><span>Calidad de vida y rendimiento físico</span></p><p ><span> </span></p><p ><span>La calidad de vida relacionada con la salud y el rendimiento físico se evaluaron usando los cuestionarios HAQ-S y SF-36. Adalimumab mostró, de forma estadísticamente significativa, superioridad en la mejoría en el índice total del HAQ y en el índice del componente físico (PCS, por sus siglas en inglés) del SF-36 desde el nivel basal hasta la</span><span>semana 12 comparado con placebo. Se mantuvieron las mejoras en la calidad de vida relacionada con la salud y la función física durante la fase de extensión abierta hasta la semana 156.</span></p><p ><span> </span></p><p ><span>Ensayo EspA ax-nr II</span></p><p ><span> </span></p><p ><span>673 pacientes con EspA ax-nr activa (la media de partida de la actividad basal de la enfermedad [BASDAI] fue de 7,0) que tuvieron respuesta inadecuada a ≥ 2 AINEs, o intolerancia o contraindicación a AINEs participaron en la fase abierta del estudio EspA ax-nr II durante el cual recibieron adalimumab 40</span><span>mg cada dos semanas durante 28 semanas.</span></p><p ><span> </span></p><p ><span>Estos pacientes también presentaban evidencia objetiva de inflamación en RMN en las articulaciones sacroilíacas o vertebral o PCR-us elevado. Los pacientes que alcanzaron remisión sostenida durante al menos 12 semanas (n=305) (ASDAS &lt; 1,3 en las semanas 16, 20, 24, y 28) durante la fase abierta fueron posteriormente aleatorizados para continuar recibiendo tratamiento con adalimumab 40 mg cada dos semanas (n=152) o placebo (n=153) durante 40 semanas adicionales en la</span><span>fase de doble ciego controlada con placebo (duración total del estudio 68 semanas). A los pacientes que recayeron durante la fase de doble ciego se les administró tratamiento de rescate con adalimumab 40 mg cada dos semanas durante al menos 12 semanas.</span></p><p ><span> </span></p><p ><span>La variable principal de eficacia fue la proporción de pacientes sin recaída antes de la semana 68 del estudio. Se definió recaída como ASDAS ≥ 2,1 en dos de las visitas consecutivas con cuatro semanas de diferencia. Durante la fase de doble ciego, una mayo</span><span>r proporción de pacientes tratados con adalimumab no tuvo brote de enfermedad, comparado con los tratados con placebo (70,4% vs 47,1%, p&lt;0,001) (Figura 1).</span></p><p ><span> </span></p><p ><strong><span>               </span></strong><strong><span>Figura 1: Curvas de Kaplan-Meier que resumen el tiempo de recaída en el</span></strong></p><p ><strong><span>                                                      </span></strong><strong><span>Ensayo EspA ax-nr II</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="534" height="322" alt="" /></p><p ><span> </span></p><p ><span>Nota: P = Placebo (número en riesgo (con brote)); A = Adalimumab (número en riesgo (con brote)).</span></p><p ><span> </span></p><p ><span>Entre los 68 pacientes que recayeron en el grupo de retirada del tratamiento, 65 completaron 12 semanas de tratamiento de rescate con adalimumab, de los cuales 37 (56,9%) volvieron a entrar en remisión (ASDAS &lt; 1,3) después de 12 semanas de volver a empezar con el tratamiento en fase abierta.</span></p><p ><span> </span></p><p ><span>Antes de la semana 68, los pacientes que continuaron con el tratamiento con Idacio mostraron una mejoría mayor estadísticamente significativa de los signos y síntomas de la EspA ax-nr activa comparado con los pacientes asignados a la retirada del tratamiento durante la fase de doble ciego del ensayo (Tabla 14).</span></p><p ><span> </span></p><p ><strong><span>                                                            </span></strong><strong><span>Tabla 14</span></strong></p><p ><strong><span>       </span></strong><strong><span>Respuesta de eficacia en la fase controlada con placebo del ensayo EspA ax-nr II</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="567" height="120" alt="" /></p><p ><span>a</span><span>Sociedad internacional de Evaluación de las Espondiloartritis</span></p><p ><span>b</span><span>Base definida como punto de partida de la fase abierta cuando los pacientes presentan enfermedad activa.</span></p><p ><span>c</span><span>Puntuación de actividad de enfermedad de Espondilitis Anquilosante</span></p><p ><span>d</span><span>Brote parcial definido como ASDAS ≥ 1,3 pero &lt; 2,1 en 2 visitas consecutivas.</span></p><p ><span>***, ** Estadísticamente significativa p &lt; 0,001 y &lt; 0,01, respectivamente, en todas las comparaciones entre adalimumab y placebo.</span></p><p ><span> </span></p><p ><em><span>Artritis psoriásica</span></em></p><p ><em><span> </span></em></p><p ><span>Adalimumab, 40 mg admini</span><span>strado en semanas alternas, se ha estudiado en pacientes con artritis psoriásica activa moderada a grave en dos ensayos controlados con placebo (ensayos de artritis psoriásica I y II). El ensayo de artritis psoriásica I de 24 semanas de duración, incluyó a 313 pacientes adultos con una respuesta inadecuada a la terapia con antiinflamatorios no esteroideos, y de éstos el 50 % estaban tomando metotrexato. El ensayo de artritis psoriásica II, de 12 semanas de duración, incluyó a 100 pacientes con respuesta inadecuada al tratamiento con fármacos antirreumáticos modificadores de la enfermedad (DMARD, por sus siglas en inglés). Una vez finalizados ambos estudios, 383 pacientes se incluyeron en un ensayo de extensión abierto, en el que se administraron 40 mg de adalimumab en semanas alternas.</span></p><p ><span> </span></p><p ><span>No existe suficiente evidencia acerca de la eficacia de Idacio en pacientes con artropatía psoriásica similar a la espondilitis anquilosante, debido al bajo número de pacientes estudiados.</span></p><p ><span> </span></p><p ><strong><span>                                                                </span></strong><strong><span>Tabla 15</span></strong></p><p ><strong><span>                        </span></strong><strong><span>Respuesta ACR en ensayos de artritis psoriásica controlados con placebo</span></strong></p><p ><strong><span>                                                          </span></strong><strong><span>(Porcentaje de pacientes)</span></strong></p><p ><img src="data:image/jpg;base64,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" width="427" height="213" alt="" /></p><p ><span>***p&lt;0,001 en todas las comparaciones entre adalimumab y placebo</span></p><p ><span>*p&lt;0,05 en todas las comparaciones entre adalimumab y placebo</span></p><p ><span>N/A no aplicable</span></p><p ><span> </span></p><p ><span>Las respuestas ACR en el ensayo de artritis psoriásica I eran similares con o sin terapia concomitante con metotrexato</span></p><p ><span>Las respuestas ACR se mantuvieron en el ensayo de extensión abierto hasta la Semana 136.</span></p><p ><span> </span></p><p ><span>En los ensayos en artritis psoriásica se evaluaron los cambios radiográficos. Se obtuvieron radiografías de manos, muñecas y pies al inicio del ensayo y en la semana 24 durante el periodo doble ciego, en el que los pacientes estaban en tratamiento con adalimumab o con placebo, y también en la semana 48, durante la fase abierta del ensayo en la que todos los pacientes estaban en tratamiento con adalimumab. Se utilizó un Índice Total de Sharp modificado, que incluía las articulaciones interfalángicas distales (es decir, no es idéntico al Índice Total de Sharp usado para la artritis reumatoide).</span></p><p ><span> </span></p><p ><span>El tratamiento con adalimumab redujo la progresión del daño articular periférico comparado con el tratamiento con placebo. Esta reducción fue medida como el cambio en el Índice Total de Sharp modificado respecto a la situación basal (media ± SD) 0,8 ± 2,5 en el grupo de placebo (en la semana 24) frente a 0,0 ± 1,9, p&lt; 0,001, en el grupo de adalimumab (en la semana 48).</span></p><p ><span> </span></p><p ><span>De los pacientes en tratamiento con adalimumab que en la semana 48 de tratamiento no mostraron progresión radiográfica respecto a la situación basal (n = 102), el 84% tampoco mostró progresión radiográfica tras 144 semanas de tratamiento.</span></p><p ><span> </span></p><p ><span>En la semana 24 del ensayo, los pacientes tratados con adalimumab mostraron una mejoría estadísticamente significativa en el rendimiento físico comparados con el grupo placebo.</span></p><p ><span>Esta mejoría en el rendimiento físico se evaluó con los cuestionarios HAQ y de sa</span><span>lud abreviado SF 36 (Short Form Health Survey). La mejora en el rendimiento físico continuó durante la fase abierta de extensión del ensayo hasta la semana 136.</span></p><p ><span> </span></p><p ><em><span>Psoriasis</span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la seguridad y eficacia de adalimumab en pacientes adultos con psoriasis en placas (superficie corporal afectada (BSA, por sus siglas en inglés) ≥ 10 % e índice de gravedad y área de psoriasis (PASI, por sus siglas en inglés – Psoriasis Area and Severity Index)</span><span>?</span><span>12 o</span><span>?</span><span>10) que eran candidatos para tratamiento sistémico o fotot</span><span>erapia en ensayos doble ciego aleatorizados. El 73 % de los pacientes reclutados en los ensayos de psoriasis I y II habían recibido previamente tratamiento sistémico o fototerapia. Se estudió también la seguridad y eficacia de adalimumab en pacientes adultos con psoriasis crónica en placas de moderada a grave con psoriasis de mano y/o pie concomitante que eran candidatos para tratamiento sistémico en un ensayo aleatorizado doble-ciego (ensayo de psoriasis III).</span></p><p ><span> </span></p><p ><span>En el ensayo clínico Psoriasis I (REVEAL) se evaluaron 1.212 pacientes dentro de tres periodos de tratamiento. En el periodo A los pacientes recibieron placebo o una dosis inicial de 80 mg de adalimumab seguido de 40 mg en semanas alternas, comenzando en la semana 1 después de la dosis inicial. Después de 16 semanas de tratamiento, los pacientes que alcanzaron como mínimo una respuesta PASI 75 (mejora de la puntuación PASI de al menos el 75 % respecto al valor inicial), entraron en el periodo abierto B y recibieron 40 mg de adalimumab en semanas alternas. Los pacientes que mantuvieron una respuesta PASI 75 en la semana 33 y que habían sido aleatorizados inicialmente a tratamiento activo en el periodo A, fueron re-aleatorizados en el periodo C para recibir 40 mg de adalimumab en semanas alternas o placebo durante otras 19 semanas. Considerando todos los grupos de tratamiento, la puntuación PASI media inicial fue de 18,9 y la valoración global del médico al inicio (PGA – Physician´s Global Assesment) abarcó desde “moderado” (53 % de los pacientes incluidos) a “grave” (41 %) o “muy grave” (6 %)</span></p><p ><span> </span></p><p ><span>El ensayo clínico Psoriasis II (CHAMPION) comparó la eficacia y seguridad de adalimumab frente a metotrexato y placebo en 271 pacientes. Los pacientes recibieron placebo, una dosis inicial de metotrexato de 7,5 mg que se fue incrementando hasta la semana 12, con un máximo de 25 mg, o una dosis inicial de 80 mg de adalimumab seguida de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) durante 16 semanas. No se dispone de datos comparativos de adalimumab y metotrexato pasadas las 16 semanas de tratamiento. A los pacientes en tratamiento con metotrexato que consiguieron una respuesta superior o igual al PASI 50 a la semana 8 y/o 12 no se les realizaron incrementos adicionales de dosis. A lo largo de todos los grupos de tratamiento, la puntuación media PASI inicial era 19,7 y la puntuación PGA inicial comprendía desde “media” (&lt;1 %) a “moderada” (48 %), a “grave” (46 %) o a “muy grave” (6 %).</span></p><p ><span> </span></p><p ><span>Los pacientes que participaron en todos los estudios de psoriasis Fase 2 y Fase 3 fueron candidatos para ser incluidos en un estudio de extensión abierto, en el que recibieron adalimumab durante al menos 108 semanas adicionales.</span></p><p ><span> </span></p><p ><span>En los ensayos de psoriasis I y II, la variable principal de eficacia fue la proporción de pacientes que consiguieron respuesta PASI 75 respecto al valor inicial en la semana 16 (ver Tablas 16 y 17).</span></p><p ><span> </span></p><p ><strong><span>                                                                 </span></strong><strong><span>Tabla 16</span></strong></p><p ><strong><span>                                                      </span></strong><strong><span>Ensayo Ps I (REVEAL)</span></strong></p><p ><strong><span>                                            </span></strong><strong><span>Resultados de eficacia a las 16 semanas</span></strong></p><p ><img src="data:image/jpg;base64,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" width="479" height="235" alt="" /></p><p ><span> </span></p><p ><strong><span>                                                              </span></strong><strong><span>Tabla 17</span></strong></p><p ><strong><span>                                                  </span></strong><strong><span>Ensayo Ps II (CHAMPION)</span></strong></p><p ><strong><span>                                             </span></strong><strong><span>Resultad</span></strong><strong><span>os de eficacia a las 16 semanas</span></strong></p><p ><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAD+AegDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6RsE8Ua9qOtyw+LJdOgtNRktYoIrOFwqqqnqykk8mtD/hH/FX/Q/Xf/gvtv8A4ijwb/rfE3/Yan/9BSuqoA5X/hH/ABV/0P13/wCC+2/+Io/4R/xV/wBD9d/+C+2/+IrqqKAOV/4R/wAVf9D9d/8Agvtv/iKP+Ef8Vf8AQ/Xf/gvtv/iK6qigDlf+Ef8AFX/Q/Xf/AIL7b/4ij/hH/FX/AEP13/4L7b/4iuqooA5X/hH/ABV/0P13/wCC+2/+Io/4R/xV/wBD9d/+C+2/+IrqqKAOV/4R/wAVf9D9d/8Agvtv/iKP+Ef8Vf8AQ/Xf/gvtv/iK6qigDlf+Ef8AFX/Q/Xf/AIL7b/4ij/hH/FX/AEP13/4L7b/4iuqooA890e18Yalq/iKzl8czoml36WkZWwt8uptYJsn5euZiPoBWx/wj/ir/AKH67/8ABfbf/EUeF/8AkZ/HP/YZi/8ATdZ11VAHK/8ACP8Air/ofrv/AMF9t/8AEUf8I/4q/wCh+u//AAX23/xFdVRQByv/AAj/AIq/6H67/wDBfbf/ABFH/CP+Kv8Aofrv/wAF9t/8RXVUUAcr/wAI/wCKv+h+u/8AwX23/wARR/wj/ir/AKH67/8ABfbf/EV1VFAHK/8ACP8Air/ofrv/AMF9t/8AEUf8I/4q/wCh+u//AAX23/xFdVRQByv/AAj/AIq/6H67/wDBfbf/ABFH/CP+Kv8Aofrv/wAF9t/8RXVUUAcr/wAI/wCKv+h+u/8AwX23/wARR/wj/ir/AKH67/8ABfbf/EV1VFAHkl5e+Nrb4x6T4JXxpIbO90i41F5jYQeYrxyxoFHy4wQ57dq7H/hH/FX/AEP13/4L7b/4iuV1T/k6nwz/ANixff8ApRBXqlAHK/8ACP8Air/ofrv/AMF9t/8AEUf8I/4q/wCh+u//AAX23/xFdVRQByv/AAj/AIq/6H67/wDBfbf/ABFH/CP+Kv8Aofrv/wAF9t/8RXVUUAcr/wAI/wCKv+h+u/8AwX23/wARR/wj/ir/AKH67/8ABfbf/EV1VFAHK/8ACP8Air/ofrv/AMF9t/8AEUf8I/4q/wCh+u//AAX23/xFdVRQByv/AAj/AIq/6H67/wDBfbf/ABFH/CP+Kv8Aofrv/wAF9t/8RXVUUAcr/wAI/wCKv+h+u/8AwX23/wARXHa1e+NtN+K3hPwhF40ke11u1vriaZrCDfGYBEVC/LjB8w5z6CvW68r8Wf8AJyfw0/7B2sf+g29AHVf8I/4q/wCh+u//AAX23/xFH/CP+Kv+h+u//Bfbf/EV1VFAHK/8I/4q/wCh+u//AAX23/xFH/CP+Kv+h+u//Bfbf/EV1VFAHK/8I/4q/wCh+u//AAX23/xFI2g+KEQu/wAQLpVUZJNhbYA/74rq68z+LviC+0vw/wD2bDoOt6jZ3sMv2qbSbYytGoXhWORtBPU+gNTJ2Vyoq7LP2q4OiwayvxVZtPuH8uKdbK2KyNkjC/Jycg9PStGx03XtTsYr7T/iPPc20y7o5Y7G2ZWH12V82eCbu+u/CXwKItbq30631K5hlMybVd9jFGHqOSAfUGvXv2el1AfB27+1NJGp1K9Nsx6iPzGwRntnOKuXu83l/wAD/MhO9vP/AIP+R3v/AAj/AIq/6H67/wDBfbf/ABFH/CP+Kv8Aofrv/wAF9t/8RXz34Q+InxE1KP4eSXnjCeX/AISK+v7O6Bt4RtWP7jLhRhh69PapvC/xB+KnifRrSJNVmdjaanHHPZQxNcTXUUhWHepUhV5AzgDPUikPrb+v60Pfv+Ef8Vf9D9d/+C+2/wDiKyZpL638S23huf4oSx6vdRtNDaNYW4eRB1YfJyBUsWoeKPDPwQm1fXC2oeJLDSpLqcNtbfMqFtvyADGeOBXhGleINVu/ij8OPFmoas2tahceGL6+aPai7X2k+WoUDjIxzk0PSTXb/Jv9AWsb9/8ANf5n0R/wj/ir/ofrv/wX23/xFH/CP+Kv+h+u/wDwX23/AMRXC/B3xX4v8Y2mneItT1ewudMv7KRpbRZB50FyJOiqEG1QvBBJPTmvZKbVtxJ3OV/4R/xV/wBD9d/+C+2/+Io/4R/xV/0P13/4L7b/AOIrqqKQzlf+Ef8AFX/Q/Xf/AIL7b/4ij/hH/FX/AEP13/4L7b/4iuqooA8xm1fxVoPxl8JeFrrxEdV07WrO/nmE1pFGyNCItm0oB/z0OfoKKh8V/wDJynw1/wCwbrH/AKDb0UAdV4N/1vib/sNT/wDoKV1Vcr4N/wBb4m/7DU//AKCldVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvhf/kZ/HP8A2GYv/TdZ11Vcr4X/AORn8c/9hmL/ANN1nXVUAFFFFAEUt1bQMFmuIomPQO4BP50fabfCH7RHiQ4Q7h8309a8A+OFvDJ8a/hMf7Lj1B5Lq5VoGC/vhsXCktxj61yOqeCNc8EWPw9tdeuo5Jrnxr9pgto3LrZROjEQqx6gY7cUR1t62/FL9fwCXu/df8H/AJfifWVFeIL8ZtZtfiRpvh/U9Lsks726vrZ0hJeS38hC6sZAxViwHK4BXNS6b8XPElx4AuviRcaLYy+Fhp1zdoIZGWeKSORkSJskhtwAJIAx70rrl5ug7e9y9T2eSaKFN80iRr/edsCn18w/FnxP4l8TfAHXbjW9Djt7No7G7sr2NSiyF2BZMFmOVP8AFxkHoK6PVvjbrHg648XaRrmlWd3d6HZWt1ZyWm9ElEzBFRwSSCCRyOo7Cn1a6i7NdT3uivO/BXj6/wBc8c+IPBusW1uL7SILa5FxbKyRypKgbG1iSCDkdefavRKdhBRRRSGeV6p/ydT4Z/7Fi+/9KIK9UryvVP8Ak6nwz/2LF9/6UQV6pQBH9ot/P8jz4/N/ubhu/Khri3SYQvPGsjdELAE/hXzZ8Z7OTwp8QrL4u6XDtk0G9t4dRWMY821lTDE/Q/zqrqE0N5+1n4J8SXKb4b/Sru8iVxnEKo/lnB77Ru/GlF3t87/df8f8xvS/p+tv6+R9Q0V4fpPxW8YeJvCF54k0vQorfSpbG+mguzGWFpJCzBA/z/vNwU9AuD61l+C/iZ4rXwx8PtEmuLO+1nxLZT35vJ4H2wxxrnawD/OxY9QVAHaj+vz/AMmL+vy/zPoSivnHRvit4n8eePvhodLuINJsdVtry4urV4WlBki+RhkOpI67fQ9c1o/8Lg8cQnxzqMmkaPNo/g/UZre5cGSOWaFVJXaMsN2cZJ456U3pv5/g7Dt+n46nvtFeQJ44+JV94G1jWtN8PWPnwafFqNhLPE4iugU3SQ7RJu3Ds2cHjgUaT8Uda1T4SWfjy3h02WO+uIoghzGLRCwSRny53sGzhRgngU7WbXYm90n3PX6K+ZNc+LnjDXfBOny6fNa6VdjxeuhXEiQORMgYkMFL5XOOVyT7ium1j42atpFz4juP7Ps7jTvDOqWmk3nyOkty8pCvInzEIATwpDZHektf69P/AJJDen9ev+TPda8r8Wf8nJ/DT/sHax/6Db16lG6yRJIvR1DDPvXlviz/AJOT+Gn/AGDtY/8AQbegD1SiiigAoqOeR4raWSOPzHRCypnG4gdM9q8EtPjzqltrV1ba3pNm8EehTavttC2YpI3ZTDv3Msg4HzDH0pXS/r5/oO1z3zzofOEPmp5pGdm4bsfSkuFgktpY7oIYGUrIH+6VPXNfNGka5rmtfH/wJ4p1O2sTdaj4Vub2OG0DRgBhuVGZickcDdx9BV+6+K2reJ7bxD4S1bTrER3Xhe51ENbhj5LruRoyxYrIB/eXHI6UT92Ou+v4X/yCHvS020/G3+Z7fD4b8KroVroMGlWA0yL57e1RF2Lg5yo+p6itS30+xtNOXTrW1ihs0Ty1hRdqhfTFfM/w/wBTa31j4OWP2G1lkm8M3EkVzJ5nmQkAZGA4Ug8dRn3rV8N/Gzx1rH/CGNcafoar4mvrzT/kjlBgaE8Scucg919utXJatev52Ji7q/8AW1z2O3+Hfga1FkLbwrp0QsHaS12QAeSzfeK+hPeuF8T/AAJ8PavrVpc6ZY22nWNvC6C2s5pLMiR23M+6L72cdDWBovxv8T6rb+B2bTtMifXNXutJvMRyEKYujx/Pxn0OfrUNj8bPGd/4b8JX8dho63Wt+I5tElVopdiIrbQ6/PkH1zmpte1v6vZfqinpv/Vr/wCTPaPCPhx/Dfg2y8PXV/Nqf2dGRprhi7MCSdpJ5IAOOewplh4G8G6TeQ32neG9OtLiAMI5Y4FVow3LYPYGvHdM+N/iyX+y5r/S9KMEnilvDdwIVkDP0xKmWO37w+U7s+orZj+LmtN8StH8K6hpViLXV7q9smjjJd7cwgFWMgYq24HlcArRdv3l1/yT/VCty6Pp/wAFfoz1HQ/DnhjRZLm68P6TY2bXTlppLWNV8xs85Irbr5S+EPjnWfBfgrwlbPaWd1omu+IbrTWVQwuIXLkq4OdpXjpj8a9v+IPjyfwnqfhrRbC0We/1+8NtEzoXWMKpYnaCCxOAAMjrTelvu/L/ADDq/n+v+R31FeI6r8TvH9n4h8I6HJoem6Zea1aXktzFeI7mF4OQy7XHysMHB5967v4XeMbjx98MtH8VXlpHaXN7GTJFESUVgxBxnnHFJa3f9f1oJ6HZ0UUUDPK/Ff8Aycp8Nf8AsG6x/wCg29FHiv8A5OU+Gv8A2DdY/wDQbeigDqvBv+t8Tf8AYan/APQUrqq5Xwb/AK3xN/2Gp/8A0FK6qgAooooAKKKKACiiigAooooAKKKKACiiigDlfC//ACM/jn/sMxf+m6zrqq5Xwv8A8jP45/7DMX/pus66qgAooooA5PxF4A0PxP4o0PxHqUt4t9obtJZ+TNtVGbqSMc5xU/inwTo3i+50a41Zrnfo92L218mXYBKBgE8c8E/nW9eQrPYzwszqroVLRuUYcdmBBB9xXy7ofivxV4DeXwX8Q9e1G90vxFZi70LXJLqQSpKVBMDSA7geeOf50lvb5/P/AD0B7Xfp8j2Gw+CngbTdYs9VtYL4XFneTX0Ie7dlV5QRINp4wc9Ku6P8J/B2iWOrabZ2ty2maqJRNp8twz26iT7+xM4XNa/iDXf+EV8JQ6gqwTBPLj/0288kHI6mRg2T9etYPhb4kHxHr8elm10qPerNuttWW4fgf3Agz+dO28V6Bf7THw/CLwfH4Kl8Hzx3t5pDlP3VzdPIUVTlUUn7qg9hV0/DPwnNZ6zb31m9+2sxpFeTXL75JEQYQZ7beox3ryD41+ItUsfH0P8AazeONE8K2kMaNqugTNFBvYku0gXlsfKPbBrS+KWrXfhzxP4E1vT/ABtrlrZ32oQQucO9gbZl6SYGGdjjBJJ5J4oj71vN2B+78lc9e8PeDtF8NXt9f2Ecsl9f7BcXU775JAihUXPoAK6GgEEAjkGigAooooA8r1T/AJOp8M/9ixff+lEFeqV5Xqn/ACdT4Z/7Fi+/9KIK9UoA52/8HaPqq6zDqfn3ltrCLHc28r5jwowNoxxVC9+G/h2/8daZ4ymN0up6XAba2CS4iSMggrtxyCCa7GjtQBxGh/C7wn4dXU4NNhulstRMhksnuGaCMyDD7E6LnNRWvwn8J2WkaTp1qt5F/Y+8WVwLgmWBHXayBj/DjtXk+q+IfFnwu+JFz4k1jVtR1T4d6zfS2Nws1xJKdIcOVVlJJKqfb+gr2Tw5qEdj8MYtXiumv0W3e4Wa7vGYSDJIJlfcQMd+1JWcObpoN6S5SCH4WeD7S58OXFhZS2Unh1HjsjbylMI/3lb+9nGTU2m/DbwxpsXiaFYZ7mHxNM8+oRXEm9ZGYYbA7Vzum/Fpr/VLWy+xaIvnyLHmPXEkYZOOF8vk+1RfH/Wte8PfCmXV/D+sT6Zcx3ltEzQgZdXlVSMkZHB7YNN+fXT72hL8tfuOl0f4b6Fofhg+HdPu9TWxICASXbOyxg58oFs4Ttj0rIX4J+CV0O60RRqC2NxqI1XykuioiuAc7kx90Z7CsP40a94h0Pwz4OvNG1u4sftmsWVrcrFgGZHI3AtjI6dsVk/FLxhrsXxI1Pw3p+pXNhbaX4UuNYQ28hjL3ALBCSOoXb0PHJyKUna8n5/gub+vMIq9l6fi7f15Hbf8KX8EDSbjTVgvFhn1NdX3famLx3I/jUnkVoXnwt8IX+pzX1zZyv8AaJobm5g80+XcyxDEbuP4iOPrjmrnw58QXXir4ZeHvEN6oF1fWUcsuBgF8cnHua6qrknGXL2/T/hiU+ZX7gOBgcCvK/Fn/Jyfw0/7B2sf+g29eqV5X4s/5OT+Gn/YO1j/ANBt6ko9UooooAiureK8s57SdS0U8bRuAcZUjBrzrSfgh4C0a4tZre0u5fs9lLp6pcXTyK0EhJZCD25OKs6v8T7LTfidB4DisRNfukErGScRFkkfaWjBH7zaOSAQcVV0z4v6RrPiAabpthNcQSXVxZR3Ctn97COd6gfIpOQGPp0pab+v+X6j1Wn9d/0JdN+DPgzTL2zu4Vv5ZbKyk0+3867ZhHbvkGMe2DVew+BvgXTFQWa6ihTT5dLDG8Zj9nkOSvP149KwND+Pq62vhto/B1zEPEUlxBZk3aH95D1DccKfX9Kmj+P2mz+DU8RQeHbzC29zcTpI+1I/Ifa6CTBDOeoHGab8/wCt/wDN/eJb6f1/VvwOo074SeFdLvvD97aSX6y+H7N7GxzcZCRP1B45Pv7VV074LeDtLXQVs31FRoVzNd2WbnOySX75PHPSqmq/GKG01Lwzaab4dm1AeItNl1K3c3CxbFRNxVgR6dxVGf48aWPBOn+KLXQLyW3utOfUmEjeWqKjbWjD4IZ85IHHAoel7/1q/wBUwWtkuv8AX6m1a/BfwXZ6Rp+mwLfKunag+pW032k+ZHM/3yGx0PpTbT4K+DLHT9IsbdtQWDSNSbVbUG5JKzsckkkcjPaoYPjJpN/4u0zw7puntLPf2ltfIJ5hC7RTDOUUj5yoILAHP1rpfGPjJPCYsU/s2a8lvDIFYEpFHsQud74IXOMDjk0P3df60/4b8A+L+u//AA/4mAnwT8GxxRRK+o7YtXOuKPtP/L0cfN06cDin2HwW8EabrNjq1rFfLc2N5NfQE3blUkl+/gHjB9K4XxB8Q7jxPe/CDxJ4dvL/AE6y1rVHjntROyLKoRso4U4Ybh3FX/DPxsvH8OaprnijT4II2159HsI4p/vSBtu1srwBgsW5+lC7dv8A7Vf5Cb/H/wC2/wCCdxo3wp8H6HPpr2drO0WmTvdWkE0peOGZxhpAD/Ef61qeMPA+geOLK0t9bhm32U63NtcW8pilgkHRlYciuN1j402mk+FdN11vDt3MLvWP7FeAOFZJMsA6EjDqduQeM5FVtR+NGpaVrKaPqHgC8tb5tNutT8mW8jBWOBiDnGR8wGRgnqKTf9eiv+RXX+u9vzOsv/hn4d1LWNI1a4lv/tmkQS29vILgk4lGHLZzuY+ta3g/wlpPgfwta+G9D84WFrnyxNJvYZOTz9TXn2q/HjSdP8KWviSLQbyayl0yPVHZz5YEbvs2KxBDuOpXI4rXtfi1puo/EFPCOnWPmT7IJWM0wikMcqbhIiEfOq8A4ORnpVWd7f1/W5OlrnpNFFFIZ5X4r/5OU+Gv/YN1j/0G3oo8V/8AJynw1/7Busf+g29FAHVeDf8AW+Jv+w1P/wCgpXVVyvg3/W+Jv+w1P/6CldVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvhf/kZ/HP/AGGYv/TdZ11Vcr4X/wCRn8c/9hmL/wBN1nXVUAFFFFAEVwkslrLHBIsUrKQrsu4KfUjIz+dcXrXw30vxP8PbHwn4kkW9axERhu44vLaOSPG11GTg8c8813Nee6x8YvBehazq+k6lPeRT6OYftjC1ZkiEpwjFhxjNHW39aDO+WFPISF1DqoA+YZ6ULBDG25IUU+oUCuY8c+Mrfwf4NbXRGLmSaSK3tIs4EssrBUH05yfYGvOdY8ffEDSvinbeHVtFntEurCAqIMC6ilUmeYN/CIz+Axz1o3dvOxOyueg6x4R1jWtT1KO68UM/h7Urf7PNpUlojbBjDGOTIIyPUNVG4+Hc+pRy6TrWvnUfDn2mK4t9Pa1VHtxGQUjEgPKAgdVz71qaF4ibWNaurg3sEGmP+5sLdiokuipO+YZ5254AHoT3qGPxZJafFNvBOo7SbyyOoWEwGCyq22SM+4yCD6Z9KF0t/VtRvr/XkdgAAABwBRRRQAUUUUAeV6p/ydT4Z/7Fi+/9KIK9UryvVP8Ak6nwz/2LF9/6UQV6pQAUduKKKAOX/wCEQg1Dw3rHh/xJJBqtjqkszvGIPLCrIxO37xyQTweKv+GfD9r4X8Jad4btZGmtrCEQRtJ1Kjpmr2p6hb6TpF3ql3v+z2kTTSbF3NtUZOB34Fcj4Y+K3g/xdqljpuk3NyLjULM39qJ7doxNCGKkqT6EGhdl5fhe36g+7/r+tDtBbW6kEQRgjuFFch8TPAr/ABE8Gt4a/tb+zInnineUQeax8tw4AG4Y5FM1Xxjcn4hHwbosKy3Vppz6pdseTtztjiX3Zu/YD3rgfAHxT8V3wv7jxVY7oI7CKdVSHy2ju3ldPso9TwvXkd6W/wDXa/6oe39d/wDhztPHfw5uPHGh6DpkmurZf2TeQ3vmLa7/ADXi6DG8YH50vjD4Y2fizVv7X/tFrG/l02XSbmVIgwlt5OSACflYEnB5xnoa6TRLi+vPD5iutUtptWCt5xg2sLdySQmB/d6c9cVn+A/Fw8XaJdzSxLDf6beS6feRKeFljPJHsQQR9abV7r5/fo/8hLSz+X6r/M3dG0mx0HQrHRdNj8qzsYVghUnJCqMCr9FFNu7uxJWVkFeV+LP+Tk/hp/2DtY/9Bt69UryvxZ/ycn8NP+wdrH/oNvSGeqUUUUAeeeLPhhb+MPF+na3qWooINPuILqCNbb99E8ZyQs27IVuMrg9OOtN8J/DObwbqes/2T4muf7G1G5kvF02SBSIZn+8Q/wB4rnnbx9a9FopW0t/Wv/DBv/Xb/hzxTQ/gO2hx+EEi8Veb/wAIxc3NzFussecZuob5+MVn237OXk6SulSeOrxrPybyFoUtECn7QSSwDFsMM4z1x6V73RTA8mPwbk+2eErlPEx3eG9Lm02MNZg+cJE27jhxjAxx7Vgr+zv/AMU1pmgSeOL02Vjps+neWtqm1xIxbzMMThh0yOcDqKiuPid4s8F/F19L8aXCTeDNYuXs9O1IRKhs51ONshAwc+p9vevWvD19eL4Q/tDUrqXUplMrFkiUM4V2AAVQAeBR8Uebv/wf8/xD4Zcq6f1+hw7fBaC6bw1HqWuC7h8Pi1+zSCzEdwphXbhZA3CtgZXB6da6Px14Bk8a3mizL4hutLi02V5HgijWRLjcpX5g3GRnIODg1Yt/HtpcXMUC+H9ejMjBd0lgyqM9yc8Csn4zeLte8DfDO88SeHxaG4glijb7ShbAeRUyACORu70Sffv+LCK7dvwMLTvgeum6T4H02HxO7xeEr6S8hL2gzPuJ+U4YYwCeeaZP8BrKXwzqGiR+JruFZNYOt2E6QrvspyxY/wC+OcduKTxr8Stb07xPZ+GdIljt7keG7jXp52jD7mRTsTB4AJVs9/SuV1348alDpfhDWLgnQdG13R5bn7ekImX7aB8sJ3AgLkfU568UPq/6/q8fw8wSvb+v60l+J6X4q+G194t0DQNP1LxQ73WlalFqb3JtV/fvGCAoQMAi8+9R+LPhc/ijxufE39vfZG/se40jyPsu8bZQQXzvHI9K63whqGq6r4J0bUtcto7bU7q0jluIojlVcqCcVuU5R3i/P8rP8BRltJeX53/M8Iu/2dxfeHrbQ7jxxe/Y4NGGkCNbVCvD7xIAxO0ngHHJx1FdM3whhuvEegavqesrdNoTxPauloI5xsj2FDIG+4T823H416jRRd3v8/6+8LaW/r+tAooopDPK/Ff/ACcp8Nf+wbrH/oNvRR4r/wCTlPhr/wBg3WP/AEG3ooA6rwb/AK3xN/2Gp/8A0FK6quV8G/63xN/2Gp//AEFK6qgAooooAKKKKACiiigAooooAKKKKACiiigDlfC//Iz+Of8AsMxf+m6zrqq5Xwv/AMjP45/7DMX/AKbrOuqoAKKKKACvn7xv8G/GXiTWPiJdWFxo6Q+J4bOK1864lDR+S2WLgRHGR0wTX0DRStrcd7Hl3xU8KaprXwt02G0iE2oaJd2eoGGIlhL5JG9V4Gfl3Y4GcCuv1i1ufE2hWsOmXKQWd6V+1TZIl8gjLKnHDH7ucjAJ710VIqqo2qoA9BT3v63/AK+4W1rdFY8Z8RfB/VtS+Iq63peq29ppbSafII8sslqtqzHy4wBjDA+oxz1rZutEudd/aK0vxBCpGn+HdKmgkl7PPM3CD1woJPpxXp1IFVc7VAzycULS3lf8VYHrfzt+AtFFFABRRRQB5Xqn/J1Phn/sWL7/ANKIK9UryvVP+TqfDP8A2LF9/wClEFeqUAFFFFAGV4ksLrVPCmraZZeX9pu7WWCPzWKpuZSBkgEgc+hrx3wJ8I/F3hnxf4H1XUbjSXtvD+hyaXcCC4kZ3dnZgyAxgEYI6kd693ooWj5v66r9WD1Vv66f5HmK6Jc6H+0XP4mlUtp2v6Qtkso6RTxOCFb03KTj3Brqb7w9dar4kN7fTRpZWsLCyijJJWZlIaZuMbgDheuMk10hVW+8oPfmlpdFHtf8f+HH1b/r+tDx74a/DLWPAOsy6vrWs281tb6abICFmPnYnkl82TIGGw4GOe/Na/wh8P3uk6b4k1i+iaF/EGsz6lFEwwyRHaqZHYkLn8a9JZQylWAIPUGlqut/61d/zJ/r8LBRRRSGFeV+LP8Ak5P4af8AYO1j/wBBt69UryvxZ/ycn8NP+wdrH/oNvQB6pRRRQAUUUUAFFFFAHCal4Fj8W+D9f8M+L7G0NrqFzLLC1vM0jRhjlXyyLtcH0zWl4O8Kf8I/8ONO8I6tLHqa21ubaZ3G5Z1yeoPqOtdFeXlrp9jPfX1xHbWsCGSWaVtqoo5JJPQVl6T4u8L69ci20XxBp+ozmITiO2uFkYxk4DYB6e9C2aXl+APv/Wpn2/w38AWtzHc23g7SIZomDpIlogKkdCDisn4xeD9c8efDS88L6C1lHc3MsL+ZeStGihJFc/dRic7cVpeIPHNro+ty6LbW7Xl7bWEmp3SKf9TAnA+rMeAPYmuV8F/GOLxDa6pNq2mixWysLXUFaJi4dZ03LH/v5wMd80viXpr/AF934D2f9f11GeLPhfq+t6vY+INPmsYdUXQZ9CuY5ZX8vZIpAdWCZO0knBAzntWNffA24jsdM0u0lsdX0u08PyaN9k1F2RYpWYN9oTCt82evQ8DmvYbS61ebw4l5cWUUOpNF5n2bedqnqFJ9ex96g8LeJdP8WeHYNa07cschaOSN/vRSKdro3uCCKbV7r+uv+b+/0Enaz/rp/kiDwN4bfwf4B0TwxJetevptqkDTt/GQP5entXRUUU23J3YkrKyCiiikMKKKKAPK/Ff/ACcp8Nf+wbrH/oNvRR4r/wCTlPhr/wBg3WP/AEG3ooA6rwb/AK3xN/2Gp/8A0FK6qvONA8Nrqep+J7o65rFmTrMy+VaXjRRjCpztHet0eDIjnHinxEccH/iZNx+lAHVUVwWoab4c0m5S21T4ianYzuNyx3GtCNmHqAcGrtr4Vsr22S6s/GGvXMEgyskWqFlYexHBoA7CiuTj8H28sYkj8V+IXQ/xLqTEVRh0fQbh5Eg8fatK0Wd4TWMlcdc46dD+VAHdUVw2m6JoespJJpHj3V9QSNtrtbax5oU+h25waqSw+EINROmzfE6+jvQ/lm3fXVEgb+7tznPtQB6JRXAS6f4Zg1YaRN8RtSj1FmCi0fWwJST0GzOf0rV/4QuP/oaPEf8A4MW/woA6qiuV/wCELj/6GjxH/wCDFv8ACj/hC4/+ho8R/wDgxb/CgDqqK5X/AIQuP/oaPEf/AIMW/wAKP+ELj/6GjxH/AODFv8KADwv/AMjP45/7DMX/AKbrOuqrzDw34QSTxH40T/hJNfTytWjTK6gwLf6BaHLccnnGfQD0rpf+ELj/AOho8R/+DFv8KAOqorlf+ELj/wCho8R/+DFv8KP+ELj/AOho8R/+DFv8KAOqorgIdL0i48T3XhuLxd4lOo2tutzLGb5wAjMVBzjB5BqrDF4fn1ZdNj8YeJd7zvaxym+cRSTKMtGGxgsADx7GjcD0miuKvvDdlp4gE/irxH5lxIIoY11Fi0jdcAY9AT9BVSLTNHm8T3HhtPF3iX+0be3W6kjN84AjJwDnGDyKAPQKK83soNCv7y2toPFvif8A0t3S3la+cRzsmdwVsc9D+VT6tpml6PcR2tx4o8UTXMkbzLBb3ryP5a43PgDoMjn3oA9Borz+x03RdRex+yeMfEMiahD59rINRbbMuMnacdQOorW/4QuP/oaPEf8A4MW/woA6qiuV/wCELj/6GjxH/wCDFv8ACj/hC4/+ho8R/wDgxb/CgDldU/5Op8M/9ixff+lEFeqV4VqXhVF/aX8O2X/CQa4Q/hy9k843zGRcTwjaGxwDnkewr0v/AIQuP/oaPEf/AIMW/wAKAOqorlf+ELj/AOho8R/+DFv8Kr33he10+xlvLjxR4l8uIZIS/dmPsABkmgDsqK8t0648M6loeoavH4w8UW8OnS+RdR3N5JFLFJxhShGcncuPXIrT0nStL1i4u7W28U+J47qzZVnt5750kj3DKkgjoR0PsaAO/orgrrR9MtZ7mF/FfiV3tYxJMI7922A/dHA6nsOtZ2kt4d1nStS1G28WeKok0x2ju4ri7kjlhYDOCpGeR09aAPTqK868OafYeJrKW7stc8ZWscb7MXtxLAzHGcgMMke9QXEekQeLI/DS694ynu3wGlgnleGIkZw8gG1TjnB9RR1sHmemUVxNj4dsdQ89YPFXiQSW8himjbUWDRt6EY9Oauf8IXH/ANDR4j/8GLf4UAdVXlfiz/k5P4af9g7WP/Qbeuq/4QuP/oaPEf8A4MW/wrzTxP4VSP8AaE+Hlp/wkGuOJtP1VvNe+YyJtWDhWxwDnn1wKAPdaK5X/hC4/wDoaPEf/gxb/Cj/AIQuP/oaPEf/AIMW/wAKAOqorlf+ELj/AOho8R/+DFv8KP8AhC4/+ho8R/8Agxb/AAoA6qiuJ1Tw9p+j6bJqGoeLfEcUEeAT/aDEkk4AAxySSBVWy0vSb0X3/FWeJbd7DBuUuL9o2iBXcCcjoRzmgDovGlrdX3gDxBY2Nu1zdXOnzwxRJjLu0bAAZ46mvDPhj4G8XaH8QPAd9qHhu4srTTvDL6feylo8JOZGYKcNk9ua9X0rQbDWrT7XY+J/FDWx+5K986rIPVcjke9U9Us9H0mK9km8UeKp/sQXzltrySVgzfdQADJY9cDtQvdd/wCtmv1B+8rf10/yM3T9OnsP2ntdur5M2utaFELVnHyuYpMSIPf5gcela1x4PabV7xdK0u30qysYy9oERQLm7KYSRgP4Y84APfnsK5y0vPCGtmWSbW/GUE+nzRBEvZJYpPNkyEEYIySeenaup0fRtL1yG4ex8V+Jd9tKYJ4pL90khcc7WUjjgg/Q0re7y9v8/wDghfVvvb8v+Ac18JNG+IGj3+oz+MJZo7H7BboyXEwcvdKD5sq8nCkY9M+lXPgXp15Z+CtVvrlWSHVNZvL61Vhj9y8h2n6HGfxrTu9A0W51OTw7J4n8SXlwyAzwR37uI0bpvIGAD6HrVnT/AA3pt1BMlr4o8RRizYwyxHUGUxEDoRjjjBHtVX6+X63Fbp5/pY7miuJ0/wAP6ZqsDzaf4x8QXCRtsYrqLjBwDg5HoR+dZnhu007xFbkJ4o8QwXqb/Mtv7TdioDsgIJUZB29vpSGek0Vyv/CFx/8AQ0eI/wDwYt/hR/whcf8A0NHiP/wYt/hQB1VFcr/whcf/AENHiP8A8GLf4Uf8IXH/ANDR4j/8GLf4UAcr4r/5OU+Gv/YN1j/0G3orL1PRV0f9pL4dhdT1G+83TdW/4/bgzbMLB93PTOefoKKAO+8G/wCt8Tf9hqf/ANBSuH8afZh4wu/+FfjWD44Oz7QNOOLQnaNv2vzP3QG3HI+fGMU2z8XeN9H8Q+KLLQvhbf8AiOyGrysL2DUrWBWJRMrtkcNx9K5/VrTW9c1i51fUv2dddkvLkgyyR+KoYgxChR8qTgDgDoKAM74gR+Jm+MPwcXW7bTLnxAwu1njhdktnfyz/ABFScY9q7Pwt4bvvhF8K7/T7zV459S1O/kkh8oN5Ns8xwFQHnaoy3Tsa5r7BrX9oaJqH/DOuum50IsdPkPiqEmDcSW6z85yeufSuhvvE3j7UdTsNSu/gLrbXFgzNblfEVoiqSMElVlCtx6g0krRt3/K427yv2/PX/M5P4La9NJ4O8cfC7XdbeO+0J51jv2J3NbSbtsozzwTn8aPBeoeKfCPjTwv4C+Inh21ugsU0GheIbDBWZRC2VkHXlP1x9av3Vtrl54svPFNx+zlrD6te25tLiYeJbYCWIjBRkE20j8Ku2154stJreaH9nzWi9rG0VuZPEls/2dWGCI90x2ccfLjinr17Wf4/194u9u+n9f10G/suKo+HHiDCgH/hIrzp/wAArR8QfDfwR/wtHwxDYeHbUavcXkusXl6y7pSkWDyx9ZHQfhVDwnd+KvA9jc2Phn9nrWbK3uZ2uZY28R2soaRurfPMcE4HStRfFfj9defXR8AdV/tF7cWpmOu2R/dhiwUDzMDk54HPHpT6xfZL8F/mhdJLvf8AF/5HG/2H4q8I/GSz8U+KPCvhvX9N1fVzDDqlkpa8sXdiI9xYDOAAOOmK+lK8G0i48UaFezXemfs86zE805uSj+JLaSNZTnLqjTFVPJ5UDrXS/wDCwvif/wBEJ1X/AMHdj/8AHKS0io9hvWTkeqUV5X/wsL4n/wDRCdV/8Hdj/wDHKP8AhYXxP/6ITqv/AIO7H/45QB6pRXlf/Cwvif8A9EJ1X/wd2P8A8co/4WF8T/8AohOq/wDg7sf/AI5QB1Xhf/kZ/HP/AGGYv/TdZ11VeFeH/HfxHi1/xdJD8FdTuJJtUjeaMaxZKYG+xWy7CS+Cdqq2RxhwOoNdD/wsL4n/APRCdV/8Hdj/APHKAPVKK8r/AOFhfE//AKITqv8A4O7H/wCOUf8ACwvif/0QnVf/AAd2P/xygDStZoT+0NqkSyoZP+Edtht3c5+0TV5/pdje/wDCG+EfDIydctPFTS3KfxoqSSO8h/2SpHPfcK6keOPiOLk3I+AOoicjaZBrFhuI9M780o8dfEhZzOvwD1ISkYLjWbDcfx30LS3l/ncHrfz/AMrGvq0lw3x68MQTZ+yLpN5JED087dGCfrsJ/Ammxzw/8NBX0fmI0g8PR5QEZP79zjFc7qXir4j6jcWV2fgVq0V5YyGW3nXWrDKZG1h/rOQQSCP6gVcHjj4ji5Nz/wAKB1HzyNpl/tiw3Eemd+aF08r/AI3/AMxvr52/C3+RgeC7W60/xpo+o25F1o2oXF2I9KlYmTRJSWJZf9lgCCD0Lcda6fxBeafdX1r8SvC/iG3uXhs5tO+zonnreKXB2IAQQ4dQP51XXxz8SEkaVPgFqSyN1YaxYAn8d9VbDxV8QNNgENr8ANSX52k3f2zp+SzdTw/H4UraJdg6t9yi2iav4U+GPw00+4b/AIncGu2xdUP3TK0hlQewR2H0Fe4141c+K/iReaxZ6jdfAnVpTY7mt4zrVhhHYFS/+s5O0kD0ya0f+FhfE/8A6ITqv/g7sf8A45VXvfzd/wAv8ie3pb8W/wBT1SivK/8AhYXxP/6ITqv/AIO7H/45R/wsL4n/APRCdV/8Hdj/APHKQw1T/k6nwz/2LF9/6UQV6pXzTqHjTx+/7Q2g6g/wh1GPUI9Au4o9OOq2heWMzRFpA+/aApAGCcndx0r0L/hYXxP/AOiE6r/4O7H/AOOUAeqVV1C+stNsJLzULuK0t0xumlYBVycDJPvXmv8AwsL4n/8ARCdV/wDB3Y//ABymTePPiVcRNDP8BNTljbqj6zYMD+BegCnb+GrvX7Hxxo17rkL2c99b39prccaqTKNjhWxw4Qog+nHWtbwFaa1qXxA8SeMNSkja1lt7fTLWSKIxrc+VuZ5QpJO3c5APfB7VTXxz8R0g+zr8AtRWH/nmNYsAv5b6kX4gfE5VCr8B9VVR0A1qxwP/ACJQtP68rfloD1/r5/mW/AmpQ2cfjbUdcuktWTXZlllnbARQEEeSe23FZen2unP/AMJrY+MNVtr3w5f3UMi6kH+z+YzgARl0IztIUAg96qJ4k+IUeq3t9H8BdT2X4X7VA2sWDJK6jAfBfrjg+uB6VePjX4hta/ZW/Z+vzb/88jq+n7fy34pdF6Jfl/kHV+tzT8I30HhDSdZj1jxG0/hu2vkh0y/v5t7FHVf3ZkP3wHJUE/0qjJp+kx/EKy13wNrkj3l1qBi1ixjumlhlTaQ7MhJCMuBgjHpVS+8WfELUdNbTbn4BambRsBohrNhtI9Pv8D6VPD42+IlvI8lv+z/qETv95k1iwBb6kPzVdU/6/ruLpY2dKedPj34khhz9kfR7OWYdhNvkA/EqP0Feg141p/iv4j6fdXt6PgTq0l3euHmmOtWGWwMKv+s4AHQVo/8ACwvif/0QnVf/AAd2P/xyktkh9W/62seqV5X4s/5OT+Gn/YO1j/0G3o/4WF8T/wDohOq/+Dux/wDjlee+IvGnj+b46+A76f4Q6jb31vY6msFg2q2jNdKyw72Dh9q7MDIJ53cdDQB9LUV5X/wsL4n/APRCdV/8Hdj/APHKP+FhfE//AKITqv8A4O7H/wCOUAeqUV5X/wALC+J//RCdV/8AB3Y//HKP+FhfE/8A6ITqv/g7sf8A45QB0fxNS3l+HeowXVq9xFMY4/kYqYiXAEuRyNh+bPtXk2q6f4gh8AeKNAvL06qV1CwN1rsHL3dk0ibg+ONyICCBxjnua7VvH/xNdCj/AAH1RlPBB1qwIP8A5EpieOviRHEYo/gFqSxnqo1mwAP4b6Qzd8GXeqjxV4h0g6gdU0G0W3exuiFyhZTvhyoAYLhT7bsVB8LJJpdG8QXF9/x9nXLzzi3UYkwv/joWsqLx58SoE8uH4CanEnXams2AH/odULPxV8R7DVb29tPgVq0a3xEk8P8AbVhtaQDG8fvOCQAD64FPr8v8hdPn+jNGXQF8TeGT4nbVU0q6fWF1ezuZV3IEiykQYZGVZMnGf4qTwRdto83iXxp4svYdNg8RapFHZ+aDEHVY1ijbaTkFypIB5ximnx38SWhWE/APUjGuMIdZsMDHtvqvqPi/4iarZizvfgJqkkG5WMZ1qww2OQPv/wAqFp/Xp+OgPX+vX/MwvD7+ItGMl9aalK2vXnit49S06QKRLA0m0N03ALEFYHOMCu501Zn+OniyzjZxZTaPZvNtONsxaVQR6HYP0FZf/CdfEjz/ADx8AtS83+//AGzYbvz31S07xX8R9Pub28X4E6tJd30gknmOtWGWwMKP9ZwAOAKFsk+n+Vv+CD1u+/8Anf8A4B6HoPhO28O3TSWF/dtDIp8yGVwyu2FAY8DkBf1NWtK8Oabo87T2iyF9rIpkbOxWcuVHtuJNcH/wsL4n/wDRCdV/8Hdj/wDHKhX4mfEZrxrNfghqRuUQSNENdsNwU8A48zpQB61RXlf/AAsL4n/9EJ1X/wAHdj/8co/4WF8T/wDohOq/+Dux/wDjlAHqlFeV/wDCwvif/wBEJ1X/AMHdj/8AHKP+FhfE/wD6ITqv/g7sf/jlAB4r/wCTlPhr/wBg3WP/AEG3orl4/EHifXv2kfAR8SeBbrwqYdO1XyRcXsFz9oysO7HlMdu3A69d3HSigD1Lwb/rfE3/AGGp/wD0FK8p+JuvatYftBeGtDh1rWbfSr/Sruaa10+SQl5URthVUyc5A9vWuisPiv8ADnwjr3ijRvEvi6w0zUE1eWRrediGCsiEHp3rjtZ8c/CfVPjRoHxEj+L+iQJo9tLbLYm3djKJFIJ37hg8/wB2la8l8/yf6jvZP+uqO88Ca343034IJqnjq3d/ES+YlvDKAssxZ9sCuB/GxKg1i/D34heLPGXwO16e2jjbx1oxuLOWBh/y8Lkoce46e4pviD4t/CHxBqeltN8T9GXTLOQzS2uJN8z4wpDqw24yT0PNef2eqfCbRvGninW/Dvxu0rSrDxFEiyWaW7u0MqkESiRn5bOeo7037179V/X36/gC0t5P+vuO2+GfxC07xhf/ANlf21rOl69aWMq6louqSMJGkAX97GSMjBB4GOG6cVqfs5a1rPiH4ZXWqa9q13qd3/adxCJbmUuQikBQM9K5qTx58H77xpY+L9U+KXh6bVtPs5bW2lgtWiyZAAWk+Yl8DoBgcmm/Cfx38I/hp4Sn8PzfFzRtWSS7lullWFoCpc5II3NmqT1bfb8b/wCX+RFtEl3/AE/zOuufEniK3/ajtvC8mrPJoj6C98LQRqqrJ5hXORyeF715xpvxi8SRv4a8VXV5JNbaxruoWE9kT+7WCMfuwq9mG3r3yc1sXHjz4UT/ABtt/iMfi9oYih046b9g+zvkoWLbvM3def7tZOn6l8A7PW7CaT4o6VPpOm6hdala2JRgVlnGGDP3Uc4GB161nrZfP/0q/wCRo7Xfy/8ASbfmX/h78TvE1/4n+Hlxqd/Jcw+MYb43UDHKRNG5MZjH8OANvuOvNfSlfMPhTWvgT4Z8QaLqB+Kml3droEdzFpduUZTCJn3MXbncQCQOBXqX/C/vg3/0ULSv++2/wq9LIjW7PTKK8z/4X98G/wDooWlf99t/hR/wv74N/wDRQtK/77b/AApDPTKK8z/4X98G/wDooWlf99t/hR/wv74N/wDRQtK/77b/AAoA6Lwv/wAjP45/7DMX/pus66qvEfD3xx+Etrr/AIvnuPHmmRxXmqRzQMXbEiCxtULDjpuRx9VNdF/wv74N/wDRQtK/77b/AAoA9MorzP8A4X98G/8AooWlf99t/hR/wv74N/8ARQtK/wC+2/woA9MrifDd/qUvxP8AGWm3WoTXNparaPbxSYxDvRiwGAO471k/8L++Df8A0ULSv++2/wAK5nSfiz8JdN8ca/4il+KeizxaskCrbrG6tF5akD5sndnPoKFuD2PRda1uZvH2h+ELZzH9rhmvrp1OG8qPaAo9NzsM+wPrVbQ77UW+LfirS7jUJriygtLOaCF8bYS/mbguAP7o65Nedax8YfhH/wALI0DxZa+PtLlWCCfT7lFdsrHJtZX6dmQA+ze1WLD4s/Cey8ea34mb4qaLJFqVvDAtssThovK3YO7J3Z3HsKS6fP8AX/gA+vy/r8zsvF+tSWvj3R9F1LUJ9J0O8sp3+2RSGLdchlCoX7fKWIHc+uKwNF8d6m3w28J+Nr6YyfabtNPveMLPG8piWYDs24K3HqRWDb/GTwHqvhSTSte+MGjiSeSVJbmCAxSvCWO0LyQh28Z5/CoPE3xO+Ct94f8AD/hHSfG+k22l2t5byybWbbFDAQ4Xp1JVR+JNOOlr91+ev4aA+vz/AC/pn0LRXmf/AAv74Nf9FC0r/vtv8KP+F/fBv/ooWlf99t/hQB6ZRXmf/C/vg3/0ULSv++2/wo/4X98G/wDooWlf99t/hQBX1T/k6nwz/wBixff+lEFeqV836j8ZPhfL+0ToGvx+NNObS7fw/eWstyGOxJWmhZVPHUhSfwr0T/hf3wb/AOihaV/323+FAHplFeZ/8L++Df8A0ULSv++2/wAKP+F/fBv/AKKFpX/fbf4UAdD8Qr7VtM8C32oaPkz27RySKrhHeESL5ioT0cpuA9zVH4a69/wkmkalqtveyz6a94UtIrlibi3CoodJc8ht+44PIBFcl4m+MHwZ8RaOtj/wszS7WSK4huopAWYB4pA67lwNy5XkZqLQPi18F9F1HWNTb4j6LJd6vMk8/kq0UeVQIMLzyQOTnmiPW/8AW39f8OD6HV2c1348m8SRRaveaVaWV9/Z0Mlk+yQBADIwJBwSxxnsBx1qX4faddWd14gZte1XVrJbz7NbtqNx5zDyxhyDgfx5H/Aa898KfGD4TeH9T8T2a/EDShb3162oW0+5ioMijcp46hgT9CKkuPjF8NdH8A2+j+GvirpEOpwbD9qkhMomYvukJXjG8luc8Z70LRL0X39Qev3v7uh1mrXc+kfGPw9bnxRqKDVDMs1pcKfskgCEpHH8uBICM9ckA5rf0fWpofiJrPg65kaUQ2sWpWjscsIpGZGQ+u1049m9q82/4Wz8MNR1GyuPEfxY0C+h0+7+2WscFu0TK4BChmLNuxuPQDNM034wfCN/ifrPi268faXEhsodMtVLtlkRmkd+nQs4A/3aF0T8/wDgfiD6teX5/wCR71RXmf8Awv74N/8ARQtK/wC+2/wo/wCF/fBv/ooWlf8Afbf4UAemV5X4s/5OT+Gn/YO1j/0G3qx/wv74N/8ARQtK/wC+2/wrzvxH8ZPhfd/HfwFrdv4006XTrCx1OO5uFY7YmkWHYDx32tj6UAfSFFeZ/wDC/vg3/wBFC0r/AL7b/Cj/AIX98G/+ihaV/wB9t/hQB6ZRXmf/AAv74N/9FC0r/vtv8KP+F/fBv/ooWlf99t/hQB6PcKz2sqpK0TFSA6Yyp9RkEV5XpuueJpv2c4Net7x7vWFhMkk0jhXlRZyHAPQMUBA98VZm+PnweeB1i+ImkI5UhWZmIB+mBmuH0/x78H7b4W23gq6+LWkSvayLLHdxRsg3LN5y5Qk5GQARnkUu/wAh9j0v4aeIf+EmstV1S1vJpdLNyI7a3u2JubZlQCRZM8j5skA849iKu+E9Yn8Utrmp+e8VvDeS6fahMfIsZ2s+DkFi2evYCuD0P4tfBjSdZ1fWpfiRosl7qzRGfyFaKP5F2g7eeTnk59PSs7wb8YPhN4bTXtJ/4WBpQhkv5b21mLMVZZjuIPHUNnI+lN6/d+On/BF0+f8An/wDZsvHmtaT8DNG1Z5X1PXtTvTp1u8q7i8rzuoYgYzhVJxx0rvPBur2Oo2l5Zw317cahp83kXyXw2yxy4B5XoAQcjHGK8ZsfG3wdt/h9pnhm6+LWjy3el3ov7W9jiZAkokZxlCTkfMQeeQasXPxW+HGm/2jq2h/FjRE17Vb2Ca6l+zs0TxxqE8sKT8o2j72Sc/lTW7v/W3/AAQfl/W//AO41Xw1f23jjRJIPGXiCW4vb5ria1+14t1hQFmURgcL91evetS31fVG8S+KvBlrcAXttZx3unzS84WUOu0/7rp+RFcuPjN8Gz4sbXpfiVpL7bQWsMOWHl/MWds453fIOnG33rI0j4w/CMfEjX/Fd14/0uNZ7aDT7ZC7ZMcZZmbp3Z+P92pXRev/AAP0/EH1fp/X5nrehvq0Kw2t/Yzo0qNK8klwJhE2QNme4PJH0rJ8MaR4gtvEtzqeuKGke18hpRNvDsJWYFV/hG0jisf/AIX98G/+ihaV/wB9t/hR/wAL++Df/RQtK/77b/Cn1uHSx6ZRXmf/AAv74N/9FC0r/vtv8KP+F/fBv/ooWlf99t/hQB6ZRXmf/C/vg3/0ULSv++2/wo/4X98G/wDooWlf99t/hQBX8V/8nKfDX/sG6x/6Db0VzX/Ce+DvHH7SPgFvCXiC11gWem6qLg27E+XuWHbnI77W/KigD0rwjbW8s/iZpLeN2/tqfllBP3Urzz4geMta0D4z6J4Tsr7TNO0rUdNubuSW4tEYxvGjEDJI4JAr0jwb/rfE3/Yan/8AQUrkPE3gPXtY/aD8LeNEsrKfRNKs57adZpfnYyKwBC7SDgkd6W8l8/yf6j2T/rqcbYfGXV7rwR4Nhl8M2kHizxVqD2FsJYdsKxq+03G3rjHIFetppniez1rTVefTtS06RmF4WtFikj+U4K4OCM9c81jfEf4cS+KdT8MeJNDnitdb8M3a3VqsoxFMuRujbHTIHXtVG78H+L9X+MOj+NJ1g0/TtPsnjm09btnF1Mc7WOAAMZHJzVJ/n+FiWvy/G5J4g+I+k6D8aPD3gWfTYRaapFIj3ZjG1Lj5THHn6Zz/ALwrspNc8Lx+MYfCLtCNZmtmu0t/IPMQOC27GOvbOa8k8ffCPxV4u8CwXVvfiHxfBqQ1SBHmj+zwy7uQHEe8jbgYJ7CvStLi8cP4n0q61Wy0eLThpuy8ZCXuFusjhGwB5fWlHaz/AK0v+eg5b6f1r/lqdX9is/8An0h/79ij7FZ/8+kP/fsVPRQBB9is/wDn0h/79ij7FZ/8+kP/AH7FT0UAQfYrP/n0h/79ij7FZ/8APpD/AN+xU9FAEH2Kz/59If8Av2KPsVn/AM+kP/fsVPRQBx/heztD4m8cA2sRA1mID5Bx/wAS+zrqfsVn/wA+kP8A37Fc54X/AORn8c/9hmL/ANN1nXVUAQfYrP8A59If+/Yo+xWf/PpD/wB+xU9FAHEeN/E2n+FxpljDaWh1LVpjDb+cgEcaqNzyNjnCjsOpIFb2kNpd5ocN/Hc2eowMpb7VFGoRx3PFZXibw3d33izw74n09IprnSDNG0ErbRJHKoDYODggqD+dL4T8JtoPhK+0mWRVa/uLm4ZIz8sPnMTtX2GaWvK+49Lo5++8TXM3wl1bx3pFpZooikuLGOaEEGFWIDHHdgM+2RWv4x1K50X4V6j4k021svt1rY/agJocqSFyeBXOaZoGr3X7PU3ga3hj/tm0tH0t45n2KGUlQ2cHgrhh6g11Hi7Q9X1r4S6j4dsYIf7Su9P+yhXlwisVxndjp+FOWily/IUd1f5/gdHBb28unxTCztzK8YbBjAGSPpXEeHbvWLjx3rnhzUb7SL+G2tI50ltIFSS1lZiPLZcncMAHNbtzqHiOxv8ARdPs9KtZ4ZreQXLNOQ8MiqNmBjBUngnjtVHSfD13J41j8aatptppF7HYPZyx203mCbc6tuZsDIXbxn+8abtzeWv6kq/L56foXvCuqWevWV7HPZW6X+mXcljdqsYx5iH7w9mUqw+tdD9is/8An0h/79iuO+H2mXFvP4o1yZDHHrerSXUCkYzEqrGrf8C2bvoRXcUui9F99tSur9X+ZB9is/8An0h/79ij7FZ/8+kP/fsVPRQB5Nqlra/8NTeGk+zRbT4ZviV2DGftEFepfYrP/n0h/wC/YrzLVP8Ak6nwz/2LF9/6UQV6pQBB9is/+fSH/v2KrX9jusJlsIbSK5K/I8sQKqfUjvWhVLVZNRh0yWTSbOK8uxjZDNJ5avzzlsHHGe1JjRw/g++1jWdJ8Q281zo17cWF61ra6jBCBHIoVSSyAnBUlh15K1a+H1/d61ZawmryaXqRsNRktYbyziVVnRVU5K5O0hiy++M07S/D2paHP4h8QabpFmmo6u8LHTlm2RAoNrMXC43EZ5x2FXvCnhn+x9W13WntIbCXWZYpHtLdsxxlE27s4ALHucdhVLz7fjp/wRf5kFjqB1/UNei0eG0hh0yb7EkksQIeYKC7H2XIGO5zXHQ+M9R0/wAPav8AbG0nVruPWYtHsbu1hVUkeQqMugJwUy2eedtbnhez1bw7L4w0y0tIrm+k1N9QtYp5PLWeKXBzuwehDDp2qpf/AA1l1JNU1WK3ttL1K6vLTUIraJsxLLbnOWIAyW5BIHpUrpfsr/hf9QfW3nb8bfob3hvVBdeKvEHhbU7e2mu9IMMi3CQhBLFKm4EjsQQw/AVzEfjmRrOHxMbO0/sSbXf7HWDyRvC+Z5Ql3eu/t6Vqy6b4i0C68R+NLbT7S61nVZbaNbFpyFWGNQu0MF5c5YjjuBVKH4c6gLK38OuYRosOuf2ysu/94R5nmiLbjs5656U1ur/1qv0/UHs7f1o/1Oo0bUbafxTrHhi9toDeaesdwjiMDzIZM7T9QVYH6Cuk+xWf/PpD/wB+xXG6Pps118X/ABD4mAItEsLfTY27SOrM7kfTco/Ou5oWy/r+tA6v+v61IPsVn/z6Q/8AfsV5b4rtbUftIfDVBbRBTp2r5GwYPy29es15X4s/5OT+Gn/YO1j/ANBt6APTfsVn/wA+kP8A37FH2Kz/AOfSH/v2KnooAg+xWf8Az6Q/9+xR9is/+fSH/v2KnooAxtc029n0iWHQfsNnfuQEnuLcSJGM8nbxnjtmvNH8QeIvDmna3Nrl5puqJBqVppcF1HYCFInlZRI7DJyF3j8eK9icsI2MYBfB2g8AmuZ07w81t4HbStSsLbVLm5LzXkMpBjmlkcu+SR0BPHHQCl/X9fiBn+GNW+2eLvEXhXUYrS6uNI8iVLmKFVEkcqEgEdmBU/himQXl94ot9bbw19hsxaXRsbeee3Eil0I8xyOM4OQBkdKueCfBcHhUapeyCI6jq04muDCu2ONVXbHEg/uqo/Ekmqfw70+bQYfEGhXK4ni1Se6j3ceZFM29WHtyR9RT/wAv8g8/P/MzNDi8Xyt4jtL7WtHn+xSRwxXv9nCNYm27pCV3HdjKjqK2vh7fT+IPB0eoasmnXU4uJ4VubNFEdwiSMqyAc7cgZxU9hp+u6J4Siit9PtdS1S5uGnvo5J/LQmRiz4bac4yAOOgrKtNK1bwPoN7caFpdpNc6nq32qTTxKUjhR9oZY8DlsLuxgAknpTW+v9PQH/XpqXo9RuP+FtzeGZLWy/s7+yFvo9sPzhzKUOT6YFTaZq1q2v694fvbWBrzSo0uVYRD97BIGKnAHUFWBx6D1po0XVv+Fvt4kMEI0w6QLHf5vz+YJS/3cdMH1qtoumzXPxe8SeJgCLMWNtpsTdpGRndyPpvUfnUrZL1/N2/Qb3fy/S/6kvhLxFY+IRNb3VjbW92p3RxrFjzI9qEsM+hfFVPA01/MH03UrCKaGJZWFw6EyK3nOAjlup24Ix2rvfLTzBJsG8DAbHIFOqhEH2Kz/wCfSH/v2KPsVn/z6Q/9+xU9FICD7FZ/8+kP/fsUfYrP/n0h/wC/YqeigDyjxNDDD+0n8NvJiSPOm6vnaoGflt6Kf4r/AOTlPhr/ANg3WP8A0G3ooA6rwb/rfE3/AGGp/wD0FKf4+8aab8P/AATfeKdVBaC12gRqcGRmYAAfn+lM8G/63xN/2Gp//QUrA8baDqHjnVrvw88H2fSoLGRDJdWjSRzySqVyhDLyq59fvGple2hUbX1O6ttY0650GHXFu4k0+WFbgTu4VAhGckngVxnir4l2+hat4Pg0qC11my8RaidP+1Q3QxCdpO4bQQ3Q8ZFeLaX4d+KLfAKDwjNoN6+peFdZhnhjlXYNUs45d6qpJ6+x7AV1Xibw1dXuofD7UfDngbUdLgTxE2qX8DIC0W5MNI4DEDJP6VppzabXX3O3+b9LGeqi772f3q//AAPW57hHruiTalJpkOsWUl9GpZ7ZZ1MigdSVzkAVXt/Fnhe7x9l8SaZPu348u7jbOz7/AEP8Pf0r538N+GPGifFbwlrU3gvUNK03T9Q1ISxhldIkl5Vt24swY8knj0o0D4eX1n8FvF0978PZNQ8SvqtxLZwTL5czxPKpBVgc4xlsAjOMd6hP3bvt/l/mW171vP8Az/yPoseJ/DbaVNqw8QacdPgbZLdC6Tyo29GbOAfrUH/CZeEfJmm/4SjSfLgKiV/tseI933cnPGe3rXzmvg7xu3gf4w2dz4b1JrnX1t5LFHRS07bAGACkjI71T1TwF4kluvE7W/g+9KXXgu20+322wGblQu5B6HrTen3fo3+lvmCV/v8A1S/W/wAj6Jt/GCz/ABC1Dw0YrNbOzsFvDeC+jL5LYKtF95Rg53HitaTxN4ci0ttVl1/Tk09X8trprpBEG6bd2cZ9q+WtV8AfELVbjVBp2iX1tPL4NsbFZJV2CWeJ4mkh3epCsK67xb4R1HV/gL4i/sjwjrMOt63JZPcWd2weWSSN4wxCg4ACp174pyVv6/vNfkStf68l+p7Dr3xG8G+H/DF/4hutfsprOyPlyfZ51kPmHpHwfvH0rVTxP4deGzl/t3Twt6u63zcp++HT5efm544r5h8S/D3xhqVt8S4NN8MXiR366XJZp5YQTmFVEgUeo5rofG3gvxhq2r+Nbu30a7uV8S6HaWemAgZtJEf5lfn5P72f60v6/D/Mf9fivyPpSis/Q7S6sPDmmWN9P9oure1iiml/vuqAM34kGtCm1Z2EndXOV8L/APIz+Of+wzF/6brOuqrlfC//ACM/jn/sMxf+m6zrqqQwooooAKKKKAGiNFdpAgDt1YDk06iigApGVXQq6hlPBBGQaWigAAAAAGAOwooooAKKKKAPK9U/5Op8M/8AYsX3/pRBXqleV6p/ydT4Z/7Fi+/9KIK9UoAKKKKACiiigBpjQyLIUBdQQGxyKdRRQAUUUUANREjQJGgRR2AwKdRRQAV5X4s/5OT+Gn/YO1j/ANBt69UryvxZ/wAnJ/DT/sHax/6Db0AeqUUUUAFFFFABRRRQAU3y08wSbBvAwGxzj0p1FABRRRQAU1ESNAkahFHYDAp1FABRRRQAUUUUAFFFFAHlfiv/AJOU+Gv/AGDdY/8AQbeijxX/AMnKfDX/ALBusf8AoNvRQB1Xg3/W+Jv+w1P/AOgpW42raamtx6K15H/aEkLTrb5+bywQC30yRWH4N/1vib/sNT/+gpXlGvaa8P7VN9fpYE3M3hljp0rRkq90r8bT0yB+lK+q+f4JsdtH8vzSPf2dERndgqqMsScACqum6pp+sabFqOm3SXNpLnZKn3WwccfiK+VvD6eLNQtdBsYlvbm7ufD+qL4lik3MfP8Am8sSA9H3fdHXHTiqulXNpp3wc+H+k2tvqMd5d215HcW8Nu5hecR4/egKWLjjaB3z6UPS/wDXVr9AWtv66L/M+l9S8caVpfxC0bwTc212dQ1iGWa3lRVMWIxlgx3ZB/CtfSdZtdZhuZrRZBFb3MlrvcAB2jbaxXnkbgRn2NfJWh+JNRi1P4R65qEtxdajaaHqCSGYMX83DLGrZ5yTgV6B8SdKGjx/CHRnmlQDVo0vWjkZDIGXMhYgjgsST9aq1rLzt+Nib/lf8Ln0LuHrWVoeuR69bXFzFp95aQxTvAjXSKnnbTgugBJ2k9CcZ9K+QtO1C6s7HRLldQulkt/HctmC87kJZHblcE48v5j7VZiurqT9nDw95l5ci4Hi/YWEriQRfaDnnOQNv6Ulrbzt+PL/AJlS0v5X/Dm/yPq/xF4ktPDVtYz3Vne3S3l3HZoLOHzSjPnDN6KMcmtrI9a+MtS1G7g/tGxt764WCz+IcK2qCVjstyrbsc/cz17U/wAcTTR6n8Vr60vbqO6tde077A0U7jYCU8wxgHH97OPehapef/2v/wAkDVm/L/OX+R9l5FFfIWq33iWDVviHpfhu7vG0pNT0uWdYpGcrbMB9oZTycf3iK9l+EUurya947VmkfwyuqKNGZiShTZ+88snqm7HTjOaa1V/66f5/gyW7f16/5HrFFFFIZyvhf/kZ/HP/AGGYv/TdZ11Vcr4X/wCRn8c/9hmL/wBN1nXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeV6p/ydT4Z/wCxYvv/AEogr1SvK9U/5Op8M/8AYsX3/pRBXqlABRRRQAUUUUAFFFFABRRRQAUUUUAFeV+LP+Tk/hp/2DtY/wDQbevVK8r8Wf8AJyfw0/7B2sf+g29AHqlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeV+K/+TlPhr/2DdY/9Bt6KPFf/ACcp8Nf+wbrH/oNvRQBd0C48YR6n4nXRtK0e5tP7Zmw93qEsMmdqZ+VYHGPxrc+1/ETP/IA8N5/7C8//AMjUvg3/AFvib/sNT/8AoKUsPhe7j+IEnidtQiMLRvELcQkNhgnVt3OCmenejqAn2r4if9C/4c/8G8//AMjUn2r4h/8AQv8Ahv8A8G0//wAjVznibxv4v0/XvFFloul6XPBoFhFqTfaJHDzxkOWQY4DYQ4PSrsPjK+1pbZmH/CM2F1FHLDdXS72nDqG+U/cXr/ESfYULXb+v6sD0/r+u5rfaviFkf8U/4b9v+JvP/wDI1Kbr4iHr4f8ADn/g3n/+Rq8z1x5rlviZdXdzJNceHrOFdNnkbLwkReZ5insWbqR1xiup8fa1qkfwSttQjd4Lu/8AsEM7rwY1mljWQ+3DEfjQtfw/HYNvx/Df8zovtXxCxn/hH/DeP+wvP/8AI1H2r4hY/wCRf8N4/wCwvP8A/I1eS+LL250X4pHwTpK/Z9A1K40k3MMXyom+WRXUY6B1jUH159a7Xw9/yHviT4ZRSmk2TQvbxxkosRlgLOi46DIBwP71S3aLn2v+Fv8AMaXvKPp+J0v2n4hH/mX/AA3/AODaf/5Go+0/EP8A6F/w3/4Np/8A5GqH4WMzfB/wmzMWY6ZASSck/IK5u4+KV5pOrOusWdsbIWt9dH7KS5i+ztwpfO1yy8nGMHirl7snHtf8CY+8k/61OkOqeOVvBZHSPC4unQyCH+2Zt5UcZx9mzj3pbnVfHVjB513pPhe2iyF3y61Mi5JwBk21cPcaprMPxOsPElxa6c9xJ4WuLqGNG8oZ3owSR2JGBkfNx34qr4q8U3XiTwh4k0vUra3aTSL3TmjnijZFcSujAgMSRjBGc80v6/GwX/r5JnoUereO5bqW1j0nwu88QDSRLrUxZAehI+zZGam+1/EX/oAeHP8Awbz/APyNXMa5421HQ73xtNaaLp7XGjWtrOkhJDXCvnhyBnjHH1qtqnxA8Z6a/iSNtP0d20XT4tW3BpMSQsGJjx/f+Q/N06cUDNzS7L4iabqeuXo0jw7L/at4t2V/tSceVi3hh25+zc/6ndnj72O2Tqfa/iL/ANADw5/4N5//AJGrk1+JWtNpWoXy2dl/oviC10tVKt80Mywnd977w80+3HSoz8RPF25LhdL0o239vPojIZJN5OSEkBxgYPUY59qPL+un+aDpf+uv+TOw+1/EX/oAeHP/AAbz/wDyNUP9reOvtv2L+yfC/wBq2eZ5P9tTb9vTdj7NnHvXOJ8QfEf2a+tZrTTUv9Pvrm0mlXeySeXGHTZFneS24A8/Lg1z8eua/rXjbSfFHhrTtOj1O/8AC32p47xmCf6wHblRk+gJ6Ur7dv8AgN/oH9fil+p6T9r+Iv8A0APDn/g3n/8Akaj7X8Rf+gB4c/8ABvP/API1Lo3iW88RfDSDxNptpHb3txZmdLefLKsgB+UkYJGRjNc63xD1aXwWniqy0uG4s/7JgvplTczwyOQWGB94KmWwOePem9G12/4P+QLW39dv8zoftfxF/wCgB4c/8G8//wAjUfa/iL/0APDn/g3n/wDkatTw7e3epaDBqF3cWlx9ozLDNZhhHJETmNsEk5K4J5rmPEnifxXa+ND4b8PWOmSO2mPfpLeO/wB5XC7SF9c9f/1UPR2f9dQWuv8AXYurq3jprx7JdJ8Lm6RBI0I1qbeqngEj7NnHvU32v4i/9ADw5/4N5/8A5Grzjw/4tk1TxdqXjSy02GG7uPCdtcG3mlEaeYJ5gQzntkdfSt+y+JeoXGuyeHJLe1/tCTUI7K2uPLdImVoDMXKE54CkAZ5yOlO239dbCvv/AF0TOo+1/EX/AKAHhz/wbz//ACNUK6t46a8ezXSfC7XKKHaEa1NvVT0JH2bIFZV54x8UWs0GgyaXar4gaCe5KxK88Toj7UwFIK78g8n5feuQbV/Fq/ELVfEGjaDYWmqHwza3d5ZX7spBWWYsgKD73GAT7VN1v0/4f/If9fiv8z0r7X8Rf+gB4c/8G8//AMjUfa/iL/0APDn/AIN5/wD5Grj4fixeat4R1nxZommw/YNEhhmura4z5su6JZXCkHC7VYYyDkg9K9UtbiO8soLuLPlzxrIueuCMiqtYVzzK68N/EO5+KWm+OfsHh1WsdMn037J/aU5D+ZIj79/2fjGzGMc5611P2v4i/wDQA8Of+Def/wCRq6qikM5X7X8Rf+gB4c/8G8//AMjUfa/iL/0APDn/AIN5/wD5GrqqKAOV+1/EX/oAeHP/AAbz/wDyNR9r+Iv/AEAPDn/g3n/+Rq6qigDlftfxF/6AHhz/AMG8/wD8jUfa/iL/ANADw5/4N5//AJGrqqKAOV+1/EX/AKAHhz/wbz//ACNR9r+Iv/QA8Of+Def/AORq6qigDlftfxF/6AHhz/wbz/8AyNR9r+Iv/QA8Of8Ag3n/APkauqooA5X7X8Rf+gB4c/8ABvP/API1ctqvhv4h6p8R/DXjI2Hh2JtDt7y3Ft/aU5E3niMZ3fZ/l2+X6HOe1ep0UAcr9r+Iv/QA8Of+Def/AORqPtfxF/6AHhz/AMG8/wD8jV1VFAHK/a/iL/0APDn/AIN5/wD5Go+1/EX/AKAHhz/wbz//ACNXVUUAcr9r+Iv/AEAPDn/g3n/+RqPtfxF/6AHhz/wbz/8AyNXVUUAcr9r+Iv8A0APDn/g3n/8Akaj7X8Rf+gB4c/8ABvP/API1dVRQByv2v4i/9ADw5/4N5/8A5Go+1/EX/oAeHP8Awbz/APyNXVUUAcr9r+Iv/QA8Of8Ag3n/APkaj7X8Rf8AoAeHP/BvP/8AI1dVRQByv2v4i/8AQA8Of+Def/5Go+1/EX/oAeHP/BvP/wDI1dVRQByv2v4i/wDQA8Of+Def/wCRqPtfxF/6AHhz/wAG8/8A8jV1VFAHK/a/iL/0APDn/g3n/wDkaj7X8Rf+gB4c/wDBvP8A/I1dVRQB4vqcviKX9pL4d/2/YadaEabq3lfYrt593ywZ3b4kx2xjOeelFaniv/k5T4a/9g3WP/QbeigDqvBv+t8Tf9hqf/0FK6SG7tbiaeGCdJJLdgkqqclCRkA+nBrm/Bv+t8Tf9hqf/wBBSoIfD2sQ/ECfWobpobKaYSSKJiVlTydm0p0zv2nd1wPegDHk8I3+rfFLxNeajBfW2h6hpttZ74powl0FL+YhAJcDDgZwO/NehCztRZLZfZ4/syII1iKgqFAwBj0rlvEXjWbRPEcGgWfh671W9uLOS8jEMiIrBCAy5Y8HkVT0v4laf4gtbH+w7OVru9h81Y7wiBU5IK7j98ggghM474oW1l/Wr/4IPe/9dP8AgGpe+BPD15NKwt2tYbiJILm3tyEiuI0OVV1x0GT0xwcUy58HQahq2rtqF1cz6VqNrHbnT3nLQxlOQ6L/AAHp07gGuYvNS8Q6n461Xw5daobUaVov28NYlogZ5GYJk5ywUIeDwc8ipbjx7qI/Z2Tx4kajUpdNjlHy/KJWITdj03HNL7N/66r9GP7XL/XR/qjpm8DaHLaXkd2J7u5u5IpZLyVwZg8WPKKsAMbCMjA65znJq7Z+G7Gx0/ULaCWfzdRZpLm6ZgZZGK7dxOMcAADjAxXkni7xjr3gvWY/DlnqM9y2r2FoYp7hvMa3nkuFhdwT2IbIHQEcV2ui6hfQ+P8AxT4LN/cyW1rY217azyP5ksXmb1ZdzZzygIznqaH8L+f4b/kJb/d+O35nV+HtCtfDfhux0GylmltLKJYIjOwZ9gGACQBmuUt/hH4Vhkh3zajcW8AuUjtprotEsc+fMj2/3STn196v/C7UL7VvhV4e1HU7qS7vJ7YPLNIcs7ZPJqKb4iWVn4og0bUNPnskuJriGKeZgpbyULs+w87CAcN0OKqXxO4o7KxSPwh8NSWgtby/1e8iWxk02MTXhPlwOQdowB0wME5PHepJPhToMsOoJLqmsSPqIt/tEr3W5nMJyh5GM9M8Vg3Xia41L4meD9YhsLyLTbjT72eIJLu+0oFUr+7H8R6jvzUXjLxxHr/w98Y6alrc6XqOn6ZDe4E3zqshO0HbyrAqQVNL+vxf/DlJdP66f8A7DUvh3pGqy65JdahqAOtwRW9yEkQfLH93b8vB65ovvh3pOoSaw9xqGoZ1ewTTbjbIg/dKCBj5eD8x596zrvxXpui65q88mk3k19puhxXkkiy/LNFk/Kqk4ByDzio5PihMslzCvhK+aWPTl1WNfNjHmQH7xzngj070nb+vn/wRL+vw/wCAWZvhR4cmlkZr3VFjlmguXhS6Ko00IUJJgD72EUHtxVkfDfRxbiD+0dR2jVP7X/1qZ8/Of7v3c9qzG+LFj/Ymt6tFpE8kGkraSN+8UGVLhVZWHpjdyKfffFKOxuNQDeG76S207Uk024mV0+V3C7WAzkglxVWd/P8A4b/gC3X9ef8AwSxJ8K9Al1mbVzqGqpdzXM1w7x3ITPmoEkThR8pCr78dasWnw10PT4NOisb7UrdrC0awSRbjLvATnYxIPHoRgj1qGH4htK99at4du4r+yvBaTQl1KRgxmRZGkHCqVHfuQK5K48Zzar4y8IeKNA0y91BL7Sr1hp8c4XcUdRzk7eCDzUq23T/gf5Ff1+J69ZafZ6dpcOmWMCwWkEYijjXoqgYxWFbeCNK0/Q9N0bSri706008FUWCQEygqVIfcDu4NWfDvia38UeEYfEGm2so81W/0aXCukikqyHsCCCKwo/iVYv4XtPEX9l3X2KfT5b+QggmDy2VSjD1yx56fKab63Euljo9K8O2Oi/ZI9PluYrW0tFs4rXzSYVVejbf73vXK6x4c1bVPi9a6ksd7a6UmkSWj3lvNEoLtIDt2klug6hfxrrdC1WbWNPN5JY/ZY2b9ywlWRZoyoKyKw7HP6Vl+IPF76J4g0/Q4NFuNQur+CaaHy3VVzGASpJPHWh6NN+f4p/5gtVp/Wxn3Xwt8MXQu4ibuK2utNTS2gilCokKMWXbxkMGJOc1WuPhH4buzczXF/q8l5PJDcC8N6wmimjUqsiMPutgkHtjtVa3+L+l/Y9O1LUtHu9O0y/t5po7mVlOHiGXjKg5zwcHviqOv/Fe6hsbuDSNKU6hbzWgyZ1kiaKaQJkMuRuB4K9s0bu39b/0w/r+vyOk1D4a6HqEGmk32q2t/pxYx6jb3rpdPv++Hk6sG7g+gxirNx4B0ae++1x3F9bO9kNPnEU//AB8QAk7XJBPVm5BB5PNVNT+IVrpkOq3TabLPaaK8cepzROD9mZgpOB/FtDAnHasOL4oX1pa+KdU1HRmuNP0zVotPt/ssilmV1h2k5x1MufxxRvp/Xb8bhtr/AF3/AEOlm+HfhyS5u2gjms7a+hjgvLO3cLDcpGMIGXHYccEZHBzXWqqoioihVUYAHQCvO9R+KdvpMNydQ0SaC5sQjXlqZ4zLErsQpVQTvOBuwOgIq6nj938bS+Ev7BnW/wD3csJMg2z2zA7pwcfdUgAjrlgO9PcNjuKK4K6+Iqw6ydH/ALGnhup0uzaCdwhlMAJJK9VVsZVu4+tQeGfH99qfhvw/9q0wT67qtk16LaKVQvlrjLZ7csABS3V/66/5AeiUVj+GfEVj4p8Pwazp4dI5CyNHIMNG6sVZD7ggitigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPK/Ff/Jynw1/7Busf+g29FHiv/k5T4a/9g3WP/QbeigDqvBv+t8Tf9hqf/wBBSuqrlfBv+t8Tf9hqf/0FKtWd9rEvi69s7m3mhsof9SwhzHKhVSG8zPDBtw2/SgDlPElvqlx8bdAbTZGtwuk3Ub3Elm80SlmTCkgqAeCRz2rq9J8I6PpnhW28OvbreW0AJJmUEs5JYt7Ekk8dKq698QPDPhzUrjTtTuLgXVvbi7kjhtpJSsWcb/lB4GDn0qwvjLRbqOL+x5H1iaWNZEisQHO1hlSTkKuR/eIoXw2/rdg9zMvPAMf9pSaho+qS2M9xZPp07TKZ90JbcMZYEMpzg8jk8Gq9z4JnltofCMd3t8HjSTYyWZhG9XGAkiyZzng8Yx3qnqHi/wAQ3Gu61pVjFBp8+haWuoToT5wldyxSPOBgbUOSO546Ve1fx+tr8I7PxtZW+6TUIbX7NE/QSTsiKD7Avz9KN1/XW/8AwR9f68v+ARXnwzttYS6m13Ujd38lpDZ29zFD5f2dYn8xGAJOW34JOcHAGBW3pXhiTT9S1jWp76O51jVUjjknEBSNEjUhFCbicfMxPzck1lWPiPV4/EfiHwndXEM+oWFhFqFtdGLCsjhhhlB7Oh+oIrX8CazeeIfh9omt6hs+13tqk0vlrhdx64FG6f8AW9/8mTt/Xp/wB3grw7N4S8F6b4cmvlvjYx+UJ1h8reMk/d3N6+tcfN8J7q61pLy68VPNbJqFzeCJrNfMZJ42Romk3ZOA+FOOAMYrr7fxr4dutbTR4rx/tEjzRxs0TLG7xf6xQ5GCV7/Q1yeo+PIm+I3htLLU5o9DntL2e4LQFYpljQEOrkfMBz0oeru+v/D/AKD2Vl/XT9SK1+FOqxQaXazeNJWt9JtLmxs2iswkqxSpsG59xyygDBAGcdKrt8IdTk0vVbSTxdGz6lpMOlSMNNCqojZiJMB85O4556857VqeLvHNvdfDnxVd+GdRmtNU0uwF2C8BR1VlLIwDjkHB59qvjxnoek3Gu3up67csum2trJeW7Qkpahw2GXC5O7Bz16Cjq7/1v/wQ7W/rb/gEGqfD/UNS1DVrs69BF/aOirpBX7GTswSfM/1nP3j8v600/D7UDeG4/t63ydD/ALFx9iP/AH8/1n/jv61cn+KHhC2N8s11dK1jsadfscuURukn3fuf7XSrU/xB8M20Gpzy3Uwj0y4gtrlhbudjTbTH25B3ryOOaVr6f1rf/N/eG39en+SOMk+Dd82j32lQ+L/IttQs7S3ugtiCWe3wFdSXO0EAZXnnv2rUvPhpqN1aa3AfEcIOqarBqe82JPlmPZ8n+sGc7Bzx1PFbE3xN8HwXUlvLfTKY706dI/2aTYk+AQhbGBnIx61JH8RvC80DPHcXJlWaS3a3+yyecHRN7ZTGeFwc+hqub7X9dH/kFre7/XYwb34Z6rdeK7rXofFSW7T38d79n+w74yFhMW1gZPm4+YHjBHQ07Rvhlf6DDoT2PicSXekLcwpJPZBkeOZ95BVXGGBxznHtVW++Itpp/j+zvpNUuLjw1e6D9vijt7dpckyLh8KC33Tz6V6Amv6XL4ZHiO3uDc6a0H2lZYVL7o8ZyAOTxS2jf+uq/QN3b+u/6jfDug2nhvQYdJs2Z0Qs7O/V3ZizMfqSawNK8DS6D4fj0vSdWTJuHkne7tvNWWJmdjDtDLhcv69vetGXxx4bhtILqS9YQT2iXsUnlNh42YIuDjqWZRjrzWvpmp2+rWjXVtHPGqyNGVniaNgVODwwzQ1fcLmL4e8LXPhrTdF0nT9YP9m6ekqy27Qg+fuJK4bOUVSeBzxgUax4YutT8ZaP4gh1KK3XTYZ4vIe3LmQyADO7eMYwOxp+veN/D/hzUk03Upp/tj27XSww27ys0akBiAoOcZFc5H4zjvfiBpN5Y6yJfDV3oc9+QFAT5HX5+meATkUb/j+T/wAmG39ehnz/AAee+8OaJoOo+II5bTTvtSyGOzKNMJgw4PmHYV3ZB56VozfD3xBqHhKXRdc8bvqNwrwvbXJsVjEXlSB13IG+cnaATkfhW9a+PvDN2lwY7yRHgWFzHJC6O6y58oqpGW3YOMelSR+N9Als2uI5bh3Wd7Y24t387zEGWXZjdwOaNgMO5+G7zy6/CNb22HiIIdSgNvlncKEZo23AJuVQCCG9qqah8L7m4s9esdP8QJaWeq39vqCxPZ+Z5DxeVxkOMg+SvpjJ61SuviXYW/jqw1KPVp7rwzd6LJdLFb2zSHesqqW2qC2QM5HbBrr5PH/hdNPTUI79rm1a1W9aS3iaQRwtnEj4Hyjg9fQ+lG1n/Wj/AOAG+n9bf8Eoah4I1aTxjN4h0XxXJpIv4Y4dStharKtxsyFZCx/dtgkZ57elR6t4D1DUtds/EEPiCO11iyuxJb3P2UsFttuGt2XzBkN1Jz1AOOK7iCeG6torm3kWWGVQ6OpyGUjIIqSjb5BueYWvwr1CHW7PULjxa1wlrdXkyqbNQ7pcAhlZ9xJIzgHHQAY71Z0r4a3mjr4fubPxEp1LRbeSxjmks8xy27Y+RkDg5BAO7d1zx2r0aijYHqY/hrw/a+GdCj0u0dpAHeaSRhgySOxZmx2ySa2KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8r8V/8nKfDX/sG6x/6Db0UeK/+TlPhr/2DdY/9Bt6KAOq8G/63xN/2Gp//AEFK6quV8G/63xN/2Gp//QUrPuvEk9x8S9M0WKT7PHBcyxTRmQhpwbYurbe656H1BoAxNYN9N8dL2z02C1uJpvDXlMs82zbmZsHoc9eldHofw/0rRvDOl6bDJJBfWFskAv7VvKlbaO/Zh7MCK2dR1Pwvo98bvVb/AEzT7vytxluZY45PLBxnLEHbn8Ks3Ot6RZ2Md9cajAtvKAY3DhvNz024+9ntjOaFpG39bv8AzG9ZX/rZL9DitQ8F67HrOsalp97b3c+t6YNPupJ/3RRlLBJQACD8rkEccgVS1Dwjqd74eHw5t4baPSNOsLR7G+3sZFuIXVlDrjAB2DoT3ravPHcravLpej6RJLdW1g+pTpd5hIiDbVAGCdzYOAcdOa0pfGmkxfDj/hOtzNppsxeKP4iCMhfrk4+tLZX/AK62+53Fu7f10/Sxn2HhnVB4g1/xVfx241PUbKKxht45SUjRAx5fHUs5PTgYrQ8A6PqHh74faLoeqrCt5Y26wyeS5dCR3BIH8qyJPiJFpR1GLxLaxWE9ppY1ZdkhZXiJIK5IHzBgAfqK0fAviLVfFGivquoRaStvIw+zvpl79qR177jtGCD2ql1X9bv9bi7P+tl+ljh5/h/401LxNZ32py6cyW93fhrlJn8w288bIm1duFKgjgdTzmoofAvxFjsfDtqsukQTeH9PurCG7EjOZd8QSKQoVwDwMjJr1p9a0ePU10uTVbRb9zhbYzqJGOM8LnPTmuY17xqun+OfDHh/T7zTpxqN3Lb3kZl3TQhYXkBAB45UZzU9Lf12/Up9+3/DnETfDvxpcaX4sjeDS0uNd0SCwwLqRv36bwzMxXJB35z+FX9b8C+K9Si8arDb2CnXNMs7O33XTfK8Qbdu+TgfNx9K7nWPFVnH4X1y/wDD+paff3um2clx5SzCQKVUkbgpyAdpqvofiZ720tNQ1PVdKt4JNJhvZ4N+yWF2GWdstxH2GR17097/ANd3/mLa39fy/wDAOX1vwX4n1G78WzQW1iF1fQ4dPg3XJBEq7s7vk4HzdfasrU/h340ntNesbMaWINYOnTs8s77opLcRK6YC8giPIP6V6e/i7wpHHPI/ibS1S32+axvIwI933d3PGe2etTSeJPDsK3TTa9p8a2iq1wWuUAhDfdL8/KD2z1p3s7/13D+vy/yPNrjwL4slsNVi+z6f5l34oh1pP9JbHkp5eQfk+9+7PHv1plz4I8ct4v1W+t00w6TqN/JPLbvcuGdGgSNScJ2Kklc4ORnpXpcvibw3DcC2m1/To5jIsIja6QMXYZC4z1I5AoXxN4ce1muk1/Tmt4ZPJklF0hVJP7pOcA+3Wptpb+ui/RDvrf8Arr/mzznw54F8XeH4/D0xi025nsdBOizR+cyqp3ArIDtO4ccjiu78OeGk8P8AgKz8MJL5wt7YwlyMBic5/DJNY+qeOoNN8a6HayahpieHdRsLi7a/kmAAMZTaQ+du0767FL6yk08ahHeQvZlPMFwsgMZTru3dMe9N6p3/AK1f63JWj0/rRf8AAPO7PwJqVr4As/DGoWtnrSy2/wBivPMmaIRwhTsEZweQ2DnjnnsK6rwzZeItK07TNK1W4hvorawVJr0ufNknBA6YwRjvnOa0hrejNFFMurWZjmha4jcTrh41+84OeVGRk9KlsNU03VYXm0zULa9jRjGz28qyBWHUEg8H2p31YHnniSa7T46+Hk0+G3uLhtFvF8uaXy+DJF3wfyxWfp/w58S6HNYJpE9mv2XRby0W4dz8lzNJ5gITbgoG9+navSNRvvDmm30d1qt3p1pdiNmSW5dEcIPvEFucDvT7XxFoF7dx2lnrdhcXEsXnpFFcIzPH/fAByV9+lStrev43/wA2U3rf0/Cx45J8M/HkuptrccmlW2oxwWMiA3EkgluLd5Cwclc7WD9e3pxXTeIPC3jTVzoniBbTQ5dYsJpTJpszMbaSKRQrDftzvBUENt9RXVax478K6NoGpazNrVpPBpygzrBMrspP3VIB4JPrWnJ4h0GGO3kn1qxiW5AMJe4QCQHj5cnnn0qheZw8Xg7XtN1/TNY03T9IQJps9jNZwkwRQtJIJMphTuA6HgE9azNH+GeteFV1G10ia1v7TVtKSxuBcOU8mVQ43qMHKkSH5eOld1F448Mya5q+kNq9rDPpKo10ZZVRU3DPUntxk+9XG8VeGVtRdN4i00QGQxCU3Ue0uOCuc4yMjipsmrf1rf8AzDZ3/rp/kSeHdHj8P+F9M0OKVpUsLaO3Dt1baoGa1KyZPE/huG6uLWbxBp0dxbbDNE10gaLccLuGcjJ6Z61Kde0MX72H9sWX2xFZmt/PXzAAMk7c54FU3fViSsrI0aK5zRPG/hrXfDo1+11a2SwMrxeZLKqgFXZecnjO3IB7Gt21urW9tY7qzuI7mCQZSWJwysPUEcGkMmooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyvxX/ycp8Nf+wbrH/oNvRR4r/5OU+Gv/YN1j/0G3ooA6rwb/rfE3/Yan/9BSuqwM5xzXKv4KjF/e3dl4j1rTxezm4khtp4xHvIAJAZCR0Hej/hD7n/AKHTxH/4ERf/ABqgDlPF8dmfjZoH2rR21JX0a8UxpCJD96PqD+X41Z8GfDmTQ/DOlyi7ew1u3hKb+JkRCxZYyrcYAIHykdOtX5vhjZT+IbfxBL4r8SNqVvE0MU32xBtRuSu3Zt5wO3atP/hD7n/odPEf/gRF/wDGqFol/XV/5g9Wczd6N4l07xrqniKXT0v5NV0b+zyLIkhZkYlCQ3Kqwc55OMdTWdeeHb1Phda/B8WNw122ihk1D5fs5mjZWMZOcjLY7YxXb/8ACH3P/Q6eI/8AwIi/+NU3/hCpPOM3/CYeIfMI2l/Phzj0z5VK2lv66/qx9b/10/yObS11YeMm8cXHh69kistHj05bJFUzSyNJukIBOCqjH15rf8G6BHpeqa/q1rYNplpq88c0dkyhdjKmGcqOFLHqPap/+EPuf+h08R/+BEX/AMao/wCEPuf+h08R/wDgRF/8aqr/ANfO/wCZNv6+VjzvxJpPii+8YeZbeGLqJLXxFb3izW+zy5oRGUMpJOSwzgjsBWfZaN4ujsfB2m3Xg+5n1DQL68a6uXK+VcCSKYCQPnJDF1z3HNeqf8Ifc/8AQ6eI/wDwIi/+NUf8Ifc/9Dp4j/8AAiL/AONVNvd5f66f5FN3d/66/wCZ5Xp+jeKGfUrqXwrqFsLnwlJpwh2oFScM+I0UHp8wx69ambw7rT22pIfDd4TP4Ih00AxD57ld37vr1GRXp3/CH3P/AEOniP8A8CIv/jVH/CH3P/Q6eI//AAIi/wDjVN6pr+vtf/JML7f1/L/8ijzoeGLv+1Fl/wCEVm8s+DvsJP2df+Pnj5P97rWNN4d8WxeFtZsE8L31xPq/hiztEI2jy5olZXR8ng8jHrXr3/CH3P8A0OniP/wIi/8AjVH/AAh9z/0OniP/AMCIv/jVOT5r+f8Awf8A5IlK1vL/AIH+R5VrHhbVrvSPHgXwnctc393p0tqPJUmQRpEJCpz2KtV/UNL120+JepXun+D7qXS7i8snWeGJQ0QWCRGeMEgZyVUk9Aa9G/4Q+5/6HTxH/wCBEX/xqj/hD7n/AKHTxH/4ERf/ABqj+vy/yBKyseYeGfC+safD4Nm1zwnc3NvpkWpWs8DokrKZZQ0bYzyCAea9K+Hvhy48N/D200O9UK4ad/JByIUkld1j/wCAqwH4VL/wh9z/ANDp4j/8CIv/AI1R/wAIfc/9Dp4j/wDAiL/41S6WH1ucXpfhK6i8AQ6P4k0W5mRhPpsUdphpLeCR2Pm57cBOB0xXXeDG12w0XStN17T5Jb+aKR7m+RVVSUYKhkGch3XB4z0NTf8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAZPirSZrz4o+E9Q/saS8s7S3vFnmEQZYy6KEBz6kGvOLfwb4iPhHwlp1joNzp2oRLqcM03lhfs/mpIsRYg9MlP8ivXf+EPuf+h08R/+BEX/AMao/wCEPuf+h08R/wDgRF/8apW0t/XX/MfW55bceF9X13wBrbr4L1LTvEC6QmnN9quVcT7HDBIgDgjhiCcdcVvalpOu3WpeLftOg3N1aeJNLiis8hSbZ1RlMcnPy8sGz9a7T/hD7n/odPEf/gRF/wDGqP8AhD7n/odPEf8A4ERf/Gqcve3/AKuJaWt/W3+R5fqPhLxHZ+HPGuiT6Nc6tNf6RZRQXMaqwnljiCMOTnduGa0te8O3lvrsBTwhfajoGraOthcWunukLQS5JcyKSOGDAE9Rtrvv+EPuf+h08R/+BEX/AMao/wCEPuf+h08R/wDgRF/8aoeru/63/wAwWmi/rb/I4TX/AA/qlr4i0bxNo3hu4c6AkFjPaD521CE4zhifm8rqCep3VWj07xNdeO9G1BvCd5aQ2ev3M0nl7BEYZIZFWXrkkkru9Oleif8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUf1+TF0t/XY868O6H4o0i08G3Fzod08GhXt/HeWoClnEzSbJkGfmA3D3wxrvvh7od5oWiakl2hhS91O5vbe2brbxO2VT26E47bqn/wCEPuf+h08R/wDgRF/8ao/4Q+5/6HTxH/4ERf8Axqncb1/r1/zOqorlf+EPuf8AodPEf/gRF/8AGqP+EPuf+h08R/8AgRF/8apAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAdVRXK/8ACH3P/Q6eI/8AwIi/+NUf8Ifc/wDQ6eI//AiL/wCNUAdVRXK/8Ifc/wDQ6eI//AiL/wCNUf8ACH3P/Q6eI/8AwIi/+NUAcr4r/wCTlPhr/wBg3WP/AEG3orpbXwDp8Pi7TvFF5rGrapqOmxTQ2rXk6ssayhQ/Cquc7V6+lFAH/9k=" width="488" height="254" alt="" /></p><p ><span> </span></p><p ><span>En el ensayo de psoriasis I, el 28 % de pacientes respondedores PASI 75 re-aleatorizados a placebo en la semana 33 experimentaron una “pérdida de respuesta adecuada” (puntuación PASI entre las semanas 33 y 52 resultante en &lt;PASI 50 respecto al valor inicial, con un incremento mínimo de 6 puntos relativa a la semana 33), comparado con el 5 % que continuaron con adalimumab (p&lt;0,001). De los pacientes que dejaron de responder adecuadamente después de la re-aleatorización a placebo e incluidos en la extensión abierta del ensayo, el 38 % (25/66) y el 55 % (36/66) recuperaron la respuesta PASI 75 después de 12 y 24 semanas de tratamiento, respectivamente.</span></p><p ><span> </span></p><p ><span>Un total de 233 respondedores PASI 75 en las semanas 16 y 33 recibieron tratamiento continuo con adalimumab durante 52 semanas en el estudio de Psoriasis I, y continuaron con adalimumab en el estudio de extensión abierto. Las tasas de respuesta PASI 75 y PGA “sin lesiones” o “mínimas lesiones” en estos pacientes fue de 74,7% y 59,0%, respectivamente, después de 108 semanas adicionales de tratamiento abierto (un total de 160 semanas). En un análisis en el cual todos los pacientes que salieron del estudio por efectos adversos o falta de eficacia, o quienes aumentaron la dosis, fueron considerados no respondedores, los índices de respuesta PASI 75 y PGA “sin lesiones” o “mínimas lesiones” después de 108 semanas adicionales de tratamiento abierto (total de 160 semanas) fue de 69,6% y 55,7%, respectivamente.</span></p><p ><span> </span></p><p ><span>Un total de 347 respondedores estables participaron en una evaluación de retirada y re-tratamiento en un estudio de extensión abierto. Durante el periodo de retirada, los síntomas de psoriasis reaparecieron con un tiempo medio de recaída (descenso a PGA “moderado” o peor) de aproximadamente 5 meses. Ninguno de estos pacientes experimentó un rebote durante el periodo de retirada. Un total del 76,5% (218/285) de los pacientes que entraron en el periodo de retratamiento tuvieron una respuesta PGA de “sin lesiones” o “mínimas lesiones” después de 16 semanas de retratamiento, independientemente de si recayeron o no durante la retirada (69,1% [123/178] y 88,8% [95/107] para los pacientes que recayeron y no recayeron durante la retirada respectivamente). El perfil de seguridad observado durante el retratamiento fue similar al de antes de la retirada.</span></p><p ><span> </span></p><p ><span>El DLQI (Dermatology Life Quality Index – índice de calidad de vida en dermatología) demostró mejoras significativas en la semana 16 respecto al nivel inicial comparado con placebo (Ensayos I y II) y metotrexato (ensayo II). En el ensayo I las mejoras en la puntuación del resumen de los componentes físico y mental del SF-36 también fueron significativas comparadas con placebo.</span></p><p ><span> </span></p><p ><span>En una extensión abierta del ensayo, en aquellos pacientes que habían incrementado la dosis de 40 mg en semanas alternas a 40 mg semanales debido a una respuesta PASI inferior al 50%, 92 de 349 pacientes (26,4 %) y 132 de 349 pacientes (37,8%) consiguieron respuesta PASI 75 en las semanas 12 y 24, respectivamente.</span></p><p ><span> </span></p><p ><span>El ensayo de psoriasis III (REACH) comparó la eficacia y seguridad de adalimumab versus placebo en 72 pacientes con psoriasis crónica en placas de moderada a grave y psoriasis de mano y/o pie. Los pacientes recibieron una dosis inicial de 80 mg de adalimumab seguida de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) o placebo durante 16 semanas. En la semana 16, una proporción estadísticamente significativa mayor de pacientes que recibieron adalimumab, obtuvieron una PGA de “sin lesiones” a “casi sin lesiones” para manos y/o pies comparada con los pacientes que recibieron placebo (30,6% versus 4,3%, respectivamente [p = 0,014]).</span></p><p ><span> </span></p><p ><span>En el ensayo Psoriasis IV se comparó la eficacia y seguridad de adalimumab frente a placebo en 217 pacientes adultos con psoriasis ungueal de moderada a grave. Los pacientes recibieron una dosis inicial de 80 mg de adalimumab seguido de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) o placebo durante 26 semanas seguido de un periodo de tratamiento abierto de adalimumab durante 26 semanas más. La valoración de la afectación ungueal de la psoriasis incluyó el Índice de Gravedad de la Psoriasis Ungueal modificado (mNAPSI), la Evaluaci</span><span>ón Global del Médico de la Psoriasis Ungueal (PGA-F) y el Índice de Gravedad de la Psoriasis Ungueal (NAPSI) (ver Tabla 18). Adalimumab demostró un beneficio para el paciente en el tratamiento de la psoriasis ungueal con diferentes grados de afectación cutánea (BSA ≥ 10% (60 % de los pacientes) y BSA &lt; 10% y ≥ 5% (40 % de los pacientes)).</span></p><p ><span> </span></p><p ><strong><span>                                                                           </span></strong><strong><span>Tabla 18</span></strong></p><p ><strong><span>                            </span></strong><strong><span>Ensayo Ps IV resultados de eficacia a las semanas 16, 26</span></strong><strong><span>y 52</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="547" height="213" alt="" /></p><p ><span>a</span><span>p&lt;0,001, adalimumab vs. placebo</span></p><p ><span> </span></p><p ><span>Los pacientes tratados con adalimumab mostraron mejoría estadísticamente significativa en la semana 26 en comparación con placebo en el DLQI.</span></p><p ><span> </span></p><p ><em><span>Hidradenitis supurativa</span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la seguridad y la eficacia de adalimumab en estudios aleatorizados, doble ciego, controlados con placebo y en un estudio de extensión abierto en pacientes adultos con hidradenitis supurativa (HS) de moderada a grave que eran intolerantes, tenían contraindicación o respuesta inadecuada a tratamiento con antibióticos sistémicos durante al menos tres meses. Los pacientes en HS-I y HS-II estaban en un estadío de la enfermedad Hurley II o Hurley III con al menos tres abscesos o nódulos inflamatorios.</span></p><p ><span> </span></p><p ><span>En el estudio HS-I (PIONEER I) se evaluó a 307 pacientes en dos periodos de tratamiento. En el Periodo A, los pacientes recibieron placebo o adalimumab a una dosis inicial de 160 mg, en la semana 0, 80 mg en la semana 2, y 40 mg semanales comenzando en la semana 4 hasta la semana 11. No se permitió el uso concomitante de antibiótico durante el estudio. Después de 12 semanas de tratamiento, los pacientes que habían recibido adalimumab en el Periodo A fueron realeatorizados en el Periodo B a 1 de 3 grupos de tratamiento (adalimumab 40 mg semanal, adalimumab 40 mg en semanas alternas o placebo de la semana 12 a la semana 35). Los pacientes aleatorizados a placebo en el Periodo A fueron asignados para recibir adalimumab 40 mg semanal en el Periodo B.</span></p><p ><span> </span></p><p ><span>En el estudio HS-II (PIONEER II) se evaluó a 326 pacientes en dos periodos de tratamiento. En el Periodo A, los pacientes recibieron placebo o adalimumab a una dosis inicial de 160 mg, en la semana 0,80 mg en la semana 2, y 40 mg semanales comenzando en la semana 4 hasta la semana 11. Un 19,3% de los pacientes tenían tratamiento inicial continuado con antibióticos orales durante el estudio. Después de 12 semanas de tratamiento, los pacientes que habían recibido adalimumab en el Periodo A fueron re-aleatorizados en el Periodo B a 1 de 3 grupos de tratamiento (adalimumab 40 mg semanal, adalimumab 40 mg en semanas alternas o placebo de la semana 12 a la semana 35). Los pacientes aleatorizados al grupo placebo en el Periodo A fueron asignados para recibir placebo en el Periodo B.</span></p><p ><span> </span></p><p ><span>Los pacientes que participaron en los estudios HS-I y HS-II fueron reclutados en un estudio de extensión abierto en el que se administraba adalimumab 40 mg semanal. La exposición media en toda la población tratada con adalimumab fue de 762 días. Durante los tres estudios los pacientes utilizaron líquido antiséptico tópico a diario.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Respuesta clínica</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la reducción de las lesiones inflamatorias y la prevención del empeoramiento de abscesos y fistulas drenantes utilizando la Respuesta Clínica de Hidradenitis Supurativa (HiSCR, reducción del recuento total de abscesos y nódulos inflamatorios de al menos un 50% sin incremento en el recuento de abscesos ni incremento en el recuento de fístulas drenantes con respecto al inicio). La reducción del dolor cutáneo asociado a la HS se evaluó utilizando una Escala de Evaluación Numérica en los pacientes que entraron al estudio con una puntuación basal al inicio de 3 o más en una escala de 11 puntos.</span></p><p ><span> </span></p><p ><span>Una proporción significativamente mayor de pacientes tratados con adalimumab versus placebo alcanzó el HiSCR en la semana 12. Una proporción significativamente mayor de pacientes en el Estudio HS-II experimentó una disminución clínicamente relevante en el dolor cutáneo asociado a HS (ver Tabla 19), en la semana 12. El riesgo de brote de la enfermedad se redujo significativamente en los pacientes tratados con adalimumab durante las 12 semanas iniciales de tratamiento.</span></p><p ><span> </span></p><p ><strong><span>                                 </span></strong><strong><span>Tabla 19: resultados de eficacia a la semana 12, Estudios HS-I y II</span></strong></p><p ><img src="data:image/jpg;base64,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" width="567" height="230" alt="" /></p><p ><span> </span></p><p ><span>El tratamiento con adalimumab 40 mg semanal redujo significativamente el riesgo de empeoramiento de abscesos y fistulas drenantes. En las 12 primeras semanas de tratamiento en los Estudios HS-I y HS-II, de manera aproximada, dos veces la proporción de pacientes en el grupo de placebo comparado con aquellos en el grupo de adalimumab experimentaron un empeoramiento de abscesos (23,0% vs. 11,4%, respectivamente) y fístulas drenantes (30,0% vs. 13,9%, respectivamente).</span></p><p ><span> </span></p><p ><span>En la semana 12 se demostraron mejorías superiores desde el inicio comparado con placebo en la calidad de vida relacionada con la salud específica para piel, medida por el Índice de Calidad de Vida en Dermatología (DLQI, Estudios HS-I y HS-II); la satisfacción global del paciente con el tratamiento farmacológico medida por el Cuestionario de Satisfacción con el Tratamiento – medicación (TSQM, Estudios HS-I y HS-II), y la salud física medida por la puntuación del componente físico del SF-36 (estudio HS-I).</span></p><p ><span> </span></p><p ><span>En la semana 12, en los pacientes con al menos una respuesta parcial a adalimumab 40 mg semanal, la tasa HiSCR en la semana 36 fue superior entre aquellos pacientes que continuaron en tratamiento semanal con adalimumab que en aquellos pacientes en los que se redujo la frecuencia de la dosis a semanas alternas o en los que se retiró el tratamiento (ver Tabla 20).</span></p><p ><span> </span></p><p ><strong><span>Tabla 20: Proporción de pacientesa que alcanzaron respuesta HiSCRb en las semanas 24 y 36 después de la reasignación de tratamiento desde adalimumab semanal en la semana 12</span></strong></p><p ><img src="data:image/jpg;base64,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" width="501" height="210" alt="" /></p><p ><span> </span></p><p ><span>En aquellos pacientes que tuvieron al menos una respuesta parcial en la semana 12, y que recibieron tratamiento semanal continuo con adalimumab, el índice HiSCR en la semana 48 fue del 68,3% y del 65,1% en la semana 96. No se identificaron nuevos hallazgos de seguridad durante el tratamiento a largo plazo con adalimumab 40 mg semanal durante 96 semanas.</span></p><p ><span> </span></p><p ><span>En aquellos pacientes en los que el tratamiento con adalimumab fue retirado en la semana 12 en los Estudios HS-I y HS-II, el índice HiSCR alcanzó niveles similares a los observados antes de la retirada 12 semanas después de la reintroducción de adalimumab 40 mg semanal (56,0%).</span></p><p ><span> </span></p><p ><em><span>Enfermedad de Crohn</span></em></p><p ><em><span> </span></em></p><p ><span>Se valoró la seguridad y la eficacia de adalimumab en más de 1.500 pacientes con enfermedad de Crohn moderada a grave (Índice de Actividad de la Enferm</span><span>edad de Crohn (CDAI) ≥220 y ≤450) en ensayos aleatorizados doble-ciego controlados con placebo. Se permitieron tratamientos con dosis estables de aminosalicilatos, corticoesteroides y/o agentes inmunomoduladores, y el 80 % de los pacientes continuaron reci</span><span>biendo como mínimo uno de estos medicamentos.</span></p><p ><span> </span></p><p ><span>Se evaluó la inducción de la remisión clínica (definida como CDAI &lt; 150) en dos ensayos, ensayo de enfermedad de Crohn I (CLASSIC I) y ensayo de enfermedad de Crohn II (GAIN). En el ensayo de enfermedad de Crohn I, 299 pacientes que no habían recibido tratamiento previo con antagonistas del TNF, fueron aleatorizados a uno de los siguientes 4 grupos de tratamiento: placebo en las semanas 0 y 2, 160 mg de adalimumab en la semana 0 y 80 mg en la semana 2, 80 mg en la semana 0 y 40 mg en la semana 2, o bien 40 mg en la semana 0 y 20 mg en la semana 2. En el ensayo de enfermedad de Crohn II, 325 pacientes que habían dejado de responder o eran intolerantes a infliximab fueron aleatorizados para recibir 160 mg de adalimumab en la semana 0 y 80 mg en la semana 2 o bien placebo en las semanas 0 y 2. Los pacientes no-respondedores primarios fueron excluidos de los ensayos y por tanto no fueron evaluados.</span></p><p ><span> </span></p><p ><span>En el ensayo de enfermedad de Crohn III (CHARM) se evaluó el manteni</span><span>miento de la remisión clínica. En el ensayo de enfermedad de Crohn III, 854 pacientes recibieron en el periodo abierto 80 mg en la semana 0 y 40 mg en la semana 2. En la semana 4 los pacientes fueron aleatorizados a 40 mg en semanas alternas, 40 mg semanales o placebo, con una duración total del ensayo de 56 semanas. Los pacientes que respondieron clínicamente (disminución en CDAI ≥ 70) en la semana 4 fueron estratificados y analizados por separado de aquellos que no habían respondido en la semana 4. La red</span><span>ucción de la dosis de corticoesteroides se permitió después de la semana 8.</span></p><p ><span> </span></p><p ><span>Las tasas de inducción de la remisión y respuesta de los ensayos de enfermedad de Crohn I y II se presentan en la Tabla 21.</span></p><p ><span> </span></p><p ><strong><span>                                                              </span></strong><strong><span>Tabla 21</span></strong></p><p ><strong><span>                                 </span></strong><strong><span>Inducción de Remisión clínica y la Respuesta</span></strong></p><p ><strong><span>                                                   </span></strong><strong><span>(Porcentaje de pacientes)</span></strong></p><p ><span> </span><img src="data:image/jpg;base64,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" width="567" height="35" alt="" /><img src="data:image/jpg;base64,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" width="568" height="141" alt="" /></p><p ><span> </span></p><p ><span> </span></p><p ><span>Todos los p-valores se refieren a la comparación del par de valores proporcionales para adalimumab</span><em><span>versus</span></em><span>placebo</span></p><p ><span>* p &lt; 0,001</span></p><p ><span>** p &lt; 0,01</span></p><p ><span> </span></p><p ><span>Se observaron incidencias similares de remisión para las pautas de inducción 160/80 mg y 80/40 mg en la semana 8, siendo los efectos adversos más frecuentes en el grupo 160/80 mg.</span></p><p ><span> </span></p><p ><span>En el ensayo de enfermedad de Crohn III, en la semana 4, el 58 % (499/854) de los pacientes presentaban respuesta clínica, y fueron evaluados en el análisis primario. En aquellos pacientes que presentaban respuesta clínica en la semana 4, el 48 % habían recibido previamente tratamiento con otro anti-TNF. Las tasas de mantenimiento de la remisión y la respuesta se presentan en la Tabla 22. Los resultados de remisión clínica permanecieron relativamente constantes, independientemente de si había un tratamiento previo con antagonistas del TNF o no.</span></p><p ><span> </span></p><p ><span>Las hospitalizaciones y cirugías relacionadas con la enfermedad se redujeron de forma estadísticamente significativa con adalimumab comparado con placebo en la semana 56.</span></p><p ><span> </span></p><p ><strong><span>                                                                      </span></strong><strong><span>Tabla 22</span></strong></p><p ><strong><span>                                  </span></strong><strong><span>Mantenimiento de la remisión clínica y la respuesta</span></strong></p><p ><strong><span>                                                       (Porcentaje de pacientes)</span></strong></p><p ><img src="data:image/jpg;base64,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" width="567" height="233" alt="" /></p><p ><span>* p &lt; 0,001 comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p ><span>** p &lt; 0,02 comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p ><span>a</span><span>De aquellos que recibían corticoesteroides al inicio del ensayo</span></p><p ><span> </span></p><p ><span>Entre los pacientes que no respondieron en la semana 4, el 43 % de los pacientes en tratamiento de mantenimiento con adalimumab respondió hasta la semana 12, comparado con el 30 % de los pacientes con placebo. Estos resultados sugieren que algunos pacientes que no habían respondido en la semana 4 se benefician del tratamiento continuado de mantenimiento hasta la Semana 12. El tratamiento continuado pasada la semana 12 no dio lugar a una tasa de respuesta significativamente superior (ver sección 4.2).</span></p><p ><span> </span></p><p ><span>Se realizó un seguimiento durante 3 años en tratamiento abierto con adalimumab en 117/276 pacientes del ensayo I de enfermedad de Crohn y 272/777 pacientes de los ensayos II u III de enfermedad de Crohn. De estos, 88 y 189 pacientes respectivamente continuaron en remisión clínica. Se mantuvo la respuesta clínica (CR-100) en 102 y 233 pacientes respectivamente.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Calidad de vida</span></span></em></p><p ><em><span> </span></em></p><p ><span>En los ensayos de enfermedad de Crohn I y II, se consiguió una mejora estadísticamente significativa de la puntuación total en el</span><em><span>Cuestionario de la Enfermedad Inflamatoria Intestinal</span></em><span>(IBDQ) específico de la patología, realizado en la semana 4 en pacientes aleatorizados al tratamiento con adalimumab 80/40 mg y 160/80 mg comparado con placebo. Estos resultados se pudieron reproducir en las semanas 26 y 56 en los grupos de tratamiento con adalimumab comparado con placebo durante el ensayo de enfermedad de Crohn III.</span></p><p ><span> </span></p><p ><em><span>Colitis ulcerosa</span></em></p><p ><em><span> </span></em></p><p ><span>La seguridad y eficacia de múltiples dosis de adalimumab se evaluó en pacientes adultos con colitis ulcerosa activa de moderada a grave (puntuación Mayo 6 a 12 con subpuntuación endoscópica de 2 a 3) en ensayos aleatorizados controlados con placebo y doble ciego.</span></p><p ><span> </span></p><p ><span>En el estudio UC-I, se aleatorizó a 390 pacientes sin tratamiento previo con el antagonista de TNF que recibieron bien placebo en las semanas 0 y 2; bien 160 mg de adalimumab en la semana 0 seguidos de 80 mg en la semana 2; o bien 80 mg de adalimumab en la semana 0 seguidos de 40 mg en la semana 2. Después de la semana 2, los pacientes en ambos brazos de adalimumab recibieron 40 mg cada dos semanas. Se evaluó la remisión clín</span><span>ica (definida como puntuación Mayo ≤ 2 con ninguna subpuntuación &gt; 1) en la semana 8.</span></p><p ><span> </span></p><p ><span>En el estudio UC-II, se administró a 248 pacientes 160 mg de adalimumab en la semana 0, 80 mg en la semana 2 y después 40 mg cada dos semanas; y se administró placebo a</span><span>246. Se evaluaron los resultados clínicos de la inducción de la remisión en la semana 8 y el mantenimiento de la remisión en la semana 52.</span></p><p ><span> </span></p><p ><span>Los pacientes inducidos con 160/80 mg de adalimumab alcanzaron remisión clínica en la semana 8 en mayores porcentajes de forma estadísticamente significativa frente a placebo en el estudio UC-I (18% vs. 9% respectivamente, p=0,031) y en el estudio UC-II (17% vs. 9% respectivamente, p=0,019). En el estudio UC-II, entre aquellos tratados con adalimumab que estaban en remisión en la semana 8, 21/41 (51%) estaban en remisión en la semana 52.</span></p><p ><span> </span></p><p ><span>Los resultados del estudio poblacional UC-II se muestran en la Tabla 23.</span></p><p ><span> </span></p><p ><strong><span>                                                              </span></strong><strong><span>Tabla 23</span></strong></p><p ><strong><span>                         </span></strong><strong><span>Respuesta, remisión y curación de la mucosa en el ensayo UC-II</span></strong></p><p ><strong><span>                                                           </span></strong><strong><span>(porcentaje de pacientes)</span></strong></p><p ><img src="data:image/jpg;base64,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" width="567" height="204" alt="" /></p><p ><span>La Remisión Clínica es una puntuación Mayo ≤ 2 con ninguna subpuntuación &gt; 1;</span></p><p ><span>La Respuesta Clínica se reduce en una puntuación Mayo respecto al inicio ≥3 puntos y ≥30%, más una reducción de la subpuntación del sangrado rectal [RBS] ≥1 o una RBS absoluta de</span><span>0 ó 1.</span></p><p ><span>*p&lt;0,05 se refiere a la comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p ><span> </span></p><p ><span>**p&lt;0,001 se refiere a la comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p ><span> </span></p><p ><span>a</span><span>En aquellos que recibían corticoesteroides en estado basal.</span></p><p ><span> </span></p><p ><span>De aquellos pacientes que respondieron en la semana 8, el 47% estaban en respuesta, el 29% estaban en remisión, el 41% presentaban curación de la mucosa y el 20% estuvieron en remisión libre de esteroides por</span><span>≥ 90 días en la semana 52.</span></p><p ><span> </span></p><p ><span>Aproximadamente en el 40% de los pacientes del estudio UC-II habían fracasado tratamientos previos anti-TNF con infliximab. La eficacia de adalimumab se redujo en estos pacientes comparado con los pacientes naïve (sin tratamien</span><span>to previo) para anti-TNF. Entre los pacientes en los que habían fracasado tratamientos previos anti-TNF en la semana 52 estaban en remisión un 3% con placebo y un 10% con adalimumab.</span></p><p ><span> </span></p><p ><span>Los pacientes de los estudios UCI y UC-II tenían la opción de formar parte en una extensión del estudio abierto a largo plazo (UC-III). Después de 3 años de tratamiento con adalimumab, el 75% (301/402) continuaban estando en remisión clínica por puntuación Mayo parcial.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Tasas de hospitalización</span></span></em></p><p ><em><span> </span></em></p><p ><span>Durante las 52 semanas de los estudios UC-I y UC-II, se observaron tasas menores de hospitalizaciones por cualquier causa y de hospitalizaciones relacionadas con la UC en pacientes del brazo de tratamiento con adalimumab comparado con los pacientes del brazo placebo. El número de hospitalizaciones por cualquier causa en el grupo de tratamiento con adalimumab fue de 0,18 por paciente-año versus 0,26 por paciente-año en el grupo placebo y las cifras correspondientes para las hospitalizaciones relacionadas con la UC fue de 0,12 por paciente año versus 0,22 por paciente-año.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Calidad de vida</span></span></em></p><p ><span> </span></p><p ><span>En el estudio UC-II, el tratamiento con adalimumab consiguió una mejoría en la puntuación del</span><em><span>Cuestionario de la Enfermedad Inflamatoria Intestinal</span></em><span>(IBDQ).</span></p><p ><span> </span></p><p ><em><span>Uveítis</span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la seguridad y la eficacia de adalimumab en pacientes adultos con uveítis no infecciosa intermedia y posterior, y panuveítis, excluyendo pacientes con uveítis anterior aislada, en dos estudios aleatorizados, doble ciego, controlados con placebo (UV I y II). Los pacientes recibieron placebo o adalimumab a una dosis inicial de 80 mg seguido de 40 mg en semanas alternas comenzando una semana después de la dosis inicial.</span></p><p ><span>Se permitieron dosis estables concomitantes con un inmunosupresor no biológico.</span></p><p ><span> </span></p><p ><span>En el estudio UV I se evaluaron 217 pacientes con uveítis activa a pesar del tratamiento con corticoesteroides (prednisona oral a una dosis de entre 10 y 60 mg/día). Al comienzo del estudio todos los pacientes recibieron una dosis estandarizada de 60 mg/día de prednisona durante 2 semanas seguido de una pauta de reducción obligatoria, con una discontinuación completa de corticoesteroides en la semana 15.</span></p><p ><span> </span></p><p ><span>En el estudio UV II se evaluaron 226 pacientes con uveítis inactiva que requerían tratamiento crónico basal con corticoesteroides (de 10 a 35 mg/día de prednisona oral) para controlar su enfermedad. Posteriormente, los pacientes se sometieron a una pauta de reducción obligatoria con una discontinuación completa de corticoesteroides en la semana 19.</span></p><p ><span> </span></p><p ><span>La variable principal de eficacia en ambos estudios fue “tiempo hasta fallo del tratamiento”. Se definió el fallo a tratamiento mediante un resultado multi-componente basado en lesiones vasculares inflamatorias coriorretinianas y/o retinianas, grado de celularidad en la cámara anterior (CA), grado de turbidez vítrea (VH por sus siglas en inglés) y mejor agudeza visual corregida (BCVA por sus siglas en inglés).</span></p><p ><span> </span></p><p ><span>Los pacientes que completaron los estudios UV I y UV II fueron elegibles para inscribirse en un estudio de extensión no controlado a largo plazo con una duración planificada originalmente de 78 semanas. Se permitió a los pacientes continuar con el medicamento del estudio después de la Semana 78 hasta que tuvieran acceso a adalimumab.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Respuesta clínica</span></span></em></p><p ><em><span> </span></em></p><p ><span>Los resultados de ambos estudios demostraron una reducción estadísticamente significativa del riesgo de fallo a tratamiento en pacientes tratados con adalimumab versus aquellos pacientes que recibieron placebo (ver Tabla 24). Ambos estudios demostraron un efecto temprano y sostenido de adalimumab en la tasa de fallo a tratamiento versus placebo (ver Figura 2).</span></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="557" height="244" alt="" /></p><p ><span>Nota: El fallo a tratamiento hasta o después de la semana 6 (estudio UV I), o hasta o después de la semana 2 (Estudio UV II), se contabilizó como evento. Las retiradas por razones diferentes al fallo a tratamiento fueron monitorizadas hasta el momento de la retirada.</span></p><p ><span>a</span><span>HR de adalimumab vs placebo de regresión proporcional de riesgos con el tratamiento como factor.</span></p><p ><span>b</span><span>Valor p bilateral del test Log Rank.</span></p><p ><span>c</span><span>NE = no estimable. Menos de la mitad de que un sujeto en riesgo tuviera un evento.</span></p><p ><span> </span></p><p ><strong><span>Figura 2. Curvas de Kaplan-Meier que resume el tiempo hasta fallo del tratamiento en o después de la semana 6 (estudio UV I) o de la semana 2 (estudio UV II)</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="497" height="226" alt="" /></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="546" height="256" alt="" /></p><p ><span> </span></p><p ><span>Nota: P# = Placebo (Número de Eventos/Número en Riesgo); A# = Adalimumab (Número de Eventos/Número en Riesgo).</span></p><p ><span> </span></p><p ><span>En el estudio UV I se observaron diferencias estadísticamente significativas para cada componente del fallo a tratamiento en favor de adalimumab versus placebo. En el estudio UV II, sólo se observaron diferencias estadísticamente significativas para la agudeza visual, pero los otros componentes fueron numéricamente favorables a adalimumab.</span></p><p ><span> </span></p><p ><span>De los 424 sujetos incluidos en la extensión no controlada a largo plazo de los estudios UV I y UV II, 60 de los sujetos se consideraron no elegibles (p.ej. por desviaciones o por complicaciones secundarias a - retinopatía diabética, debido a la cirugía de cataratas o a una vitrectomía) y fueron excluidos del - análisis primario de eficacia. De los 364</span><span>pacientes restantes, 269 pacientes evaluables (74%) alcanzaron las 78 semanas de tratamiento abierto con adalimumab. Basándose en el enfoque de los datos observados, 216 (80,43%) fueron en inactividad (no lesiones inflamatorias activas, grado de celularidad en la cámara anterior ≤ 0,5+, grado VH ≤ 0,5+) con una dosis concomitante de esteroides ≤ 7,5 mg al día, y 178 (66,2%) estaban en inactividad sin esteroides. La BCVA fue mejorada o mantenida (&lt; 5 letras de deterioro) en el 88,46% de los ojos a la semana</span><span>78. Los datos más allá de la Semana 78 fueron generalmente consistentes con estos resultados, pero la cantidad de sujetos reclutados disminuyó después de este tiempo. Generalmente,</span><span>entre</span><span>los pacientes que discontinuaron el estudio, el 18% fue debido a efectos adversos, y el 8% fue debido a una respuesta insuficiente al tratamiento de adalimumab.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Calidad de vida</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se midieron los resultados notificados por los pacientes respecto a la funcionalidad relacionada con la visión usando el cuestionario NEI VFQ-25. Adalimumab fue numéricamente favorable para la mayoría de las sub-puntuaciones con diferencias medias estadísticamente significativas para visión general, dolor ocular, visión cercana, salud mental, y puntuación total en el estudio UV I, y para visión general y salud mental en el estudio UV II. En los efectos relacionados con la visión, no hubo resultados numéricamente favorables a adalimumab para visión de color en el estudio UV I y para visión de color, visión periférica y visión cercana en el estudio UV II.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Inmunogenicidad</span></span></p><p ><span> </span></p><p ><span>Durante el tratamiento con adalimumab se pueden desarrollar anticuerpos anti-adalimumab. La formación de anticuerpos anti-adalimumab se asocia con un incremento en el aclaramiento y una reducción de la eficacia de adalimumab. No existe una correlación aparente entre la presencia de anticuerpos anti-adalimumab y la incidencia de los efectos adversos.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Población pediátrica</span></span></p><p ><span> </span></p><p ><em><span>Artritis idiopática juvenil (AIJ)</span></em></p><p ><em><span> </span></em></p><p ><em><span style="text-decoration: underline"><span>Artritis idiopática juvenil poliarticular (AIJp)</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se han evaluado la seguridad y la eficacia de adalimumab en dos ensayos (pJIA I y II) en niños con artritis idiopática juvenil poliarticular o de curso poliarticular, que tenían una variedad de tipos de AIJ (más frecuentemente factor reumatoide negativo o poliartritis positiva y oligoartritis extendida).</span></p><p ><span> </span></p><p ><span>pJIA I</span></p><p ><span> </span></p><p ><span>Se ha evaluado la seguridad y eficacia de adalimumab en un ensayo multicéntrico, aleatorizado, doble ciego, de grupo paralelo en 171 niños (de 4 a 17 años) con AIJ poliarticular. En una fase inicial abierta los pacientes fuero</span><span>n estratificados en dos grupos, tratados con metotrexato (MTX) o no tratados con metotrexato (no-MTX). Los pacientes del estrato no-MTX fueron tanto pacientes naïve como pacientes a los que se les había retirado el metotrexato al menos dos semanas antes de la administración del fármaco. Los pacientes permanecieron en dosis estables de FAMEs o prednisona (≤ 0.2 mg /kg/día o 10 mg/día máximo). En la fase inicial abierta todos los pacientes recibieron 24 mg/m2 hasta un máximo de 40 mg de adalimumab en semanas</span><span>alternas durante 16 semanas. La distribución de pacientes por edad y dosis mínima, media y máxima recibida durante la fase inicial abierta se presenta en la Tabla 25.</span></p><p ><span> </span></p><p ><strong><span>                                                             </span></strong><strong><span>Tabla 25</span></strong></p><p ><strong><span>Distribución de pacientes por edad y dosis de adalimumab recibida en la fase inicial abierta</span></strong></p><p ><strong><span> </span></strong></p><p ><img src="data:image/jpg;base64,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" width="560" height="105" alt="" /></p><p ><span> </span></p><p ><span>Los pacientes que demostraron respuesta ACR pediátrico-30 en la semana 16 fueron candidatos para ser aleatorizados en una fase doble ciego, y recibir adalimumab 24 mg/m</span><span>2</span><span>hasta</span><span>un máximo de 40 mg o placebo durante 32 semanas adicionales o hasta el brote de la enfermedad, , en semanas alternas. Los criterios de brote de la enfermedad se definieron como un empeoramiento ≥ 30% desde el nivel basal en ≥ 3 de 6 criterios ACR-pediátric</span><span>os básicos. Después de 32 semanas de tratamiento o en el brote de la enfermedad, los pacientes fueron candidatos para ser enrolados en la fase de extensión abierta.</span></p><p ><span> </span></p><p ><strong><span>                                                            </span></strong><strong><span>Tabla 26</span></strong></p><p ><strong><span>                         </span></strong><strong><span>Respuesta ACR-pediátrico 30 en el ensayo de AIJ</span></strong></p><p ><span> </span></p><p ><img src="data:image/jpg;base64,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" width="568" height="380" alt="" /></p><p ><span>a</span><span>Respuestas ACR-pediátrico 30/50/70 en la semana 48 significativamente mayores que aquellos pacientes tratados con placebo.</span></p><p ><span>b</span><span>p = 0,015</span></p><p ><span>c</span><span>p = 0,031</span></p><p ><span> </span></p><p ><span>Entre aquellos pacientes respondedores a la semana 16 (n=144), las respuestas ACR-pediátrico 30/50/70/90 se mantuvieron durante seis años en la fase de extensión abierta en pacientes que recibieron adalimumab a lo largo del ensayo. Un total de 19 sujetos, de los cuales 11 pertenecían inicialmente al grupo de edad de 4 a 12 y 8 al grupo de 13 a 17 años, fueron tratados durante 6 años o más.</span></p><p ><span> </span></p><p ><span>La respuesta global fue generalmente mejor y, menos pacientes desarrollaron anticuerpos cuando fueron tratados con adalimumab y Metotrexato comparado con adalimumab sólo. Teniendo en cuenta estos resultados, se recomienda el uso de Idacio en combinación con Metotrexato y para uso en monoterapia en pacientes para los que el uso de Metotrexato no es apropiado (ver sección 4.2).</span></p><p ><span> </span></p><p ><span>pJIA II</span></p><p ><span> </span></p><p ><span>Se ha evaluado la eficacia y la seguridad de adalimumab en un estudio abierto, multicéntrico en 32 niños (2-&lt;4 años o con 4 años y peso inferior &lt;15 kg) con AIJ poliarticular activa de moderada a grave. Los pacientes recibieron 24 mg/m2 de área de superficie corporal de adalimumab hasta un máximo de 20 mg en semanas alternas como una dosis única vía inyección subcutánea durante al menos 24 semanas. Durante el estudio la mayoría de los sujetos se trataron con metotrexato concomitante, con unas pocas notificaciones de tratamientos con corticoesteroides o AINEs.</span></p><p ><span> </span></p><p ><span>En las semanas 12 y 24, la respuesta PedACR30 fue del 93,5%y del 90,0%, respectivamente, usando la aproximación de observación de datos. La proporción de pacientes con PedACR50/70/90 en la semana 12 y en la semana 24 fue del 90,3%/61,3%/38,7% y del 83,3%/73,3%/36,7%, respectivamente. De aquellos pacientes que respondieron ACR 30 pediátrico en la semana 24 (n=27 de 30 pacientes), la respuesta ACR 30 pediátrica se mantuvo hasta 60 semanas en la fase de extensión abierta en los pacientes que recibieron adalimumab a lo largo de este periodo de tiempo. En total, 20 sujetos fueron tratados durante 60 semanas o más.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Artritis asociada a entesitis</span></span></em></p><p ><em><span> </span></em></p><p ><span>Se evaluó la seguridad y eficacia de adalimumab en un estudio multicéntrico, aleatorizado, doble-ciego en 46 pacientes pediátricos (de 6 a 17 años) con artritis asociada a entesitis moderada. Los pacientes se aleatorizaron para recibir 24 mg/m2 de área de superficie corporal (ASC) de adalimumab hasta un máximo de 40 mg o placebo durante 12 semanas. Tras el periodo doble ciego se continuó con un periodo abierto (PA) durante el que los pacientes recibieron 24 mg/m2 de ASC de adalimumab hasta un máximo de 40 mg en semanas alternas por vía subcutánea durante 192 semanas adicionales. La variable principal del ensayo fue el porcentaje de cambio respecto al inicial de la Semana 12 en el número de articulaciones activas con artritis (inflamación¡”o at’ibuida a la deformación o articulaciones con pérdida de movilidad más dolor y/o sensibilidad), que se alcanzó con una media de -62,6% (cambio porcentual medio de -88,9%) en pacientes en el grupo de adalimumab comparado con el -11,6% (cambio porcentual medio -50%) en pacientes en el grupo placebo. Durante el PA se mantuvo la mejora en el número de articulaciones activas con artritis hasta la semana 156 para los 26 de 31 pacientes (84%) del grupo de adalimumab que permanecieron en el estudio. A pesar de que no sea estadísticamente significativo, la mayoría de los pacientes mostraron mejoras clínicas en variables secundarias como el número de zonas de entesitis, el recuento de articulaciones dolorosas (RAD), el recuento de articulaciones inflamadas (RAI), la repuesta ACR pediátrica y la respuesta ACR 70 pediátrica.</span></p><p ><span> </span></p><p ><em><span>Psoriasis pediátrica en placas</span></em></p><p ><span> </span></p><p ><span>La eficacia de adalimum</span><span>ab fue evaluada en un ensayo aleatorizado, doble ciego y controlado de 114 pacientes pediátricos desde los 4 años de edad con psoriasis crónica en placas grave (definida por un PGA ≥ 4 o un BSA &gt; 20 % ó &gt; 10% con lesiones muy gruesas o con una respuesta PASI ≥ 20 ó ≥ 10 con afectación clínica relevante en cara, genitales o manos/pies) con un control inadecuado con terapia tópica, helioterapia o fototerapia.</span></p><p ><span> </span></p><p ><span>Se administró a los pacientes</span><span>adalimumab</span><span>0,8mg/kg (hasta 40 mg) o 0,4 mg/kg (hasta 20 mg)</span><span>en semanas</span><span>alternas,</span><span>o metotrexato (MTX) 0,1 – 0,4 mg/kg semanalmente (hasta 25 mg). En la semana 16, el número de pacientes aleatorizados al tratamiento con adalimumab 0,8 mg/kg con respuesta de eficacia positiva (por ejemplo, PASI 75) fue mayor que de los pacientes aleatorizados al tratamiento 0,4</span><span> </span><span>mg/kg en semanas alternas o aquellos con MTX.</span></p><p ><span> </span></p><p ><strong><span>Tabla 27:</span></strong><strong><span>Resultados de eficacia de psoriasis pediátrica en placas a las 16 semanas</span></strong></p><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td><p><span> </span></p></td><td><p style="text-align:center"><span>MTX</span><span>a</span></p><p style="text-align:center"><span>N=37</span></p></td><td><p style="text-align:center"><span>Adalimumab 0,8mg/kg</span></p><p style="text-align:center"><span>en semanas alternas</span></p><p style="text-align:center"><span>N=38</span></p></td></tr><tr><td><p><span>PASI 75</span><span>b</span></p></td><td><p style="text-align:center"><span>12 (32,4%)</span></p></td><td><p style="text-align:center"><span>22 (57,9%)</span></p></td></tr><tr><td><p><span>PGA: Sin lesiones/mínimas lesiones</span><span>c</span></p></td><td><p style="text-align:center"><span>15 (40,5%)</span></p></td><td><p style="text-align:center"><span>23 (60,5%)</span></p></td></tr></table><p ><span>a</span><span>MTX = metotrexato</span></p><p ><span>b</span><span>P=0,027, adalimumab 0,8 mg/kg versus MTX</span></p><p ><span>c</span><span>P=0,083, adalimumab 0,8 mg/kg versus MTX</span></p><p ><span> </span></p><p ><span>A los pacientes que alcanzaron una respuesta PASI 75 y PGA de sin lesiones o mínimas lesiones se les retiró el tratamiento durante un máximo de 36 semanas y fueron monitorizados para evaluar la pérdida del control de la enfermedad (empeoramiento de PGA en al menos 2 grados).</span></p><p ><span>Tras este periodo de tiempo se reinició el tratamiento con adalimumab 0,8 mg/kg en semanas alternas durante 16 semanas observándose un índice de respuesta muy similar al obtenido previamente en el ensayo doble ciego: respuesta PASI 75 de 78,9% (15 de 19 pacientes) y PGA de sin lesiones o mínimas lesiones de 52.6% (10 de 19 pacientes).</span></p><p ><span> </span></p><p ><span>Durante la fase abierta del estudio, la respuesta PASI 75 y el PGA</span><span>de sin lesiones o mínimas lesiones</span><span>se mantuvieron</span><span>durante al menos 52 semanas adicionales sin nuevos hallazgos relevantes de seguridad.</span></p><p ><span> </span></p><p ><em><span>Hidradenitis supurativa en adolescentes</span></em></p><p ><em><span> </span></em></p><p ><span>No hay ensayos clínicos con adalimumab en pacientes adolescentes con HS. La eficacia de adalimumab para el tratamiento de pacientes adolescentes con HS se predice en base a la eficacia demostrada y la relación exposición/respuesta en pacientes adultos con HS y la probabilidad de que el curso de la enfermedad, la fisiopatología, y los efectos del fármaco sean sustancialmente similares a los de adultos con los mismos niveles de exposición. La seguridad de la dosis recomendada de adalimumab en la población adolescente con HS está basada en el perfil de seguridad del conjunto de indicaciones de adalimumab en pacientes adultos y pediátricos a dosis similares o más frecuentes (ver sección 5.2).</span></p><p ><span> </span></p><p ><em><span>Enfermedad de Crohn pediátrica</span></em></p><p ><em><span> </span></em></p><p ><span>Se valoró adalimumab mediante un ensayo clínico multicéntrico, aleatorizado, doble ciego diseñado para evaluar la eficacia y seguridad del tratamiento de inducción y mantenimiento con dosis</span><span>dependientes del peso corporal (&lt; 40 kg o ≥ 40 kg) en 192 pacientes pediátricos con edades comprendidas entre 6 y 17 (inclusive) años, con enfermedad de Crohn de moderada a grave definida como una puntuación en el índice de actividad de la enfermedad de Cr</span><span>ohn pediátrica (PCDAI) &gt; 30. Los sujetos tenían que haber fallado a terapia convencional (incluyendo un corticoesteroide y/o un inmunomodulador) para EC. Además, previamente los sujetos podían haber perdido respuesta o sido intolerantes a infliximab.</span></p><p ><span> </span></p><p ><span>Todo</span><span>s los sujetos recibieron un tratamiento de inducción abierto con dosis dependientes del peso corporal al inicio: 160 mg en la semana 0 y 80 mg en la semana 2 para pacientes ≥ 40 kg, y 80 mg y 40 mg, respectivamente, para pacientes con peso &lt; 40 kg.</span></p><p ><span> </span></p><p ><span>En la</span><span>semana 4, los sujetos fueron aleatorizados 1:1 según su peso corporal en ese momento a los regímenes de mantenimiento a Dosis Bajas o a Dosis Estándar que se muestran en la Tabla 28.</span></p><p ><span> </span></p><p ><strong><span>                                                            </span></strong><strong><span>Tabla 28</span></strong></p><p ><strong><span>                                                </span></strong><strong><span>Pauta de mantenimiento</span></strong></p><table cellspacing="0" cellpadding="0" ><tr><td><p><strong><span>Peso del paciente</span></strong></p></td><td><p><strong><span>Dosis bajas</span></strong></p></td><td><p><strong><span>Dosis estándar</span></strong></p></td></tr><tr><td><p><span>&lt; 40 kg</span></p></td><td><p><span>10 mg semanas alternas</span></p></td><td><p><span>20 mg semanas alternas</span></p></td></tr><tr><td><p><span>≥ 40 kg</span></p></td><td><p><span>20 mg semanas alternas</span></p></td><td><p><span>40 mg semanas alternas</span></p></td></tr></table><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Resultados de eficacia</span></span></em></p><p ><span> </span></p><p ><span>La variable principal del estudio fue la remisión clínica en la semana 26, definida como una puntuación en el PCDAI ≤ 10.</span></p><p ><span> </span></p><p ><span>Las tasas de remisión clínica y de respuesta clínica</span><span>(definidas como una reducción en la puntuación del PCDAI de al menos 15 puntos desde el inicio) se presentan en la Tabla 29. Las tasas de interrupción de corticosteroides o inmunomoduladores se presentan en la Tabla 30.</span></p><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td colspan="4"><p><strong><span>                                                     Tabla 29</span></strong></p><p><strong><span>                                Estudio de EC pediátrica</span></strong></p><p><strong><span>                         PCDAI remisión y respuesta clínica</span></strong></p></td></tr><tr><td><p><strong><span> </span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis estándar</span></strong></p><p style="text-align:center"><strong><span>40/20 mg semanas alternas</span></strong></p><p style="text-align:center"><strong><span>N = 93</span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis bajas</span></strong></p><p style="text-align:center"><strong><span>20/10 mg semanas alternas</span></strong></p><p style="text-align:center"><strong><span>N = 95</span></strong></p></td><td><p style="text-align:center"><strong><span>Valor P</span></strong><span>*</span></p></td></tr><tr><td><p><strong><span>Semana 26</span></strong></p></td><td><p><strong><span> </span></strong></p></td><td><p><strong><span> </span></strong></p></td><td><p><strong><span> </span></strong></p></td></tr><tr><td><p><span>   Remisión clínica</span></p></td><td><p><span>38,7%</span></p></td><td><p><span>28,4%</span></p></td><td><p><span>0,075</span></p></td></tr><tr><td><p><span>   Respuesta clínica</span></p></td><td><p><span>59,1%</span></p></td><td><p><span>48,4%</span></p></td><td><p><span>0,073</span></p></td></tr><tr><td><p><strong><span>Semana 52</span></strong></p></td><td><p><strong><span> </span></strong></p></td><td><p><strong><span> </span></strong></p></td><td><p><strong><span> </span></strong></p></td></tr><tr><td><p><span>   Remisión clínica</span></p></td><td><p><span>33,3%</span></p></td><td><p><span>23,2%</span></p></td><td><p><span>0,100</span></p></td></tr><tr><td><p><span>   Respuesta clínica</span></p></td><td><p><span>41,9%</span></p></td><td><p><span>28,4%</span></p></td><td><p><span>0,038</span></p></td></tr><tr><td colspan="4"><p><span>* valor p para la comparación Dosis estándar</span><em><span>versus</span></em><span>Dosis baja.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td colspan="4"><p style="text-align:center"><strong><span>Tabla 30</span></strong></p><p style="text-align:center"><strong><span>Estudio de EC pediátrica</span></strong></p><p style="text-align:center"><strong><span>Interrupción de corticoesteroides o inmunomoduladores y remisión de fistulas</span></strong></p></td></tr><tr><td><p style="text-align:center"><strong><span> </span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis estándar</span></strong></p><p style="text-align:center"><strong><span>40/20 mg semanas alternas</span></strong></p></td><td><p style="text-align:center"><strong><span>Dosis bajas</span></strong></p><p style="text-align:center"><strong><span>20/10 mg semanas alternas</span></strong></p></td><td><p style="text-align:center"><strong><span>Valor p</span></strong><strong><span>1</span></strong></p></td></tr><tr><td><p><strong><span>Interrupción</span></strong><strong><span>de corticoesteroides</span></strong></p></td><td><p style="text-align:center"><strong><span>N= 33</span></strong></p></td><td><p style="text-align:center"><strong><span>N=38</span></strong></p></td><td><p><strong><span> </span></strong></p></td></tr><tr><td><p><span>Semana 26</span></p></td><td><p style="text-align:center"><span>84,8%</span></p></td><td><p style="text-align:center"><span>65,8%</span></p></td><td><p style="text-align:center"><span>0,066</span></p></td></tr><tr><td><p><span>Semana 52</span></p></td><td><p style="text-align:center"><span>69,7%</span></p></td><td><p style="text-align:center"><span>60,5%</span></p></td><td><p style="text-align:center"><span>0,420</span></p></td></tr><tr><td><p><strong><span>Interrupción</span></strong><strong><span>de inmunomoduladores</span></strong><strong><span>2</span></strong></p></td><td><p style="text-align:center"><strong><span>N=60</span></strong></p></td><td><p style="text-align:center"><strong><span>N=57</span></strong></p></td><td><p><strong><span> </span></strong></p></td></tr><tr><td><p><span>Semana 52</span></p></td><td><p style="text-align:center"><span>30,0%</span></p></td><td><p style="text-align:center"><span>29,8%</span></p></td><td><p style="text-align:center"><span>0,983</span></p></td></tr><tr><td><p><strong><span>Remisión de fistulas</span></strong><strong><span>3</span></strong></p></td><td><p style="text-align:center"><strong><span>N=15</span></strong></p></td><td><p style="text-align:center"><strong><span>N=21</span></strong></p></td><td><p style="text-align:center"><span> </span></p></td></tr><tr><td><p><span>Semana 26</span></p></td><td><p style="text-align:center"><span>46,7%</span></p></td><td><p style="text-align:center"><span>38,1%</span></p></td><td><p style="text-align:center"><span>0,608</span></p></td></tr><tr><td><p><span>Semana 52,</span></p></td><td><p style="text-align:center"><span>40,0%</span></p></td><td><p style="text-align:center"><span>23,8%</span></p></td><td><p style="text-align:center"><span>0,303</span></p></td></tr><tr><td colspan="4"><p><span>1</span><span>   valor p para la comparación Dosis estándar</span><em><span>versus</span></em><span>Dosis bajas.</span></p><p><span>2</span><span>  el tratamiento con inmunosupresores solo se puede interrumpir en o después de la Semana 26 a criterio del investigador si el sujeto cumple los criterios de respuesta clínica.</span></p><p><span>3</span><span>  definido como cierre de todas las fistulas que fueron drenando desde el inicio hasta al menos dos visitas consecutivas post-basal</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span> </span></p><p ><span>En ambos grupos de tratamiento se observaron aumentos estadísticamente significativos (mejoras) desde el inicio hasta las semanas 26 y 52 en el Índice de Masa Corporal y velocidad de crecimiento.</span></p><p ><span> </span></p><p ><span>En ambos grupos de tratamiento se observaron también mejoras estadística y clínicamente significativas desde el inicio para parámetros de calidad de vida (incluyendo IMPACT III).</span></p><p ><span> </span></p><p ><span>100 pacientes (n=100) del estudio de enfermedad de Crohn pediátrica continuaron en una extensión abierta del estudio a largo plazo.  Tras 5 años de tratamiento con adalimumab, el 74% de los 50 pacientes que siguieron en el estudio (37/50) continuaron en remisión clínica, y el 92% de los pacientes (46/50) continuaron en respuesta clínica según PCDAI.</span></p><p ><span> </span></p><p ><em><span>Colitis ulcerosa pediátrica</span></em></p><p ><span> </span></p><p ><span>Se evaluaron la seguridad y la eficacia de adalimumab en un ensayo clínico multicéntrico, aleatorizado y doble ciego con 93 pacientes pediátricos de entre 5 y 17 años con colitis ulcerosa de moderada a grave (puntuación Mayo 6 a 12 con subpuntuación endoscópica de 2 a 3, confirmada por lectura endoscópica central) que presentaban respuesta inadecuada o intolerancia a los tratamientos convencionales. Aproximadamente el 16% de los pacientes había fracasado a un tratamiento anti-TNF anterior. Los pacientes que recibían corticoides durante la selección pudieron reducir progresivamente su tratamiento con corticoesteroides después de la semana 4.</span></p><p ><span> </span></p><p ><span>En el periodo de inducción del estudio, se aleatorizó con doble ciego a 77 pacientes en una proporción de 3:2 para que recibieran tratamiento con adalimumab con una dosis de inducción de 2,4 mg/kg (máximo de 160 mg) en la semana 0 y la semana 1, y de 1,2 mg/kg (máximo de 80 mg) en la semana 2; o una dosis de inducción de 2,4 mg/kg (máximo de 160 mg) en la semana 0, placebo en la semana 1, y 1,2 mg/kg (máximo de 80 mg) en la semana 2. Ambos grupos recibieron 0,6 mg/kg (máximo de 40 mg) en la semana 4 y la semana 6. Tras una enmienda al diseño del estudio, los 16 pacientes restantes inscritos en el periodo de inducción recibieron tratamiento sin enmascaramiento con adalimumab con una dosis de inducción de 2,4 mg/kg (máximo de 160 mg) en la semana 0 y en la semana 1, y de 1,2 mg/kg (máximo de 80 mg) en la semana 2.</span></p><p ><span> </span></p><p ><span>En la semana 8, se aleatorizó de forma igualitaria y doble</span><span>ciego a 62 pacientes que mostraron respuesta clínica según la puntuación Mayo parcial (PMS; definida como un descenso de PMS de ≥ 2 puntos y ≥ 30% desde el inicio) para recibir tratamiento de mantenimiento con adalimumab a una dosis de mantenimiento de 0,6 mg/kg (máximo de 40 mg) cada semana , o a una dosis de mantenimiento de 0,6 mg/kg (máximo de 40 mg) en semanas alternas. Previo a una enmienda al diseño del estudio, se aleatorizaron a 12 pacientes adicionales que mostraron respuesta clínica según la PMS para recibir placebo, pero no se les incluyó en el análisis de confirmación de eficacia.</span></p><p ><span> </span></p><p ><span>La exacerbación de la enfermedad se definió como un aumento de la PMS de al menos 3 puntos (para pacientes con una PMS de 0 a 2 en la semana 8), de al menos 2 puntos (para pacientes con una PMS de 3 a 4 en la semana 8), o de al menos 1 punto (para pacientes con una PMS de 5 a 6 en la semana 8).</span></p><p ><span> </span></p><p ><span>Se aleatorizó a los pacientes que cumplían los criterios de exacerbación de la enfermedad en la semana 12 o después de esta para recibir una dosis de reinducción de 2,4 mg/kg (máximo de 160 mg) o una dosis de 0,6 mg/kg (máximo de 40 mg) y siguieron recibiendo su régimen de dosis de mantenimiento respectivo posteriormente.</span></p><p ><em><span> </span></em></p><p ><em><span style="text-decoration: underline"><span>Resultados de eficacia</span></span></em></p><p ><span> </span></p><p ><span>Las variables coprimarias del estudio fueron la remisión clínica según la PMS (definida como PMS ≤ 2 y ninguna subpuntuación individual &gt; 1) en la semana 8, y la remisión clínica según la puntuación Mayo completa (FMS, Full Mayo Score) (definida como una puntuación Mayo de ≤ 2 y ninguna subpuntuación individual &gt; 1) en la semana 52 en pacientes que alcanzaron una respuesta clínica según la PMS en la semana 8. Las tasas de remisión clínica según PMS en la semana 8 de los pacientes en cada uno de los grupos de inducción doble ciego de adalimumab se presentan en la Tabla 31.</span></p><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td colspan="3"><p style="text-align:center"><strong><span>Tabla 31: Remisión clínica según PMS a las 8 semanas</span></strong></p></td></tr><tr><td><p><span> </span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>a</span></strong></p><p style="text-align:center"><strong><span>Máximo de 160 mg en la semana 0/placebo en la semana 1</span></strong></p><p style="text-align:center"><span>N = 30</span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>b, c</span></strong></p><p style="text-align:center"><strong><span>Máximo de 160 mg en la semana 0 y en la semana 1</span></strong></p><p style="text-align:center"><span>N = 47</span></p></td></tr><tr><td><p><span>Remisión clínica</span></p></td><td><p style="text-align:center"><span>13/30 (43.3%)</span></p></td><td><p style="text-align:center"><span>28/47 (59.6%)</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span>a</span><span>Adalimumab 2.4 mg/kg (máximo de 160 mg) en la semana 0, placebo en la semana 1, y adalimumab 1.2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>b</span><span>Adalimumab 2.4 mg/kg (máximo de 160 mg) en la semana 0 y en la semana 1, y 1.2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>c</span><span>Sin incluir la dosis de inducción abierta de Adalimumab de 2,4 mg/kg (máximo de 160 mg) en la semana 0 y la semana 1, y de 1,2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>Nota 1:Ambos grupos de inducción recibieron 0,6 mg/kg (máximo de 40 mg) en la semana 4 y la semana 6</span></p><p ><span>Nota 2: Se consideró que los pacientes a los que les faltaban valores en la semana 8 no habían cumplido el criterio de evaluación</span></p><p ><span> </span></p><p ><span>En la semana 52, se evaluaron la remisión clínica según la FMS en los pacientes que respondieron en la semana 8, la respuesta clínica según la FMS (definida como un descenso en la puntuación Mayo de ≥ 3 puntos y ≥ 30% desde el inicio) en los pacientes que respondieron en la semana 8, la curación mucosa (definida como subpuntuación endoscópica Mayo de ≤ 1) en los pacientes que respondieron en la semana 8, la remisión clínica según la FMS en los pacientes que presentaron remisión en la semana 8 y la proporción de sujetos que presentó remisión sin corticoesteroides según la FMS en los pacientes que respondieron en la semana 8, de los pacientes que recibieron dosis de mantenimiento de Humira doble ciego máximo de</span><span>40 mg en semanas alternas (0,6 mg/kg) y máximo de 40 mg cada semana (0,6 mg/kg) (Tabla 32).</span></p><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td colspan="3"><p style="text-align:center"><strong><span>Tabla 32:</span></strong><strong><span>Resultados de eficacia a las 52 semanas</span></strong></p></td></tr><tr><td><p><span> </span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>a</span></strong></p><p style="text-align:center"><strong><span>Máximo de 40 mg en semanas alternas</span></strong></p><p style="text-align:center"><span>N = 31</span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>b</span></strong></p><p style="text-align:center"><strong><span>Máximo de 40 mg cada semana</span></strong></p><p style="text-align:center"><span>N = 31</span></p></td></tr><tr><td><p><span>Remisión clínica en respondedores según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>9/31 (29.0%)</span></p></td><td><p style="text-align:center"><span>14/31 (45.2%)</span></p></td></tr><tr><td><p><span>Respuesta clínica en respondedores según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>19/31 (61.3%)</span></p></td><td><p style="text-align:center"><span>21/31 (67.7%)</span></p></td></tr><tr><td><p><span>Curación mucosa en respondedores según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>12/31 (38.7%)</span></p></td><td><p style="text-align:center"><span>16/31 (51.6%)</span></p></td></tr><tr><td><p><span>Remisión clínica en pacientes en remisión según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>9/21 (42.9%)</span></p></td><td><p style="text-align:center"><span>10/22 (45.5%)</span></p></td></tr><tr><td><p><span>Remisión sin corticoesteroides en respondedores según PMS en la semana 8</span><span>c</span></p></td><td><p style="text-align:center"><span>4/13 (30.8%)</span></p></td><td><p style="text-align:center"><span>5/16 (31.3%)</span></p></td></tr><tr><td colspan="3"><p><span>a</span><span>Adalimumab 0.6 mg/kg (máximo de 40 mg) en semanas alternas</span></p><p><span>b</span><span>Adalimumab 0.6 mg/kg (máximo de 40 mg) cada semana</span></p><p><span>c</span><span>En pacientes con tratamiento concomitante de corticoesteroides en el inicio</span></p><p><span>Nota: Los pacientes sin valores en semana 52 o aleatorizados para recibir tratamiento de reinducción o de mantenimiento fueron considerados no respondedores para las variables de la semana 52.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span> </span></p><p ><span>Las variables exploratorias de eficacia adicionales fueron la respuesta clínica según el índice de actividad de la colitis ulcerosa pediátrica (Paediatric Ulcerative Colitis Activity Index, PUCAI) (definido como un descenso de PUCAI de ≥ 20 puntos desde el inicio) y la remisión clínica según PUCAI (definida como PUCAI &lt; 10) en la semana 8 y en la semana 52 (Tabla 33).</span></p><p ><span> </span></p><table cellspacing="0" cellpadding="0" ><tr><td colspan="3"><p><strong><span>                    Tabla 33:</span></strong><strong><span>Resultados de los criterios de valoración exploratorios según PUCAI</span></strong></p></td></tr><tr><td><p><span> </span></p></td><td colspan="2"><p style="text-align:center"><span>Semana 8</span></p></td></tr><tr><td><p><span> </span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>a</span></strong></p><p style="text-align:center"><strong><span>Máximo de 160 mg en la semana 0 / placebo en la semana 1</span></strong></p><p style="text-align:center"><span>N = 30</span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>b,c</span></strong></p><p style="text-align:center"><strong><span>Máximo de 160 mg en la semana 0 y en la semana 1</span></strong></p><p style="text-align:center"><span>N = 47</span></p></td></tr><tr><td><p><span>Remisión clínica según PUCAI</span></p></td><td><p style="text-align:center"><span>10/30 (33.3%)</span></p></td><td><p style="text-align:center"><span>22/47 (46.8%)</span></p></td></tr><tr><td><p><span>Respuesta clínica según PUCAI</span></p></td><td><p style="text-align:center"><span>15/30 (50.0%)</span></p></td><td><p style="text-align:center"><span>32/47 (68.1%)</span></p></td></tr><tr><td rowspan="2"><p><span> </span></p></td><td colspan="2"><p style="text-align:center"><span>Semana 52</span></p></td></tr><tr><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>d</span></strong></p><p style="text-align:center"><strong><span>Máximo de 40 mg en semanas alternas</span></strong></p><p style="text-align:center"><span>N=31</span></p></td><td><p style="text-align:center"><strong><span>Adalimumab</span></strong><strong><span>e</span></strong></p><p style="text-align:center"><strong><span>Máximo de 40 mg cada semana</span></strong></p><p style="text-align:center"><span>N=31</span></p></td></tr><tr><td><p><span>Remisión clínica según PUCAI</span></p><p><span>para respondedores según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>14/31 (45.2%)</span></p></td><td><p style="text-align:center"><span>18/31 (58.1%)</span></p></td></tr><tr><td><p><span>Respuesta clínica según PUCAI para respondedores según PMS en la semana 8</span></p></td><td><p style="text-align:center"><span>18/31 (58.1%)</span></p></td><td><p style="text-align:center"><span>16/31 (51.6%)</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span>a</span><span>Adalimumab 2.4 mg/kg (máximo de 160 mg) en la semana 0, placebo en la semana 1, y adalimumab 1.2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>b</span><span>Adalimumab 2.4 mg/kg (máximo de 160 mg) en la semana 0 y en la semana 1, y 1.2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>c</span><span>Sin incluir la dosis de inducción abierta de adalimumab 2.4 mg/kg (máximo de 160 mg) en la semana 0 y la semana 1, y de 1.2 mg/kg (máximo de 80 mg) en la semana 2</span></p><p ><span>d</span><span>Adalimumab 0.6 mg/kg (máximo de 40 mg) en semanas alternas</span></p><p ><span>e</span><span>Adalimumab 0.6 mg/kg (máximo de 40 mg) cada semana</span></p><p ><span>Nota 1: Ambos grupos de inducción recibieron 0,6 mg/kg (máximo de 40 mg) en la semana 4 y la semana 6</span></p><p ><span>Nota 2: Se consideró que los pacientes sin valores en la semana 8 no habían cumplido los criterios de evaluación</span></p><p ><span>Nota 3: Los pacientes sin valores en semana 52 o aleatorizados para recibir tratamiento de reinducción o de mantenimiento fueron considerados no respondedores para las variables de la semana 52</span></p><p ><span> </span></p><p ><span> </span></p><p ><span>De los pacientes tratados con adalimumab que recibieron tratamiento de reinducción durante el periodo de mantenimiento, 2/6 (33%) consiguieron una respuesta clínica según FMS en la semana 52.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Calidad de vida</span></span></em></p><p ><span> </span></p><p ><span>Se observaron mejoras clínicamente significativas desde el inicio en las puntuaciones IMPACT III y WPAI (Work Productivity and Activity Impairment, puntuación del deterioro de la actividad y la productividad laboral) de los grupos tratados con adalimumab.</span></p><p ><span> </span></p><p ><span>Se observaron aumentos clínicamente significativos (mejoras) desde el inicio en la velocidad de crecimiento en los grupos tratados con adalimumab, y aumentos clínicamente significativos (mejoras) desde el inicio en el índice de masa corporal en sujetos con dosis alta de mantenimiento de un máximo de 40 mg (0,6 mg/kg) cada semana.</span></p><p ><span> </span></p><p ><em><span>Uveítis pediátrica</span></em></p><p ><span> </span></p><p ><span>La seguridad y la eficacia de adalimumab se evaluaron en un ensayo controlado, aleatorizado, doble ciego con 90 pacientes pediátricos de edades entre 2 y &lt;18 años con uveítis anterior no infecciosa asociada a AIJ activa, los cuales fueron refractarios a al menos 12 semanas de tratamiento con metotrexato. Los pacientes recibieron placebo, o 20 mg de adalimumab (si &lt; 30 kg) o 40 mg de adalimumab (si ≥ 30 kg) en semanas alternas en combinación con su dosis basal de metotrexato.</span></p><p ><span> </span></p><p ><span>La variable principal fue “el tiempo hasta fallo del tratamiento”. Los criterios determinantes del fallo fueron un empeoramiento o una no mejora mantenida de la inflamación ocular; una mejora parcial con desarrollo de comorbilidades oculares mantenidas; o un empeoramiento de las comorbilidades, impidiendo el uso de medicamentos concomitantes y una suspensión del tratamiento por un largo periodo de tiempo.</span></p><p ><span> </span></p><p ><em><span style="text-decoration: underline"><span>Respuesta clínica</span></span></em></p><p ><span> </span></p><p ><span>Adalimumab retrasó de forma significativa el tiempo hasta fallo del tratamiento en comparación con el placebo (Ver Figura 3, P &lt; 0,0001 del log rank test). La mediana del tiempo hasta fallo del tratamiento fue de 24,1 semanas para los pacientes tratados con placebo, mientras que la mediana del tiempo hasta fallo del tratamiento no se pudo estimar para los pacientes tratados con adalimumab porque menos de la mitad de ellos experimentaron fallo del tratamiento. Adalimumab disminuyó significativamente el riesgo de fallo del tratamiento en un 75% respecto a placebo, tal y como muestra el cociente de riesgo (HR = 0,25 [ICI 95 %: 0,12- 0,49]).</span></p><p ><span> </span></p><p ><strong><span>Figura 3: Curva de Kaplan-Meier que resume el tiempo hasta fallo del tratamiento en el estudio de uveítis pediátrica</span></strong></p><p style="text-align:center" ><strong><span> </span></strong></p><table cellspacing="0" cellpadding="0" ><tr><td><p style="text-align:center"><strong><span>PROBABILIDAD EN EL FALLO DEL TRATAMIENTO</span></strong></p></td><td colspan="5"><p><img src="data:image/jpg;base64,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" width="546" height="454" alt="Humira PED UV KM Curve REVISED 3" /></p></td></tr><tr><td><p><span> </span></p></td><td colspan="5"><p style="text-align:center"><strong><span>TIEMPO (SEMANAS)</span></strong></p></td></tr><tr><td><p><span> </span></p></td><td><p><span>Tratamiento</span></p></td><td><p style="text-align:center"><img src="data:image/jpg;base64,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" width="49" height="13" alt="Humira PED UV KM Curve 11" /></p></td><td><p><span>Placebo</span></p></td><td><p><img src="data:image/jpg;base64,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" width="48" height="9" alt="Humira PED UV KM Curve 11" /></p></td><td><p><span>Adalimumab</span></p></td></tr><tr><td><p><span> </span></p></td><td colspan="5"><p><span>Nota: P = Placebo (Número en riesgo); A = Adalimumab (Número en riesgo).</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p ><span> </span></p></div></text></section><section id="565fdcdf-a90f-4378-a6e9-776ab591b3f3"><title value="5.2. Propiedades farmacocinéticas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029827" /><display value="5.2 Propiedades farmacocinéticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span style="text-decoration: underline"><span>Absorción y distribución</span></span></p><p ><span> </span></p><p ><span>La absorción y distribución de adalimumab tras la administración subcutánea de una dosis única de 40</span><span> </span><span>mg, fue lenta, alcanzándose las concentraciones plasmáticas máximas a los 5 días después de la administración.</span></p><p ><span> </span></p><p ><span>La media de biodisponibilidad absoluta de adalimumab fue del 64</span><span> </span><span>%, estimada a partir de tres ensayos con una dosis subcutánea única de 40 mg. Tras la administración intravenosa de dosis únicas en un rango de 0,25 a 10 mg/kg, las concentraciones fueron proporcionales a la d</span><span>osis. Tras la administración de dosis de 0,5 mg/kg (</span><span>?</span><span>40 mg), el aclaramiento osciló en el rango de 11 a 15</span><span> </span><span>ml/hora, el volumen de distribución (V</span><span>ss</span><span>) entre 5 y 6 litros, y la semivida media de eliminación terminal fue aproximadamente dos semanas. Las concen</span><span>traciones de adalimumab en el líquido sinovial, determinadas en varios pacientes con artritis reumatoide, oscilaron entre el 31 y el 96 % de las plasmáticas.</span></p><p ><span> </span></p><p ><span>Tras la administración subcutánea de 40 mg de adalimumab en semanas alternas en pacientes adultos con artritis reumatoide (AR), la media de las concentraciones en el punto mínimo en el estado estacionario fue aproximadamente 5 μg/ml (sin tratamiento concomitante con metotrexato) y 8 a 9 μg/ml (con metotrexato concomitante). Los niveles plasmáticos de adalimumab en el estado estacionario aumentaron más o menos proporcionalmente con la dosis tras la administración subcutánea de 20, 40 y 80 mg en semanas alternas y cada semana.</span></p><p ><span> </span></p><p ><span>Tras la administración subcutánea en semanas alternas de 24 mg/m</span><span>2</span><span>(máximo de</span><span>40</span><span> </span><span>mg) en pacientes con artritis idiopática juvenil poliarticular (AIJ), que tenían entre 4 y 17 años, la concentración plasmática media de adalimumab en estado estacionario (valores medidos de la semana 20 a la 48) fue 5,6 ± 5,6 μg/ml (102</span><span> </span><span>%</span><span> </span><span>CV) con adalimumab sin metotrexato concomitante y 10,9 ± 5,2 μg/ml (47,7</span><span> </span><span>%</span><span> </span><span>CV) con metotrexato concomitante.</span></p><p ><span> </span></p><p ><span>En pacientes con AIJ poliarticular que tenían de 2 a 4 años o con 4 años y un peso inferior a 15 kg dosificados con 24 mg/m</span><span>2</span><span>de adalimumab, la concentración plasmática media de adalimumab en estado estacionario fue 6,0 ± 6,1 μg/ml (101%CV) para adalimumab sin metotrexato concomitante y 7,9 ± 5,6 μg/ml (71,2</span><span> </span><span>%</span><span> </span><span>CV) con metotrexato concomitante.</span></p><p ><span> </span></p><p ><span>Tras la administración de 24 mg/m</span><span>2</span><span>(máximo de 40 mg) por vía subcután</span><span>ea en semanas alternas en pacientes de 4 a 17 años con artritis asociada entesitis, la concentración media de adalimumab en estado estacionario (valores medidos en la semana 24) fue de 8,8 ±6,6 μg/ml para adalimumab sin metotrexato concomitante y 11,8 ± 4,3 μg/ml con metotrexato concomitante.</span></p><p ><span> </span></p><p ><span>Tras la administración subcutánea de 40 mg de adalimumab cada dos semanas en pacientes adultos con espondiloartritis axial no radiográfica, la concentración media (±SD) en el estado estacionario en la semana 68 fue de 8,0 ± 4,6 μg/ml.</span></p><p ><span> </span></p><p ><span>En pacientes adultos con psoriasis, la media de la concentración en el punto mínimo en el estado estacionario fue de 5 μg/ml durante el tratamiento en monoterapia con adalimumab 40 mg en semanas alternas.</span></p><p ><span> </span></p><p ><span>Tras la administración subcután</span><span>ea de 0,8</span><span> </span><span>mg/kg (máximo de 40 mg) en semanas alternas a pacientes pediátricos con psoriasis en placas crónica, la media (± DS) de las concentraciones de adalimumab en el punto mínimo del estado estacionario fue 7,4 ± 5,8</span><span> </span><span>μg/ml (79</span><span> </span><span>%</span><span> </span><span>CV).</span></p><p ><span> </span></p><p ><span>En pacientes adul</span><span>tos con hidradenitis supurativa, con una dosis de 160 mg de adalimumab en la semana 0 seguido de 80 mg en la semana 2 se alcanzaron concentraciones séricas mínimas de adalimumab de aproximadamente 7 a 8 μg/ml en la semana 2 y la semana 4. La concentración media en el estado estacionario en la semana 12 hasta la semana 36 fue aproximadamente de 8 a 10 μg/ml durante el tratamiento con adalimumab 40 mg semanal.</span></p><p ><span> </span></p><p ><span>La exposición de adalimumab en pacientes adolescentes con HS se predijo usando modelos de farmacoci</span><span>nética poblacional y simulación basado en la farmacocinética del conjunto de indicaciones en otros pacientes pediátricos (psoriasis pediátrica, artritis idiopática juvenil, enfermedad de Crohn pediátrica, y artritis asociada a entesitis). La pauta posológica recomendada para HS en adolescentes es 40 mg en semanas alternas. Debido a que la exposición a adalimumab se puede ver afectada por el tamaño corporal, los adolescentes con mayor peso corporal y una respuesta inadecuada se pueden beneficiar de la dosis</span><span>recomendada en adultos de 40 mg semanales.</span></p><p ><span> </span></p><p ><span>En pacientes con enfermedad de Crohn, con la dosis de carga de 80 mg de adalimumab en la semana 0, seguida de 40 mg de adalimumab en la semana 2, se alcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 5,5 μg/ml durante el periodo de inducción. Con la dosis de carga de 160 mg de adalimumab en la semana 0, seguida de 80 mg de adalimumab en la semana 2, se alcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 12 μg/ml durante el periodo de inducción. Se observaron niveles medios en el punto mínimo en el estado estacionario de aproximadamente 7 μg/ml en pacientes con enfermedad de Crohn que recibieron una dosis de mantenimiento de 40 mg de adalimumab en semanas alte</span><span>rnas.</span></p><p ><span> </span></p><p ><span>En pacientes pediátricos con enfermedad de Crohn de moderada a grave, la dosis de inducción con adalimumab fue de 160/80 mg u 80/40 mg en las semanas 0 y 2, respectivamente, dependiendo de un corte de 40 kg de peso corporal. En la semana 4, los pacientes fueron aleatorizados 1:1 en grupos de tratamiento de mantenimiento según su peso corporal a la Dosis Estándar (40/20 mg en semanas alternas) o Dosis Baja (20/10 mg en semanas alternas). La media (± DS) de la concentración sérica valle de adalimumab a</span><span>lcanzada en la semana 4 fue 15,7±6,6 μg/ml para pacientes ≥ 40 kg (160/80 mg) y 10,6±6,1 μg/ml para pacientes &lt; 40 kg (80/40 mg).</span></p><p ><span> </span></p><p ><span>Para aquellos pacientes que permanecieron en el tratamie</span><span>nto aleatorizado, la media (±DS) de la concentración valle de adalimumab en la Semana 52 fue de 9,5±5,6 μg/ml para el grupo de la Dosis Estándar y 3,5±2,2 μg/ml para el grupo de Dosis Bajas. Se mantuvo la media de las concentraciones valle en los sujetos que continuaron el tratamiento con adalimumab en semanas alternas durante 52 semanas. Para aquellos pacientes en los que se produjo una escalada de dosis de la pauta de semanas alternas a semanalmente, la media (± DS) de las concentraciones séricas de adalimumab en la semana 52 fueron 15,3±11,4 μg/ml (40/20 mg semanalmente) y 6,7±3,5 μg/ml (20/10 mg semanalmente).</span></p><p ><span> </span></p><p ><span>En pacientes adultos con colitis ulcerosa, con la dosis de carga de 160 mg de adalimumab en la semana 0, seguida de 80 mg de adalimumab en la semana 2 se alcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 12 μg/ml durante el periodo de inducción. Se observaron niveles medios en el punto mínimo en el estado estacionario de 8 μg/ml en pacientes con colitis ulcerosa que recibieron una dosis de mantenimiento de 40 mg de adalimumab en semanas alternas.</span></p><p ><span> </span></p><p ><span>Tras la administración subcutánea de una dosis basada en el peso corporal de 0,6 mg/kg (máximo de 40 mg) en semanas alternas en pacientes pediátricos con colitis ulcerosa, la concentración sérica media de adalimumab en el punto mínimo del estado estacionario fue de 5,01 ± 3,28 μg/ml en la semana 52. Para pacientes que recibieron 0,6 mg/kg (máximo de 40 mg) cada semana, la concentración sérica media (± DE) de adalimumab en el punto mínimo del estado estacionario fue de 15,7 ± 5,60 μg/ml en la semana 52.</span></p><p ><span> </span></p><p ><span>En pacientes adultos con uveítis, una dosis de carga de 80 mg de adalimumab en la semana 0 seguida de 40 mg de adalimumab en semanas alternas comenzando en la semana 1, permitió alcanzar concentraciones medias en el estado estacionario de aproximadamente 8 a 10 μg/ml.</span></p><p ><span> </span></p><p ><span>La exposición de adalimumab en pacientes pediátricos con uveítis se predijo utilizando el modelo farmacocinético de población y la simulación basada en la farmacocinética de indicación cruzada en otros pacientes pediátricos (psoriasis pediátrica, artritis idiopática juvenil, enfermedad de Crohn pediátrica y artritis asociada a entesitis). No se dispone de datos de exposición clínica sobre el uso de una dosis de carga en niños menores de 6 años. Las exposiciones previstas indican que, en ausencia de metotrexato, una dosis de carga puede llevar a un aumento inicial de la exposición sistémica.</span></p><p ><span> </span></p><p ><span>La modelización y simulación de la farmacocinética/farmacodinámica y la farmacocinética de la población predijo una exposición a adalimumab y eficacia similar en pacientes tratados con 80 mg cada dos semanas comparado con 40 mg semanal (incluyendo pacientes adultos con AR, HS, CU, EC o Ps, pacientes con HS adolescente, y pacientes pediátricos ≥ 40 kg con EC y CU).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Relación exposición-respuesta en población pediátrica</span></span></p><p ><span> </span></p><p ><span>Basándose en los datos de ensayos clínicos en pacientes con AIJ (AIJp y ARE) se estableció una relación exposición-respuesta entre las concentraciones plasmáticas y la respuesta PedACR50. La concentración plasmática aparente de adalimumab que produce la mitad del máximo de probabilidad de respuesta PedACR50 (EC50) fue 3 μg/ml (95% IC: 1-6 μg/ml).</span></p><p ><span> </span></p><p ><span>Las relaciones exposición-respuesta entre la concentración de adalimumab y la eficacia en pacientes pediátricos con placas psoriásicas crónicas graves se establecieron por PASI 75 y PGA de sin lesiones o mínimas, respectivamente. PASI 75 y PGA de sin lesiones o mínimas aumentó con el aumento de las concentraciones de adalimumab ambas con un EC50 aparente de aproximadamente 4,5 μg/ml (95% IC 0,4-47,6 y 1,9-10,5, respectivamente).</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Eliminación</span></span></p><p ><span> </span></p><p ><span>Los análisis farmacocinéticos poblacionales con datos de aproximadamente 1.300 pacientes con AR revelaron una tendencia a una correlación directa entre el incremento aparente del aclaramiento de adalimumab y el peso corporal. Después de un ajuste según las diferencias de peso corporal, se observó que el efecto del sexo y la edad sobre el aclaramiento de adalimumab era mínimo. Los niveles plasmáticos de adalimumab libre (no unido a anticuerpos anti-adalimumab, AAA) se observó que eran inferiores en pacientes con AAA cuantificables.</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Insuficiencia renal o hepática</span></span></p><p ><span> </span></p><p ><span>Adalimumab no se ha estudiado en pacientes con insuficiencia hepática o renal.</span></p><p ><span> </span></p></div></text></section><section id="0eeb5701-4acf-477d-a65c-f84b3c4deb2d"><title value="5.3. Datos preclínicos sobre seguridad" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029834" /><display value="5.3 Datos preclínicos sobre seguridad" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Los datos de los estudios no clínicos no muestran riesgos especiales para los seres humanos según los estudios convencionales de toxicidad a dosis única, a dosis repetidas y genotoxicidad.</span></p><p ><span> </span></p><p ><span>Se ha llevado a cabo un estudio de toxicidad en el desarrollo embrio-fetal/perinatal en monos cinomolgos con dosis de 0,30 y 100 mg/kg (9-17 monos/grupo) que no ha revelado evidencia de daños fetales debidos a adalimumab. No se llevaron a cabo ni estudios de carcinogénesis ni de evaluación estándar de la fertilidad y de la toxicidad postnatal con adalimumab debido a la falta de modelos apropiados para estudiar un anticuerpo con reactividad cruzada limitada al TNF del roedor y al desarrollo de anticuerpos neutralizantes en roedores.</span></p><p ><span> </span></p></div></text></section></section><section id="8be805ff-904d-4950-9d09-90f4d6269847"><title value="6. Datos farmacéuticos" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029836" /><display value="6. DATOS FARMACÉUTICOS" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="d1470631-5558-4cc4-8630-980aba802e8b"><title value="6.1. Lista de excipientes" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029837" /><display value="6.1 Lista de excipientes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Dihidrogenofosfato de sodio dihidrato</span></p><p ><span>Fosfato disódico dihidrato</span></p><p ><span>Manitol</span></p><p ><span>Cloruro de sodio</span></p><p ><span>Ácido cítrico, monohidrato</span></p><p ><span>Citrato de sodio</span></p><p ><span>Polisorbato 80</span></p><p ><span>Hidróxido de sodio (para ajuste del pH)</span></p><p ><span>Agua para preparaciones inyectables</span></p><p ><span> </span></p></div></text></section><section id="ef29ddc9-4ea0-4dd4-a967-0e5f5d8f85a2"><title value="6.2. Incompatibilidades" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029838" /><display value="6.2 Incompatibilidades" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>En ausencia de estudios de compatibilidad, este medicamento no debe mezclarse con otros.</span></p><p ><span> </span></p></div></text></section><section id="a1509cdb-26aa-4ef5-bfbc-eeab171af8af"><title value="6.3. Periodo de validez" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029839" /><display value="6.3 Periodo de validez" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>2 años</span></p><p ><span> </span></p></div></text></section><section id="6c597f5f-2efd-4f8d-9033-e24a5bf70006"><title value="6.4. Precauciones especiales de conservación" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029840" /><display value="6.4 Precauciones especiales de conservación" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Conservar en nevera (2ºC – 8ºC). No congelar. Conservar la jeringa precargada o la pluma precargada en el embalaje exterior para protegerla de la luz.</span></p><p ><span> </span></p><p ><span>Una única jeringa precargada o pluma precargada de Idacio se puede almacenar a una temperatura máxima de 25ºC durante un periodo de hasta 28 días. La jeringa precargada o la pluma precargada se debe proteger de la luz y desechar si no se usa dentro del periodo de 28 días.</span></p><p ><span> </span></p></div></text></section><section id="7355ad90-922b-4fcb-b5ad-08f5def16002"><title value="6.5. Naturaleza y contenido del envase" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029841" /><display value="6.5 Naturaleza y contenido del envase [y de los equipos especiales para su utilización, administración o implantación]" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en jeringa precargada</span></span></p><p ><span>0,8 ml de solución inyectable en jeringa precargada (vidrio tipo I) con una aguja 29G de pared fina y de ½ pulgada, con capuchón sin látex y protector de aguja, un émbolo (goma sintética) y alas de sujeción para los dedos.</span></p><p ><span> </span></p><p ><span>Tamaños de envase:</span></p><ul ><li><span>2 jeringas precargadas con 2 toallitas impregnadas en alcohol.</span></li><li><span>6 jeringas precargadas con 6 toallitas impregnadas en alcohol.</span></li></ul><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en pluma precargada</span></span></p><p ><span>0,8 ml de solución inyectable en pluma precargada PhysiojectTM que contiene una jeringa precargada (vidrio tipo I) con una aguja 29G de pared fina y de ½ pulgadas con capuchón sin látex y un émbolo (goma sintética). La pluma es un dispositivo de inyección mecánico, desechable, portátil y de un solo uso.</span></p><p ><span> </span></p><p ><span>Tamaños de envase:</span></p><ul ><li><span>2 plumas precargadas, con 2 toallitas impregnadas en alcohol.</span></li><li><span>6 plumas precargadas, con 6 toallitas impregnadas en alcohol.</span></li></ul><p ><span> </span></p><p ><span>Puede que solamente estén comercializadas algunas presentaciones.</span></p><p ><span> </span></p></div></text></section><section id="af8286c3-360c-4573-8591-dac1264432c5"><title value="6.6. Precauciones especiales de eliminación y otras manipulaciones" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029842" /><display value="6.6 Precauciones especiales de eliminación [y otras manipulaciones]" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él se realizará de acuerdo con la normativa local.</span></p><p ><span> </span></p></div></text></section></section><section id="af24ae01-c853-4b0e-90e9-0b4ecbe75c53"><title value="7. Titular de la autorización de comercialización" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029844" /><display value="7. TITULAR DE LA AUTORIZACIÓN DE COMERCIALIZACIÓN" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>Fresenius Kabi Deutschland GmbH</span></p><p ><span>Else-Kröner-Straße 1</span></p><p ><span>61352 Bad Homburg v.d.Höhe</span></p><p ><span>Alemania</span></p><p ><span> </span></p></div></text></section><section id="d8260324-edab-456f-be65-1381e769043c"><title value="8. Número(s) de autorización de comercialización" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029845" /><display value="8. NÚMERO(S) DE AUTORIZACIÓN DE COMERCIALIZACIÓN" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en jeringa precargada</span></span></p><p ><span>EU/1/19/1356/002</span></p><p ><span>EU/1/19/1356/004</span></p><p ><span> </span></p><p ><span style="text-decoration: underline"><span>Idacio 40 mg solución inyectable en pluma precargada</span></span></p><p ><span>EU/1/19/1356/003</span></p><p ><span>EU/1/19/1356/005</span></p><p ><span> </span></p></div></text></section><section id="2abdc3a5-be56-4085-812e-d8a37624c094"><title value="9. Fecha de la primera autorización/ renovación de la autorización" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029846" /><display value="9. FECHA DE LA PRIMERA AUTORIZACIÓN/RENOVACIÓN DE LA AUTORIZACIÓN" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span> </span></p><p ><span>Fecha de la primera autorización: 2 de Abril de 2019</span></p><p ><span>Fecha de la última renovación:</span></p><p ><span> </span></p></div></text></section><section id="376ba5fd-4543-4fea-a3d8-58bd8230c426"><title value="10. Fecha de la revisión del texto" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029847" /><display value="10. FECHA DE LA REVISIÓN DEL TEXTO" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p ><span>La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos</span><a href="http://www.ema.europa.eu/"><span style="text-decoration: underline"><span>http://www.ema.europa.eu/</span></span></a><span>.</span></p></div></text></section></section></Composition></resource></entry></Bundle></resource></entry><entry><fullUrl value="f3566a33-e259-4a57-9b40-3e1bfefbdffa" /><resource><Bundle><id value="f3566a33-e259-4a57-9b40-3e1bfefbdffa" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="f3566a33-e259-4a57-9b40-3e1bfefbdffa" /></identifier><type value="document" /><timestamp value="2025-06-04T14:15:22.4390336+02:00" /><entry><fullUrl value="f3566a33-e259-4a57-9b40-3e1bfefbdffa" /><resource><Composition><meta><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiCompositionPackageLeaflet" /><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiComposition" /><profile value="http://ema.europa.eu/fhir/StructureDefinition/EUQRD-NAP-template-new-ORG-100003943-Package-Leaflet-es" /></meta><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://ema.europa.eu/fhir/CodeSystem/100000155531" /><code value="100000155538" /><display value="Prospecto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2025-06-04" /><author><reference value="Company Name" /></author><title value="Prospecto" /><section><title value="Prospecto" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029894" /><display value="Prospecto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="text-align:center"><strong><span>Prospecto: Información para el paciente</span></strong></p><p style="text-align:center"><strong><span> </span></strong></p><p style="text-align:center"><strong><span>Idacio 40 mg solución inyectable en jeringa precargada</span></strong></p><p style="text-align:center"><span>adalimumab</span></p><p style="text-align:center"><span> </span></p><p><strong><span>Lea todo el prospecto detenidamente antes de empezar a usar este medicamento, porque contiene información importante para usted.</span></strong></p><ul><li><span>Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li><span>Su médico le dará una tarjeta de información para el paciente, que contiene información de seguridad importante que necesita conocer antes y durante el tratamiento con Idacio.</span></li></ul><p><span>Conserve esta tarjeta de información para el paciente durante su tratamiento y los 4 meses posteriores a su última inyección (o de su hijo) de Idacio.</span></p><ul><li><span>Si tiene alguna duda, consulte a su médico o farmacéutico.</span></li><li><span>Este medicamento se le ha recetado solamente a usted y no debe dárselo a otras personas, aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.</span></li><li><span>Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.</span></li></ul><p><span> </span></p><p><strong><span>Contenido del prospecto</span></strong></p><ol style="list-style-type: decimal"><li><span>Qué es Idacio y para qué se utiliza</span></li><li><span>Qué necesita saber antes de empezar a usar Idacio</span></li><li><span>Cómo usar Idacio</span></li><li><span>Posibles efectos adversos</span></li><li><span>Conservación de Idacio</span></li><li><span>Contenido del envase e información adicional</span></li><li><span>Instrucciones de uso</span></li></ol><p><span> </span></p></div></text><section id="af5d615f-3f5c-46fb-8bb8-66c3eff776ba"><title value="1. Qué es Idacio y para qué se utiliza" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029895" /><display value="1. Qué es X y para qué se utiliza" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span>Idacio contiene como sustancia activa adalimumab, un medicamento que actúa sobre el sistema inmunitario (de defensa) de su organismo.</span></p><p><span> </span></p><p><span>Idacio está indicado en el tratamiento de las siguientes enfermedades inflamatorias:</span></p><ul><li><span>artritis reumatoide,</span></li><li><span>artritis idiopática juvenil poliarticular,</span></li><li><span>artritis asociada a entesitis,</span></li><li><span>espondilitis anquilosante,</span></li><li><span>espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante,</span></li><li><span>artritis psoriásica,</span></li><li><span>psoriasis,</span></li><li><span>hidradenitis supurativa,</span></li><li><span>enfermedad de Crohn,</span></li><li><span>colitis ulc</span><span>erosa y</span></li><li><span>uveítis no infecciosa.</span></li></ul><p><span> </span></p><p><span>La sustancia activa de Idacio, adalimumab, es un anticuerpo monoclonal. Los anticuerpos monoclonales son proteínas que se unen a una diana específica del cuerpo.</span></p><p><span> </span></p><p><span>La diana de adalimumab es otra proteína llamada factor de necrosis tumoral (TNFα), que se encuentra en niveles elevados en las enfermedades inflamatorias descritas arriba. Mediante el ataque al TNFα, Idacio bloquea su acción y reduce el proceso de inflamación en esas enfermedades.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Artritis reumatoide</span></span></p><p><span> </span></p><p><span>La artritis r</span><span>eumatoide es una enfermedad inflamatoria de las articulaciones.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la artritis reumatoide en adultos. Si usted padece artritis reumatoide activa moderada a grave, puede que se le administren antes otros medicamentos modificadores de la enfermedad tales como metotrexato. Si el efecto de estos medicamentos no es suficiente, se le administrará Idacio para tratar su artritis reumatoide.</span></p><p><span> </span></p><p><span>Idacio también puede usarse en el tratamiento de la artritis reumatoide grave, activa y progresiva sin tratamiento previo con metotrexato.</span></p><p><span> </span></p><p><span>Idacio puede reducir el daño de los cartílagos y huesos de las articulaciones producido por la enfermedad y mejora el rendimiento físico.</span></p><p><span> </span></p><p><span>Habitualmente Idacio se usa junto con metotrexato. Si su médico considera que el metotrexato no es apropiado, Idacio puede administrarse solo.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Artritis idiopática juvenil poliarticular y artritis asociada a entesitis</span></span></p><p><span> </span></p><p><span>La artritis idiopática juvenil poliarticular y la artritis asociada a entesitis son enfermedades inflamatorias de las articulaciones que suelen aparecer por primera vez en la infancia.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la artritis idiopática juvenil poliarticular en niños y adolescentes de edades comprendidas entre los 2 y los 17 años y la artritis asociada a entesitis en niños entre 6 y 17 años. Los pacientes pueden haber recibido primero otros fármacos modificadores de la enfermedad, como metotrexato. Si el efecto de estos medicamentos no es suficiente, los pacientes recibirán Idacio para tratar su artritis idiopática poliarticular o artritis asociada a entesitis.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Espondilitis anquilosante y espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante</span></span></p><p><span> </span></p><p><span>La espondilitis anquilosante y la espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante son enfermedades inflamatorias que afectan a la columna vertebral.</span></p><p><span> </span></p><p><span>Idacio se utiliza en adultos para tratar estas enfermedades. Si tiene espondilitis anquilosante o espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante, será tratado primero con otros medicamentos. Si el efecto de estos medicamentos no es suficiente, recibirá Idacio para reducir los signos y síntomas de su enfermedad.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Artritis psoriásica</span></span></p><p><span> </span></p><p><span>La artritis psoriásica es una enfermedad inflamatoria de las articulaciones asociada con la psoriasis.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la artritis psoriásica en adultos. Idacio puede reducir el daño articular que produce la enfermedad en el cartílago y en el hueso y mejorar el rendimiento físico.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Psoriasis en placas en adultos y niños</span></span></p><p><span> </span></p><p><span>La psoriasis en placas es una enfermedad inflamatoria de la piel que causa áreas enrojecidas, escamosas, con costras y cubiertas por escamas plateadas. La psoriasis en placas también puede afectar las uñas, provocando que se deterioren, se engrosen y se levanten del lecho de la uña, lo cual puede ser doloroso. Se cree que la psoriasis está causada por un defecto en el sistema inmune del cuerpo que lleva a un incremento en la producción de células de la piel.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la psoriasis en placas de moderada a grave en adultos. Idacio también se utiliza para tratar la psoriasis en placas grave en niños y adolescentes entre 4 y 17 años de edad que no hayan respondido o no sean buenos candidatos para el uso de medicamentos aplicados sobre la piel ni para tratamientos con luz ultravioleta.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Hidradenitis supurativa en adultos y adolescentes</span></span></p><p><span> </span></p><p><span>La hidradenitis supurativa (a veces denominada acné inverso) es una enfermedad inflamatoria de la piel de larga duración y a menudo dolorosa. Los síntomas pueden incluir nódulos sensibles (bultos) y abscesos (forúnculos) que pueden secretar pus. Normalmente afecta a áreas específicas de la piel, como debajo del pecho, de las axilas, zona interior de los muslos, ingle y nalgas. También puede haber cicatrices en las áreas afectadas.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la hidradenitis supurativa en adultos y adolescentes a partir de 12 años. Idacio puede reducir el número de nódulos y abscesos, y el dolor que normalmente va asociado a esta enfermedad. Puede haber recibido otros medicamentos previamente. Si el efecto de estos medicamentos no es suficiente, recibirá Idacio.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Enfermedad de Crohn en adultos y niños</span></span></p><p><span> </span></p><p><span>La enfermedad de Crohn es una enfermedad inflamatoria del intestino.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la enfermedad de Crohn en adultos y niños de edades comprendidas entre los 6 y los 17 años. Si padece enfermedad de Crohn será tratado primero con otros medicamentos. Si no responde suficientemente a estos medicamentos, recibirá Idacio para reducir los signos y síntomas de la enfermedad de Crohn.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Colitis ulcerosa en adultos y niños</span></span></p><p><span> </span></p><p><span>La colitis ulcerosa es una enfermedad inflamatoria del intestino grueso.</span></p><p><span> </span></p><p><span>Idacio se utiliza para tratar la colitis ulcerosa en adultos de moderada a grave en adultos y niños de 6 a 17 años. Si usted sufre colitis ulcerosa es posible que primero le receten otros medicamentos. Si el efecto de estos medicamentos no es suficiente, le recetarán Idacio para reducir los signos y los síntomas de su enfermedad.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Uveítis no infecciosa en adultos y niños</span></span></p><p><span> </span></p><p><span>La uveítis no infecciosa es una enfermedad inflamatoria que afecta a ciertas partes del ojo.</span></p><p><span> </span></p><ul><li><span>La inflamación puede dar lugar a una disminución de la visión y/o la presencia de motas en el ojo (puntos negros o líneas delgadas que se mueven a lo largo del campo de visión). Idacio actúa reduciendo esta inflamación.</span></li></ul><p><span> </span></p><p><span>Idacio se utiliza para tratar:</span></p><ul><li><span>adultos con uveítis no infecciosa con inflamación que afecta a la parte posterior del ojo.</span></li><li><span>niños desde los 2 años de edad con uveítis crónica no infecciosa con inflamación que afecta a la parte frontal del ojo.</span></li></ul><p><span> </span></p></div></text></section><section id="f7020f6d-01e4-4640-8326-64ed6b0a4e68"><title value="2. Qué necesita saber antes de empezar a usar Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029896" /><display value="2. Qué necesita saber antes de empezar a [tomar][usar] X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="f3498d18-02c7-4a7a-958c-8a2719c6f6e4"><title value="No use Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029897" /><display value="No [tome][use] X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><ul><li><span>si es alérgico a adalimumab o a alguno de los demás componentes de este medicamento (incluidos en la sección 6).</span></li></ul><p><span> </span></p><ul><li><span>si padece una infección grave, incluida tuberculosis, sepsis (infección de la sangre) u otras infecciones oportunistas (infecciones inusuales asociadas con un sistema inmunitario debilitado). En caso de tener síntomas de cualquier infección, por ejemplo: fiebre, heridas, cansancio, problemas dentales, es importante que informe a su médico (ver “Advertencias y precauciones”).</span></li></ul><p><span> </span></p><ul><li><span>si padece insuficiencia cardiaca moderada o grave. Es importante que le diga a su médico si ha tenido o tiene algún problema cardiaco serio (ver “Advertencias y precauciones”).</span></li></ul><p><span> </span></p></div></text></section><section id="ba0d2998-7ddc-400a-a3c1-a8acadb04cbc"><title value="Advertencias y precauciones" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029898" /><display value="Advertencias y precauciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>Consulte a su médico o farmacéutico antes de empezar a usar Idacio.</span></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Reacción alérgica</span></span></p><p><span> </span></p><ul><li><span>Si presenta una reacción alérgica con síntomas como opresión en el pecho, dificultad para respirar, mareo, hinchazón o sarpullido, interrumpa la administración de Idacio y póngase en contacto con su médico inmediatamente ya que, en casos raros, estas reacciones pueden poner en peligro la vida.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Infección</span></span></p><p><span> </span></p><ul><li><span>Si padece cualquier infección, incluyendo las crónicas o las localizadas (por ejemplo: una úlcera en la pierna), consulte a su médico antes de comenzar el tratamiento con Idacio. Si no está seguro, póngase en contacto con su médico.</span></li></ul><p><span> </span></p><ul><li><span>Con el tratamiento con Idacio podría contraer infecciones con más facilidad. Este riesgo puede ser mayor si presenta una función pulmonar reducida. Estas infecciones pueden ser más graves e incluyen tuberculosis, infecciones causadas por virus, hongos, parásitos o bacterias u otros organismos infecciosos inusuales y sepsis (infección de la sangre). En casos raros, estas infecciones pueden poner en peligro su vida. Por esta razón es importante que en el caso de que tenga síntomas como fiebre, heridas, cansancio o problemas dentales, se lo diga a su médico. Su médico le puede recomendar interrumpir temporalmente el tratamiento con Idacio.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Tuberculosis (TB)</span></span></p><p><span> </span></p><ul><li><span>Dado que se han descrito casos de tuberculosis en pacientes en tratamiento con Idacio, su médico le examinará en busca de signos o síntomas de tuberculosis antes de comenzar su tratamiento con Idacio. Esto incluirá la realización de una evaluación médica minuciosa, incluyendo su historia médica y pruebas de diagnóstico (por ejemplo, radiografía de tórax y la prueba de la tuberculina). La realización y resultados de estas pruebas debe anotarse en su tarjeta de información para el paciente. Es muy importante que informe a su médico en caso de haber padecido tuberculosis o haber estado en contacto con un paciente de tuberculosis. Se puede desarrollar tuberculosis durante el tratamiento incluso si usted ha recibido el tratamiento preventivo para la tuberculosis. Si apareciesen síntomas de tuberculosis (tos persistente, pérdida de peso, malestar general, febrícula) o de cualquier otra infección durante o una vez finalizado el tratamiento, póngase en contacto inmediatamente con su médico.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Infección por viaje/recurrente</span></span></p><p><span> </span></p><ul><li><span>Informe a su médico si ha vivido o viajado por regiones en las que infecciones fúngicas como histoplasmosis, coccidiomicosis o blastomicosis son frecuentes.</span></li></ul><p><span> </span></p><ul><li><span>Informe a su médico si tiene antecedentes de infecciones recurrentes u otras patologías o factores que aumenten el riesgo de infecciones.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Virus de la Hepatitis B</span></span></p><p><span> </span></p><ul><li><span>Informe a su médico si es usted portador del virus de la hepatitis B (VHB), si tiene infección activa con VHB o si piensa que podría correr riesgo de contraer el VHB. Su médico le debe realizar un análisis para el VHB. Adalimumab puede reactivar la infección por VHB en personas portadoras de este virus. En casos raros, especialmente si está tomando otros medicamentos que suprimen el sistema inmune, la reactivación de la infección por VHB puede poner en peligro su vida.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Paciente mayor de 65 años</span></span></p><p><span> </span></p><ul><li><span>Si tiene más de 65 años puede ser más susceptible de padecer infecciones mientras está en tratamiento con Idacio. Tanto usted como su médico deben prestar atención especial a la aparición de signos de infección mientras esté siendo tratado con Idacio. Es importante informar a su médico si tiene síntomas de infecciones, como fiebre, heridas, sensación de cansancio o problemas dentales.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Intervenciones quirúrgicas o dentales</span></span></p><p><span> </span></p><ul><li><span>Si le van a realizar una intervención quirúrgica o dental, informe a su médico de que está tomando Idacio. Su médico le puede recomendar que interrumpa temporalmente el tratamiento con Idacio.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Enfermedad desmielinizante</span></span></p><p><span> </span></p><ul><li><span>Si padece o desarrolla una enfermedad desmielinizante (una enfermedad que afecta a la capa aislante que rodea los nervios, como la esclerosis múltiple), su médico decidirá si debe ser tratado o continuar en tratamiento con Idacio. Informe inmediatamente a su médico si siente síntomas tales como cambios en la visión, debilidad en brazos o piernas o entumecimiento u hormigueo en cualquier parte del cuerpo.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Vacunas</span></span></p><p><span> </span></p><ul><li><span>Ciertas vacunas contienen formas vivas pero debilitadas de bacterias o virus que causan enfermedades y no se deben administrar durante el tratamiento con Idacio en el caso de que estas vacunas causeninfecciones. Consulte con su médico antes de la administración de cualquier tipo de vacuna. Si es posible, se recomienda que los niños reciban todas las vacunas establecidas en los calendarios de vacunaciónpara su edad antes de iniciar el tratamiento con Idacio. Si recibe Idacio mientras está embarazada, su hijo puede tener un riesgo mayor de sufrir infecciones durante unos 5 meses siguientes a la última dosis que haya recibido de Idacio durante su embarazo. Es importante que informe al médico de su hijo y a otros profesionales sanitarios sobre su uso de Idacio durante el embarazo, para que ellos puedan decidir si su hijo debe recibir alguna vacuna.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Insuficiencia cardiaca</span></span></p><p><span> </span></p><ul><li><span>Es importante que informe a su médico si ha padecido o padece problemas graves de corazón. Si padece insuficiencia cardíaca leve y está en tratamiento con Idacio, su médico debe hacerle un seguimiento continuo de su insuficiencia cardíaca. En caso de que aparezcan nuevos síntomas de insuficiencia cardíaca o empeoren los actuales (por ejemplo: dificultad al respirar, o hinchazón de los pies), debe ponerse en contacto con su médico inmediatamente.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Fiebre, cardenales, hemorragia o aspecto pálido</span></span></p><p><span> </span></p><ul><li><span>En algunos pacientes, el organismo puede ser incapaz de producir un número suficiente del tipo de células sanguíneas que luchan contra las infecciones (glóbulos blancos) o de las que contribuyen a parar las hemorragias (plaquetas). Si tiene fiebre persistente, o sufre cardenales o sangra muy fácilmente o está muy pálido, consulte inmediatam</span><span>ente a su médico. Su médico puede decidir la interrupción del tratamiento.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Cáncer</span></span></p><p><span> </span></p><ul><li><span>En muy raras ocasiones se han dado casos de ciertos tipos de cáncer en niños y adultos tratados con adalimumab u otros agentes que bloquean el TNFα. Las personas con artritis reumatoide de grados más graves y que padezcan la enfermedad desde hace mucho tiempo pueden tener un riesgo mayor que la media de desarrollar un linfoma y leucemia (cánceres que afectan a las células sanguíneas y a la médula ósea). Si está en tratamient</span><span>o con Idacio el riesgo de padecer linfoma, leucemia y otros tipos de cáncer puede incrementarse. Se ha observado, en raras ocasiones, un tipo de linfoma específico y grave en pacientes en tratamiento con adalimumab. Algunos de estos pacientes recibían tratamiento también con los medicamentos azatioprina o mercaptopurina. Informe a su médico si está tomando azatioprina o mercaptopurina con adalimumab.</span></li></ul><p><span> </span></p><ul><li><span>Además, se han observado casos de cáncer de piel (tipo no melanoma) en pacientes que usan adalimumab. Avise</span><span>a su médico si durante o después del tratamiento aparecen nuevas zonas dañadas en su piel o si las marcas o zonas dañadas existentes cambian de apariencia.</span></li></ul><p><span> </span></p><ul><li><span>Se han registrado cánceres, diferentes del linfoma, en pacientes con una determinada enfermedad pulmonar, denominada enfermedad pulmonar obstructiva crónica (EPOC), tratados con otro agente bloqueante del TNFα. Si tiene EPOC, o fuma mucho, debe consultar a su médico si el tratamiento con un bloqueante del TNFα es adecuado en su caso.</span></li></ul><p><span> </span></p><p><span style="text-decoration: underline"><span>Síndrome similar</span></span><span style="text-decoration: underline"><span>al lupus</span></span></p><p><span> </span></p><ul><li><span>En raras ocasiones el tratamiento con Idacio podría dar lugar a un síndrome similar al lupus. Contacte con su médico si tiene síntomas como erupción persistente sin explicación, fiebre, dolor de las articulaciones o cansancio.</span></li></ul><p><span> </span></p></div></text></section><section id="ea252847-ecb0-4287-9c20-20b6e5a91132"><title value="Niños y adolescentes" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029899" /><display value="Niños [y adolescentes]" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><ul><li><span>Vacunación: si es posible su hijo debe ponerse al día con todas las vacunas antes de usar Idacio.</span></li><li><span>No administre Idacio a niños menores de 2 años con artritis idiopática juvenil poliarticular.</span></li><li><span>No use la jeringa precargada de 40 mg o la pluma precargada de 40 mg si se recomiendan dosis distintas de 40 mg.</span></li></ul><p><span> </span></p><p><strong><span>Otros medicamentos e Idacio</span></strong></p><p><strong><span> </span></strong></p><p><span>Informe a su médico o farmacéutico si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.</span></p><p><span> </span></p><p><span>Idacio se puede tomar junto con metotrexato o con ciertos medicamentos antirreumáticos modificadores de la enfermedad (sulfasalazina, hidroxicloroquina, leflunomida y preparaciones inyectables a base de sales de oro), corticoesteroides o medicamentos para el dolor, incluidos los antiinflamatorios</span><span>no esteroideos (AINEs).</span></p><p><span> </span></p><p><span>No debe utilizar Idacio junto con medicamentos cuyos principios activos sean anakinra o abatacept debido a un incremento del riesgo de infecciones graves. La combinación de adalimumab y otros antagonistas de TNFα y anakinra o abatacept no se recomienda debido al posible aumento del riesgo de infecciones, incluidas infecciones graves y otras posibles interacciones farmacológicas. Si tiene alguna duda, consulte a su médico.</span></p><p><span> </span></p></div></text></section><section id="677b38a2-d228-45a0-ad05-c4fa5032d6d4"><title value="Embarazo y lactancia" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029902" /><display value="Embarazo [y][,] lactancia [y fertilidad]" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>Si está embarazada, cree que podría es</span><span>tar embarazada o tiene intención de quedarse embarazada, consulte a su médico o farmacéutico antes de utilizar este medicamento.</span></p><p><span> </span></p><p><span>Se le recomienda evitar quedarse embarazada y debe hacer uso de métodos anticonceptivos adecuados durante el tratamiento con Idacio y continuar con su uso durante al menos 5 meses después de la última administración de Idacio. Si se queda embarazada, debe acudir a su médico.</span></p><p><span> </span></p><p><span>Idacio se debe usar durante el embarazo solo si es necesario.</span></p><p><span> </span></p><p><span>Según un estudio en embarazo, no hubo un mayor riesgo de defectos congénitos cuando la madre había recibido tratamiento con adalimumab durante el embarazo comparado con las madres con la misma enfermedad que no recibieron tratamiento con adalimumab.</span></p><p><span> </span></p><p><span>Idacio se puede usar durante la lactancia.</span></p><p><span> </span></p><p><span>Si utiliza Idacio mientras está embarazada, su hijo puede tener un riesgo más alto de contraer una infección.</span></p><p><span> </span></p><p><span>Es importante que informe al pediatra y a otros profesionales sanitarios sobre el uso de Idacio durante el embarazo antes de que el bebé reciba ninguna vacuna (para más información ver sección “Vacunación”).</span></p><p><span> </span></p></div></text></section><section id="493d0d95-5fda-41db-be66-cf49370fd7ee"><title value="Conducción y uso de máquinas" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029903" /><display value="Conducción y uso de máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>La influencia de Idacio sobre la capacidad para conducir, montar en bicicleta o utilizar máquinas es pequeña. Puede producirse sensación de que la habitación da vueltas (vértigo) y alteraciones de la visión después de utilizar Idacio.</span></p><p><span> </span></p><p><strong><span>Idacio contiene sodio</span></strong></p><p><strong><span> </span></strong></p><p><span>Este medicamento contiene menos de 23 mg de sodio (1mmol) por dosis de 0,8 ml, esto es, esencialmente “exento de sodio”.</span></p><p><span> </span></p></div></text></section></section><section id="bdec1c78-02d5-44ab-80ce-c3c5b3876a47"><title value="3. Cómo usar Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029905" /><display value="3. Cómo [tomar][usar] X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span>Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico. En caso de duda, consulte de nuevo a su médico.</span></p><p><span> </span></p><p><span>Idacio se inyecta bajo la piel (vía subcutánea). Los pacientes que necesiten una dosis menor de 40 mg deben usar la presentación del vial de 40 mg de Idacio.</span></p><p><span> </span></p><p><span>La dosis recomendada de Idacio en cada uno de los usos aprobados se muestra en la siguiente tabla.</span></p><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Artritis reumatoide, artritis psoriásica, espondilitis anquilosante o espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Adultos</span></p></td><td><p><span>40 mg en semanas alternas</span></p></td><td><p><span>En artritis reumatoide, el tratamiento con metotrexato se mantiene junto con  Idacio. Si su médico decide que el metotrexato no es adecuado, Idacio puede administrarse solo.</span></p><p><span> </span></p><p><span>Si tiene artritis reumatoide y no recibe metotrexato junto con Idacio, su médico puede decidir administrar 40 mg semanalmente u 80 mg en semanas alternas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Artritis idiopática juvenil poliarticular</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Niños, adolescentes y adultos desde los 2 años que pesen 30 kg o más</span></p></td><td><p><span>40 mg en semanas alternas</span></p></td><td><p><span>No aplica</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 2 años que pesen entre 10 kg y menos de 30 kg</span></p></td><td><p><span>20 mg en semanas alternas</span></p></td><td><p><span>No aplica</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Artritis relacionada con entesitis</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Niños, adolescentes y adultos desde 6 años que pesen 30 kg o más</span></p></td><td><p><span>40 mg en semanas alternas</span></p></td><td><p><span>No aplica</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 6 años que pesen entre 15 kg  y menos de 30 kg</span></p></td><td><p><span>20 mg en semanas alternas</span></p></td><td><p><span>No aplica</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Psoriasis en placa</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Adultos</span></p><p><span> </span></p></td><td><p><span>Dosis inicial de 80 mg (dos inyecciones de 40 mg en un día), seguida de 40 mg</span><span>en semanas alternas</span><span>, comenzando una semana después de la dosis inicial.</span></p><p><span>Debe continuar inyectándose Idacio durante tanto tiempo como le haya indicado su médico.</span></p></td><td><p><span>Dependiendo de su respuesta, su médico puede aumentar la dosis a 40 mg semanales u 80 mg en semanas alternas</span><span>.</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 4 a 17 años que pesen 30 kg o más</span></p></td><td><p><span>Dosis inicial de 40 mg, seguida de 40 mg una semana después.</span></p><p><span> </span></p><p><span>A partir de entonces, la dosis habitual es de 40 mg en semanas alternas.</span></p></td><td><p><span>No aplica</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 4 a 17 años que pesen entre 15 kg y menos de 30 kg</span></p></td><td><p><span>Dosis inicial de 20 mg, seguida de 20 mg una semana después.</span></p><p><span> </span></p><p><span>A partir de entonces, la dosis habitual es de 20 mg en semanas alternas.</span></p></td><td><p><span>No aplica</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Hidradenitis supurativa</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Adultos</span></p></td><td><p><span>Dosis inicial de 160 mg (como cuatro inyecciones de 40 mg en un día o dos inyecciones de 40 mg por día en dos días consecutivos), seguido de una dosis de 80 mg (como dos inyecciones de 40 mg en el mismo día) dos semanas después. Después de dos semanas más, continúe con una dosis de 40 mg cada semana u 80 mg en semanas alternas, según se lo haya indicado su médico.</span></p></td><td><p><span>Se recomienda que utilice a diario un líquido antiséptico en las zonas afectadas.</span></p><p><span> </span></p></td></tr><tr><td><p><span>Adolescentes desde 12 a 17 años que pesen 30 kg o más</span></p></td><td><p><span>Dosis inicial de 80 mg (como dos inyecciones de 40 mg en un día), seguidas de 40 mg en semanas alternas comenzando una semana después.</span></p></td><td><p><span>Dependiendo de su respuesta, su médico puede incrementar la dosis a 40 mg semanales u 80 mg en semanas alternas</span><span>.</span></p><p><span>Se recomienda que utilice a diario un líquido antiséptico en las zonas afectadas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Enfermedad de Crohn</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Niños, adolescentes y adultos desde 6 años que pesen 40 kg o más</span></p></td><td><p><span>Dosis inicial de 80 mg (como dos inyecciones de 40 mg en un día), seguidas de 40 mg dos semanas después.</span></p><p><span> </span></p><p><span>Si se requiere una respuesta más rápida, su médico puede prescribir una dosis inicial de 160 mg (como cuatro inyecciones de 40 mg en un día o dos inyecciones de 40 mg por día durante dos días consecutivos) seguida de 80 mg (como dos inyecciones de 40 mg en un día) dos semanas después.</span></p><p><span>A partir de entonces, la dosis habitual es de 40 mg en semanas alternas.</span></p></td><td><p><span>Dependiendo de su respuesta, su médico puede incrementar la dosis a 40 mg semanales u 80 mg en semanas alternas</span><span>.</span></p><p><span> </span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 6 a 17 años que pesen menos de 40 kg</span></p></td><td><p><span>Dosis inicial de 40 mg, seguida de 20 mg dos semanas después.</span></p><p><span> </span></p><p><span>Si se requiere una respuesta más rápida, su médico puede prescribirle una primera dosis de 80 mg (dos inyecciones de 40 mg en un día), seguidas de 40 mg dos semanas después.</span></p><p><span> </span></p><p><span>A partir de entonces, la dosis habitual es de 20 mg en semanas alternas.</span></p></td><td><p><span>Dependiendo de su respuesta, su médico puede incrementar la frecuencia de la dosis a 20 mg semanales.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Colitis ulcerosa</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Adultos</span></p></td><td><p><span>La dosis inicial es de 160 mg (cuatro inyecciones de 40 mg en un día o dos inyecciones de 40 mg por día en dos días consecutivos) seguida de 80 mg (dos inyecciones de 40 mg en un día).</span></p><p><span>A partir de entonces, la dosis habitual es de 40</span><span> </span><span>mg en semanas alternas.</span></p></td><td><p><span>Dependiendo de su respuesta, su médico puede incrementar la dosis a 40</span><span> </span><span>mg semanales u 80 mg cada dos semanas.</span></p></td></tr><tr><td><p><span>Niños y adolescentes de 6  a 17 años de edad con un peso de 40 kg o superior</span></p></td><td><p><span>Primera dosis de 160 mg (cuatro inyecciones de 40 mg en un día o dos inyecciones de 40 mg al día en dos días consecutivos), seguida de 80 mg (dos inyecciones de 40 mg al día) dos semanas después. A partir de entonces, la dosis habitual es de 80 mg en semanas alternas.</span></p></td><td><p><span>Debe continuar utilizando la dosis habitual de 80 mg en semanas alternas, incluso después de cumplir los 18 años.</span></p></td></tr><tr><td><p><span>Niños y adolescentes de 6 a 17 años de edad con un peso inferior a 40 kg</span></p></td><td><p><span>Primera dosis de 80 mg (dos inyecciones de 40 mg al día), seguida de 40 mg (una inyección de 40 mg) dos semanas después. A partir de entonces, la dosis habitual es de 40 mg en semanas alternas.</span></p></td><td><p><span>Debe continuar utilizando la dosis habitual, 40 mg en semanas alternas, incluso después de cumplir los</span></p><p><span>18 años.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><table cellspacing="0" cellpadding="0"><tr><td colspan="3"><p><strong><span>Uveítis no infecciosa</span></strong></p></td></tr><tr><td><p><strong><span>Edad o peso corporal</span></strong></p></td><td><p><strong><span>Cantidad y frecuencia de administración</span></strong></p></td><td><p><strong><span>Notas</span></strong></p></td></tr><tr><td><p><span>Adultos</span></p></td><td><p><span>Dosis inicial de 80 mg (dos inyecciones en un día), seguida de 40 mg en semanas alternas comenzando una semana después de la dosis inicial. Debe continuar inyectándose Idacio durante el tiempo que le haya indicado su médico.</span></p><p><span> </span></p></td><td><p><span>Se puede continuar el tratamiento con corticoesteroides u otros medicamentos que afectan el sistema inmune mientras se usa Idacio. Idacio también se puede administrar sólo.</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 2 años que pesen menos de 30 kg</span></p></td><td><p><span>20 mg en semanas alternas</span></p></td><td><p><span>Su médico puede prescribir una dosis inicial de 40 mg que puede ser administrada una semana antes de empezar con la pauta habitual.</span></p></td></tr><tr><td><p><span>Niños y adolescentes desde 2 años que pesen 30 kg o más</span></p></td><td><p><span>40 mg en semanas alternas</span></p></td><td><p><span>Su médico puede prescribir una dosis inicial de 80 mg que puede ser administrada una semana antes de empezar con la pauta habitual.</span></p><p><span>Se recomienda el uso de Idacio junto con metotrexato.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr >
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                        <td >
                                        </td>
                                </tr><![endif]--></table><p><span> </span></p><p><strong><span>Forma y vía de administración</span></strong></p><p><span> </span></p><p><span>Idacio se administra mediante inyección bajo la piel (vía subcutánea).</span></p><p><span> </span></p><p><span>Para instrucciones de uso, consulte la sección 7 “Instrucciones de uso”.</span></p></div></text><section id="2eab8fdf-fdd4-4cff-87e9-28921feaf4fd"><title value="Si usa más Idacio del que debe" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029907" /><display value="Si [toma][usa] más X del que debe" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span>Si accidentalmente se inyecta Idacio con más frecuencia de la que necesita, debe informar de ello a su médico o farmacéutico. Siempre lleve la caja del medicamento consigo, incluso si está vacía.</span></p><p><span> </span></p></div></text></section><section id="5e564906-9672-433f-a4ac-6a93e2ff6b01"><title value="Si olvidó usar Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029908" /><display value="Si olvidó [tomar][usar] X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>Si se olvida administrar una inyección, debe inyectarse la siguiente dosis de Idacio tan pronto como lo recuerde. Después se administrará la siguiente dosis como habitualmente, como si no se hubiese olvidado una dosis.</span></p><p><span> </span></p></div></text></section><section id="978b6407-41b2-4c28-b7e1-4966c28239aa"><title value="Si interrumpe el tratamiento con Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029909" /><display value="Si interrumpe el tratamiento con X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>La decisión de dejar de usar Idacio debe ser discutida con su médico. Sus síntomas pueden volver tras la interrupción del tratamiento.</span></p><p><span> </span></p><p><span>Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico o farmacéutico.</span></p><p><span> </span></p></div></text></section></section><section id="fdd3e900-2727-4c98-85dc-427012e18c33"><title value="4. Posibles efectos adversos" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029910" /><display value="4. Posibles efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span> </span></p><p><span>Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran. La mayoría de los efectos adversos son leves a moderados. Sin embargo, algunos pueden ser graves y requerir tratamiento. Los efectos adversos pueden aparecer hasta 4 meses después o más desde la última inyección de Idacio.</span></p><p><span> </span></p><p><strong><span>Busque atención médica urgentemente</span></strong><span>si nota cualquiera de los siguientes signos de reacción alérgica o insuficiencia cardiaca:</span></p><ul><li><span>erupción grave, habones;</span></li><li><span>hinchazón de la cara, manos, pies;</span></li><li><span>dificultad para respirar, tragar;</span></li><li><span>falta de aliento al hacer ejercicio o al estar tumbado, hinchazón de pies.</span></li></ul><p><span> </span></p><p><strong><span>Póngase en contacto con su médico tan pronto como sea posible</span></strong><span>si nota alguno de los siguientes efectos:</span></p><ul><li><span>signos y síntomas de infección tales como fiebre, ganas de vomitar, heridas, problemas dentales, sensación de quemazón al orinar;</span></li><li><span>sensación de debilidad o cansancio, tos;</span></li><li><span>síntomas de problemas nerviosos como hormigueo, entumecimiento, visión doble o debilidad en brazos o piernas;</span></li><li><span>signos de cáncer de piel tales como una protuberancia o una herida abierta que no se cura;</span></li><li><span>signos y síntomas de alteraciones en la sangre como fiebre persistente, cardenales, hemorragias y palidez.</span></li></ul><p><span> </span></p><p><span>Los siguientes efectos adversos se han observado con adalimumab:</span></p><p><span> </span></p><p><strong><span>Muy frecuentes</span></strong><span>(pueden afectar a más de 1 de cada 10 personas)</span></p><ul><li><span>reacciones en el lugar de inyección (incluyendo dolor, hinchazón, enrojecimiento o picor);</span></li><li><span>infecciones del tracto respiratorio inferior (incluyendo resfriado, moqueo, sinusitis, neumonía);</span></li><li><span>dolor de cabeza;</span></li><li><span>dolor abdominal (de vientre);</span></li><li><span>náuseas y vómitos;</span></li><li><span>sarpullido;</span></li><li><span>dolor en los músculos.</span></li></ul><p><span> </span></p><p><strong><span>Frecuentes</span></strong><span>(pueden afectar hasta 1 de cada 10 personas)</span></p><ul><li><span>infecciones graves (incluyendo envenenamiento sanguíneo y gripe);</span></li><li><span>infecciones intestinales (incluyendo gastroenteritis);</span></li><li><span>infecciones de la piel (incluyendo celulitis y herpes);</span></li><li><span>infección de oído;</span></li><li><span>infecciones de la boca (incluyendo infección dental y dolor frío);</span></li><li><span>infecciones en el sistema reproductor;</span></li><li><span>infección del tracto urinario;</span></li><li><span>infecciones por hongos;</span></li><li><span>infección en las articulaciones;</span></li><li><span>tumores benignos;</span></li><li><span>cáncer de piel;</span></li><li><span>reacciones alérgicas (incluyendo alergia estacional);</span></li><li><span>deshidratación;</span></li><li><span>cambios de humor (incluyendo depresión);</span></li><li><span>ansiedad;</span></li><li><span>dificultad para dormir;</span></li><li><span>alteraciones sensoriales como hormigueo, escozor o entumecimiento;</span></li><li><span>migraña;</span></li><li><span>síntomas de compresión de la raíz nerviosa (incluyendo dolor en la parte baja de la espalda y la pierna);</span></li><li><span>alteraciones visuales;</span></li><li><span>inflamación del ojo;</span></li><li><span>inflamación del párpado e hinchazón del ojo;</span></li><li><span>vértigo (sensación de que la habitación da vueltas);</span></li><li><span>sensación de pulso acelerado;</span></li><li><span>alta presión sanguínea;</span></li><li><span>rubor;</span></li><li><span>hematomas (una hinchazón palpable con sangre coagulada);</span></li><li><span>tos;</span></li><li><span>asma;</span></li><li><span>dificultad para respirar;</span></li><li><span>hemorragia gastrointestinal;</span></li><li><span>dispepsia (indigestión, hinchazón y ardor);</span></li><li><span>reflujo ácido;</span></li><li><span>síndrome Sicca (que incluye ojos y boca seca);</span></li><li><span>picores;</span></li><li><span>sarpullido con picor;</span></li><li><span>moratones;</span></li><li><span>inflamación de la piel (como eczema);</span></li><li><span>rotura de uñas de las manos y los pies;</span></li><li><span>aumento de la transpiración;</span></li><li><span>pérdida de pelo;</span></li><li><span>psoriasis de nueva aparición o empeoramiento de la psoriasis existente;</span></li><li><span>espasmos musculares;</span></li><li><span>sangre en orina;</span></li><li><span>problemas renales;</span></li><li><span>dolor de pecho;</span></li><li><span>edema (acumulación de líquido en el organismo que provoca la hinchazón del tejido afectado);</span></li><li><span>fiebre;</span></li><li><span>disminución de plaquetas en sangre, lo que incrementa el riesgo de sangrado o moratones;</span></li><li><span>problemas de cicatrización.</span></li></ul><p><span> </span></p><p><strong><span>Poco frecuentes</span></strong><span>(pueden afectar hasta 1 de cada 100 personas)</span></p><ul><li><span>infecciones inusuales (que incluyen tuberculosis y otras infecciones) que ocurren cuando la resistencia a la enfermedad disminuye;</span></li><li><span>infecciones neurológicas (incluyendo meningitis viral);</span></li><li><span>infecciones del ojo;</span></li><li><span>infecciones bacterianas;</span></li><li><span>diverticulitis (inflamación e infección del intestino grueso);</span></li><li><span>cáncer, incluido el cáncer que afecta al sistema linfático (linfoma) y el melanoma (un tipo de cáncer de piel);</span></li><li><span>alteraciones inmunológicas que pueden afectar a los pulmones, piel y ganglios linfáticos (más frecuentemente como una enfermedad llamada sarcoidosis);</span></li><li><span>vasculitis (inflamación de los vasos sanguíneos);</span></li><li><span>temblor;</span></li><li><span>neuropatía (lesión nerviosa);</span></li><li><span>derrame cerebral;</span></li><li><span>visión doble;</span></li><li><span>pérdida de oído, zumbidos;</span></li><li><span>sensación de pulso irregular como brincos;</span></li><li><span>problemas del corazón que pueden causar dificultad para respirar o hinchazón de tobillos;</span></li><li><span>ataque al corazón;</span></li><li><span>saco en la pared de una arteria mayor, inflamación y coagulación en una vena, bloqueo de un vaso sanguíneo;</span></li><li><span>enfermedades pulmonares que pueden causar dificultad para respirar (incluyendo inflamación);</span></li><li><span>embolia pulmonar (bloqueo de una arteria del pulmón);</span></li><li><span>derrame pleural (almacenamiento anormal de fluido en el espacio pleural);</span></li><li><span>inflamación del páncreas que causa un dolor grave en el abdomen y la espalda;</span></li><li><span>dificultad para tragar;</span></li><li><span>edema facial (hinchazón);</span></li><li><span>inflamación de la vesícula, piedras en la vesícula;</span></li><li><span>grasa en el hígado (acumulación de grasa en las células del hígado);</span></li><li><span>sudores nocturnos;</span></li><li><span>cicatrices;</span></li><li><span>crisis muscular anormal;</span></li><li><span>lupus eritematoso sistémico (un trastorno inmunitario que incluye inflamación de la piel, corazón, pulmones, articulaciones y otros órganos);</span></li><li><span>interrupciones del sueño;</span></li><li><span>impotencia;</span></li><li><span>inflamaciones.</span></li></ul><p><span> </span></p><p><strong><span>Raros</span></strong><span>(pueden afectar hasta 1 de cada 1000 personas)</span></p><ul><li><span>leucemia (cáncer que afecta a la sangre y la médula ósea);</span></li><li><span>reacción alérgica grave con shock;</span></li><li><span>esclerosis múltiple;</span></li><li><span>alteraciones nerviosas (como inflamación del nervio óptico y síndrome de Guillain-Barré, una enfermedad que puede provocar debilidad muscular, sensaciones anormales, hormigueo en los brazos y la parte superior del cuerpo);</span></li><li><span>parada cardiaca;</span></li><li><span>fibrosis pulmonar (cicatriz en el pulmón);</span></li><li><span>perforación intestinal (agujero en la pared del intestino);</span></li><li><span>hepatitis (inflamación del hígado);</span></li><li><span>reactivación del virus de la hepatitis B;</span></li><li><span>hepatitis autoinmune (inflamación del hígado causada por el propio sistema inmunológico del cuerpo);</span></li><li><span>vasculitis cutánea (inflamación de los vasos sanguíneos en la piel);</span></li><li><span>síndrome de Stevens-Johnson (una enfermedad potencialmente mortal con síntomas tipo gripal y erupción con ampollas);</span></li><li><span>edema facial (hinchazón) asociado con reacciones alérgicas;</span></li><li><span>eritema multiforme (erupción inflamatoria en la piel);</span></li><li><span>síndrome similar al lupus;</span></li><li><span>angioedema (inflamación localizada de la piel);</span></li><li><span>reacción liquenoide en la piel (sarpullido rojizo-morado con picor)</span></li></ul><p><span> </span></p><p><strong><span>Frecuencia no conocida</span></strong><span>(no se puede estimar la frecuencia a partir de los datos disponibles)</span></p><ul><li><span>linfoma hepatoesplénico de células T (cáncer sanguíneo raro que a menudo es mortal);</span></li><li><span>carcinoma de células de Merkel (un tipo de cáncer de piel);</span></li><li><span>Sarcoma de Kaposi, un cáncer poco común relacionado con la infección por el virus del herpes humano 8. El sarcoma de Kaposi suele manifestarse con mayor frecuencia como lesiones cutáneas de color púrpura.</span></li><li><span>fallo hepático;</span></li><li><span>empeoramiento de una enfermedad llamada dermatomiositis (visto como erupción cutánea acompañada de debilidad muscular).</span></li><li><span>Aumento de peso (para la mayoría de pacientes, el aumento de peso fue reducido)</span></li></ul><p><span> </span></p><p><span>Algunos efectos adversos observados en los ensayos clínicos con adalimumab no tienen síntomas y sólo pueden ser identificados mediante un análisis de sangre. Estos incluyen:</span></p><p><span> </span></p><p><strong><span>Muy frecuentes</span></strong><span>(pueden afectar a más de 1 de cada 10 personas)</span></p><ul><li><span>bajo recuento sanguíneo de células blancas;</span></li><li><span>bajo recuento sanguíneo de células rojas;</span></li><li><span>aumento de lípidos en sangre;</span></li><li><span>aumento de enzimas hepáticas.</span></li></ul><p><span> </span></p><p><strong><span>Frecuentes</span></strong><span>(pueden afectar hasta 1 de cada 10 personas)</span></p><ul><li><span>alto recuento sanguíneo de células blancas;</span></li><li><span>bajo recuento sanguíneo de plaquetas;</span></li><li><span>aumento de ácido úrico en sangre;</span></li><li><span>valores anormales de sodio en sangre;</span></li><li><span>bajo nivel de calcio en sangre;</span></li><li><span>bajo nivel de fosfato en sangre;</span></li><li><span>azúcar en sangre alto;</span></li><li><span>valores altos de lactato deshidrogenasa en sangre;</span></li><li><span>presencia de autoanticuerpos en sangre;</span></li><li><span>bajo nivel de potasio en sangre.</span></li></ul><p><span> </span></p><p><strong><span>Poco frecuentes</span></strong><span>(pueden afectar hasta 1 de cada 100 personas)</span></p><ul><li><span>valores de bilirrubina elevados (análisis de función hepática).</span></li></ul><p><span> </span></p><p><strong><span>Raros</span></strong><span>(pueden afectar hasta 1 de cada 1000 personas)</span></p><ul><li><span>recuentos bajos en sangre para células blancas, células rojas y plaquetas.</span></li></ul></div></text><section id="514aaa2f-5f60-4c24-9131-bc492a02e245"><title value="Comunicación de efectos adversos" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029912" /><display value="Comunicación de efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span>Si experimenta cualquier tipo de efecto adverso, consulte con su médico o farmacéutico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través</span><span>del sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="text-decoration: underline"><span>Apéndice V</span></span></a><span style="text-decoration: underline"><span>.</span></span><span>Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.</span></p><p><span> </span></p></div></text></section></section><section id="06b3f939-1f80-47d2-b57a-81d1559fd7fa"><title value="5. Conservación de Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029913" /><display value="5. Conservación de X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><span>Mantener este medicamento fuera de la vista y del alcance de los niños.</span></p><p><span> </span></p><p><span>No utilice este medicamento después de la fecha de caducidad que aparece en la etiqueta/caja después de “CAD”. La fecha de caducidad es el último día del mes que se indica.</span></p><p><span> </span></p><p><span>Conservar en nevera (entre 2ºC y 8ºC). No congelar.</span></p><p><span> </span></p><p><span>Conservar la jeringa precargada en el embalaje exterior para protegerla de la luz.</span></p><p><span> </span></p><p><span>Almacenamiento alternativo:</span></p><p><span> </span></p><p><span>Cuando sea necesario (por ejemplo, cuando esté de viaje), una única jeringa precargada de Idacio se puede almacenar a temperatura ambiente (hasta 25ºC) durante un periodo máximo de 28 días (asegúrese de protegerlo de la luz). Una vez la jeringa precargada se ha sacado de la nevera para almacenar a temperatura ambiente,</span><strong><span>se debe usar en los siguientes 28 días o desecharse</span></strong><span>, incluso si luego se vuelve a meter en la nevera.</span></p><p><span> </span></p><p><span>Debe anotar la fecha en la que retiró la jeringa de la nevera, y la fecha después de la cual debe desecharla.</span></p><p><span> </span></p><p><span>Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.</span></p></div></text></section><section id="6b3f99aa-27e0-43c2-99ee-e77f3ea1d416"><title value="6. Contenido del envase e información adicional" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029914" /><display value="6. Contenido del envase e información adicional" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="e5b3d847-b2e9-4def-8af5-bfb35b5dfef7"><title value="Composición de Idacio" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029915" /><display value="Composición de X" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><ul><li><span>El principio activo es adalimumab. Cada jeringa precargada contiene 40 mg de adalimumab en 0,8 ml de solución.</span></li><li><span>Los demás componentes son: Dihidrogenofosfato de sodio dihidrato, fosfato disódico dihidrato, manitol, cloruro de sodio, ácido cítrico, monohidrato, citrato de sodio, polisorbato 80, hidróxido de sodio y agua para preparaciones inyectables.</span></li></ul><p><span> </span></p></div></text></section><section id="4b59da73-f0ec-449a-885c-7e523dc52fe7"><title value="Aspecto del producto y contenido del envase" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029916" /><display value="Aspecto del producto y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>Idacio 40 mg solución inyectable (inyectable) en jeringa precargada se presenta como 0,8 ml de una solución estéril, incolora y clara de 40 mg de adalimumab.</span></p><p><span> </span></p><p><span>La jeringa precargada de Idacio se presenta en una jeringa de vidrio con protector de aguja y alas de sujeción para los dedos. Cada envase contiene 2 ó 6 jeringas precargadas y 2 ó 6 toallitas empapadas en alcohol.</span></p><p><span> </span></p><p><span>Idacio puede estar disponible en vial, en jeringa precargada y en pluma precargada.</span></p><p><span> </span></p><p><strong><span>Titular de la autorización de comercialización</span></strong></p><p><span> </span></p><p><span>Fresenius Kabi Deutschland GmbH</span></p><p><span>Else-Kröner-Straße 1</span></p><p><span>61352 Bad Homburg v.d.Höhe</span></p><p><span>Alemania</span></p><p><span> </span></p><p><strong><span>Responsable de la fabricación</span></strong></p><p><strong><span> </span></strong></p><p><span>Fresenius Kabi Austria GmbH</span></p><p><span>Hafnerstraße 36,</span></p><p><span>8055 Graz</span></p><p><span>Austria</span></p><p><span> </span></p></div></text></section><section id="481a039b-87fa-4ea4-99c5-14477ea665fc"><title value="Fecha de la última revisión de este prospecto" /><code><coding><system value="http://ema.europa.eu/fhir/CodeSystem/200000029659" /><code value="200000029919" /><display value="Fecha de la última revisión de este prospecto: [{MM/AAAA}][{mes AAAA}]." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p><strong><span> </span></strong></p><p><span>La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos:</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline"><span>http://www.ema.europa.eu</span></span></a><span>.</span></p><p><span> </span></p><p><strong><span>7. Instrucciones de uso</span></strong></p><p><strong><span> </span></strong></p><p><span>Asegúrese de leer, comprender y seguir estas instrucciones de uso antes de inyectar Idacio. Su médico debe mostrarle cómo preparar e inyectar Idacio, de forma adecuada, usando la jeringa precargada antes de utilizar el medicamento por primera vez. Consulte a su mèdico si tiene alguna duda.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="567" height="298" alt="" /></p><p><span> </span></p><p><strong><span>Leer con cuidadado estas instrucciones antes de usar su jeringa precargada de Idacio.</span></strong></p><p><strong><span> </span></strong></p><p><strong><span>Información importante</span></strong></p><p><strong><span> </span></strong></p><ul><li><span>Sólo utilice la jeringa precargada de Idacio si su profesional sanitario le ha enseñado a usar la jeringa precargada correctamente.</span></li></ul><p><span> </span></p><ul><li><span>Idacio es una jeringa precargada de un solo uso.</span></li></ul><p><span> </span></p><ul><li><span>La jeringa precargada de Idacio tiene un protector transparente de aguja que cubre la aguja después de que se completa la inyección.</span></li></ul><p><span> </span></p><ul><li><span>Los niños menores de 12 años no pueden inyectarse a ellos mismos y la inyección debe ser realizada por un adulto entrenado.</span></li></ul><p><span> </span></p><ul><li><span>Mantenga la jeringa precargada de Idacio y el contenedor para eliminar objetos punzantes fuera del alcance y la vista de los niños.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>agitar. La agitación puede dañar la jeringa precargada y el medicamento.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>use la jeringa precargada Idacio si el líquido se ve turbio o cambia de color, o si tiene partículas o escamas. El líquido debe ser claro e incoloro.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>intente activar el protector transparente de aguja antes de inyectarse.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>introduzca los dedos en la abertura del protector transparente de la aguja.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>use una jeringa precargada de Idacio que haya sido congelada o expuesta a la luz directa del sol.</span></li></ul><p><span> </span></p><ul><li><strong><span>No</span></strong><span>utilice la jeringa precargada Idacio si se ha caído o aplastado, ya que la jeringa precargada se puede romper incluso si no puede ver la rotura.</span></li></ul><p><span> </span></p><p><span>Utilice en su lugar una jeringa nueva precargada.</span></p><p><span> </span></p><p><strong><span>Información de almacenamiento</span></strong></p><p><strong><span> </span></strong></p><ul><li><span>Mantenga la jeringa precargada en su caja original para protegerla de la luz.</span></li></ul><p><span> </span></p><ul><li><span>Conserve la jeringa precargada en la nevera, entre 2°C y 8°C.</span></li></ul><p><span> </span></p><ul><li><span>Si es necesario, por ejemplo, cuando se viaja, una únicajeringa precargada puede almacenarse a temperatura ambiente hasta 28 días</span></li></ul><p><span> </span></p><p><strong><span>Familiarícese con su jeringa precargada Idacio</span></strong></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Antes de usar</span></span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="503" height="360" alt="" /></p><p><span> </span></p><p><span style="text-decoration: underline"><span>Después de usar</span></span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="494" height="239" alt="" /></p><p><span> </span></p><p><strong><span>Paso 1: Prepare su inyección</span></strong></p><p><span> </span></p><p><span>Cada caja de Idacio jeringa precargada viene con dos o seis jeringas.</span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Prepare una superficie plana y limpia, como una mesa o un mostrador, en un área bien iluminada.</span></li><li><span>Usted también necesitará (Figura A):</span></li></ol></div><ul><li><span>una toallita impregnada en alcohol (incluida en la caja)</span></li><li><span>una bola de algodón o gasa, y</span></li><li><span>un contenedor para eliminar objetos punzantes.</span></li></ul><p><span> </span></p><p><span>Abra su contenedor para eliminar objetos punzantes para que esté listo para su uso.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="233" height="165" alt="" /></p><p><span>Figura A</span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Saque la caja de la nevera (Figura B).</span></li></ol></div><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Compruebe la fecha de caducidad (CAD) (Figura B).</span></li></ol></div><p><strong><span>Advertencia: No</span></strong><span>usar si la fecha de caducidad ya ha pasado.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="342" height="271" alt="" /></p><p><em><span>Figura B</span></em></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><strong><span>Precaución: No</span></strong><span>coja la jeringa por el émbolo o por el protector de la aguja. Si lo hace podría dañar la jeringa o activar el protector transparente de aguja.</span></li></ol></div><p><span>Saque una jeringa de la caja original:</span></p><ul><li><span>coloque dos dedos en el centro del protector transparente de la aguja</span></li><li><span>tire de la jeringa hacia arriba y hacia afuera del embalaje (Figura C).</span></li></ul><p><span> </span></p><p><span>Póngala sobre una superficie plana y limpia.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="335" height="263" alt="" /></p><p><span>Figura C</span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Coloque el resto de las jeringas en su caja original en la nevera (Figura D).</span></li></ol></div><p><span>Consulte la información de almacenamiento para saber cómo almacenar su(s) jeringa(s) sin usar.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="336" height="181" alt="" /></p><p><span>Figura D</span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Deje la jeringa a temperatura ambiente durante 30 minutos antes de la inyección para que se atempere.</span></li></ol></div><p><span>Inyectarse medicamentos fríos puede ser doloroso (Figura E).</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAByAHQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD7LooooAKKKQkAc8UALRms651W2guBbNcRrOV3iLOXZemQvXHv0ql9uurr7O0NuscU7bFknOSDgn7o+h7igDc3qM89KjW6gZtqyZNYjf2gLd3fUnR4rlI2EUSKpUsoP3gT0PrXnMer68nxO8a6bHr12kFjBbG2EhV1iZo2JOCCOuKAPZd65xuGadmuD/tjVkuFja6juEEe9jPCv8124q5aeJl8qA3UL2hm5UofMX15HUcUAdhRWZZ6vbXSF45opUBKGSJwyhh/CfQ+xrSBBGRzQAtFFFACGig0UALRRQeBQAjMqjJNYt3qEj3S2ls4Erkr5rLlIj6H1b0FO1K8lDCG2VpJm6BOSid3x/Ko7SzjMH2aFvtWny5O5m+eNuvXvz+IPqOgBwni7w/q0d9pXjPw3by3PiXQZtlzbg5bUrSQ4kj/AJOvoVxXo8dirQsrBhG8izIh4MbZDfzq7HEsahdxY4A3N1Nc/r3jvwb4XcR+IvE+maW5/hublUP5E0Ab32aDLsYwTJjdnvjpXKa3pmnxa1PeR2cS3F3GqzSBRmULkLuPfFaeg+MfC3ihC/h7xDp+qqOv2W4WTH5Gq+vc3yY/udaAMSSCKVXBGBIuxiOCRWN4jl1Wx0S8vdFs2vtQSHy7W3X++Tjcfbp+ANLrXi/wr4cIXXfEOn6c2Bhbi4VD+RqbRvEnh7xDEZdD1qz1JOpNvMr4/KgDM8G6PN4S0W102zn3Xgzc6lcSfMtxK/zNuHckn8AK9D0nWluovOjBWMf6yFvvR/7Q9VrCmgjmTy2yFOGYLxu+tU2kmt7mO6LtHcpkQQR88dw2Oue/YfhmgD0pHWRAyMGB7inVhaPfxyIjKPLjl/gJyYn7oa3aAENFBooAWoLmQJHtZgoIJLHsB1NT1jaxKvkOjOyiRlhygJPzHnAAPOBQBwuseFbjVNXPiPR9ev8Awz4kkAVHcb7aeNfuI6E7WGOeCG5NegaFFqUWjwf2yLX+02UG5a1BEbPjBK55xTLCSN5PLh1FblFHzROB5ifXuPxFa1AGN4pfWo/CeqN4ctludY+zP9jjdwgaXHy5J4HNfK3wy/Zk1vWvE2ra/wDG+3kupnwYIheLJ5rHO5mKE4xxgV9hVyfxE1/XfDHgW+1rw34fl8QanAU8qwhRmaXLgHAUZ4BJ/CgD4w+O3gy2+A3xD8PeJPh1eXGmC5VnEPmlgjIwyOeqkdQa+jPiz8QpPDHwhHjGGNY7y6sYjbxnossq5HX0yT+FfLepa9cfGL456dZ/GS/bwbbW5WKOymtnj2gtnyyWwULf3m4r2L9sYrZ/DfQ7G2Xy7b7SihV6AKp2igDgvgt8I9O+Iui3Xj34gyXGqS307rCkkpG4A4ZyRyecgD2rM+K3gmT4G+KtH8beArqe2sLiXy5LcyFgrjnaT3Vhnr0xXv8A8ELeO2+BXhNY+AbTzD7lnYn9TXI/tSxJJ8GvMPBjvYiv45FAHr3hvXIPEnhTTNcteIr63SZR6ZGareJrPxBc2kcXhzULPTJpG23F7PGZGiiwfuDoWz68DrXGfs+zSTfAPw20jFiqTKCfQTOAPyFepHGMevrQBgeCdHtfD8ktlDdX+otqJ3TX93IW3Tj7rDPY8j5RjpXqVlci6tVk6How9CK85mkG8hr3MyEMkUS7ipHIJAyeoHWu20mcPcyhVIjlVZ1z23DOKANg0UGigBa5PxFrel6HcWk+reJNP0SB7hsvfTJGsmE+6NxHNdYa5vWdLstWubeG+0ew1OFZ2yt7CsiplOCNwPOaAHaB4o0HxFc3K6N4j0jWPJwWFhcpK0YPTdtJxnFdFWHo2iaTo80w0/RtK0x5ANwsYEjLAdN2AM1uUAZHiTxJo/hLw7deINfuvsmm2gVpptjPsBYKDhQT1I7Vl+DPiJ4P+INlc3nhHWE1KC1kEcrLGyFGIzjDAHpWzrui2HiLQb3Q9Vt1uLG+haCaNv4lIwa+VV/Zr+Inw+8Qz3/wr+I6abBdnb5NydrMOwIwVfHrigCj+2xaaWIfC18iRJqjvKjMMB2iABGfYGrXxs0rUdf/AGT/AAnqU3mTXllp9jczlx82DEAxP5ir+n/sv+LvFni+38Q/GDxsdcWIjNtESS6g52Z4Cqf9kV9AeJNNsbi0Ok3FpG9g9t5D25X5DHjG3HpjigDxX9nPXLfV/gjpVpHMDcaY0lrMueV+csvH+6w/KuR/aw1u3t/A2leHxIGu72687yweQiA84+pAqGT4A+NfB2vXWo/Crxs2mW05+a3uM8D0PBVse4zV7w3+z/rF94xi8WfFDxOfEF3CVZIFyVJByASeig9gMUAemfCLRJPDnwf8OaTcIUnS2Ekit1DOS5H5tXdE9OlN2qFCqMADoB0p3agDmtS8X+GNNv57DUPFmi6fOoAMU93GkiH3UsK6zwpfWuoppl5ZX8V7DJaFRPA4ZJNrkZBBI7Vzd9oOj397JdXHh/SL2U43Sz26O547kqTXT+Gbe3spdOsba3it0jtCwiiUKqhnJGAPrQB2FFFFAC1g6uke+RXjZgNtxgEjO089D6Gt6s/VI8RC52bzF1X1U8EflQBDZKkTLJHp0FlARjdwrEdRwPr3NU/G3idPBvgfVvFElq13Hptu07Qq20vjtmuO1XxRqGnaufDfh3w7d+IvEKqHSSdilpbxt9yR5DwOOMKCSRWj4u0HxB4w+DGr+F5ruwk169s2t5ZIQyQCUjnGckD86APPbf8AaVNxf2+nR/DvXGvdStBeaVCAu69X+Ij+6Bhjk/3afqnxI8H+MIvhfr2o+Gbya41DXDbWatctEbC5VlVmYKQHAPY5HFdHa/DbWYPif4S8Sl7UWWjeG20mZQx3mY91GPu+9clY/BTxXb6b4AtpLixL+HvEc2rXOJGw0TyBgF45bA6UAT3X7TFvZy6lNL4J1V9L0nUm06+1CMqY4MPsVvfPXFdD4g+I8KeLvF+jnTZC/hmwW7d94xOChbaB29K5bUvgn4qu/hD4z8Jxz2Av9b1x9SgcyMEEZl3gMcZBxVf4k/DXx7dfEHxRqPhjVNMgsPE+npbXLXKt5sO1SpC4456ZPTJ4oA5rxP8AE/xdeaj8PL7QNDuE0/Wtl15K3CA3RaMt5JPbHXPQ1t6z8dbHRtUn02bQZpJtOSP+0lWdAbd2UEoo6yFe+KS6+HPiq38KfDlNLbT5tT8JhDNDPKyRz4j2MA4UkfXFWI/BnjTQfHureJ9Bs9G1C119Y5r3Tb6ZlNvcBdpMcgQ5X6gZ9BQBqWHxRTWvHMnhzw/oct8lv5LXVy8yReWsi7gyofmYAHnFejnC/eIwOcmvHvE3w/8AE3iXxppusRaZpGi3NlcxyDWLS6k89oVA3RNGFAbnIBLdO1egeKLjxLDaRSeF4bC8uIn3z2V2xQzxYI2o44Vs45II+lAF+4h3n5rGMyOwWOWM85bgcjBHb866nQ40fWLuSMExW6rbIxOchRg1wXhTXbfVI7rVG0y+0ubTP3clhdLt/wBIYYUDsQAScr6g9q9N0Gyex0qOOXmViXc+pPJoA1DRQaKAFpGUOhVuhpaKAOYvLaSK48hHZHBzC6nb5iH70RPb2qxa3iGIXMSm1soSVEe355W6cjtz26k/rrXtol5bNExI7gjqD61zBWW11BTdBBdof3bucRXHYbv7r+9AHVxzeYoyuxiA2xuo+tS15J4v1rVrzUdK8C+H5prXxBrknnX12owdPs4zl3B9+EXHUsT2r0qG+WOFmYM0ayLAh6s5yFz+f9TQBo1zWvf8f6euyt77VCGkUyAGMgNnjBPSuS1nWNNn165sI7yM3NlGhuIw3MQbJXPpmgCD+Imj8eKiknSMSFjkxpvYDrj/ACKxvEdvf6nol3p+lXrWN5NCXtbhO0g5wfbp+BNAGxNcLDGZHyVBwxXnaPU/571T8qW5uEs9plkcFoZ0ONg7sxHTGevQ/pWH4M1i48U6DBqiQi3vE3W2pxzfKlvKhw2T655A6kEfWuu0mxW8U2enFlsAf31yww0/+yPRaALOj2UN/eKq5ksLP7rMMGaTu5/WuyHSoba2htYFhhQIijAAqagBDRQaKAFooooAKhubWG7gaGdA6HsamooA5i50W4tX8y3RLxAu1VkOJEHor9RVKPUIbZreOa4ezEDFliu48jOMH5x7E9e9dpUE1pbXC7ZoEcf7S5oA5+O4nntX2xRzmSdJ2MFyrjAdTtGcdl/WuATRfET/ABM8Z6t/wj1wtrqEFsttJLJFtZkRgc4fpkjpmvTJfC+iyuHayRSP7vFN/wCEV0X/AJ9cj03GgDmZ7WaG6E1zcWVom0xt59wOfQhR19MZqC3itX8qG0juNXkh4XC+TEO3JPJ4rsofDejW+fLsY85zkjJrTjhiiGI41T6DFAHL2Xhua4w+pGOKHO4WluoSMH1OOp+tdRFDHBGI41CqOwqSigAooooAQ0UGigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUUUUUAf/2Q==" width="116" height="114" alt="" /></p><p><span>Figura E</span></p><p><span> </span></p><p><strong><span>Advertencia: No</span></strong><span>caliente la jeringa de cualquier otra manera, como en un microondas, agua caliente o luz solar directa.</span></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia: No</span></strong><span>retire el protector de la aguja mientras la jeringa alcanza la temperatura ambiente.</span></p><p><span> </span></p><p><span> </span></p><p><strong><span>Paso 2: Lávese las manos</span></strong></p><p><span> </span></p><ol style="list-style-type: decimal"><li><span>Lávese las manos con agua y jabón y séquelas bien. (Figura F)</span></li></ol><p><strong><span>Advertencia:</span></strong><span>Los guantes no reemplazarán la necesidad de lavarse las manos.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="232" height="219" alt="" /></p><p><span>Figura F</span></p><p><span> </span></p><p><span> </span></p><p><strong><span>Paso 3: Compruebe la jeringa precargada</span></strong></p><p><span> </span></p><ol style="list-style-type: decimal"><li><span>Compruebe la jeringa para asegurarse de:</span></li></ol><ul><li><span>La jeringa, el protector de aguja transparente, y la cubierta de la aguja no están agrietados o dañados (Figura G).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="226" height="112" alt="" /></p><p><span> </span></p><p><span>Figura G</span></p><ul><li><span>El protector de la aguja está bien sujeto (Figura H).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="238" height="72" alt="" /></p><p><span> </span></p><p><span>Figura H</span></p><ul><li><span>El muelle del capuchón no está extendido (Figura I).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="234" height="155" alt="" /></p><p><span> </span></p><p><span>Figura I</span></p><p><span> </span></p><p><strong><span>Advertencia: No</span></strong><span>utilice la jeringa si muestra algún signo de daño.</span></p><p><span> </span></p><p><span>Si es así, deseche la jeringa en un contenedor para eliminar objetos punzantes y póngase en contacto con su médico o farmacéutico.</span></p><p><strong><span> </span></strong></p><p><strong><span>3.2</span></strong><span>Compruebe el líquido para asegurarse de que:</span></p><ul><li><span>El líquido es transparente, incoloro y libre de partículas (Figura J).</span></li></ul><p><span> </span></p><p><strong><span>Advertencia:</span></strong><span>No use la jeringa si el líquido contiene partículas, si está turbio, si está coloreado</span><span>o si tiene escamas.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="248" height="137" alt="" /></p><p><span>Figura J</span></p><p><strong><span> </span></strong></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Compruebe la etiqueta para asegurarse de que:</span></li></ol></div><ul><li><span>El nombre en la jeringa dice Idacio (Figura K).</span></li><li><span>La fecha de caducidad de la jeringa no ha pasado (Figura K).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="273" height="254" alt="" /></p><p><em><span>Figura K</span></em></p><p><span> </span></p><p><strong><span>Advertencia: No</span></strong><span>use la jeringa si:</span></p><ul><li><span>El nombre en la jeringa no es Idacio.</span></li><li><span>La fecha de caducidad de la jeringa ha pasado.</span></li></ul><p><span>Si es así, deseche la jeringa en un contenedor para eliminar objetos punzantes y póngase en contacto con su médico o farmacéutico.</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="537" height="82" alt="" /></p><p><span> </span></p><p><strong><span>Paso 4: Elija el sitio de inyección</span></strong></p><p><span> </span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>        </span><span>Elija un sitio</span><span>de inyección (Figura L):</span></li></ol></div><ul><li><span>En la parte delantera de los muslos.</span></li><li><span>Abdomen (inyectar al menos a 5 centímetros de distancia del ombligo).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="166" height="167" alt="" /></p><p><span> </span></p><p><em><span>Figura L</span></em></p><p><strong><span> </span></strong></p><p><strong><span>4.2</span></strong><span>Elija un sitio diferente (por lo menos a 2.5 centímetros de distancia del último lugar de inyección) cada vez para reducir el enrojecimiento, la irritación u otros problemas en la piel.</span></p><p><span> </span></p><p><strong><span>Advertencia: No</span></strong><span>se inyecte en un área que esté dolorida (sensible), con hematomas, enrojecida, dura, con cicatrices o donde tenga estrías.</span></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia:</span></strong><span>Si usted tiene psoriasis,</span><strong><span>no</span></strong><span>se inyecte en ninguna lesión o zonas enrojecidas, engrosadas, levantadas o escamosas.</span></p><p><span> </span></p><p><span> </span></p><p><strong><span>Paso 5: Limpie el sitio de inyección</span></strong></p><p><span> </span></p><p><strong><span>5.1</span></strong><span>Limpie la piel del lugar de la inyección con una toallita impregnada en alcohol (Figura M)</span></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia: No</span></strong><span>sople ni toque el lugar de la inyección después de la limpieza.</span></p><p><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAC9ARcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD7LooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqOeeG3iMs8ixoOrMcCgCSisJvFWkq5UPI2OMhDirdvrml3OPLu0DH+F/lP60AaVFIrK4ypBHqKWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisbU9dhsyYLfE9z/AHQeF+v+FAFrUtTg06DfId0h+5GOrVxl1Jc6lN515IT/AHUH3Vp7GW5uGuLl/MlbvjgewobjigCi0CjjbUfkVdbp71GaAGQtcQHME7xn/ZbFaUWt6tF/y8CQf7ag1m0tAG6nia9X79vE/wBMj/GrUfieMn99auvurZ/wrmN3FN3emKAO5h13TZcZmMZ9HUir8c8My7opFcf7JzXnIepUkKkFW2n24NAHotFcRBqmoQkbbl2Ho/zD9a1YPEhwBcW//AkP9DQB0VFZ8OsWEwGLgIfR+KurNE4+SRG+jZoAfRTd65wGz9KdQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVe6vLeyhM1zIEUevU/SszVtegscwwYmuf7oPC/WuWk+1X8/2i8cyHsOw/CgDQvteur8tDZ7reDu38Tf4VnpGsY9/U0/KRL0wao3F0FB54oAtPdLGQvFQvdA1zd3rUUc4UsDzUDa7CuPmoA6b7QKcsqtzmuet9WSbvWnHMGUds0AaG4Y4pCetVRLjpS+dzg0AWM5FJikRtw4p2KAG9KQybRTyKiNAEqzHjH61Ks3qKqqKfigC2sq/T61cs7hVkC5rIJx/FSxzbHDZFAHeWcmVFaS/dFc3ptwGQc8V0ETZUUAS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYWvapJbxC1s2H2iTq3/PMev1rS1G7Flp01z3Rfl+vauIjl+9NK5LsdzMT1NACRWaxnzJG3ueSTzzSy3KoDtNVLi/XJCnisG+1iGFTlwT6UAal1fAZJbFcrquuJGrLG341hat4k4b94FX615/q3iYHcFfPvQBsat4hWGfc0neqlx4kURJIr5x15rz2+1CS8lK8nPaoFJVNskjNnr81AHtmj6ssyK8cwbPoa7W0u3YKNwxjrXzNY6hdaXOJrO4K+qnofqK9b8M+KY9WiWMN5dyMb4yf1HtQB6jHNuHB49asL83esWzViBucmtaMNgAUAXUfAxS76jjXAyeKfkDtQA7eaMjANMyBTGk49KAJt6ik3+lVS/qaYZ1HegCyx9TTC2O9VJLyJchmrNu9YC5WFdxoA7jR7sY2luldlaShlFeJ6Pq1wb/axwDXq+j3G+JcmgDo6KRTlc0UALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHM+L59tnb24ODI+4/Qf/rrjLmdkjwCcda6DxXP5utRwjBEUYz9Tz/hXMXrbY2NAHH654g+yk5kKDua8/wBT8Vowby5d3vW14yMUlrNlsNXkE0xaYqOwoA07/W5rknax/GsXdJNveR/4sUjtjNMiY+W3uaAJAFQHb+ZqNm5qzY2M+p6hb6fbrumuZFiQAZ5JwP519IaJ+zPp8ZSXXPEEs44Jjtogmf8AgRz/ACoA+aIree5kEMETPIxwFQZJNdzpHw7+I0ElvqFp4Y1D5SHRvKIz9Qa+vvDXgLwn4TiVdG0iGGXGDO43yt/wI81sarepY6fJJn52BVB6mgDyTTrWX7JC00ZjlKgujfwnuK1Y4f7y8ip1QKPU9zTxgUAR7BjpUb4VanZgBVKWQZ5NADWbrVSSYLmobq9WMEKawbrUiSQDmgDWlvlXPzVmz6k2SA35VizX55y2azpdQC5+agDde+Zj1zQLyBFLSdTXIzaqQcK1QLqDMcu+aAOuTXLO3vEOOc4r1Lw3qwuFTacCvm+81DMq7PXrXsXgW4lkiiZuBxQB7lbtuhBoqKxz9mX6UUAWqKKKACiiigAooooAKKKKACiiigApG6UtUtVuPsukXM/QrGcfXtQBwV/MLjU7m56hnO36DgfpXL6zdiGFhuxxW1JIEg6815z4o1MKXXNAHB+LtRMgeJT94156NzSSN74rpNUka4kkkOdo6VhpHtJB780AU5iQpOKfBDJIUhhjaSRuioMkn6V6F4J+FeteOrpZl/0HSY2/e3ki8H2QfxH9K9ubw34f+H8Nrb+HrNfOfImvJvnlkP17D2GBQB5z8H/AOoWviuDxL4j02a0tLIeZbxzLtaWQ8Dg8gDr9cV79qPjJ4ci3ijT3b5q406lNcMCZGJPYUn9l3N7Jumbyo/fqaALreMfEN1ciO1uSCT2jXCj8q0pbu8vNsl5N5sirjIXaPyqpb2dtZR7IkC+p7mkkuFXvQBOSKY0qrWfJfKgOWrLudbhTPzUAbc1yoHWsa81BFDfNWBeeIBzh8Vzt3rW7OZKANy91LdnDYFYVxqGM/NxWJc6qWJw1Zct8Wz8xNAGzPqWc7TWZNeNnJas1rhmPBqPLP+NAFmS6J6UxWkb1q7pGiahrN6trptlNeTn+CJc4+vp+Ne6+CPgwLWaPUPFQjkK4ZLJG3AH/AGz3+g4oA858I/DHxD4oKXMcP2OxP/LzcAgEf7I6t/L3r6K8N+CtL8PWkcak3U6jmWUd/YdBXTRxxxRLHGioijAVRgAU6gAooooAKKKKACiiigAooooAKKKKACiiigArB8XPt8Ny9gXQH863qwPGCsfC1yyjOxkbj03CgDzqZt0GM15p4ttUMMsnO5QTxXok0w+z7u+K5/8A4RXVvFbSR2qiC1OVe6l+4v09T7CgDyi10x9TZLO3tnnmkO1URcsx+ler+EPgdZ21xHq3jJtwX5k05G4/4GR/Ifn2rvfDmgeHPBNoIdMT7Vfldsl24y7ew/uj2FWbrUZJnPmNtHpQBoz30NvapZWEKQwRjakcY2qoHbFc9fWKagV+1yEhTnap/rTnvFVeMD61Sm1SJAQZBQBfihs7RNsMap796bJfxoDyM1zN1riqCFbp69653UPEYwSr0AdjeaxHHnLiucvPEAGcNiuIvvELMT8/NYVxrEj5+agDtLzxASf9Z+tYF3rjtn565lr2SVtq5dj2Xk1qWPhHxlq206f4b1GZW6MYGVT+JwKAIZ9Vkcn5qoveO+csa7qw+CfxDvwGm0+3sVP/AD83C5H4Lk112nfs43ki7tW8URRH+5a25f8A8eYj+VAHiDXLZ61H5u5gqgux6KBkmvqTTfgD4HsyGvmvdSb0mm2L+SY/nXd6N4O8L+Hx/wASbQrKzfoZI4RvP1Y8n86APlPw98MfHHiQq9ror2dscf6Refulx9DyfwFeweG/gHpFmY5/Emoy6lL3gh/dRfifvH8xXtIGKWgCjpuj6Xo9mtnpdhDZwL/BCgUf/Xq9jFFFABRRRQAUUUUAFFFFAATgVWnu44RkmpJnKoa5LWLtxuUHigC7d+KFtyQkSv8AU1ky+OrlT8llFj3Y1zVxIzMetVCu40AdO3j7UM/LY2/5t/jTD4+1TtZW3/j3+NcwY+aXy+emTQB1dv4x8QXjlLXToJCOu1WwP1rQXWfFbEbrOyj/AN4t/Q1ieE9RihvZNJn+RpvniY9GPdfr3rspLZvTpQBmLqniT+M2A9lVz/Wq+qanqE2iXcNy0MgeMjCRlf6mtBraQttjUk1HM1jp6GS6kWWTH3eqj/GgDkNE8PyX9st3qOYbMchDw0v+Aq5qupPuh0+xAhT7qqnRQKq6v4tjUP8AvAFHQDtXCv4vhj1lZmkyNrKD6E//AKqAPQFC28QGfm7nqTWdqF9EqNImVx3JrjrvxgWBAb8zXNX3idiGDT4U9hQB1d5rQwwEn61z13rZwR5mPxrjrrXs5O/8azW1C4ujiFXkJ9KAOivNcc5/eVg3OpO5OWpg0nVrg58tYge7tVi38M3QO6W/2t/sCgCqkFzcDzJGW3j/AL8pxn6CrES6fZ3ccm+PUCnLLMD5Z9sAgn860E8OWa/NPNJM3cs1Wk03TYeRCpI7nmgDa0v4laxpKhNG0nRbMAYzDYAE/U5ya2F+MvxAbo9kPra//XrkWe2jHyKBVaS8iUcGgDv4/jB4+Y4aWwx/17f/AF66DSvir4nmkC3Zs2HfbDj+teMnUEHQ1fsNTAlGGoA+otD8UtqSDzgqsfSuoSTeARXiXgy9aVkw1eyWZzCtAFyiiigAooooAKKKKACiiigAooooAr3A+RvpXGauPnau0n+430rkdWhYs2KAOQlzuOBSRx7sck+9TzQ7WPc1GN2Bz29KAFEQ3cjj86BGN209eue9OwBtYtk+vrTw0fTGG96AKl1asyBkYpIjBkdTypHQit/TfiPpdpbfZvFEwsLiIf64qfLlx3BHQ+1ZbcjDHcvoaztQ0yDUIGiuI0ZW/hIoAxvEvx0sVuZodHO+EHaHHG73rzjUvipqV8T5cbtn0Brs5Ph1ozylwrhT2zxVy18F6FbH5bNXI/vc0AePTa/4h1HcscEpDVEmkeJro7vJ8r3bNe+Q6XYQDEdrEuPRala2hIwYlH4UAeA3Gl+ILaLMt4z8dAuaw5YdTZ/3nmH8K+kJtJspvvQLVCXw3p7jiICgD5+hW4ibJtd7erDNacWpXsX3bUge1ewSeE7Yn92q/lVV/CcfOFFAHma67fL/AMu7U7+3rwn/AFDV6FJ4RHUIMVWbwhz9z8hQBwTa3eN/ywNRNql83SIivQR4OOeV/SnDweo5K/pQB5v9qv5DjZSeTfydeK9NXwoi/wAP6VZj8LL/AHf0oA8yh068dgDmun0bQJnlUtmu3tfDChh8n6V2Gj+HI0ZSUH5UAWPBmi/Z1QkGvV7ePZEBWJpNikCqFGK6BPuCgB1FFFABRRRQAUUUUAFFFFABRRRQBFIMg1hahb7g1dAwqpNDuBoA4K7szuJx0rNkt8H0xXb3VnuzxWJc2OM8UAc/jbzt/Sk3kDO7P6VdktWAJxVRoTigBu78KZnt+tBQ4xzTcHB9KAHAcUxlwM07ft6flUbF87s5oATGeaPVcUfnSbu57UAIwGR6Uny0pO4+lNA5x6UAL5Y7CkEeScin5wcUu7060AR+WOeKDDwMCpRmlweeOnSgCAxrnpik8kdKtbD659qkWAkjigCp5A3fdqeK03Y44rRhtWbHetK3sCSOKAKFpYZI+Xj1rprGxC4+WpLSx6fLW1DAqDNADoItqirY4FNVeKfQAUUUUAFFFFABRRRQAUUUUAFFFFABTWXNOooAqSQhs1SmswwPy5FaxWmlPagDmJtP4OBWbNpp/u4rs3hDVWktA3agDhpLBh/Dn8KqyWbYPGBXbyWKk8rVWTTgf4aAOLe1wRxUbQMD0Nda+mZ/hqu+mn+5+VAHMeScY25FM8puldK2nHP3aZ/ZvsaAOdMXH3aBHxW+dNOPu8Uf2aemOKAMEREkfKfrTxbH0zW8mnHPSp003n7tAHPLatkcGpksm3fdro003pxVlNN55FAHPR2DEcrV2HTyf4c/hXQR6eABxVyO0A6igDFg07GMitSGyVcfLir6wKvaplSgCKOEKeBU6rzShRTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAQjNNK0+igCIxjrio2iUjpVmigCkbdaYbVa0KKAMw2a84pv2MelatFAGT9iB7Un2IAdK16KAMn7GBUgs1z0rSooApLbKO1SLEo6CrNFAEIj9qeFp9FACbRS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==" width="279" height="189" alt="" /></p><p><em><span>Figura M</span></em></p><p><span> </span></p><p><span> </span></p><p><strong><span>Paso 6: Aplíquese su inyección</span></strong></p><p><span> </span></p><p><strong><span>6.1</span></strong><span>Quite el protector de la aguja</span></p><p><span> </span></p><ul><li><span>Sujete siempre la jeringa por el protector transparente.</span></li><li><span>Sostenga la jeringa hacia arriba y tire del protector de la aguja hacia fuera (Figura N).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="294" height="202" alt="" /></p><p><em><span>Figura N</span></em></p><p><span> </span></p><p><span>Se podrían ver gotas de líquido en la punta de la aguja.</span></p><ul><li><span>Deseche el protector de la aguja.</span></li></ul><p><strong><span>Advertencia: No</span></strong><span>toque la aguja.</span></p><p><span> </span></p><p><strong><span>6.2</span></strong><span>Pellizque la piel</span></p><ul><li><span>Sostén la jeringa como si cogiese un bolígrafo.</span></li><li><span>Con la otra mano pellizque suavemente la piel (sin apretar) para evitar inyectarse en un músculo (Figura O).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAB+AP0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD7LooooAKKKKACiiigAooooAKKKKACioprm3t13XE8cQ9XYCuc1PxlZ2oaOxX7TIP4uiD/ABoA6joKoz6xpVvkTahApHUbwT+QrynVvEOoagf9Ju2Kf8814UfhWL9pAJOcfWgD2lPEmgu20arbqf8Aabb/ADq/b3drdrutbmKdfWNww/SvAHulzksM1Gt60EyzwzNG4OQ6NtIoA+iaK8MXx74jhO06g0gH+yucflV2LxjrV7ECurSDPUKFUj8hQB7KzqilnYKo7k4FZkviLQYQTJrFnx1AmUn8ga8euBc3snmXl5LcEf8APWQsR+ZqhJb+VkcY+lAHsDeOfC6nH9qZ/wB2Fz/7LVW5+Inhm3Uss09x7Rwn/wBmxXj74B+Y4HvTQpmtRJj5W5X3FAHqn/C1PD+Tiz1Agd/LT/4qrtn8R/C92217iW1P/TePH8s14q6e3FRqo/555P1oA+krbVNNvP8Aj01C2n9o5Vb+Rq3XzOudwIjx+OK2bDXNW08j7FqFxCo/gDEr+R4oA9/oryex+IWuW7KLpIb1O+V2MfxHH6V09j8Q9GuSFvIprJz1LDeo/Ec/pQB2NFULfWtIuxm31K2k9hIAfy61cEsbDKyKR7GgB9FIGU9GB+lLQAE4GazL6/a3QsDWi/3DXJa7MVUigCndeLJ4XIDkD2NZ7eN7pc/vK5W+nJlO41nEsT0yKAO2bxze9pKhbx3qAPEjfpXGtwOtV3LY+UHA79KAO1bx3qoBxN/n8qT/AITvVsZ+0AflXCs789x6YqAzydB+XSgDvH8cao4x9tK59DVK48YaoTh9UmUH0kxXESy3CthQQKzRb3+oalHZ27qrNklnOFUDvQB2Vx4i8xy8lwZXPdjkn86pya8uMbgSe2aTT/DenwO32tnu5h1LNhfwA/rmultWtrX5bW3hib1jQKf5UAc6o1K4XzI7Kd0b7rCMgH8cU2TTtZYbjZsB/tSoD/OurWZ5pApbcc9Sa0Fs02gsMk0Aeff2bq7cG2VR/wBdFP8AWj+x9TYEMY1+pz/IV6GLVOmylNnH12igDzZtE1PIxLFx/vf4VLHp2rW8m+FVLHrtPB+teh/ZIhzsH5VHJHFGvC8+woA4Zj4iI/1MKL7sR/IGmxrqrD/SLqFfaNSx/UCuwkhaRflXk1mXFncQndtyPTFAGL5BZMSsz54PYGnCKZUEa/JGBgAdBWnHtb767fYipfLQ8jrQBmR2rMcVa+wf3v5VfWNaf/OgDN+xDuKUWQz3zWjtzUqItAGYLXgdPwpwi9Bk1qeWpPFNMIVuehoAr2yhHDBa6bTpeRzzWGkfJ4H9a17FcMpzQB3mnSZjHPOK0qxNLf5VHWtpfuigBk5xC1cF4gkb5+cV3dz/AKg15/r/AMzvQBw1zlpj1P1NRLHuz6e9X5I8k9ielM2OB7fSgCqYfl561E0RPb68VfWIj7wBBNL5PbkAdqAM17bPVSajFoXGRk/hWntCt9R1pVUA/L3oAyXssDdiufkkbTtUdpeFlG0MO2K7U/6sjvx2rF1bTob6BopFByKAIrPVITuXdk5yK1IbsE53Yrze60nV9PfNpcrJGv8ABJnP5/8A66q/8JBrtn8s1hnHG5Wz/SgD2LTJFaUnOeRXTCRSAN3HtXglj44uo5PntXBrpbfxwHH7xZF57rQB6wrDrnBqQPGo3biTXm8PjOyI+aRhjsVIq2PGVjjHmMfoKAO7aRWzjPPrUDMgPNcpB4q0+QgfaFBPqQDWrHqEFwu6OUMPY0AbKEdRg0kjbs/KD+FVbS4VgV3Z/Grhw3SgCuYI9pJjUn6U3yIsf6tfwFWTt6Co93NAEH2eE4ymOaje2j3ZXirLNzSDH4mgCi1uc+opvlMvQZFaGNwxil2e3NAFNQ45459acoAXd3NWvLAHXmk28HOP8KAIVQgZJ5Pp6VftzjvioFUgc9aliO0igDq9KYbQM10SfdFcxpJOQfpXTx/coAjuf+Pdq4LXFBZjnpXfXAzCa4jW0yzD160AcW6nd69/pS4yORUsoKMe/vTBQBFtzheeKdt4AyeKe2c9MUHkjsB+tAEDZ3d8dMZqlLcCOTJO36GrdwwXJ9u1UbXymKySRqzE8k84oAja8Zgdsbye6rmqzzTZO6FgPdTXS2vlyR7uB2xirE0cOxMKBk8mgDiXSR1wYG/75NUZtMeXg2zEf7tei/ZI3Hy4JpTZIEzgcUAeUTaDJncLRufRai/sG9/gtHx9MV63BZIWPmD8KuiyhPRFFAHjcfhnV5F+W3Cg9zVqPwhqz/xIp/OvXls4+AqD8BUq2oB5x+FAHj//AAhOqdpEH4VGvhTX7O8ikhkZUVssYyRn2Ir2b7MuM00265yBx796AMPSreZYU89SHXrmt1RtXpke9II+fb+dOYjHA5oAgOc9aj/Clc4bmgNx7n1oAaBnmn7cUbwBzUZlTPPP4UAPBwafzioRIM/dPrSiRj0WgB7LuGM4prLnq3T1pNzdMUu40AB3ADn+tSwglhmq7Z6jgCrUGfMFAHT6UuAK6WP7tc/pafKK6JRhaAEcZQ1yWtwMVJrr6yNStt6H1oA8xuVbceOar9O1bmoWu2UfLkfSsiRGx93J+lAEXGcilPSk2tk/Wncg8UAU51LIw6Z44rn3u/7PkMc2VXqH7V1DL8p4zntWVeWyyZ3LnIoAhs9aiBJjkDK3OQc4q/8A2gJY1IbhTXEanosGWkQGNsfeTiuWuL/WNPLCzvpioPQjf/OgD3C2vVY8nOR0q210Dhc/rXz3H418V2uf9HE4HdoD/TFXLf4o6zbri90Qt7puX+YNAHvEdx82W55q59oTZuDZrxS3+LMWwCfRr9SRyUj3f4VZX4rW4c7dH1Nh7Qf/AF6APYxeJndu5HtS/bUxnNeNn4p2+4E6PqSj1MI/xp3/AAtK1b5RpWo/hD/9egD2P7cme1I16igEnivHR8T42XA0PVWx/wBMVH9aF+KlgJRHdadqNqrf8tJYflH4gmgD2BtQQJ9age/GSV5rjLXXobqJZIn8xW5BFaEVy0uMZwaAN77Q0hyf0qVMEjP51lxbtwOTWiJCq0AWAV+7tpd2Owqt5khPyrTgkhYbiSPpQBKXGfX0puWzwOaGEY5amPKq9MZoAduZQeQKQ9Qc8ioTIWYN0pd3HBzQBL827r9c1dtVJcDFZynJ649K19OQmQelAHW6XHiNeO1bS8Ais/T49sY9a0R3oAKhnj8xCKmo60Achqdl8zHFcpdwMkvpXpl1biRTxzXLajY4J9qAOPwwfdmkCqT159qu3Fuy5G0561TcFDu7mgCGQcVXmX5WxjFWpD/s4I61Ay7gQRyaAME2qXmpx282fK5ZhnGR6Vvro1iIcxwRLx02Disq6je3uFuIR8w7etJHr207XOw45DECgDWj0OxmUMYU57baR/DOmHl7dDj/AGahtdajMS5YZ9M1c/tKNzjf2oApjwrpo+7bR4+lTL4Z0sD/AI90P4VIuoLgDzOamW99G/WgCu3h3SuE+yx5PfFIvhfTQQ32dPyqz9qDSqd1WhdKF4oAojw5Zdolx6baim8L6fLw0KEe61r/AGxAvbNN+2Jk96AMqDwtYQH92gQei8VfTS4YwVUYHbFTfbUH8NNbUI+f05oAkjs0XnqalKKoOaypNWKHHBFH24zgdvagC+0sUR+UZNRG5ZjheKqj5uvFKWxwOn86AJcMTktRw31qEMS3NSc7sE0ALuxnjp0pVPQkUAE49KmWNcZZvagBYVZj6LXUaVbElSRWRZW+584BFdlptthRkUAadugRBxipxSKMAUooAKKKKAEIyKpXVosg96vUEZFAHG32mnJwvSufnsH3k7cgflXpctusnWs240tXBIH/ANegDzV4WTPy/nUDQtu6d67q40UnJ21ny6Kyg4BOfxoA4+W339VrOudPjdeYwc9q7aTSXx93+lQtpJYfdoA83m0VAS0WUPfBrMmsL6H5orqYcf3zXp8miuQdq8fSqc2hsQflzxQB5HdXfiC3YraXEkjZ+6QDUlte/EXG4abbTR+pYgn8jXr2h6ZHZSXDSQqXcjlhnithrS1ZXP2dFfHBUYNAHi6694sjP+keH0DDus2R/KrUfirWEIW40abP+ywNesDTo3HzRj8qiOjWxc5iX1zigDzmPxFfS/8AMJulHvt/xqwuragxG3T5s+5H+Nd//Zduo4iGfpTlsY+nkgfhQBwyX+oNxJp8w9wB/jT/ALYy/M0M2fQrXd/ZOflHFQSWKk8oDQBwR1RhKMafcNz129P1rUtrqOTBCMrHseK6Q2Kj+D9KrT6ehXcqjcB2FAFYKxxxS+XtBJOPrUm6RUx5ZLCq0kU8x6En0FACtcQx5ycmoTfAt8op40m6k/hwOlWodBbdllJoApi8ZmwP0rQtY7iZhhcA+taVroeGGE6e1dLYaRtx8tAEWk6e4ALc11kMflrjFR29usS4Aq1QAUCiigAooooAKKTn2paACgjNHOKOaAGtGrdqia1jI+7U2T6UZPpQBUaxjI+6Ki/s5M/drQyfQfnRk4oAym0xD/CPyqNtJQ5G2tjJ/uj86d26UAc++hoRkKAaj/sfaeFz6V0R6/dFLj2FAHOjSz/c+tH9ltn7proT/uj86XHPQUAc2dLx/BS/2Zz9w10e1fSjavpQBzg0wc/KetNOlH0rpdq46UbV9KAOYOjs3G2mHQWb/Cuq2r6UYHpQByo8Ox/3alTQYlwdg/EV02B6UmB6UAYS6NGB93ipl0lFI+UVsYo6dKAKMVhEmDgGraRKgwBT6KACiiigAoHSigdKAP/Z" width="253" height="126" alt="" /></p><p><em><span>Figura O</span></em></p><p><strong><span> </span></strong></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Introduzca la aguja</span></li></ol></div><ul><li><span>Con un movimiento rápido y corto, empuje la aguja hasta el fondo de la piel en un ángulo entre 45°y 90° (Figura P).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="227" height="138" alt="" /></p><p><em><span>Figura P</span></em></p><p><span> </span></p><ul><li><span>Después de insertar la aguja, suelte la piel pellizcada.</span></li></ul><p><strong><span> </span></strong></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Inyecte</span></li></ol></div><p><span> </span></p><ul><li><span>Use su pulgar para empujar suavemente el émbolo hacia abajo (Figura Q).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="265" height="201" alt="" /></p><p><em><span>Figura Q</span></em></p><p><span> </span></p><ul><li><span>Empuje otra vez el émbolo para asegurarse de que se ha inyectado la dosis completa (Figura R).</span></li><li><span>Sujete la jeringa con firmeza sin moverla, en el mismo ángulo (Figura R).</span></li></ul><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="310" height="207" alt="" /></p><p><em><span>Figura R</span></em></p><p><span> </span></p><p><strong><span>No</span></strong><span>retire la aguja de la piel cuando el émbolo llegue al final.</span></p><p><span> </span></p><p><span>Suelte lentamente el pulgar hacia arriba.</span></p><p><span>Esto permitirá que la aguja se mueva hacia arriba dentro del protector transparente de la aguja y cubra toda la aguja. (Figura S).</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="271" height="185" alt="" /></p><p><span>Figura S</span></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia:</span></strong><span>Llame a su médico o farmacéutico si:</span></p><ul><li><span>No se inyectó la dosis completa o</span></li><li><span>El protector transparente de la aguja no se activa después de la inyección.</span></li></ul><p><strong><span>Advertencia: No</span></strong><span>vuelva a utilizar una jeringa en caso de inyección parcial.</span></p><p><strong><span>No</span></strong><span>intente volver a tapar la aguja, ya que puede pincharse</span></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Si hay sangre o líquido en el sitio de la inyección, presione suavemente una bola de algodón o gasa sobre la piel (Figura T).</span></li></ol></div><p><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCACWAOgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD7LooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKrXN9b2ilppAMdu9c5eeJvMfy7f5F7nvQB0V1qFpaD9/MFP8AdHJ/Kqo13Tj/AMtW/wC+DXHSXHmyli3P1oDccZzQB266tp7D/j5H4g1INSsG6XcX4tiuHRmxkninGSOgDulu7Vvu3EZ+jCpFdGGVYMPY5rz8yR96ia7jTpkH60Aej0ZrzT+0yvKyOv0Y1KutXA/5epR/wM0AejU0ui9WA/GvOm1qduGuJGHuxq5Y6pukBJ596AO7BBGRzRVKzuPNjBq72oAKKKKACiiigAooooAKKKKACiiigAooooAKKKjnmSC3eaQ4VRk0AJNcQ28ZkmcIvvXM6j4mCgpa9PWua1jWpru5Zy+IwflHtWFLf553UAal9qU07FnkJrKF4VY81nXWohV61mf2mjA/NQB10N8N3JrVhfzfu9K85i1mNZgrPj3zXc6TN5kAYHIPegDVdtq7RVdpgg5pbqURrWNLcFieaALkl56GqctwT3qpJNgcmsy61JIwRuoA2POH96l87jrxXKf2umcbsUo1hR/F+tAHUmYdqsWtztkBzgVxba2B/FTY9ew4+agD3TQ7wOijdXTKcivJfCes+c6rur1a3bdCretAEtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn4v1HybdbKNsM/LY9K6e4mS3t3nkOFQZJryHWdTa8v5bhm6sdvsKAM6+uAIm5xWXZ2OtauP8AiWafNcITjeq4X8zxVm1tLjXNYg0u1+9K3zt/cXua9ju5LHwv4Z2xARQ28e1B60AeEapo15pzGPUriOJx1RG3Ef0rk7u7jhcrDkj1J5NaHiDW5b++mnZyd7E81zkMN1qV4lrZwPcXEhwsaDJNADpZ/M+ZH/CvVfALyy+HkkmYkh2AJ9K8rv7X+yrgaeu261RzsKJ8yxk9vc17BpNu2i+GbSxk/wCPgRgyY7MeT+tAFy+udzkDpWPNcKinJqK8vVQHLc1zF/qh5w1AGhf6ptBCtXLXmpM7H5qqXd+zZLNgViXF2TkA8UAaL6gyt9+kGoEj75rn3mJOafG7GgDcN+T1Y0iXmWHzVkhqkjf5xzQB634Gu2NzGM19Cae26yQ181+BX/0yP619I6Wc6elAF6iiigAooooAKKKKACiiigAooooAKKKhuZjBbPIBlgOAe5oA43xtrXlquk25LSvywXk+wrgv7B8SX+fsumSDPeUhB+telafY2drK15cATX0h3NMwyQfb0q2+oZbClgR6DigDH8DeFpPD9pNd6lsbUbhsEochE7KD+prgvi54sl+3LosKvHGgyxYFQ30r1lb1sbi2R+VZurWuk65ZPZ6rYxXELcZYZI+h6igD5TmuGlcKvzM3AA9a9gsfD954S8Gpa6baed4n1ZMyyN0s4z2z24/X6VS0fwDa+H/Gsmp3VxHdWNu3mWkZ5O7PG4f7P68V0mreIMs8kkmC3J9TQBzuheErDw2xvryYX+qNz5h+7H9Pf3o1XWFj3fPljWJqfijJZY24rj73VmmYlnzmgDZvdVZ2JLZrBur7rlqz5bxmHFVGMj8mgB09yzkjNVfmatPTtE1TVpjHp1jNduBkrEhYgfhVmbw7qllk3ul3cOOvmQsoH6UAYWw1IikCrEiKPuiqzMyn1FAD811fgXwbqPjPXVtLYGG1j+ae425CD0+tQeD/AATrnjHUkhsbVo7UN+9unUhEHfnufYV9Z+F/DOm+FdEi0vTItqKMu5+9I3diaAOZ0P4VaPorLIl7dTOP7xUD+Vd7bwLbwiJM7R61LRQAUUUUAFFFFABRRSMcA0AMknjiBLtgVh3nizS7Nir72P8AsgVS8RXckcRVTivNbyZ5ZDubNAHoT/EXSUPFrcN+A/xqE/EvSx0sLn8xXm3l7hSeTx0oA9H/AOFmafg40644/wBoVdtfEieILPzoYXgiDFcOckkV5YYcRt9K3PBuoI2n3VoW/eQS5I9iKAO589I1Yck981Te/ijzhvmPRazrm/DZ8sgnsa5/VNWWytHmziU/KpB4yelAHQX2uLGNpOWPb0rAvPEUm0hpAg9Aa4e+8RbcxRFnJ+8/qawLzVpXH3zQB12o+KQgO1smuJ1PXprhmzJ19KyLm8kdiAait7Wa5kwB+J7UAEk8kvtTobG5uPuRsffoK2bbToIgCw8x/fpV37o44FAGVDoTEDz50jHcDk1v6To/hWCcS6r9rvVH/LNJBGp+vGf1qm2T1qM7vwoA9n0Xx94X0OySz0vQfskS9kcZP1OOa24fiZo1y21rJhn1YH+lfPg3g8GtSz37l7UAfQSJ4T19c3Gk2ku7/npEp/pUkPgDwVHOtxD4dsQ45B8oHFeaeHbyaK5RQ5xXsOlTNJbqSeaANCC3htohFBEkSDoqLgCpaKKACiiigAooooAKKKKACkb7ppaRvumgDjPEq7lavOZ4z5p9M16vrVr5sZOK8+v7J1kPGBQBkqAPlxn6VIqkgELj600xuhPp2pN23Hr3oAl/dkgVhR3D6D4gN8FJtZl8uYAdux/CtgycHvVe5iW6QrIM0AbUlzHNCHtiGWQbgVPBrlfE0ck2ngwRklGDHn0psdneaezCwn/dk58t+Vp7XV6y7ZtOVvdX4oA85utQ2krgqw6jFQ2tvfahL5cNvI5PTIxXeyWaSyiRdJG7qSzVILLUGQxoyWinqYx8350AcVcaFJaXEcE8qGduWij52D3NaVrp0yjbt2r9K6uy0a2tiXYb5D1Z+SavfZkz90UAcvFpchNTLpLEcnmukFsFIJFP8pVbOKAOb/sbPXNPGhk9AfxrpVI9Ppmnbge1AHNjRSp+4cD0q1Dpe3HrW5977tTQ2zuR3NAD9Gtdk6nHNeraOpFuua4rSdPYOuVrvrGLZEo70AaFFFFABRRRQAUUUUAFFFFABRRRQBVuIN6kVzV/pQcHC11xGRzUEkIYcjIoA8wvNLdScA1jzWTqx+U16tPp6SA8ZrHudGU/w0AebNCy9iaYQVNdpcaJjotZkujupyFoA5snLZNLxzzxWs+luB92om02Qfw0AZ2aaGyeavnT5B/DSfYZOfloApFsMMdKkDbsAcVcXT5OuKsx6Y5P3cGgChsCx7jkmoDlj93HNb/9nyYGENSRaLNJ/AfyoA54RNkVPHaMT0JrqYdBZeqVq2+h9PloA5K302RsfKa6Cx0c8HbXQ2+lKg+6BWnFaqgGFoAo2VisYB21sxrtFCxgCpKACiiigAooooAKKKKACiiigAooooAKKKKAGlQajaEH3qaigCi9ojfw1WfTo2/hrXpCqntQBgPpCN/DUD6MnPy810pjWm+WtAHLnRV/ufpSf2Gn939K6jyhR5QoA5pdFUH7lTppKj+Gt/yxS+WKAMlNMjXqo/KrUdnGo4WroUU7FAFdbdfSpVjVR0p9FADdi+lOAxRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=" width="232" height="150" alt="" /></p><p><em><span>Figura T</span></em></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="551" height="84" alt="" /></p><p><span> </span></p><p><strong><span>Paso 7: Deseche su jeringuilla</span></strong></p><p><span> </span></p><p><strong><span>7.1</span></strong><span>.</span><span>Deseche la jeringa usada en un contenedor para eliminar objetos punzantes inmediatamente después de usarla (Figura U).</span></p><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="195" height="290" alt="" /></p><p><em><span>Figura U</span></em></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia:</span></strong><span>Mantenga el contenedor para eliminar objetos punzantes fuera del alcance de los niños.</span></p><p><strong><span> </span></strong></p><p><strong><span>Advertencia: No</span></strong><span>tire la jeringa en la basura doméstica.</span></p><p><span>Si usted no tiene un contenedor para eliminar objetos punzantes, puede utilizar un recipiente doméstico que sea:</span></p><ul><li><span>Hecho de plástico resistente;</span></li><li><span>Pueda cerrarse con una tapa hermética y resistente a los pinchazos; esto evitará que salgan los objetos punzantes,</span></li><li><span>Vertical y estable durante su uso,</span></li></ul><ul><li><span>Resistente a las fugas y</span></li><li><span>Etiquetado correctamente para advertir de la presencia de residuos peligrosos en el interior del recipiente.</span></li></ul><p><span> </span></p><p><strong><span>7.2</span></strong><span>Cuando su contenedor para eliminar objetos punzantes esté casi lleno, tendrá que seguir las recomendaciones locales para la correcta eliminación del contenedor.</span></p><p><span> </span></p><p><strong><span>No</span></strong><span>recicle su contenedor para eliminar objetos punzantes usado.</span></p><p><span> </span></p><p><span> </span></p><p><strong><span>Paso 8: Anote su inyección</span></strong></p><p><span> </span></p><div style="list-style-type: decimal"><ol style="list-style-type: decimal"><li><span>Para ayudarle a recordar cuándo y dónde debe realizar su próxima inyección, debe mantener un registro de las fechas y lugares de inyección utilizados para sus inyecciones (Figura V).</span></li></ol></div><p><span> </span></p><p><img src="data:image/jpg;base64,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" width="217" height="222" alt="" /></p><p><em><span>Figura V</span></em></p><p><span> </span></p></div></text></section></section></section></Composition></resource></entry></Bundle></resource></entry></Bundle>